FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Heyn, GS
   Correa, LH
   Magalhaes, KG
AF Heyn, Gabriella Simoes
   Correa, Luis Henrique
   Magalhaes, Kelly Grace
TI The Impact of Adipose Tissue-Derived miRNAs in Metabolic Syndrome,
   Obesity, and Cancer
SO FRONTIERS IN ENDOCRINOLOGY
LA English
DT Review
DE miRNA; adipose tissue; obesity; cancer; metabolic syndrome
ID BODY-MASS INDEX; BROWN FAT; ADIPOCYTE DIFFERENTIATION; MACROPHAGE
   POLARIZATION; INSULIN-RESISTANCE; TUMOR-SUPPRESSOR; CELL-GROWTH;
   MICRORNAS; EXPRESSION; RISK
AB Obesity is a multifactorial and complex condition that is characterized by abnormal and excessive white adipose tissue accumulation, which can lead to the development of metabolic diseases, such as type 2 diabetes mellitus, nonalcoholic fatty liver disease, cardiovascular diseases, and several types of cancer. Obesity is characterized by excessive adipose tissue accumulation and associated with alterations in immunity, displaying a chronic low-grade inflammation profile. Adipose tissue is a dynamic and complex endocrine organ composed not only by adipocytes, but several immunological cells, which can secrete hormones, cytokines and many other factors capable of regulating metabolic homeostasis and several critical biological pathways. Remarkably, adipose tissue is a major source of circulating microRNAs (miRNAs), recently described as a novel form of adipokines. Several adipose tissue-derived miRNAs are deeply associated with adipocytes differentiation and have been identified with an essential role in obesity-associated inflammation, insulin resistance, and tumor microenvironment. During obesity, adipose tissue can completely change the profile of the secreted miRNAs, influencing circulating miRNAs and impacting the development of different pathological conditions, such as obesity, metabolic syndrome, and cancer. In this review, we discuss how miRNAs can act as epigenetic regulators affecting adipogenesis, adipocyte differentiation, lipid metabolism, browning of the white adipose tissue, glucose homeostasis, and insulin resistance, impacting deeply obesity and metabolic diseases. Moreover, we characterize how miRNAs can often act as oncogenic and tumor suppressor molecules, significantly modulating cancer establishment and progression. Furthermore, we highlight in this manuscript how adipose tissue-derived miRNAs can function as important new therapeutic targets.
C1 [Heyn, Gabriella Simoes; Correa, Luis Henrique; Magalhaes, Kelly Grace] Univ Brasilia, Dept Cell Biol, Lab Immunol & Inflammat, Brasilia, DF, Brazil.
RP Magalhaes, KG (corresponding author), Univ Brasilia, Dept Cell Biol, Lab Immunol & Inflammat, Brasilia, DF, Brazil.
EM kellymagalhaes@unb.br
CR Alberti KGMM, 2005, LANCET, V366, P1059, DOI 10.1016/S0140-6736(05)67402-8
   Alexander R, 2011, EXPERT OPIN THER TAR, V15, P623, DOI 10.1517/14728222.2011.561317
   Arcidiacono B, 2012, EXP DIABETES RES, DOI 10.1155/2012/789174
   Arner E, 2012, DIABETES, V61, P1986, DOI 10.2337/db11-1508
   Babar IA, 2011, CANCER BIOL THER, V12, P908, DOI 10.4161/cbt.12.10.17681
   Bai JJ, 2015, CANCER BIOMARK, V15, P599, DOI 10.3233/CBM-150500
   Bayraktar R, 2018, CANCER METAST REV, V37, P33, DOI 10.1007/s10555-017-9724-7
   Beg MS, 2017, INVEST NEW DRUG, V35, P180, DOI 10.1007/s10637-016-0407-y
   Belarbi Y, 2015, J CLIN ENDOCR METAB, V100, pE1084, DOI 10.1210/jc.2015-1530
   Belgardt BF, 2015, NAT MED, V21, P619, DOI 10.1038/nm.3862
   Bhaskaran K, 2014, LANCET, V384, P755, DOI 10.1016/S0140-6736(14)60892-8
   Bousquet M, 2010, P NATL ACAD SCI USA, V107, P21558, DOI 10.1073/pnas.1016611107
   Brandao BB, 2017, REDOX BIOL, V12, P82, DOI 10.1016/j.redox.2017.01.020
   Bruning U, 2011, MOL CELL BIOL, V31, P4087, DOI 10.1128/MCB.01276-10
   Castano C, 2018, P NATL ACAD SCI USA, V115, P12158, DOI 10.1073/pnas.1808855115
   Chabot S, 2012, MOL THER, V20, P1590, DOI 10.1038/mt.2012.95
   Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010
   Chen C, 2014, CELL SIGNAL, V26, P1155, DOI 10.1016/j.cellsig.2014.02.003
   Chen J, 2011, CANCER RES, V71, P4138, DOI 10.1158/0008-5472.CAN-10-4274
   Chen SZ, 2015, OBESITY, V23, P2445, DOI 10.1002/oby.21319
   Chen YH, 2013, DIABETES, V62, P2278, DOI 10.2337/db12-0963
   Chen Y, 2017, NUTR METAB, V14, DOI 10.1186/s12986-017-0176-4
   Chen Y, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2742
   Chistiakov DA, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/354517
   Cho WCS, 2011, RNA BIOL, V8, P125, DOI 10.4161/rna.8.1.14259
   Choi SE, 2013, AGING CELL, V12, P1062, DOI 10.1111/acel.12135
   Chou NH, 2018, ANTICANCER RES, V38, P3309, DOI 10.21873/anticanres.12596
   Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102
   Cinti S, 2018, TRENDS ENDOCRIN MET, V29, P651, DOI 10.1016/j.tem.2018.05.007
   Colangelo T, 2013, NEOPLASIA, V15, P1204, DOI 10.1593/neo.13998
   Correa LH, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8070662
   Cypess AM, 2010, CURR OPIN ENDOCRINOL, V17, P143, DOI 10.1097/MED.0b013e328337a81f
   Dahlman I, 2017, AM J PHYSIOL-ENDOC M, V312, pE482, DOI 10.1152/ajpendo.00251.2016
   De Pergola G, 2013, J OBES, V2013, DOI 10.1155/2013/291546
   Deiuliis JA, 2016, INT J OBESITY, V40, P88, DOI 10.1038/ijo.2015.170
   Deshmukh AS, 2019, CELL METAB, V30, P963, DOI 10.1016/j.cmet.2019.10.001
   Donatelli SS, 2014, P NATL ACAD SCI USA, V111, P4203, DOI 10.1073/pnas.1319269111
   Duarte FV, 2014, GENES-BASEL, V5, P865, DOI 10.3390/genes5040865
   Duroux-Richard I, 2016, BLOOD, V128, P3125, DOI [10.1182/blood-201602-697003, 10.1182/blood-2016-02-697003]
   Egawa H, 2016, INTEGR MOL MED, V3, P1, DOI [10.15761/IMM.1000187, DOI 10.15761/IMM.1000187]
   Eichhorn SW, 2014, MOL CELL, V56, P104, DOI 10.1016/j.molcel.2014.08.028
   Ejarque M, 2019, INT J OBESITY, V43, P1256, DOI 10.1038/s41366-018-0219-6
   El Ouaamari A, 2008, DIABETES, V57, P2708, DOI 10.2337/db07-1614
   Esposito K, 2013, J ENDOCRINOL INVEST, V36, P132, DOI 10.1007/BF03346748
   Esposito K, 2012, DIABETES CARE, V35, P2402, DOI 10.2337/dc12-0336
   Esteves JV, 2017, J DIABETES RES, V2017, DOI 10.1155/2017/7267910
   Faria SS, 2020, J BREAST CANCER, V23, P233, DOI 10.4048/jbc.2020.23.e35
   Feng YH, 2016, BIOMED REP, V5, P395, DOI 10.3892/br.2016.747
   Feng YH, 2015, GYNECOL MINIM INVASI, V4, P102, DOI 10.1016/j.gmit.2015.03.003
   Fiorenza CG, 2011, NAT REV ENDOCRINOL, V7, P137, DOI 10.1038/nrendo.2010.199
   Fu T, 2014, MOL CELL BIOL, V34, P4130, DOI 10.1128/MCB.00596-14
   Ginsberg Henry N, 2009, J Cardiometab Syndr, V4, P113, DOI 10.1111/j.1559-4572.2008.00044.x
   Giordano A, 2014, EUR J ENDOCRINOL, V170, pR159, DOI 10.1530/EJE-13-0945
   Giroud M, 2016, MOL METAB, V5, P615, DOI 10.1016/j.molmet.2016.06.005
   Gordon S, 2010, IMMUNITY, V32, P593, DOI 10.1016/j.immuni.2010.05.007
   Grundy SM, 2005, CIRCULATION, V112, P2735, DOI 10.1161/CIRCULATIONAHA.105.169404
   Gual P, 2005, BIOCHIMIE, V87, P99, DOI 10.1016/j.biochi.2004.10.019
   Han MS, 2013, SCIENCE, V339, P218, DOI 10.1126/science.1227568
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hanna J, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00478
   He M, 2020, J MOL CELL BIOL, V12, P152, DOI 10.1093/jmcb/mjz015
   Hirono T, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-43355-8
   Hotamisligil GS, 2017, NATURE, V542, P177, DOI 10.1038/nature21363
   HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936
   Howe LR, 2013, CLIN CANCER RES, V19, P6074, DOI 10.1158/1078-0432.CCR-12-2603
   Huang C, 2016, INT IMMUNOPHARMACOL, V32, P46, DOI 10.1016/j.intimp.2016.01.009
   Huang YX, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/7372636
   Hulin JA, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14454-1
   Ikeda K, 2018, TRENDS ENDOCRIN MET, V29, P191, DOI 10.1016/j.tem.2018.01.001
   Jazwa A, 2015, ARCH IMMUNOL THER EX, V63, P139, DOI 10.1007/s00005-014-0315-9
   Ji CB, 2019, NAT REV ENDOCRINOL, V15, P731, DOI 10.1038/s41574-019-0260-0
   Ji WD, 2017, GENES-BASEL, V8, DOI 10.3390/genes8010021
   Jordan SD, 2011, NAT CELL BIOL, V13, P434, DOI 10.1038/ncb2211
   Ortega FJ, 2013, CLIN CHEM, V59, P781, DOI 10.1373/clinchem.2012.195776
   Jung HJ, 2015, FRONT GENET, V5, DOI 10.3389/fgene.2014.00472
   Jung UJ, 2014, INT J MOL SCI, V15, P6184, DOI 10.3390/ijms15046184
   Kang T, 2016, STEM CELL TRANSL MED, V5, P440, DOI 10.5966/sctm.2015-0177
   Kang T, 2013, J BIOL CHEM, V288, P34394, DOI 10.1074/jbc.M113.514372
   Kang YE, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154003
   Karbiener M, 2014, COMPUT STRUCT BIOTEC, V11, P101, DOI 10.1016/j.csbj.2014.09.005
   Karbiener M, 2014, STEM CELLS, V32, P1578, DOI 10.1002/stem.1603
   Karbiener M, 2011, RNA BIOL, V8, P850, DOI 10.4161/rna.8.5.16153
   Karkeni E, 2016, J CLIN ENDOCR METAB, V101, P1615, DOI 10.1210/jc.2015-3410
   Kim HJ, 2014, DIABETES, V63, P4045, DOI 10.2337/db14-0466
   Kim YJ, 2009, STEM CELLS, V27, P3093, DOI 10.1002/stem.235
   Koliaki C, 2019, METABOLISM, V92, P98, DOI 10.1016/j.metabol.2018.10.011
   Kong L, 2011, ACTA DIABETOL, V48, P61, DOI 10.1007/s00592-010-0226-0
   Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303
   Kulyte A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50210-3
   Landrier JF, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8080859
   LaPierre MP, 2017, MOL METAB, V6, P1010, DOI 10.1016/j.molmet.2017.06.020
   Larsson SC, 2007, BRIT J CANCER, V97, P1005
   Latreille M, 2014, J CLIN INVEST, V124, P2722, DOI 10.1172/JCI73066
   Lavalette C, 2018, REV EPIDEMIOL SANTE, V66, pS248, DOI [10.1016/j.respe.2018.05.040, DOI 10.1016/J.RESPE.2018.05.040]
   Lee EK, 2011, MOL CELL BIOL, V31, P626, DOI 10.1128/MCB.00894-10
   Lee J, 2010, J BIOL CHEM, V285, P12604, DOI 10.1074/jbc.M109.094524
   Lee YH, 2014, BBA-MOL BASIS DIS, V1842, P358, DOI 10.1016/j.bbadis.2013.05.011
   Li C, 2018, TRANSL RES, V191, P29, DOI 10.1016/j.trsl.2017.10.004
   Li CY, 2015, MED ONCOL, V32, DOI 10.1007/s12032-014-0422-9
   Li GL, 2017, DNA CELL BIOL, V36, P672, DOI 10.1089/dna.2017.3712
   Li LS, 2013, CLIN EXP MED, V13, P109, DOI 10.1007/s10238-012-0186-5
   Li MH, 2015, BIOL CHEM, V396, P235, DOI 10.1515/hsz-2014-0241
   Lin Q, 2009, FEBS J, V276, P2348, DOI 10.1111/j.1742-4658.2009.06967.x
   Ling HY, 2009, CLIN EXP PHARMACOL P, V36, pe32, DOI 10.1111/j.1440-1681.2009.05207.x
   Ling HY, 2013, BIOCHEM CELL BIOL, V91, P195, DOI 10.1139/bcb-2012-0053
   Liu PH, 2019, JAMA ONCOL, V5, P37, DOI 10.1001/jamaoncol.2018.4280
   Liu T, 2009, CANCER RES, V69, P1702, DOI 10.1158/0008-5472.CAN-08-3365
   Liu WY, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003626
   Liu XZ, 2018, MEDICINE, V97, DOI [10.1097/MD.0000000000012860, 10.1097/md.0000000000012860]
   Liu YC, 2014, INT J BIOL SCI, V10, P520, DOI 10.7150/ijbs.8879
   Lu J, 2005, CANCER RES, V65, P4769, DOI 10.1158/0008-5472.CAN-04-2293
   Lu J, 2012, OBES RES CLIN PRACT, V7, pe445, DOI DOI 10.1101/gr.132514.111.22
   Lumeng CN, 2008, DIABETES, V57, P3239, DOI 10.2337/db08-0872
   McGregor RA, 2011, CURR MOL MED, V11, P304
   Miranda K, 2018, INT J OBESITY, V42, P1140, DOI 10.1038/s41366-018-0114-1
   Montella M, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1769-9
   Mori MA, 2014, J CLIN INVEST, V124, P3339, DOI 10.1172/JCI73468
   Mori M, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001314
   Munoz-Fontela C, 2016, NAT REV IMMUNOL, V16, P741, DOI 10.1038/nri.2016.99
   Najafi-Shoushtari SH, 2010, SCI 80, V328, P233, DOI [10.1016/j.devcel.2010.12.007, DOI 10.1016/J.DEVCEL.2010.12.007.PEROXIREDOXIN]
   Nedaeinia R, 2016, CANCER GENE THER, V23, P246, DOI 10.1038/cgt.2016.25
   O'Brien J, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00402
   Ogawa R, 2010, BIOCHEM BIOPH RES CO, V398, P723, DOI 10.1016/j.bbrc.2010.07.008
   Olefsky JM, 2010, ANNU REV PHYSIOL, V72, P219, DOI 10.1146/annurev-physiol-021909-135846
   Ouchi N, 2007, CLIN CHIM ACTA, V380, P24, DOI 10.1016/j.cca.2007.01.026
   Peirce V, 2014, NATURE, V510, P76, DOI 10.1038/nature13477
   Peng J, 2017, ONCOTARGET, V8, P70550, DOI 10.18632/oncotarget.19742
   Peng Y, 2016, SIGNAL TRANSDUCT TAR, V1, DOI 10.1038/sigtrans.2015.4
   Peng Z, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-2093-y
   Poy MN, 2009, P NATL ACAD SCI USA, V106, P5813, DOI 10.1073/pnas.0810550106
   Qin JJ, 2010, NATURE, V464, P59, DOI 10.1038/nature08821
   Raggi F, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01097
   Rorbach G, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25578-3
   Sergentanis TN, 2015, CL LYMPH MYELOM LEUK, V15, P563, DOI 10.1016/j.clml.2015.06.003
   Shah MY, 2011, GENOME MED, V3, DOI 10.1186/gm272
   Shaham L, 2012, LEUKEMIA, V26, P2011, DOI 10.1038/leu.2012.90
   Shamsi F, 2017, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00205
   Shao C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090167
   Sharma P, 2011, INDIAN J CLIN BIOCHE, V26, P317, DOI 10.1007/s12291-011-0175-6
   Song SD, 2013, BIOMED REP, V1, P393, DOI 10.3892/br.2013.88
   Sun L, 2014, METABOLISM, V63, P272, DOI 10.1016/j.metabol.2013.10.004
   Sun L, 2011, NAT CELL BIOL, V13, P958, DOI 10.1038/ncb2286
   Sun YM, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-6
   Svoronos AA, 2016, CANCER RES, V76, P3666, DOI 10.1158/0008-5472.CAN-16-0359
   Tan WG, 2018, ONCOL LETT, V15, P2735, DOI 10.3892/ol.2017.7638
   Togliatto G, 2016, INT J OBESITY, V40, P102, DOI 10.1038/ijo.2015.123
   Tomasetti M, 2014, ANTIOXID REDOX SIGN, V21, P2109, DOI 10.1089/ars.2013.5215
   Trajkovski M, 2012, NAT CELL BIOL, V14, P1330, DOI 10.1038/ncb2612
   Trajkovski M, 2011, NATURE, V474, P649, DOI 10.1038/nature10112
   Treiber T, 2019, NAT REV MOL CELL BIO, V20, P5, DOI 10.1038/s41580-018-0059-1
   Turati F, 2013, ANN ONCOL, V24, P609, DOI 10.1093/annonc/mds244
   Villarroya J, 2019, J ENDOCRINOL, V243, pR19, DOI 10.1530/JOE-19-0295
   Virtue A, 2017, J BIOL CHEM, V292, P1267, DOI 10.1074/jbc.M116.739839
   Virtue AT, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aav1892
   Walden TB, 2009, J CELL PHYSIOL, V218, P444, DOI 10.1002/jcp.21621
   Wang B, 2018, P NATL ACAD SCI USA, V115, P7392, DOI 10.1073/pnas.1703029115
   Wang F, 2013, ONKOLOGIE, V36, P754, DOI 10.1159/000356978
   Wang J, 2019, MOL MED REP, V19, P3403, DOI 10.3892/mmr.2019.10015
   Wang W, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389-018-0106-y
   Wankhade UD, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/2365609
   WARBURG O, 1956, SCIENCE, V124, P269
   Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246
   Weisberg SP, 2003, J CLIN INVEST, V12, P112, DOI [10.1172/JCI200319246, DOI 10.1172/JCI200319246.INTRODUCTION]
   Williams MD, 2012, EXP DIABETES RES, DOI 10.1155/2012/484696
   Withers SB, 2020, NON-CODING RNA, V6, DOI 10.3390/ncrna6010005
   Wu YY, 2017, CELL PHYSIOL BIOCHEM, V43, P945, DOI 10.1159/000481648
   Xie HM, 2009, EXPERT OPIN THER TAR, V13, P1227, DOI 10.1517/14728220903190707
   Xu G, 2015, INT J OBESITY, V39, P1523, DOI 10.1038/ijo.2015.95
   Xu XY, 2013, CELL METAB, V18, P816, DOI 10.1016/j.cmet.2013.11.001
   Yang P, 2009, EUR J CANCER, V45, P2867, DOI 10.1016/j.ejca.2009.04.019
   Ye JJ, 2014, EUR J CANCER PREV, V23, P158, DOI 10.1097/CEJ.0b013e328364f293
   Yin H, 2013, CELL METAB, V17, P210, DOI 10.1016/j.cmet.2013.01.004
   Yu J, 2014, ENDOCRINOLOGY, V155, P2155, DOI 10.1210/en.2013-2105
   Yuan F, 2019, AM J TRANSL RES, V11, P361
   Zhang HB, 2015, EMBO REP, V16, P1378, DOI 10.15252/embr.201540837
   Zhang YY, 2013, INT J MOL MED, V31, P797, DOI 10.3892/ijmm.2013.1260
   Zhang ZZ, 2018, J LIPID RES, V59, P843, DOI 10.1194/jlr.M082602
   Zhang ZP, 2011, CANCER GENET-NY, V204, P486, DOI 10.1016/j.cancergen.2011.07.004
   Zhao ZG, 2012, J INT MED RES, V40, P2041, DOI 10.1177/030006051204000601
   Zheng J, 2012, ONCOL LETT, V4, P1151, DOI 10.3892/ol.2012.928
   Zheng QL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129824
   Zhong H, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/2835761
   Zhu YJ, 2014, ACTA BIOCH BIOPH SIN, V46, P590, DOI 10.1093/abbs/gmu036
   Zhu YG, 2017, ONCOL REP, V37, P2185, DOI 10.3892/or.2017.5458
   Zhuang GQ, 2012, CIRCULATION, V125, P2892, DOI 10.1161/CIRCULATIONAHA.111.087817
   Zong WX, 2016, MOL CELL, V61, P667, DOI 10.1016/j.molcel.2016.02.011
   Zuriaga MA, 2017, FRONT CARDIOVASC MED, V4, DOI 10.3389/fcvm.2017.00027
NR 188
TC 0
Z9 0
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-2392
J9 FRONT ENDOCRINOL
JI Front. Endocrinol.
PD OCT 6
PY 2020
VL 11
AR 563816
DI 10.3389/fendo.2020.563816
PG 15
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA OC9QS
UT WOS:000579490600001
PM 33123088
OA DOAJ Gold, Green Published
DA 2020-12-15
ER

PT J
AU Pasquarelli-do-Nascimento, G
   Braz-de-Melo, HA
   Faria, SS
   Santos, ID
   Kobinger, GP
   Magalhaes, KG
AF Pasquarelli-do-Nascimento, Gabriel
   Braz-de-Melo, Heloisa Antoniella
   Faria, Sara Socorro
   Santos, Igor de Oliveira
   Kobinger, Gary P.
   Magalhaes, Kelly Grace
TI Hypercoagulopathy and Adipose Tissue Exacerbated Inflammation May
   Explain Higher Mortality in COVID-19 Patients With Obesity
SO FRONTIERS IN ENDOCRINOLOGY
LA English
DT Review
DE adipose tissue; COVID-19; Obesity; SARS-CoV-2; hypercoagulopathy; ACE-2
ID ANGIOTENSIN-CONVERTING ENZYME; ABO BLOOD-GROUP; ALDOSTERONE SYSTEM;
   INSULIN-RESISTANCE; CYTOKINE STORM; RISK-FACTORS; ACE2; LUNG;
   CORONAVIRUS; EXPRESSION
AB COVID-19, caused by SARS-CoV-2, is characterized by pneumonia, lymphopenia, exhausted lymphocytes and a cytokine storm. Several reports from around the world have identified obesity and severe obesity as one of the strongest risk factors for COVID-19 hospitalization and mechanical ventilation. Moreover, countries with greater obesity prevalence have a higher morbidity and mortality risk of developing serious outcomes from COVID-19. The understanding of how this increased susceptibility of the people with obesity to develop severe forms of the SARS-CoV-2 infection occurs is crucial for implementing appropriate public health and therapeutic strategies to avoid COVID-19 severe symptoms and complications in people living with obesity. We hypothesize here that increased ACE2 expression in adipose tissue displayed by people with obesity may increase SARS-CoV-2 infection and accessibility to this tissue. Individuals with obesity have increased white adipose tissue, which may act as a reservoir for a more extensive viral spread with increased shedding, immune activation and pro-inflammatory cytokine amplification. Here we discuss how obesity is related to a pro-inflammatory and metabolic dysregulation, increased SARS-CoV-2 host cell entry in adipose tissue and induction of hypercoagulopathy, leading people with obesity to develop severe forms of COVID-19 and also death. Taken together, it may be crucial to better explore the role of visceral adipose tissue in the inflammatory response to SARS-CoV-2 infection and investigate the potential therapeutic effect of using specific target anti-inflammatories (canakinumab or anakinra for IL-1 beta inhibition; anti-IL-6 antibodies for IL-6 inhibition), anticoagulant or anti-diabetic drugs in COVID-19 treatment of people with obesity. Defining the immunopathological changes in COVID-19 patients with obesity can provide prominent targets for drug discovery and clinical management improvement.
C1 [Pasquarelli-do-Nascimento, Gabriel; Braz-de-Melo, Heloisa Antoniella; Faria, Sara Socorro; Santos, Igor de Oliveira; Magalhaes, Kelly Grace] Univ Brasilia, Dept Cell Biol, Lab Immunol & Inflammat, Brasilia, DF, Brazil.
   [Kobinger, Gary P.] Univ Laval, Dept Microbiol Infectiol & Immunol, Quebec City, PQ, Canada.
   [Kobinger, Gary P.] Univ Laval, CHU Quebec, Ctr Rech Infectiol, Quebec City, PQ, Canada.
RP Magalhaes, KG (corresponding author), Univ Brasilia, Dept Cell Biol, Lab Immunol & Inflammat, Brasilia, DF, Brazil.
EM kellymagalhaes@unb.br
RI ; Magalhaes, Kelly Grace/A-6966-2010
OI Pasquarelli do Nascimento, Gabriel/0000-0002-8329-343X; Magalhaes, Kelly
   Grace/0000-0002-7435-5272
CR Al-Goblan AS, 2014, DIABETES METAB SYNDR, V7, P587, DOI 10.2147/DMSO.S67400
   Alessi MC, 2007, CURR OPIN LIPIDOL, V18, P240, DOI 10.1097/MOL.0b013e32814e6d29
   Alikhan R, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003747.pub4
   Anfossi G, 2009, NUTR METAB CARDIOVAS, V19, P440, DOI 10.1016/j.numecd.2009.01.006
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14768, 10.1111/jth.14820]
   Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326
   Athale S, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf9194
   Bader M, 2008, J MOL MED, V86, P615, DOI 10.1007/s00109-008-0336-0
   Barale C, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21020623
   Barrachina MN, 2019, ATHEROSCLEROSIS, V281, P62, DOI 10.1016/j.atherosclerosis.2018.12.023
   Barrasa H, 2020, ANAESTH CRIT CARE PA, V39, P553, DOI 10.1016/j.accpm.2020.04.001
   Beavers CJ, 2015, THROMB RES, V136, P712, DOI 10.1016/j.thromres.2015.07.015
   Bhala N, 2013, LANCET, V382, P769, DOI 10.1016/S0140-6736(13)60900-9
   Boini KM, 2017, FRONT BIOSCI-LANDMRK, V22, P96, DOI 10.2741/4474
   Borghi F, 2016, CELL TISSUE RES, V366, P543, DOI 10.1007/s00441-016-2515-6
   Boros LG, 2002, MOL GENET METAB, V77, P230, DOI 10.1016/S1096-7192(02)00140-3
   Brown JD, 2020, LANCET RESP MED, V8, pE28, DOI 10.1016/S2213-2600(20)30158-2
   Campello E, 2015, THROMB HAEMOSTASIS, V113, P85, DOI 10.1160/TH14-02-0156
   CDC, 2020, PEOPL WHO AR HIGH RI, P4
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Chen Q., 2019, J SENSORS, V2019, P1, DOI DOI 10.1007/s15010-020-01432-5
   Cinatl J, 2003, LANCET, V362, P293, DOI 10.1016/S0140-6736(03)13973-6
   Cinti S, 2005, J LIPID RES, V46, P2347, DOI 10.1194/jlr.M500294-JLR200
   Connors JM, 2020, BLOOD, V135, P2033, DOI 10.1182/blood.2020006000
   Csige I, 2018, J DIABETES RES, V2018, DOI 10.1155/2018/3407306
   Deng GT, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02902-w
   DePergola G, 1997, INT J OBESITY, V21, P527, DOI 10.1038/sj.ijo.0800435
   Dhurandhar NV, 2015, OBES REV, V16, P1017, DOI 10.1111/obr.12320
   Dominguez-Cherit G, 2009, JAMA-J AM MED ASSOC, V302, P1880, DOI 10.1001/jama.2009.1536
   Donoghue M, 2000, CIRC RES, V87, pE1, DOI 10.1161/01.res.87.5.e1
   Ellinghaus D, 2020, NEW ENGL J MED, V383, P1522, DOI 10.1056/NEJMoa2020283
   Elliot JG, 2019, EUR RESPIR J, V54, DOI 10.1183/13993003.00857-2019
   Emanuela F, 2012, J NUTR METAB, V2012, DOI 10.1155/2012/476380
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Feldmann M, 2020, LANCET, V395, P1407, DOI 10.1016/S0140-6736(20)30858-8
   Fensterl V, 2009, BIOFACTORS, V35, P14, DOI 10.1002/biof.6
   Finer N, 2020, CLIN OBES, V10, DOI 10.1111/cob.12365
   Flint SW, 2020, LANCET DIABETES ENDO, V8, P474, DOI 10.1016/S2213-8587(20)30156-X
   Franchini M, 2014, THROMB HAEMOSTASIS, V112, P1103, DOI 10.1160/TH14-05-0457
   Frantzeskaki F, 2017, RESPIRATION, V93, P212, DOI 10.1159/000453002
   Gardner EM, 2011, ANNU REV NUTR, V31, P353, DOI 10.1146/annurev-nutr-081810-160812
   Gentile P, 2019, J CLIN MED, V8, DOI 10.3390/jcm8060855
   Gordon-Larsen P, 2018, CIRCULATION, V137, P1543, DOI 10.1161/CIRCULATIONAHA.118.032780
   Grillet F, 2020, RADIOLOGY, V296, pE186, DOI 10.1148/radiol.2020201544
   Haga S, 2008, P NATL ACAD SCI USA, V105, P7809, DOI 10.1073/pnas.0711241105
   Halpin DMG, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.01009-2020
   Hamming I, 2007, J PATHOL, V212, P1, DOI 10.1002/path.2162
   Hemalatha Rajkumar PB, 2013, ENDOCRINOL METAB SYN, V2, P113, DOI [10.4172/2161-1017.1000113, DOI 10.4172/2161-1017.1000113]
   Hensley LE, 2004, EMERG INFECT DIS, V10, P317, DOI 10.3201/eid1002.030482
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hotamisligil GS, 2006, NATURE, V444, P860, DOI 10.1038/nature05485
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DS, 2018, AM J RESP CRIT CARE, V197, P700, DOI 10.1164/rccm.201712-2371ED
   Hussell T, 2001, EUR J IMMUNOL, V31, P2566, DOI 10.1002/1521-4141(200109)31:9<2566::AID-IMMU2566>3.0.CO;2-L
   Iacobellis G, 2015, NAT REV ENDOCRINOL, V11, P363, DOI 10.1038/nrendo.2015.58
   Iba T, 2020, J THROMB HAEMOST, V18, P2103, DOI 10.1111/jth.14975
   Ibricevic A, 2006, J VIROL, V80, P7469, DOI 10.1128/JVI.02677-05
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Jaganjac M, 2017, REDOX BIOL, V12, P483, DOI 10.1016/j.redox.2017.03.012
   Jiang SZ, 2016, EXP THER MED, V12, P2395, DOI 10.3892/etm.2016.3667
   Jing F, 2013, MOL CELL ENDOCRINOL, V378, P23, DOI 10.1016/j.mce.2012.03.005
   Jose RJ, 2019, LANCET RESP MED, V2019, P2019, DOI [10.1016/S2213-26002030216-2, DOI 10.1016/S2213-26002030216-2]
   Kanda H, 2006, J CLIN INVEST, V116, P1494, DOI 10.1172/JCI26498
   Kass DA, 2020, LANCET, V395, P1544, DOI 10.1016/S0140-6736(20)31024-2
   Katz JN, 2011, CHEST, V139, P658, DOI 10.1378/chest.10-1971
   Kawabe Y, 2019, AM J PHYSIOL-ENDOC M, V317, pE1140, DOI 10.1152/ajpendo.00311.2019
   Kawano Y, 2016, CELL METAB, V24, P295, DOI 10.1016/j.cmet.2016.07.009
   Kim ES, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e142
   Kim YH, 2012, J INFECT DIS, V205, P244, DOI 10.1093/infdis/jir731
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Klonoff DC, 2020, METABOLISM, V108, DOI 10.1016/j.metabol.2020.154224
   Kruger P, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004651
   Kruglikov IL, 2020, OBESITY, V28, P1187, DOI 10.1002/oby.22856
   Kuba K, 2006, J MOL MED, V84, P814, DOI 10.1007/s00109-006-0094-9
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Lauby-Secretan B, 2016, NEW ENGL J MED, V375, P794, DOI 10.1056/NEJMsr1606602
   Lee AW, 2019, HIST PHOTOGR, V43, P422, DOI 10.1080/03087298.2019.1789298
   Leng ZK, 2020, AGING DIS, V11, P216, DOI 10.14336/AD.2020.0228
   Levi M, 2012, SEMIN THROMB HEMOST, V38, P506, DOI 10.1055/s-0032-1305782
   Lighter J, 2020, CLIN INFECT DIS, V71, P896, DOI 10.1093/cid/ciaa415
   Lippi G, 2020, RESP MED, V167, DOI 10.1016/j.rmed.2020.105941
   Lippi G, 2020, CLIN CHIM ACTA, V506, P145, DOI 10.1016/j.cca.2020.03.022
   LITTLE P, 2013, BMJ-BRIT MED J, V347, DOI DOI 10.1136/BMJ.F6041
   Little P, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1185
   Liu BW, 2020, J AUTOIMMUN, V111, DOI 10.1016/j.jaut.2020.102452
   Liu PP, 2020, CIRCULATION, V142, P68, DOI 10.1161/CIRCULATIONAHA.120.047549
   Liumbruno GM, 2013, BLOOD TRANSFUS-ITALY, V11, P491, DOI 10.2450/2013.0152-13
   Louie JK, 2011, CLIN INFECT DIS, V52, P301, DOI 10.1093/cid/ciq152
   Lumeng CN, 2007, J CLIN INVEST, V117, P175, DOI 10.1172/JCI29881
   Luo Y, 2019, HYPERTENS RES, V42, P681, DOI 10.1038/s41440-018-0166-6
   Luther JM, 2011, DIABETOLOGIA, V54, P2152, DOI 10.1007/s00125-011-2158-9
   Luzi L, 2020, ACTA DIABETOL, V57, P759, DOI 10.1007/s00592-020-01522-8
   Maier HE, 2018, J INFECT DIS, V218, P1378, DOI 10.1093/infdis/jiy370
   Malavazos AE, 2020, EUR HEART J, V41, P2333, DOI 10.1093/eurheartj/ehaa471
   Mancuso P, 2010, J APPL PHYSIOL, V108, P722, DOI 10.1152/japplphysiol.00781.2009
   Matsuyama S., 2020, BIORXIV, DOI [10.1101/2020.03.11.987016, DOI 10.1101/2020.03.11.987016]
   Matthews VB, 2010, DIABETOLOGIA, V53, P2431, DOI 10.1007/s00125-010-1865-y
   McClean KM, 2008, THORAX, V63, P649, DOI 10.1136/thx.2007.086801
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Meng J, 2020, EMERG MICROBES INFEC, V9, P757, DOI 10.1080/22221751.2020.1746200
   Merad M, 2020, NAT REV IMMUNOL, V20, P355, DOI 10.1038/s41577-020-0331-4
   Milner JJ, 2016, PHYSIOL BEHAV, V176, P139, DOI [10.1016/j.physbeh.2017.03.040, DOI 10.1016/J.PHYSBEH.2017.03.040]
   Mirsoian A, 2014, J EXP MED, V211, P2373, DOI 10.1084/jem.20140116
   Mousavi S, 2015, ADV PHARMACOL SCI, V2015, DOI 10.1155/2015/507151
   Murira A, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00609
   Mycroft-West C.J., 2020, BIORXIV, DOI [10.1101/2020.04.28.066761, DOI 10.1101/2020.04.28.066761]
   Ni YN, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2395-8
   Nieuwdorp M, 2005, CURR OPIN PHARMACOL, V5, P155, DOI 10.1016/j.coph.2004.10.003
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Pacurari M, 2014, INT J INFLAMM, V2014, DOI 10.1155/2014/689360
   Painter SD, 2015, VACCINE, V33, P4422, DOI 10.1016/j.vaccine.2015.06.101
   Pal R, 2020, DIABETES RES CLIN PR, V163, DOI 10.1016/j.diabres.2020.108146
   Panigada M, 2020, J THROMB HAEMOST, V18, P1738, DOI 10.1111/jth.14850
   Park HL, 2014, HUM VACC IMMUNOTHER, V10, P1181, DOI 10.4161/hv.28332
   Pate VB, 2016, DIABETES, V65, P85, DOI 10.2337/db15-0399
   Patel VB, 2016, CIRC RES, V118, P1313, DOI 10.1161/CIRCRESAHA.116.307708
   Peters MC, 2020, AM J RESP CRIT CARE, V202, P83, DOI 10.1164/rccm.202003-0821OC
   Petrakis D, 2020, MOL MED REP, V22, P9, DOI 10.3892/mmr.2020.11127
   Qu R, 2020, J MED VIROL, V92, P1533, DOI 10.1002/jmv.25767
   Raiko JRH, 2012, ATHEROSCLEROSIS, V224, P208, DOI 10.1016/j.atherosclerosis.2012.06.062
   Ranucci M, 2020, J THROMB HAEMOST, V18, P1747, DOI 10.1111/jth.14854
   Rao ST, 2020, DIABETES CARE, V43, P1416, DOI 10.2337/dc20-0643
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.6775, 10.1001/jama.2020.7681]
   Prestes TRR, 2017, CURR DRUG TARGETS, V18, P1301, DOI 10.2174/1389450117666160727142401
   Rodriguez-Hernandez H, 2013, INT J ENDOCRINOL, DOI 10.1155/2013/678159
   Romani-Perez M, 2015, ENDOCRINOLOGY, V156, P3559, DOI 10.1210/en.2014-1685
   Rossi GP, 2020, ELIFE, V9, DOI 10.7554/eLife.57278
   Roumier M., 2020, INTERLEUKIN 6 BLOCKA, DOI [10.1101/2020.04.20.20061861., DOI 10.1101/2020.04.20.20061861, 10.1101/2020.04.20.20061861]
   Rubin JE, 2020, ANN INTERN MED, V172, pITC1, DOI 10.7326/AITC202001070
   Russell B, 2020, ECANCERMEDICALSCIENC, V14, DOI 10.3332/ecancer.2020.1023
   Sallard E, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104791
   Saltiel AR, 2017, J CLIN INVEST, V127, P1, DOI [10.1172/JCI92035, 10.1172/jci92035]
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Sarwar R, 2018, DIABET METAB SYND OB, V11, P533, DOI 10.2147/DMSO.S146339
   Savioli F, 2020, EINSTEIN-SAO PAULO, V18, DOI [10.31744/einstein_journal/2020ED5758, 10.31744/einstein_journal/2020ed5758]
   Schmidt FM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121971
   Sencan I, 2020, TURK J MED SCI, V50, P534, DOI 10.3906/sag-2004-21
   Sheridan PA, 2012, INT J OBESITY, V36, P1072, DOI 10.1038/ijo.2011.208
   Shimizu I, 2015, CURR OBES REP, V4, P224, DOI 10.1007/s13679-015-0157-8
   Shirato K, 2018, VIROLOGY, V517, P9, DOI 10.1016/j.virol.2017.11.012
   Shirato K, 2017, J VIROL, V91, DOI [10.1128/JVI.01387-16, 10.1128/jvi.01387-16]
   Simonnet A, 2020, OBESITY, V28, P1195, DOI 10.1002/oby.22831
   Skurk T, 2004, INT J OBESITY, V28, P1357, DOI 10.1038/sj.ijo.0802778
   Smith AG, 2007, J NUTR, V137, P1236
   Song J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132626
   Spiezia L, 2020, THROMB HAEMOSTASIS, V120, P998, DOI 10.1055/s-0040-1710018
   Stolarczyk E, 2017, CURR OPIN PHARMACOL, V37, P35, DOI 10.1016/j.coph.2017.08.006
   Sungnak W, 2020, NAT MED, V26, P681, DOI 10.1038/s41591-020-0868-6
   Tchernof A, 2013, PHYSIOL REV, V93, P359, DOI 10.1152/physrev.00033.2011
   Teran-Cabanillas E, 2017, INFLAMMATION, V40, P58, DOI 10.1007/s10753-016-0452-x
   Teran-Cabanillas E, 2013, NUTRITION, V29, P207, DOI 10.1016/j.nut.2012.04.019
   Terpos E, 2020, AM J HEMATOL, V95, P834, DOI 10.1002/ajh.25829
   Tikoo K, 2015, BIOCHEM PHARMACOL, V93, P343, DOI 10.1016/j.bcp.2014.11.013
   Tipnis SR, 2000, J BIOL CHEM, V275, P33238, DOI 10.1074/jbc.M002615200
   Tsatsanis C, 2010, J INFECT DIS, V202, P459, DOI 10.1086/653842
   Ulhaq ZS, 2020, MED MALADIES INFECT, V50, P382, DOI 10.1016/j.medmal.2020.04.002
   Upadhyay J, 2018, MED CLIN N AM, V102, P13, DOI 10.1016/j.mcna.2017.08.004
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   Valencak TG, 2017, REDOX BIOL, V12, P806, DOI 10.1016/j.redox.2017.04.012
   van der Meijden PEJ, 2019, NAT REV CARDIOL, V16, P166, DOI 10.1038/s41569-018-0110-0
   Vardhana SA, 2020, J EXP MED, V217, DOI 10.1084/jem.20200678
   Velloso LA, 1996, P NATL ACAD SCI USA, V93, P12490, DOI 10.1073/pnas.93.22.12490
   Vickers C, 2002, J BIOL CHEM, V277, P14838, DOI 10.1074/jbc.M200581200
   Vilahur G, 2017, CARDIOVASC RES, V113, P1046, DOI 10.1093/cvr/cvx086
   Wagner PD, 2015, EUR RESPIR J, V45, P227, DOI 10.1183/09031936.00039214
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wan YL, 2020, LANCET GASTROENTEROL, V5, P534, DOI 10.1016/S2468-1253(20)30118-7
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Williams AE, 2012, IMMUNOLOGY: MUCOSAL AND BODY SURFACE DEFENCES, P302
   Witkowski M, 2016, TRENDS CARDIOVAS MED, V26, P297, DOI 10.1016/j.tcm.2015.12.001
   World Health Organization, 2020, RAT US PERS PROT EQ, P1
   World Obesity Federation, 2020, COR COVID 19 OB, P5
   Xia S, 2020, CELL RES, V30, P343, DOI 10.1038/s41422-020-0305-x
   Xie Y., 2020, RADIOL CARDIOTHORAC, V2, DOI [DOI 10.1148/RYCT.2020200067, 10.1148/ryct.2020200067]
   Xiong M, 2020, BRIT J HAEMATOL, V189, P1050, DOI 10.1111/bjh.16725
   Xu H, 2020, INT J ORAL SCI, V12, DOI 10.1038/s41368-020-0074-x
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Xydakis MS, 2020, LANCET INFECT DIS, V20, P1015, DOI 10.1016/S1473-3099(20)30293-0
   Yan TT, 2020, FASEB J, V34, P6017, DOI 10.1096/fj.202000782
   Yang LL, 2020, CELL STEM CELL, V27, P125, DOI 10.1016/j.stem.2020.06.015
   Yang XH, 2007, COMPARATIVE MED, V57, P450
   Yao XH, 2020, CELL RES, V30, P541, DOI 10.1038/s41422-020-0318-5
   Bello-Chavolla OY, 2020, J CLIN ENDOCR METAB, V105, P2752, DOI 10.1210/clinem/dgaa346
   Ye L, 2019, J VIROL, V93, DOI [10.1128/JVI.01262-13, 10.1128/JVI.01262-19]
   Yuan L, 2010, J ENDOCRINOL INVEST, V33, P13, DOI 10.1007/BF03346544
   Zha L, 2020, MED J AUSTRALIA, V212, P416, DOI 10.5694/mja2.50577
   Zhang KZ, 2008, NATURE, V454, P455, DOI 10.1038/nature07203
   Zhang P, 2020, CIRC RES, V126, P1671, DOI 10.1161/CIRCRESAHA.120.317134
   Zhang Weihua, 2014, ADV NURSING, V2014, P1, DOI DOI 10.1155/2014/125707
   Zhao J., 2020, RELATIONSHIP ABO BLO, DOI [10.1101/2020.03.11.20031096, DOI 10.1101/2020.03.11.20031096]
   Zhao L, 2020, OBESITY, V28, P1367, DOI 10.1002/oby.22867
   Zheng KI, 2020, METABOLISM, V108, DOI 10.1016/j.metabol.2020.154244
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu YY, 2020, SINGLE CELL ANAL ACE, DOI [10.20944/preprints202002.0221.v1, DOI 10.20944/PREPRINTS202002.0221.V1]
   Zietz Michael, 2020, medRxiv, DOI 10.1101/2020.04.08.20058073
   Zou X, 2020, FRONT MED-PRC, V14, P185, DOI 10.1007/s11684-020-0754-0
NR 197
TC 2
Z9 2
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-2392
J9 FRONT ENDOCRINOL
JI Front. Endocrinol.
PD JUL 28
PY 2020
VL 11
AR 530
DI 10.3389/fendo.2020.00530
PG 16
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA NC6ZL
UT WOS:000561365400001
PM 32849309
OA DOAJ Gold, Green Published
DA 2020-12-15
ER

PT J
AU Faria, SS
   Correa, LH
   Heyn, GS
   de Sant'Ana, LP
   Almeida, RD
   Magalhaes, KG
AF Faria, Sara Socorro
   Correa, Luis Henrique
   Heyn, Gabriella Simoes
   de Sant'Ana, Livia Pimentel
   Almeida, Raquel das Neves
   Magalhaes, Kelly Grace
TI Obesity and Breast Cancer: The Role of Check fur updates of Crown-Like
   Structures in Breast Adipose Tissue in Tumor Progression, Prognosis, and
   Therapy
SO JOURNAL OF BREAST CANCER
LA English
DT Review
DE Adipocytes; Adipose tissue; Breast neoplasms; Macrophages; Obesity
ID ELEVATED AROMATASE EXPRESSION; BODY-MASS INDEX; METABOLICALLY HEALTHY;
   MOUSE MODEL; HIGH-FAT; INFLAMMATION; MACROPHAGES; RISK; WOMEN;
   DYSFUNCTION
AB Obesity is associated with increased risk and aggressiveness of many types of cancer. Women with obesity and breast cancer are more likely to be diagnosed with larger and higher-grade tumors and have higher incidence of metastases than lean individuals. Increasing evidence indicates that obesity includes systemic, chronic low-grade inflammation, and that adipose tissue can act as an important endocrine site, secreting a variety of substances that may regulate inflammation, immune response, and cancer predisposition. Obesity-associated inflammation appears to be initially mediated by macrophage infiltration into adipose tissue. Macrophages can surround damaged or necrotic adipocytes, forming "crown-like" structures (CLS). CLS are increased in breast adipose tissue from breast cancer patients and are more abundant in patients with obesity conditions. Moreover, the CLS index-ratio from individuals with obesity seems to influence breast cancer recurrence rates and survival. In this review, we discuss the most recent cellular and molecular mechanisms involved in CLS establishment in the white adipose tissue of women with obesity and their implications for breast cancer biology. We also explain how CLS influence the tumor microenvironment and affect breast cancer behavior. Targeting breast adipose tissue CLS can be a crucial therapeutic tool in cancer treatment, especially in patients with obesity.
C1 [Faria, Sara Socorro; Correa, Luis Henrique; Heyn, Gabriella Simoes; de Sant'Ana, Livia Pimentel; Almeida, Raquel das Neves; Magalhaes, Kelly Grace] Univ Brasilia, Dept Cell Biol, Lab Immunol & Inflammat, BR-70910900 Brasilia, DF, Brazil.
RP Magalhaes, KG (corresponding author), Univ Brasilia, Dept Cell Biol, Lab Immunol & Inflammat, BR-70910900 Brasilia, DF, Brazil.
EM kellymagalhaes@unb.br
RI ; Magalhaes, Kelly Grace/A-6966-2010
OI Heyn, Gabriella Simoes/0000-0001-7120-1086; Sant'Ana,
   Livia/0000-0003-2448-3927; Magalhaes, Kelly Grace/0000-0002-7435-5272
CR Arwert EN, 2018, CELL REP, V23, P1239, DOI 10.1016/j.celrep.2018.04.007
   Berstein LM, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064-016-3582-6
   Bhardwaj P, 2019, CARCINOGENESIS, V40, P914, DOI 10.1093/carcin/bgz088
   Bhardwaj P, 2015, CANCER PREV RES, V8, P751, DOI 10.1158/1940-6207.CAPR-15-0082
   Blucher C, 2017, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00293
   Bluher M, 2014, EUR J ENDOCRINOL, V171, pR209, DOI 10.1530/EJE-14-0540
   Bowers LW, 2015, BREAST CANCER RES TR, V149, P49, DOI 10.1007/s10549-014-3223-0
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Brown KA, 2017, J CLIN ENDOCR METAB, V102, P1692, DOI 10.1210/jc.2016-3606
   Castoldi A, 2016, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00637
   Cha YJ, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092102
   Cha YJ, 2018, BREAST CANCER RES TR, V170, P15, DOI 10.1007/s10549-018-4722-1
   Choi B, 2016, INT ARCH OCC ENV HEA, V89, P435, DOI 10.1007/s00420-015-1082-6
   Cildir G, 2013, TRENDS MOL MED, V19, P487, DOI 10.1016/j.molmed.2013.05.001
   Cinti S, 2005, PROSTAG LEUKOTR ESS, V73, P9, DOI 10.1016/j.plefa.2005.04.010
   Cinti S, 2005, J LIPID RES, V46, P2347, DOI 10.1194/jlr.M500294-JLR200
   Cinti S, 2001, P NUTR SOC, V60, P319, DOI 10.1079/PNS200192
   Cinti S, 2018, COMPR PHYSIOL, V8, P1357, DOI 10.1002/cphy.c170042
   Cleary MP, 2009, ENDOCRINOLOGY, V150, P2537, DOI 10.1210/en.2009-0070
   Correa LH, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8070662
   Correa LH, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01129
   Coughlin SS, 2019, ADV EXP MED BIOL, V1152, P9, DOI 10.1007/978-3-030-20301-6_2
   Cowen S, 2015, CANCERS, V7, P1125, DOI 10.3390/cancers7030828
   Crewe C, 2017, J CLIN INVEST, V127, P74, DOI 10.1172/JCI88883
   Paixao EMD, 2017, NUTR J, V16, DOI 10.1186/s12937-017-0295-9
   Fabian CJ, 2015, CANCER PREV RES, V8, P912, DOI 10.1158/1940-6207.CAPR-14-0335
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Geyer FC, 2017, AM J PATHOL, V187, P2139, DOI 10.1016/j.ajpath.2017.03.016
   Giles ED, 2012, CANCER RES, V72, P6490, DOI 10.1158/0008-5472.CAN-12-1653
   Giordano A, 2013, J LIPID RES, V54, P2423, DOI 10.1194/jlr.M038638
   Gonzalez-Muniesa P, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.34
   Goodwin PJ, 2015, ANNU REV MED, V66, P281, DOI 10.1146/annurev-med-051613-012328
   Greenlee H, 2019, CANCER PREV RES, V12, P21, DOI 10.1158/1940-6207.CAPR-18-0207
   Henninger AMJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105262
   Hotamisligil GS, 2017, NATURE, V542, P177, DOI 10.1038/nature21363
   HOTAMISLIGIL GS, 1994, P NATL ACAD SCI USA, V91, P4854, DOI 10.1073/pnas.91.11.4854
   Howe LR, 2013, CLIN CANCER RES, V19, P6074, DOI 10.1158/1078-0432.CCR-12-2603
   Hubler MJ, 2015, TRENDS ENDOCRIN MET, V26, P101, DOI 10.1016/j.tem.2014.12.005
   Itoh M, 2011, INT J INFLAMM, V2011, DOI 10.4061/2011/720926
   Iyengar NM, 2018, CANCER PREV RES, V11, P227, DOI 10.1158/1940-6207.CAPR-17-0283
   Iyengar NM, 2017, CANCER PREV RES, V10, P235, DOI 10.1158/1940-6207.CAPR-16-0314
   Iyengar NM, 2016, J CLIN ONCOL, V34, P4270, DOI 10.1200/JCO.2016.67.4283
   Iyengar NM, 2015, CANCER PREV RES, V8, P349, DOI 10.1158/1940-6207.CAPR-14-0243
   Iyengar Neil M, 2013, Am Soc Clin Oncol Educ Book, P46, DOI 10.1200/EdBook_AM.2013.33.46
   Jankovic N, 2017, CANCER EPIDEM BIOMAR, V26, P136, DOI 10.1158/1055-9965.EPI-16-0428
   Jung UJ, 2014, INT J MOL SCI, V15, P6184, DOI 10.3390/ijms15046184
   Kang YE, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154003
   Khadge S, 2018, J MAMMARY GLAND BIOL, V23, P43, DOI 10.1007/s10911-018-9391-5
   Khan T, 2009, MOL CELL BIOL, V29, P1575, DOI 10.1128/MCB.01300-08
   Koru-Sengul T, 2016, BREAST CANCER RES TR, V158, P113, DOI 10.1007/s10549-016-3847-3
   Kratz M, 2014, CELL METAB, V20, P614, DOI 10.1016/j.cmet.2014.08.010
   Kyrgiou M, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/bmj.j477
   Lade A, 2014, CURR OPIN ONCOL, V26, P100, DOI 10.1097/CCO.0000000000000042
   Langin D, 2011, CELL METAB, V14, P569, DOI 10.1016/j.cmet.2011.10.003
   Lees T, 2018, ENDOCR-RELAT CANCER, V25, P773, DOI 10.1530/ERC-17-0407
   Lewis CE, 2006, CANCER RES, V66, P605, DOI 10.1158/0008-5472.CAN-05-4005
   Lumeng CN, 2007, J CLIN INVEST, V117, P175, DOI 10.1172/JCI29881
   Lumeng CN, 2008, DIABETES, V57, P3239, DOI 10.2337/db08-0872
   Mantovani A, 2010, CURR OPIN IMMUNOL, V22, P231, DOI 10.1016/j.coi.2010.01.009
   McWhorter FY, 2013, P NATL ACAD SCI USA, V110, P17253, DOI 10.1073/pnas.1308887110
   Medrek C, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-306
   Miyazawa M, 2018, CANCER PREV RES, V11, P215, DOI 10.1158/1940-6207.CAPR-17-0296
   Morris PG, 2011, CANCER PREV RES, V4, P1021, DOI 10.1158/1940-6207.CAPR-11-0110
   Mullooly M, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058-016-0791-4
   Murano I, 2008, J LIPID RES, V49, P1562, DOI 10.1194/jlr.M800019-JLR200
   Murano I, 2013, NUTR METAB CARDIOVAS, V23, P723, DOI 10.1016/j.numecd.2012.03.005
   Nieman KM, 2013, BBA-MOL CELL BIOL L, V1831, P1533, DOI 10.1016/j.bbalip.2013.02.010
   Noy R, 2014, IMMUNITY, V41, P49, DOI 10.1016/j.immuni.2014.06.010
   Oh CM, 2014, ASIAN PAC J CANCER P, V15, P10027, DOI 10.7314/APJCP.2014.15.22.10027
   Onitilo AA, 2009, CLIN MED RES, V7, P4, DOI 10.3121/cmr.2009.825
   Parikh AM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183515
   Phillips CM, 2013, REV ENDOCR METAB DIS, V14, P219, DOI 10.1007/s11154-013-9252-x
   Picon-Ruiz M, 2017, CA-CANCER J CLIN, V67, P379, DOI 10.3322/caac.21405
   Pizato N, 2019, NUTRIENTS, V11, DOI 10.3390/nu11061199
   Pizato N, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20422-0
   Quail DF, 2019, NAT REV ENDOCRINOL, V15, P139, DOI 10.1038/s41574-018-0126-x
   Quail DF, 2017, NAT CELL BIOL, V19, P974, DOI 10.1038/ncb3578
   Reilly SM, 2017, NAT REV ENDOCRINOL, V13, P633, DOI 10.1038/nrendo.2017.90
   Rossi EL, 2018, MOL CARCINOGEN, V57, P393, DOI [10.1002/, 10.1002/mc.22763]
   Saltiel AR, 2017, J CLIN INVEST, V127, P1, DOI [10.1172/JCI92035, 10.1172/jci92035]
   Samocha-Bonet D, 2014, OBES REV, V15, P697, DOI 10.1111/obr.12199
   Scherer PE, 2016, DIABETES, V65, P1452, DOI 10.2337/db16-0339
   Seo BR, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010467
   Shapouri-Moghaddam A, 2018, J CELL PHYSIOL, V233, P6425, DOI 10.1002/jcp.26429
   Shaul ME, 2010, DIABETES, V59, P1171, DOI 10.2337/db09-1402
   Sini V, 2014, BRIT J CANCER, V110, P1133, DOI 10.1038/bjc.2014.2
   Soguel L, 2017, EUR J CANCER PREV, V26, P511, DOI 10.1097/CEJ.0000000000000310
   Sousa S, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0621-0
   Springer NL, 2019, AM J PATHOL, V189, P2019, DOI 10.1016/j.ajpath.2019.06.005
   Stefan N, 2013, LANCET DIABETES ENDO, V1, P152, DOI 10.1016/S2213-8587(13)70062-7
   Subbaramaiah K, 2012, CANCER DISCOV, V2, P356, DOI 10.1158/2159-8290.CD-11-0241
   Subbaramaiah K, 2011, CANCER PREV RES, V4, P329, DOI 10.1158/1940-6207.CAPR-10-0381
   Surmi BK, 2008, FUTURE LIPIDOL, V3, P545, DOI 10.2217/17460875.3.5.545
   Tiwari P, 2019, J EXP MED, V216, P1345, DOI 10.1084/jem.20181616
   Vaysse C, 2017, NPJ BREAST CANCER, V3, DOI 10.1038/s41523-017-0015-9
   Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246
   Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451
   Xu XY, 2013, CELL METAB, V18, P816, DOI 10.1016/j.cmet.2013.11.001
NR 98
TC 1
Z9 1
U1 0
U2 0
PU KOREAN BREAST CANCER SOC
PI SEOUL
PA 163 SINMUNRO 1-GA JONGRO-GU, OFFICIA  BUILDING, SUITE 2024, SEOUL,
   110-999, SOUTH KOREA
SN 1738-6756
EI 2092-9900
J9 J BREAST CANCER
JI J. Breast Canc.
PD JUN
PY 2020
VL 23
IS 3
BP 233
EP 245
DI 10.4048/jbc.2020.23.e35
PG 13
WC Oncology
SC Oncology
GA MC6EE
UT WOS:000543376900001
PM 32595986
OA DOAJ Gold, Green Published
DA 2020-12-15
ER

PT J
AU Almeida, RD
   Braz-de-Melo, HA
   Santos, ID
   Correa, R
   Kobinger, GP
   Magalhaes, KG
AF Almeida, Raquel das Neves
   Braz-de-Melo, Heloisa Antoniella
   Santos, Igor de Oliveira
   Correa, Rafael
   Kobinger, Gary P.
   Magalhaes, Kelly Grace
TI The Cellular Impact of the ZIKA Virus on Male Reproductive Tract
   Immunology and Physiology
SO CELLS
LA English
DT Review
DE Sertoli cells; Leydig cells; ZIKA virus; arboviruses; infertility
ID BLOOD-TESTIS BARRIER; SEXUAL TRANSMISSION; IMMUNE PRIVILEGE; MAST-CELLS;
   GERM-CELLS; CROSS-TALK; INFECTION; SERTOLI; IDENTIFICATION; VACCINE
AB Zika virus (ZIKV) has been reported by several groups as an important virus causing pathological damage in the male reproductive tract. ZIKV can infect and persist in testicular somatic and germ cells, as well as spermatozoa, leading to cell death and testicular atrophy. ZIKV has also been detected in semen samples from ZIKV-infected patients. This has huge implications for human reproduction. Global scientific efforts are being applied to understand the mechanisms related to arboviruses persistency, pathogenesis, and host cellular response to suggest a potential target to develop robust antiviral therapeutics and vaccines. Here, we discuss the cellular modulation of the immunologic and physiologic properties of the male reproductive tract environment caused by arboviruses infection, focusing on ZIKV. We also present an overview of the current vaccine effects and therapeutic targets against ZIKV infection that may impact the testis and male fertility.
C1 [Almeida, Raquel das Neves; Braz-de-Melo, Heloisa Antoniella; Santos, Igor de Oliveira; Correa, Rafael; Magalhaes, Kelly Grace] Univ Brasilia, Dept Cell Biol, Lab Immunol & Inflammat, BR-70910900 Brasilia, DF, Brazil.
   [Kobinger, Gary P.] Univ Laval, Dept Microbiol Infectiol & Immunol, Quebec City, PQ G1V 4G2, Canada.
   [Kobinger, Gary P.] Univ Laval, Ctr Rech Infectiol, CHU Quebec, Quebec City, PQ G1V 4G2, Canada.
RP Magalhaes, KG (corresponding author), Univ Brasilia, Dept Cell Biol, Lab Immunol & Inflammat, BR-70910900 Brasilia, DF, Brazil.
EM raquel.unb.bio@gmail.com; heloisa.antoniella@gmail.com;
   igorosantosbio@gmail.com; rafaelcorrea31@gmail.com;
   Gary.Kobinger@crchudequebec.ulaval.ca; kellymagalhaes@unb.br
RI ; Magalhaes, Kelly Grace/A-6966-2010
OI Braz de Melo, Heloisa Antoniella/0000-0003-3327-4633; Magalhaes, Kelly
   Grace/0000-0002-7435-5272; SANTOS, IGOR/0000-0001-6036-6694; Correa,
   Rafael/0000-0003-2989-2383
CR Abbink P, 2018, NAT REV MICROBIOL, V16, P594, DOI 10.1038/s41579-018-0039-7
   Abbink P, 2016, SCIENCE, V353, P1129, DOI 10.1126/science.aah6157
   Almeida RD, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6030062
   Alves MG, 2013, TISSUE BARRIERS, V1, DOI 10.4161/tisb.23992
   Alves MG, 2013, CELL MOL LIFE SCI, V70, P777, DOI 10.1007/s00018-012-1079-1
   Cardona-Ospina JA, 2018, INT J INFECT DIS, V76, P126, DOI 10.1016/j.ijid.2018.08.022
   Atkinson B, 2016, EMERG INFECT DIS, V22, P940, DOI 10.3201/eid2205.160107
   Ayres CFJ, 2016, LANCET INFECT DIS, V16, P278, DOI 10.1016/S1473-3099(16)00073-6
   Bagasra O, 2017, APPL IMMUNOHISTO M M, V25, P679, DOI 10.1097/PAI.0000000000000580
   Barbosa CM, 2018, EMERG INFECT DIS, V24, P176, DOI 10.3201/eid2401.171310
   Beaver JT, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01640
   Bhushan S, 2009, J REPROD IMMUNOL, V83, P164, DOI 10.1016/j.jri.2009.07.007
   Brault AC, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15039-8
   Cao-Lormeau VM, 2014, EMERG INFECT DIS, V20, P1085, DOI 10.3201/eid2006.140138
   Carlos A., 2016, IDCASES, V6, P100
   Cassuto NG, 2018, J GYNECOL OBSTET HUM, V47, P211, DOI 10.1016/j.jogoh.2018.02.004
   Center for Disease Control and Prevention CDC, CDC 1 FEM TO MAL SEX
   Cheng CY, 2012, PHARMACOL REV, V64, P16, DOI 10.1124/pr.110.002790
   Moizeis RNC, 2018, PATHOG GLOB HEALTH, V112, P182, DOI 10.1080/20477724.2018.1478777
   D'Ortenzio E, 2016, NEW ENGL J MED, V374, P2195, DOI 10.1056/NEJMc1604449
   de La Vega MA, 2019, J INFECT DIS, V219, P365, DOI 10.1093/infdis/jiy336
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4
   Dong SP, 2018, VIROL SIN, V33, P125, DOI 10.1007/s12250-018-0007-4
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   Enfissi A, 2016, LANCET, V387, P227, DOI 10.1016/S0140-6736(16)00003-9
   European Centre for Disease Prevention and Control, RAP RISK ASS SEX TRA
   Fernandez E, 2017, NAT IMMUNOL, V18, P1261, DOI 10.1038/ni.3849
   Filippini A, 2001, HUM REPROD UPDATE, V7, P444, DOI 10.1093/humupd/7.5.444
   Foy BD, 2011, EMERG INFECT DIS, V17, P880, DOI 10.3201/eid1705.101939
   Fujisawa M, 2001, UROL RES, V29, P144, DOI 10.1007/s002400100179
   Garg H, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10110631
   Govero J, 2016, NATURE, V540, P438, DOI 10.1038/nature20556
   Griffin BD, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15743
   Griswold MD, 1998, SEMIN CELL DEV BIOL, V9, P411, DOI 10.1006/scdb.1998.0203
   Guedes DRD, 2017, EMERG MICROBES INFEC, V6, DOI 10.1038/emi.2017.59
   Gurung P., 2019, PHYSL MALE REPROD SY
   Halabi J, 2020, J INFECT DIS, V221, P1506, DOI 10.1093/infdis/jiz533
   Han DS, 2016, ENCYCLOPEDIA OF IMMUNOBIOLOGY, VOL 5: PHYSIOLOGY AND IMMUNE SYSTEM DYSFUNCTION, P46, DOI 10.1016/B978-0-12-374279-7.19009-5
   Hedger MP, 2000, J REPROD IMMUNOL, V48, P69, DOI 10.1016/S0165-0378(00)00071-1
   Holbrook MR, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9050097
   Huits R, 2017, B WORLD HEALTH ORGAN, V95, P802, DOI [10.2471/BLT.17.181370, 10.2471/blt.17.181370]
   Hussain A, 2018, CUREUS, V10, DOI 10.7759/cureus.3290
   Hussein MR, 2005, FERTIL STERIL, V83, P1447, DOI 10.1016/j.fertnstert.2004.11.062
   Imperato PJ, 2016, J COMMUN HEALTH, V41, P674, DOI 10.1007/s10900-016-0177-7
   Jiang XH, 2014, ASIAN J ANDROL, V16, P572, DOI 10.4103/1008-682X.125401
   Joguet G, 2017, LANCET INFECT DIS, V17, P1200, DOI 10.1016/S1473-3099(17)30444-9
   Jones R.E., 2013, HUMAN REPROD BIOL
   Kaur G, 2017, ENVIRON EPIGENETICS, V3, DOI 10.1093/eep/dvx012
   Kelly DA, 2016, INTEGR COMP BIOL, V56, P630, DOI 10.1093/icb/icw103
   Kumar A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23899-x
   Lalle E, 2018, EUROSURVEILLANCE, V23, P7, DOI 10.2807/1560-7917.ES.2018.23.18.18-00197
   Lanciotti RS, 2016, EMERG INFECT DIS, V22, P933, DOI 10.3201/eid2205.160065
   Larocca RA, 2016, NATURE, V536, P474, DOI 10.1038/nature18952
   Laureti M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02180
   Li MWM, 2009, CYTOKINE GROWTH F R, V20, P329, DOI 10.1016/j.cytogfr.2009.07.007
   Luca G, 2018, PROTEIN PEPTIDE LETT, V25, P440, DOI 10.2174/0929866525666180412163151
   Mackay IM, 2015, LANCET INFECT DIS, V15, P149, DOI 10.1016/S1473-3099(14)71033-3
   MACNAMARA FN, 1954, T ROY SOC TROP MED H, V48, P139, DOI 10.1016/0035-9203(54)90006-1
   Mansuy JM, 2016, LANCET INFECT DIS, V16, P1106, DOI 10.1016/S1473-3099(16)30336-X
   Matheron S, 2016, CLIN INFECT DIS, V63, DOI 10.1093/cid/ciw509
   Matusali G, 2018, J CLIN INVEST, V128, P4697, DOI [10.1172/JCI121735, 10.1172/jci121735]
   MCCARREY JR, 1992, DEV BIOL, V154, P160, DOI 10.1016/0012-1606(92)90056-M
   McDonald EM, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006691
   Mital P, 2011, BIOL REPROD, V84, P851, DOI 10.1095/biolreprod.110.087452
   Mlera L, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010042
   Molton JS, 2018, J TRAVEL MED, V25, DOI 10.1093/jtm/tay023
   Morrison C, 2016, NAT REV DRUG DISCOV, V15, P521, DOI 10.1038/nrd.2016.159
   Mossadegh-Keller N, 2018, CELL IMMUNOL, V330, P120, DOI 10.1016/j.cellimm.2018.03.009
   Mossadegh-Keller N, 2017, J EXP MED, V214, P2829, DOI 10.1084/jem.20170829
   Munjal A, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01469
   Musso D, 2017, CLIN MICROBIOL INFEC, V23, DOI 10.1016/j.cmi.2017.07.006
   Musso D, 2015, EMERG INFECT DIS, V21, P359, DOI 10.3201/eid2102.141363
   Neto FTL, 2016, SEMIN CELL DEV BIOL, V59, P10, DOI 10.1016/j.semcdb.2016.04.009
   Nicastri E, 2016, EUROSURVEILLANCE, V21, P6, DOI 10.2807/1560-7917.ES.2016.21.32.30314
   NISTAL M, 1984, ACTA ANAT, V119, P155
   Souto IO, 2018, ENFERM INFEC MICR CL, V36, P21, DOI 10.1016/j.eimc.2016.10.009
   Patel D.A., 2003, REPROD HLTH EPIDEMIO, P3
   Picut C.A., 2017, IMMUNOPATHOLOGY TOXI
   PUDNEY J, 1991, AM J PATHOL, V139, P149
   RAGHUPATHY R, 1990, CURR OPIN IMMUNOL, V2, P757, DOI 10.1016/0952-7915(90)90046-J
   Ramaswamy S., 2014, SPERMATOGENESIS, V4, DOI DOI 10.1080/21565562.2014.996025
   Rival C, 2006, CELL TISSUE RES, V324, P311, DOI 10.1007/s00441-005-0129-5
   Robinson CL, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04444-w
   Rossi SL, 2016, AM J TROP MED HYG, V94, P1362, DOI 10.4269/ajtmh.16-0111
   Roulet V, 2006, AM J PATHOL, V169, P2094, DOI 10.2353/ajpath.2006.060191
   Roundy CM, 2017, EMERG MICROBES INFEC, V6, DOI 10.1038/emi.2017.85
   Saiz JC, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00496
   Salam AP, 2017, EMERG INFECT DIS, V23, P1922, DOI 10.3201/eid2311.171049
   Salas-Huetos A, 2020, ANDROLOGY-US, V8, P7, DOI 10.1111/andr.12714
   Schrade A, 2016, ENDOCRINOLOGY, V157, P2416, DOI 10.1210/en.2015-1927
   Shamim M, 2011, J PAK MED ASSOC, V61, P601
   Shan C, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00737-8
   Sharma A, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00110
   Sheng ZY, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00272
   Si LL, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02250
   Siemann DN, 2017, J VIROL, V91, DOI 10.1128/JVI.00623-17
   Simanjuntak Y, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006854
   Siu MKY, 2004, BIOESSAYS, V26, P978, DOI 10.1002/bies.20099
   Slavov SN, 2016, BRAZ J MED BIOL RES, V49, DOI 10.1590/1414-431X20165420
   Smith RD, 2004, HUM PATHOL, V35, P254, DOI 10.1016/j.humpath.2003.09.007
   Sourisseau M, 2007, PLOS PATHOG, V3, P804, DOI 10.1371/journal.ppat.0030089
   Stassen L, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10040198
   Strange DP, 2019, MBIO, V10, DOI 10.1128/mBio.01372-19
   Strange DP, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27027-7
   Sun HY, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010054
   Syriou V, 2018, EUR CYTOKINE NETW, V29, P73, DOI 10.1684/ecn.2018.0412
   Uraki R, 2017, SCI ADV, V3, DOI 10.1126/sciadv.1602899
   Villar L, 2015, NEW ENGL J MED, V372, P113, DOI 10.1056/NEJMoa1411037
   Vouga M, 2016, PRENATAL DIAG, V36, P799, DOI 10.1002/pd.4880
   Wang LF, 2018, EXP THER MED, V15, P300, DOI 10.3892/etm.2017.5386
   Wang M, 2017, J IMMUNOL, V198, P4327, DOI 10.4049/jimmunol.1700162
   Windschuttl S, 2014, ANDROLOGY-US, V2, P615, DOI 10.1111/j.2047-2927.2014.00227.x
   Winnall WR, 2013, J REPROD IMMUNOL, V97, P147, DOI 10.1016/j.jri.2013.01.001
   World Health Organization, SEX TRANSM INF STIS
   World Health Organization, 2018, GLOB HLTH SECT STRAT
   World Health Organization (WHO), 2016, P EM COMM ZIK VIR OB
   Wu SW, 2020, TRENDS MOL MED, V26, P215, DOI 10.1016/j.molmed.2019.09.006
   Xu K, 2018, J VIROL, V92, DOI [10.1128/JVI.01722-17, 10.1128/jvi.01722-17]
   Zanluca C, 2015, MEM I OSWALDO CRUZ, V110, P569, DOI 10.1590/0074-02760150192
   Zhao BY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14762
   Zhao ST, 2014, CELL MOL IMMUNOL, V11, P428, DOI 10.1038/cmi.2014.38
   Zheng BH, 2019, VET MICROBIOL, V238, DOI 10.1016/j.vetmic.2019.108430
   Zou J, 2018, EBIOMEDICINE, V36, P92, DOI 10.1016/j.ebiom.2018.08.056
NR 123
TC 2
Z9 2
U1 1
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4409
J9 CELLS-BASEL
JI Cells
PD APR
PY 2020
VL 9
IS 4
AR 1006
DI 10.3390/cells9041006
PG 17
WC Cell Biology
SC Cell Biology
GA LR2XW
UT WOS:000535559500217
PM 32325652
OA DOAJ Gold, Green Published
DA 2020-12-15
ER

PT J
AU Pinheiro, WO
   Fascineli, ML
   Ramos, KLV
   de Andrade, LR
   Farias, GR
   Neta, MDB
   Correa, LH
   Duarte, ECB
   Damasceno, EAM
   Magalhaes, KG
   da Silva, JR
   Azevedo, RB
   Sousa, MH
   Lacava, ZGM
AF Pinheiro, Willie O.
   Fascineli, Maria L.
   Ramos, Khellida L., V
   de Andrade, Laise R.
   Farias, Gabriel R.
   Neta, Maria de S. B.
   Correa, Luis H.
   Duarte, Eliza C. B.
   Damasceno, Emanuel A. M.
   Magalhaes, Kelly G.
   da Silva, Jaqueline R.
   Azevedo, Ricardo B.
   Sousa, Marcelo H.
   Lacava, Zulmira G. M.
TI Synergistic Antitumor Efficacy of Magnetohyperthermia and
   Poly(lactic-co-glycolic acid)-Encapsulated Selol in Ehrlich Breast
   Adenocarcinoma Treatment in Elderly Swiss Mice
SO JOURNAL OF BIOMEDICAL NANOTECHNOLOGY
LA English
DT Article
DE Magnetohyperthermia; Breast Adenocarcinoma; Selol Nanocapsule; Combined
   Therapies; Paclitaxel
ID FLUID MEDIATING MAGNETOHYPERTHERMIA; 5-PERCENT SUPPLEMENTATION; MAGNETIC
   NANOPARTICLES; PHOTODYNAMIC THERAPY; OVARIAN-CANCER; HYPERTHERMIA;
   METASTASIS; IMMUNITY; SIZE; BIODISTRIBUTION
AB Nanobiotechnology strategies for cancer treatments are currently being tested with increasing interest, except in elderly groups. It is well established that breast cancer incidence increases with age and that traditional therapies usually generate severe adverse effects, especially for elderly groups. To investigate if the benefits of nanotechnology could be extended to treating cancer in this group, citrate-coated maghemite nanoparticles (NpCit) were used for magnetohyperthermia (MHT) in combination with the administration of PLGA-Selol nanocapsule (NcSel), a formulation with antioxidant and antitumor activity. The combined therapies significantly inhibited breast Ehrlich tumor growth and prevented metastases to the lymph nodes, liver and lungs until 45 days after tumor induction, a better result than the group undergoing conventional drug treatment. The levels of TNF-alpha, associated with poor prognosis in Ehrlich tumor, were also normalized. Therefore, the results evidenced the potential use of these therapies for future clinical trials in elderly breast cancer patients.
C1 [Pinheiro, Willie O.; Fascineli, Maria L.; Ramos, Khellida L., V; de Andrade, Laise R.; Farias, Gabriel R.; Neta, Maria de S. B.; da Silva, Jaqueline R.; Azevedo, Ricardo B.; Lacava, Zulmira G. M.] Univ Brasilia, Inst Biol Sci, Dept Genet & Morphol, BR-70910900 Brasilia, DF, Brazil.
   [Pinheiro, Willie O.; Fascineli, Maria L.; Ramos, Khellida L., V; de Andrade, Laise R.; Farias, Gabriel R.; Neta, Maria de S. B.; da Silva, Jaqueline R.; Azevedo, Ricardo B.; Lacava, Zulmira G. M.] Univ Brasilia, Inst Biol Sci, CNANO, BR-70910900 Brasilia, DF, Brazil.
   [Pinheiro, Willie O.; Lacava, Zulmira G. M.] Univ Brasilia, Fac Med, Postgrad Mol Pathol, BR-70910900 Brasilia, DF, Brazil.
   [Damasceno, Emanuel A. M.] Taguatinga Reg Hosp, BR-72120970 Brasilia, DF, Brazil.
   [Magalhaes, Kelly G.] Univ Brasilia, Dept Cell Biol, Lab Immunol & Inflammat, BR-70910900 Brasilia, DF, Brazil.
   [Pinheiro, Willie O.; Correa, Luis H.; Sousa, Marcelo H.] Univ Brasilia, Fac Ceilandia, Green Nanotechnol Grp, BR-72220900 Brasilia, DF, Brazil.
   [Duarte, Eliza C. B.] Univ Brasilia, Dept Pathol, BR-70910900 Brasilia, DF, Brazil.
RP Sousa, MH (corresponding author), Univ Brasilia, Fac Ceilandia, Green Nanotechnol Grp, BR-72220900 Brasilia, DF, Brazil.
EM mhsousa@unb.br
RI Sousa, Marcelo Henrique/AAM-3003-2020; Sousa, Marcelo
   Henrique/D-5420-2012; Magalhaes, Kelly Grace/A-6966-2010
OI Sousa, Marcelo Henrique/0000-0003-1210-8329; Correa, Luis
   Henrique/0000-0003-2825-0127; Da Silva, Jaqueline R/0000-0002-6017-7057;
   Magalhaes, Kelly Grace/0000-0002-7435-5272
FU Brazilian Agency: Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq)National Council for Scientific and Technological
   Development (CNPq); Brazilian Agency: Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (CAPES)CAPES; Brazilian Agency: Fundacao de
   Apoio a Pesquisa do Distrito Federal (FAPDF); Brazilian Agency: Decanato
   de Pesquisa e Inovacao (DPI-UnB); Brazilian Agency: Fundacao de
   Empreendimentos Cientificos e Tecnologicos (FINATEC)
FX Support for research: This work was supported by the Brazilian Agencies:
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq),
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES),
   Fundacao de Apoio a Pesquisa do Distrito Federal (FAPDF), Decanato de
   Pesquisa e Inovacao (DPI-UnB) and Fundacao de Empreendimentos
   Cientificos e Tecnologicos (FINATEC). The Department of Pharmaceutical
   Chemistry, National Medicines Institute, Warsaw, Poland is gratefully
   acknowledged.
CR Lagunas-Rangel FA, 2018, AGEING RES REV, V47, P18, DOI 10.1016/j.arr.2018.06.004
   Azevedo AS, 2015, CELL ADHES MIGR, V9, P345, DOI 10.1080/19336918.2015.1059563
   BAILLIF RN, 1954, CANCER RES, V14, P554
   Bonadio R.S., 2017, NANOMEDICINE, V12, P2
   Candido N., 2014, J NANOMED NANOTECHNO, V5, P1
   Chang L, 2019, J GERIATR ONCOL, V10, P346, DOI 10.1016/j.jgo.2018.07.010
   Chatterjee D.K., 2012, THERAPEUTIC DELIVERY, V2, P1001
   Cho H, 2009, CANCER IMMUNOL IMMUN, V58, P15, DOI 10.1007/s00262-008-0516-3
   Choudhury H, 2017, REGUL TOXICOL PHARM, V91, P179, DOI 10.1016/j.yrtph.2017.10.023
   da Silva AC, 2010, EINSTEIN-SAO PAULO, V8, P361, DOI 10.1590/S1679-45082010RW1757
   de Souza LR, 2015, NANOTECHNOLOGY, V26, DOI 10.1088/0957-4484/26/50/505101
   de Souza LR, 2014, J NANOBIOTECHNOL, V12, DOI 10.1186/s12951-014-0032-x
   Di Corato R, 2015, ACS NANO, V9, P2904, DOI 10.1021/nn506949t
   Dominiak A, 2017, NEUROCHEM INT, V108, P66, DOI 10.1016/j.neuint.2017.02.014
   Estevanato LLC, 2012, INT J NANOMED, V7, P5287, DOI 10.2147/IJN.S35279
   Falqueiro AM, 2011, J APPL PHYS, V109, DOI 10.1063/1.3556950
   Longo JPF, 2016, J BIOMED NANOTECHNOL, V12, P689, DOI 10.1166/jbn.2016.2208
   Flis A, 2015, PHARMACOL REP, V67, P1, DOI 10.1016/j.pharep.2014.07.017
   Ganassin R., 2018, ARTIF CELL NANOMED B, V46, P1
   Haghniaz R, 2016, INT J NANOMED, V11, P1779, DOI 10.2147/IJN.S104617
   Hasty P, 2002, SCIENCE, V296, P1250, DOI 10.1126/science.1071808
   Hu C, 2018, BIOMATERIALS, V168, P64, DOI 10.1016/j.biomaterials.2018.03.046
   Huang Z, 2012, ANTIOXID REDOX SIGN, V16, P705, DOI 10.1089/ars.2011.4145
   Ito A, 2003, CANCER IMMUNOL IMMUN, V52, P80, DOI 10.1007/s00262-002-0335-x
   Jadia R., 2016, INT J NANOTECHNOL NA, V1, P1
   Jia W., 2015, PLOS ONE, V10, P1
   Kaur P, 2016, INT J HYPERTHER, V32, P76, DOI 10.3109/02656736.2015.1120889
   Kobayashi T, 2014, NANOMEDICINE-UK, V9, P1715, DOI [10.2217/nnm.14.106, 10.2217/NNM.14.106]
   Kossatz S, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0576-1
   Kothamasu P, 2012, BIOIMPACTS, V2, P71, DOI 10.5681/bi.2012.011
   Ksiazek I., 2014, WORLD J PHARM SCI, V2, P1146
   KSIAZEK I, 2014, INT J PHARM PHARM SC, V6, P264
   Levy M, 2008, J PHYS-CONDENS MAT, V20, DOI 10.1088/0953-8984/20/20/204133
   Liu R, 2019, ACTA PHARM SIN B, V9, P410, DOI 10.1016/j.apsb.2018.09.001
   Liu R, 2018, J CONTROL RELEASE, V278, P127, DOI 10.1016/j.jconrel.2018.04.005
   Lopez-Otin C, 2013, CELL, V153, P1194, DOI 10.1016/j.cell.2013.05.039
   Lowe AC, 2015, CANCER CYTOPATHOL, V123, P696, DOI 10.1002/cncy.21640
   Ma L, 2013, ACS NANO, V7, P9518, DOI 10.1021/nn405674m
   Miller KD, 2016, CA-CANCER J CLIN, V66, P271, DOI 10.3322/caac.21349
   Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799
   Miranda-Vilela AL, 2014, TUMOR BIOL, V35, P3391, DOI 10.1007/s13277-013-1447-y
   Miranda-Vilela AL, 2013, J BIOMED NANOTECHNOL, V9, P1261, DOI 10.1166/jbn.2013.1616
   Miranda-Vilela AL, 2011, J NUTR BIOCHEM, V22, P1091, DOI 10.1016/j.jnutbio.2010.09.009
   Misra R, 2010, DRUG DISCOV TODAY, V15, P842, DOI 10.1016/j.drudis.2010.08.006
   Neves W.P., 2017, J CANC SCI THER, V9, P393
   Orucevic A, 2015, CANCERS, V7, P1472, DOI 10.3390/cancers7030846
   Pileczki V., 2013, INT J MOL SCI, V2013
   Pinheiro WO, 2019, INT J NANOMED, V14, P3375, DOI 10.2147/IJN.S197888
   Quini CC, 2017, NANOMED-NANOTECHNOL, V13, P1519, DOI 10.1016/j.nano.2017.02.005
   Riccio G, 2016, HUM VACC IMMUNOTHER, V12, P1124, DOI 10.1080/21645515.2015.1125056
   Sharma A, 2013, MOL NEUROBIOL, V48, P386, DOI 10.1007/s12035-013-8500-0
   Shrestha S, 2016, J MATER CHEM B, V4, P245, DOI 10.1039/c5tb02007g
   Slusarczyk J, 2014, CARYOLOGIA, V67, P250, DOI 10.1080/0144235X.2014.974353
   Soares Sousa CR, 2019, INT J VET SCI RES, V5, P46
   Sochacka M, 2018, PHARMACOL REP, V70, P1073, DOI 10.1016/j.pharep.2018.06.003
   Sochacka M, 2014, PHARMACOL REP, V66, P301, DOI 10.1016/j.pharep.2013.10.004
   Sohail A, 2017, B CANCER, V104, P452, DOI 10.1016/j.bulcan.2017.02.003
   Templeton AJ, 2014, JNCI-J NATL CANCER I, V106, P1, DOI [DOI 10.1093/JNCI/DJU124, 10.1093/jnci/dju124]
   Toraya-Brown S, 2014, NANOMED-NANOTECHNOL, V10, P1273, DOI 10.1016/j.nano.2014.01.011
   Frajacomo FTT, 2016, LIFE SCI, V162, P47, DOI 10.1016/j.lfs.2016.08.009
   Vassileva V, 2008, BRIT J CANCER, V99, P2037, DOI 10.1038/sj.bjc.6604803
   Whitehead JC, 2014, J GERONTOL A-BIOL, V69, P621, DOI 10.1093/gerona/glt136
   Zanganeh S, 2016, NAT NANOTECHNOL, V11, P986, DOI [10.1038/nnano.2016.168, 10.1038/NNANO.2016.168]
NR 63
TC 0
Z9 0
U1 2
U2 2
PU AMER SCIENTIFIC PUBLISHERS
PI VALENCIA
PA 26650 THE OLD RD, STE 208, VALENCIA, CA 91381-0751 USA
SN 1550-7033
EI 1550-7041
J9 J BIOMED NANOTECHNOL
JI J. Biomed. Nanotechnol.
PD FEB
PY 2020
VL 16
IS 2
BP 179
EP 192
DI 10.1166/jbn.2020.2890
PG 14
WC Nanoscience & Nanotechnology; Materials Science, Biomaterials
SC Science & Technology - Other Topics; Materials Science
GA LB9TX
UT WOS:000524973800004
PM 32252879
DA 2020-12-15
ER

PT J
AU Schanoski, AS
   Le, TT
   Kaiserman, D
   Rowe, C
   Prow, NA
   Barboza, DD
   Santos, CA
   Zanotto, PMA
   Magalhaes, KG
   Aurelio, L
   Muller, D
   Young, P
   Zhao, PS
   Bird, PI
   Suhrbier, A
AF Schanoski, Alessandra S.
   Le, Thuy T.
   Kaiserman, Dion
   Rowe, Caitlin
   Prow, Natalie A.
   Barboza, Diego D.
   Santos, Cliomar A.
   Zanotto, Paolo M. A.
   Magalhaes, Kelly G.
   Aurelio, Luigi
   Muller, David
   Young, Paul
   Zhao, Peishen
   Bird, Phillip I.
   Suhrbier, Andreas
TI Granzyme A in Chikungunya and Other Arboviral Infections
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE chikungunya; granzyme A; NK cell; arthritis; arbovirus
ID PROTEINASE-ACTIVATED RECEPTOR-2; NATURAL-KILLER-CELLS; CD4(+) T-CELLS;
   NEUTROPHIL ELASTASE; VIRUS-INFECTION; MOUSE GRANZYME; EXTRACELLULAR
   GRANZYME; PROTEASE GRANZYME; ARTHRITIS; INFLAMMATION
AB Granzyme A (GzmA) is secreted by cytotoxic lymphocytes and has traditionally been viewed as a mediator of cell death. However, a growing body of data suggests the physiological role of GzmA is promotion of inflammation. Here, we show that GzmA is significantly elevated in the sera of chikungunya virus (CHIKV) patients and that GzmA levels correlated with viral loads and disease scores in these patients. Serum GzmA levels were also elevated in CHIKV mouse models, with NK cells the likely source. Infection of mice deficient in type I interferon responses with CHIKV, Zika virus, or dengue virus resulted in high levels of circulating GzmA. We also show that subcutaneous injection of enzymically active recombinant mouse GzmA was able to mediate inflammation, both locally at the injection site as well as at a distant site. Protease activated receptors (PARs) may represent targets for GzmA, and we show that treatment with PAR antagonist ameliorated GzmA- and CHIKV-mediated inflammation.
C1 [Schanoski, Alessandra S.] Butantan Inst, Bacteriol Lab, Sao Paulo, Brazil.
   [Le, Thuy T.; Prow, Natalie A.; Suhrbier, Andreas] QIMR Berghofer Med Res Inst, Brisbane, Qld, Australia.
   [Kaiserman, Dion; Rowe, Caitlin; Bird, Phillip I.] Monash Univ, Biomed Discovery Inst, Dept Biochem & Mol Biol, Melbourne, Vic, Australia.
   [Prow, Natalie A.; Suhrbier, Andreas] Univ Queensland, Australian Infect Dis Res Ctr, Brisbane, Qld, Australia.
   [Santos, Cliomar A.] Hlth Fdn Parreiras Horta, Cent Publ Hlth Lab, State Secretary Hlth, Aracaju, Brazil.
   [Zanotto, Paolo M. A.] Univ Sao Paulo, Inst Biomed Sci, Dept Microbiol, Lab Mol Evolut & Bioinformat, Sao Paulo, Brazil.
   [Magalhaes, Kelly G.] Univ Brasilia, Lab Immunol & Inflammat, Brasilia, DF, Brazil.
   [Aurelio, Luigi] Monash Univ, Monash Inst Pharmaceut Sci, Drug Discovery Biol, Parkville, Vic, Australia.
   [Muller, David] Monash Univ, Monash Inst Pharmaceut Sci, Dept Pharmacol, Parkville, Vic, Australia.
   [Muller, David; Young, Paul] Univ Queensland, Sch Chem & Mol Biosci, Brisbane, Qld, Australia.
RP Schanoski, AS (corresponding author), Butantan Inst, Bacteriol Lab, Sao Paulo, Brazil.; Suhrbier, A (corresponding author), QIMR Berghofer Med Res Inst, Brisbane, Qld, Australia.; Suhrbier, A (corresponding author), Univ Queensland, Australian Infect Dis Res Ctr, Brisbane, Qld, Australia.
EM alessandra.schanoki@butantan.gov.br;
   Andreas.Suhrbier@qimrberghofer.edu.au
RI de A. Zanotto, Paolo M./B-9286-2019; Young, Paul/A-6176-2010; Soares
   Schanoski, Alessandra/H-8144-2014; Magalhaes, Kelly Grace/A-6966-2010
OI de A. Zanotto, Paolo M./0000-0002-8167-0625; Young,
   Paul/0000-0002-2040-5190; Soares Schanoski,
   Alessandra/0000-0002-6514-8458; Magalhaes, Kelly
   Grace/0000-0002-7435-5272
FU Butantan Foundation; CNPqNational Council for Scientific and
   Technological Development (CNPq) [443371/2016-4]; FAPDF/PPSUS
   [193.001.621/2016]; National Health and Medical Research Council (NHMRC)
   of AustraliaNational Health and Medical Research Council of Australia
   [APP1078468]; Australian Infectious Disease Research Center; Advance
   Queensland Research Fellowship from the Queensland Government,
   Australia; National Health and Medical Research Council of
   AustraliaNational Health and Medical Research Council of Australia
FX The work in Brazil was supported by Butantan Foundation, CNPq (Grant
   443371/2016-4) and FAPDF/PPSUS #193.001.621/2016. The work in Australia
   was supported by a project grant from the National Health and Medical
   Research Council (NHMRC) of Australia (APP1078468) and intramural seed
   funding from the Australian Infectious Disease Research Center. NP was
   supported by an Advance Queensland Research Fellowship from the
   Queensland Government, Australia. AS holds a Principal Research
   Fellowship from the National Health and Medical Research Council of
   Australia.
CR Arias MA, 2014, CELL REP, V8, P419, DOI 10.1016/j.celrep.2014.06.012
   Bengsch B, 2018, J IMMUNOL METHODS, V453, P3, DOI 10.1016/j.jim.2017.03.009
   Brilot F, 2008, FRONT BIOSCI-LANDMRK, V13, P6443, DOI 10.2741/3165
   BRUNNER G, 1990, FEBS LETT, V260, P141, DOI 10.1016/0014-5793(90)80087-Y
   Burrack KS, 2015, J IMMUNOL, V194, P678, DOI 10.4049/jimmunol.1401833
   Campbell RA, 2018, J IMMUNOL, V200, P295, DOI 10.4049/jimmunol.1700885
   Chemin K, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00353
   Cheuk S, 2017, EXP DERMATOL, V26, P824, DOI 10.1111/exd.13284
   Cook LE, 2020, J VIROL, V94, DOI 10.1128/JVI.00841-19
   Cunha MD, 2017, J CLIN VIROL, V97, P44, DOI 10.1016/j.jcv.2017.10.015
   de Jong HK, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005823
   Della-Torre E, 2018, ARTHRITIS RHEUMATOL, V70, P1133, DOI 10.1002/art.40469
   Engin A, 2019, J MED VIROL, V91, P1385, DOI 10.1002/jmv.25467
   Fehniger TA, 2007, IMMUNITY, V26, P798, DOI 10.1016/j.immuni.2007.04.010
   Ferrell WR, 2003, J CLIN INVEST, V111, P35, DOI 10.1172/JCI200316913
   Garcia-Laorden MI, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/4137563
   Gardner J, 2010, J VIROL, V84, P8021, DOI 10.1128/JVI.02603-09
   Gasque P, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aam6567
   Golstein P, 2018, NAT REV IMMUNOL, V18, P526, DOI 10.1038/s41577-018-0009-3
   Gordy LE, 2011, J IMMUNOL, V187, P6335, DOI 10.4049/jimmunol.1003965
   Gryka RJ, 2017, DRUGS R&D, V17, P65, DOI 10.1007/s40268-016-0158-4
   Hammer Q, 2018, NAT IMMUNOL, V19, P800, DOI 10.1038/s41590-018-0163-6
   Hansen KK, 2005, P NATL ACAD SCI USA, V102, P8363, DOI 10.1073/pnas.0409535102
   Hermsen CC, 2003, CLIN EXP IMMUNOL, V132, P467, DOI 10.1046/j.1365-2249.2003.02160.x
   Heuberger DM, 2019, THROMB J, V17, DOI 10.1186/s12959-019-0194-8
   Hildebrand D, 2014, CELL REP, V9, P910, DOI 10.1016/j.celrep.2014.10.003
   Hoarau JJ, 2010, J IMMUNOL, V184, P5914, DOI 10.4049/jimmunol.0900255
   Hollenberg MD, 2014, BRIT J PHARMACOL, V171, P1180, DOI 10.1111/bph.12544
   Jaime P, 2017, OSTEOARTHR CARTILAGE, V25, P1708, DOI 10.1016/j.joca.2017.06.007
   Jimenez-Vargas NN, 2018, P NATL ACAD SCI USA, V115, pE7438, DOI 10.1073/pnas.1721891115
   Joeckel LT, 2014, BIOL CHEM, V395, P181, DOI 10.1515/hsz-2013-0238
   Jose RJ, 2015, J IMMUNOL, V194, P6024, DOI 10.4049/jimmunol.1500124
   Juno JA, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00019
   Kaiserman D, 2006, J CELL BIOL, V175, P619, DOI 10.1083/jcb.200606073
   Kaiserman D, 2014, J BIOL CHEM, V289, P9408, DOI 10.1074/jbc.M113.525808
   Kelso EB, 2006, J PHARMACOL EXP THER, V316, P1017, DOI 10.1124/jpet.105.093807
   Kiniry BE, 2018, J IMMUNOL, V200, P1876, DOI 10.4049/jimmunol.1701532
   La Linn M, 1998, J VIROL, V72, P5146, DOI 10.1128/JVI.72.6.5146-5153.1998
   Lauw FN, 2000, J INFECT DIS, V182, P206, DOI 10.1086/315642
   Liesche C, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01840
   Liu J, 2019, IMMUNOL CELL BIOL, V97, P586, DOI 10.1111/imcb.12248
   Lochhead RB, 2019, CELL MICROBIOL, V21, DOI 10.1111/cmi.12992
   Lohman RJ, 2012, FASEB J, V26, P2877, DOI 10.1096/fj.11-201004
   Mandrup-Poulsen T, 2017, DIABETES, V66, P2937, DOI 10.2337/dbi17-0037
   Martin-Antonio B, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18091868
   Martinez-Gutierrez M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087412
   Metkar SS, 2008, IMMUNITY, V29, P720, DOI 10.1016/j.immuni.2008.08.014
   Michlmayr D, 2018, MOL SYST BIOL, V14, DOI 10.15252/msb.20177862
   Mihara K, 2013, J BIOL CHEM, V288, P32979, DOI 10.1074/jbc.M113.483123
   Modhiran N, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa3863
   Mollah ZUA, 2017, DIABETES, V66, P3041, DOI 10.2337/db17-0517
   Mpande CAM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00324
   Muley MM, 2016, BRIT J PHARMACOL, V173, P766, DOI 10.1111/bph.13237
   Mullbacher A, 1996, P NATL ACAD SCI USA, V93, P5783, DOI 10.1073/pnas.93.12.5783
   Muraro E, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00197
   Nakaya HI, 2012, ARTHRITIS RHEUM-US, V64, P3553, DOI 10.1002/art.34631
   Petitdemange C, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004499
   Petitdemange C, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002268
   Plasman K, 2014, J PROTEOME RES, V13, P6067, DOI 10.1021/pr500968d
   Poo YS, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003354
   Poo YS, 2014, J VIROL, V88, P6862, DOI 10.1128/JVI.03364-13
   Prow NA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02736
   Prow NA, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03662-6
   Puente XS, 2003, NAT REV GENET, V4, P544, DOI 10.1038/nrg1111
   Rolle A, 2016, EMERG INFECT DIS, V22, P891, DOI 10.3201/eid2205.151449
   Rudd PA, 2012, J VIROL, V86, P9888, DOI 10.1128/JVI.00956-12
   Santiago L, 2017, ARTHRITIS RHEUMATOL, V69, P320, DOI 10.1002/art.39857
   Setoh YX, 2019, NAT MICROBIOL, V4, P876, DOI 10.1038/s41564-019-0399-4
   Setoh YX, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10100541
   Setoh YX, 2017, MSPHERE, V2, DOI [10.1128/mSphereDirect.00190-17, 10.1128/mspheredirect.00190-17]
   Sharma M, 2016, FEBS J, V283, P1734, DOI 10.1111/febs.13699
   Shields CA, 2018, AM J PHYSIOL-REG I, V315, pR336, DOI 10.1152/ajpregu.00061.2018
   Shimizu K, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01450
   Silveira GF, 2018, J VIROL, V92, DOI [10.1128/JVI.02181-17, 10.1128/jvi.02181-17]
   Soares-Schanoski A, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007880
   Sower LE, 1996, J IMMUNOL, V156, P2585
   Spaeny-Dekking EHA, 1998, J IMMUNOL, V160, P3610
   Spaeny-Dekking EHA, 2000, BLOOD, V95, P1465
   Stables MJ, 2011, BLOOD, V118, pE192, DOI 10.1182/blood-2011-04-345330
   Stewart SE, 2012, BBA-PROTEINS PROTEOM, V1824, P59, DOI 10.1016/j.bbapap.2011.05.020
   Suen JY, 2012, BRIT J PHARMACOL, V165, P1413, DOI 10.1111/j.1476-5381.2011.01610.x
   SUHRBIER A, 1991, J IMMUNOL METHODS, V145, P43, DOI 10.1016/0022-1759(91)90309-4
   Suhrbier A, 2019, NAT REV RHEUMATOL, V15, P597, DOI 10.1038/s41584-019-0276-9
   Suidan HS, 1996, BIOCHEM J, V315, P939, DOI 10.1042/bj3150939
   SUIDAN HS, 1994, P NATL ACAD SCI USA, V91, P8112, DOI 10.1073/pnas.91.17.8112
   Sun JR, 1999, BIOCHEM BIOPH RES CO, V261, P251, DOI 10.1006/bbrc.1999.0989
   SUN JR, 1995, BBA-PROTEIN STRUCT M, V1252, P28, DOI 10.1016/0167-4838(95)00108-7
   Susanto O, 2013, CELL DEATH DIFFER, V20, P1183, DOI 10.1038/cdd.2013.59
   Teo TH, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal1333
   Teo TH, 2015, J VIROL, V89, P7955, DOI 10.1128/JVI.00909-15
   Teo TH, 2013, J IMMUNOL, V190, P259, DOI 10.4049/jimmunol.1202177
   Thanapati S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188342
   Thanapati S, 2017, HUM IMMUNOL, V78, P370, DOI 10.1016/j.humimm.2017.02.006
   TRICE JM, 1985, SEMIN ARTHRITIS RHEU, V15, P45, DOI 10.1016/0049-0172(85)90009-5
   Triggianese P, 2016, INT J IMMUNOPATH PH, V29, P65, DOI 10.1177/0394632015615130
   van den Boogaard FE, 2016, AM J PHYSIOL-LUNG C, V311, pL507, DOI 10.1152/ajplung.00116.2016
   van Eck JA, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.56
   Velaga S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124927
   Waasdorp M, 2019, FASEB J, V33, P10966, DOI 10.1096/fj.201900516R
   Webster B, 2018, ELIFE, V7, DOI 10.7554/eLife.34273
   Wensink AC, 2015, J IMMUNOL, V194, P491, DOI 10.4049/jimmunol.1401214
   Wilson JAC, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006155
   Wu CH, 2019, J EXTRACELL VESICLES, V8, DOI 10.1080/20013078.2019.1588538
   Xue ML, 2012, ARTHRITIS RHEUM-US, V64, P88, DOI 10.1002/art.33323
   Yamin R, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37448-z
   Yang YH, 2005, ARTHRITIS RHEUM-US, V52, P1325, DOI 10.1002/art.21001
   Yockey LJ, 2016, CELL, V166, P1247, DOI 10.1016/j.cell.2016.08.004
   Zhao PS, 2015, J BIOL CHEM, V290, P13875, DOI 10.1074/jbc.M115.642736
   Zhao PS, 2014, J BIOL CHEM, V289, P27215, DOI 10.1074/jbc.M114.599712
   Zhao PS, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00067
NR 110
TC 4
Z9 4
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD JAN 14
PY 2020
VL 10
AR 3083
DI 10.3389/fimmu.2019.03083
PG 14
WC Immunology
SC Immunology
GA KG5XF
UT WOS:000510024400001
PM 31993061
OA DOAJ Gold, Green Published
DA 2020-12-15
ER

PT J
AU Correa, R
   Silva, LFF
   Ribeiro, DJS
   Almeida, RD
   Santos, ID
   Correa, LH
   de Sant'Ana, LP
   Assuncao, LS
   Bozza, PT
   Magalhaes, KG
AF Correa, Rafael
   Fonseca Silva, Luis Felipe
   Silva Ribeiro, Dalila Juliana
   Almeida, Raquel das Neves
   Santos, Igor de Oliveira
   Correa, Luis Henrique
   de Sant'Ana, Livia Pimentel
   Assuncao, Leonardo Santos
   Bozza, Patricia T.
   Magalhaes, Kelly Grace
TI Lysophosphatidylcholine Induces NLRP3 Inflammasome-Mediated Foam Cell
   Formation and Pyroptosis in Human Monocytes and Endothelial Cells
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE lysophosphatidylcholine; foam cells; lipid droplet; inflammasome; NLRP3;
   atherosclerosis
ID SCHISTOSOMAL-DERIVED LYSOPHOSPHATIDYLCHOLINE; PROMOTES CHOLESTEROL
   EFFLUX; GASDERMIN D; CASPASE-1 ACTIVATION; IL-1-BETA RELEASE;
   ATHEROSCLEROSIS; EXPRESSION; MICROGLIA; ROS; INTERLEUKIN-1-BETA
AB Foam cells are specialized lipid-loaded macrophages derived from monocytes and are a key pathological feature of atherosclerotic lesions. Lysophosphatidylcholine (LPC) is a major lipid component of the plasma membrane with a broad spectrum of proinflammatory activities and plays a key role in atherosclerosis. However, the role of LPC in lipid droplet (LD) biogenesis and the modulation of inflammasome activation is still poorly understood. In the present study, we investigated whether LPC can induce foam cell formation through an analysis of LD biogenesis and determined whether the cell signaling involved in this process is mediated by the inflammasome activation pathway in human endothelial cells and monocytes. Our results showed that LPC induced foam cell formation in both types of cells by increasing LD biogenesis via a NLRP3 inflammasome-dependent pathway. Furthermore, LPC induced pyroptosis in both cells and the activation of the inflammasome with IL-1 beta secretion, which was dependent on potassium efflux and lysosomal damage in human monocytes. The present study described the IL-1 beta secretion and foam cell formation triggered by LPC via an inflammasome-mediated pathway in human monocytes and endothelial cells. Our results will help improve our understanding of the relationships among LPC, LD biogenesis, and NLRP3 inflammasome activation in the pathogenesis of atherosclerosis.
C1 [Correa, Rafael; Fonseca Silva, Luis Felipe; Silva Ribeiro, Dalila Juliana; Almeida, Raquel das Neves; Santos, Igor de Oliveira; Correa, Luis Henrique; de Sant'Ana, Livia Pimentel; Magalhaes, Kelly Grace] Univ Brasilia, Dept Cell Biol, Lab Immunol & Inflammat, Brasilia, DF, Brazil.
   [Assuncao, Leonardo Santos; Bozza, Patricia T.] Fiocruz MS, Inst Oswaldo Cruz, Lab Immunopharmacol, Rio De Janeiro, Brazil.
RP Magalhaes, KG (corresponding author), Univ Brasilia, Dept Cell Biol, Lab Immunol & Inflammat, Brasilia, DF, Brazil.
EM kellymagalhaes@unb.br
RI ; Magalhaes, Kelly Grace/A-6966-2010
OI Correa, Rafael/0000-0003-2989-2383; Magalhaes, Kelly
   Grace/0000-0002-7435-5272; Correa, Luis Henrique/0000-0003-2825-0127
FU Fundacao de Amparo a Pesquisa do Distrito Federal (FapDF)
   [0193.000827/2015]; Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq)National Council for Scientific and Technological
   Development (CNPq); Fundacao de Amparo a Pesquisa do Estado do Rio de
   Janeiro (FAPERJ)Carlos Chagas Filho Foundation for Research Support of
   the State of Rio de Janeiro (FAPERJ); Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (CAPES)CAPES
FX This research was funded by Fundacao de Amparo a Pesquisa do Distrito
   Federal (FapDF), grant number #0193.000827/2015; Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq); Fundacao de Amparo a
   Pesquisa do Estado do Rio de Janeiro (FAPERJ); and Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES).
CR Assuncao LS, 2017, BBA-MOL CELL BIOL L, V1862, P246, DOI 10.1016/j.bbalip.2016.11.006
   Baldrighi M, 2017, ATHEROSCLEROSIS, V267, P127, DOI 10.1016/j.atherosclerosis.2017.10.027
   Berger J, 2002, ANNU REV MED, V53, P409, DOI 10.1146/annurev.med.53.082901.104018
   Bergsbaken T, 2009, NAT REV MICROBIOL, V7, P99, DOI 10.1038/nrmicro2070
   Bobryshev YV, 2006, MICRON, V37, P208, DOI 10.1016/j.micron.2005.10.007
   Bozza PT, 2009, BBA-MOL CELL BIOL L, V1791, P540, DOI 10.1016/j.bbalip.2009.01.005
   BROWN MS, 1979, J CELL BIOL, V82, P597, DOI 10.1083/jcb.82.3.597
   Broz P, 2016, NAT REV IMMUNOL, V16, P407, DOI 10.1038/nri.2016.58
   Carneiro AB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076233
   Cassel SL, 2009, SEMIN IMMUNOL, V21, P194, DOI 10.1016/j.smim.2009.05.002
   Ceballos-Olvera I, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002452
   Chang MC, 2017, ONCOTARGET, V8, P106177, DOI 10.18632/oncotarget.22425
   Duewell P, 2010, NATURE, V464, P1357, DOI 10.1038/nature08938
   Estruch M, 2015, BBA-MOL CELL BIOL L, V1851, P1442, DOI 10.1016/j.bbalip.2015.08.009
   Freeman L, 2017, J EXP MED, V214, P1351, DOI 10.1084/jem.20150237
   Gimbrone MA, 2016, CIRC RES, V118, P620, DOI 10.1161/CIRCRESAHA.115.306301
   Greenberg AS, 2011, J CLIN INVEST, V121, P2102, DOI 10.1172/JCI46069
   Gregersen I, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188387
   Hansson GK, 2005, NEW ENGL J MED, V353, P429
   Hansson GK, 2011, NAT IMMUNOL, V12, P204, DOI 10.1038/ni.2001
   Hara S, 1997, ARTERIOSCL THROM VAS, V17, P1258, DOI 10.1161/01.ATV.17.7.1258
   He WT, 2015, CELL RES, V25, P1285, DOI 10.1038/cr.2015.139
   HENRIKSEN T, 1983, ARTERIOSCLEROSIS, V3, P149, DOI 10.1161/01.ATV.3.2.149
   Ho-Tin-Noe B, 2017, J PATHOL, V241, P671, DOI 10.1002/path.4873
   Hou L, 2018, LAB INVEST, V98, P1052, DOI 10.1038/s41374-018-0073-0
   Hou M, 2007, CELL BIOCHEM FUNCT, V25, P33, DOI 10.1002/cbf.1374
   Huang YH, 1999, CLIN EXP IMMUNOL, V116, P326
   Ioannou GN, 2017, J LIPID RES, V58, P1067, DOI 10.1194/jlr.M072454
   Janoudi A, 2016, EUR HEART J, V37, P1959, DOI 10.1093/eurheartj/ehv653
   Jia C, 2019, INT IMMUNOPHARMACOL, V67, P311, DOI 10.1016/j.intimp.2018.12.028
   Karasawa T, 2017, INFLAMM REGEN, V37, DOI 10.1186/s41232-017-0050-9
   Kayagaki N, 2015, NATURE, V526, P666, DOI 10.1038/nature15541
   Keyel PA, 2014, CYTOKINE, V69, P136, DOI 10.1016/j.cyto.2014.03.007
   Kotla S, 2017, REDOX BIOL, V11, P350, DOI 10.1016/j.redox.2016.12.005
   KUME N, 1992, J CLIN INVEST, V90, P1138, DOI 10.1172/JCI115932
   Kureishi Y, 2000, NAT MED, V6, P1004, DOI 10.1038/79510
   Lamkanfi M, 2010, J IMMUNOL, V185, P4385, DOI 10.4049/jimmunol.1000803
   Lee J, 2017, LIPIDS HEALTH DIS, V16, DOI 10.1186/s12944-017-0595-2
   Li X, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0095004, 10.1371/journal.pone.0098139]
   Libby P, 2017, J AM COLL CARDIOL, V70, P2278, DOI 10.1016/j.jacc.2017.09.028
   Libby P, 2012, ARTERIOSCL THROM VAS, V32, P2045, DOI 10.1161/ATVBAHA.108.179705
   Liu WW, 2014, INFLAMM RES, V63, P33, DOI 10.1007/s00011-013-0667-3
   Liu X, 2016, NATURE, V535, P153, DOI 10.1038/nature18629
   Liu-Wu Y, 1998, ATHEROSCLEROSIS, V137, P351, DOI 10.1016/S0021-9150(97)00295-5
   Lopez-Pastrana J, 2015, J BIOL CHEM, V290, P17485, DOI 10.1074/jbc.M115.641191
   Magalhaes KG, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03161
   Magalhaes KG, 2010, J INFECT DIS, V202, P1369, DOI 10.1086/656477
   Martinez GJ, 2018, ATHEROSCLEROSIS, V269, P262, DOI 10.1016/j.atherosclerosis.2017.12.027
   Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3
   Matsumoto T, 2007, CURR MED CHEM, V14, P3209, DOI 10.2174/092986707782793899
   Miao EA, 2010, NAT IMMUNOL, V11, P1136, DOI 10.1038/ni.1960
   Morita M, 2015, J BIOCHEM, V158, P331, DOI 10.1093/jb/mvv044
   Nishi E, 1998, CIRC RES, V83, P508, DOI 10.1161/01.RES.83.5.508
   Nishi E, 1997, CIRC RES, V80, P638, DOI 10.1161/01.RES.80.5.638
   Parks BW, 2006, ARTERIOSCL THROM VAS, V26, P2703, DOI 10.1161/01.ATV.0000246774.02426.71
   Petrilli V, 2007, CELL DEATH DIFFER, V14, P1583, DOI 10.1038/sj.cdd.4402195
   Pfeiler S, 2019, CYTOKINE, V122, DOI 10.1016/j.cyto.2017.11.009
   QUINN MT, 1988, P NATL ACAD SCI USA, V85, P2805, DOI 10.1073/pnas.85.8.2805
   Rajamaki K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011765
   Rayamajhi Manira, 2013, Methods Mol Biol, V1040, P85, DOI 10.1007/978-1-62703-523-1_7
   Sato H, 2008, J BIOL CHEM, V283, P33483, DOI 10.1074/jbc.M804628200
   SCHAFFNER T, 1980, AM J PATHOL, V100, P57
   Schilling T, 2010, CELL IMMUNOL, V265, P87, DOI 10.1016/j.cellimm.2010.08.003
   Schmitz G, 2010, ATHEROSCLEROSIS, V208, P10, DOI 10.1016/j.atherosclerosis.2009.05.029
   Scholz H, 2017, J NEUROIMMUNOL, V310, P107, DOI 10.1016/j.jneuroim.2017.07.004
   Sharma A, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00114
   Sheikh AM, 2006, ANN NY ACAD SCI, V947, P306, DOI 10.1111/j.1749-6632.2001.tb03952.x
   Spangelo BL, 1996, ENDOCRINOLOGY, V137, P4419, DOI 10.1210/en.137.10.4419
   Stock C, 2006, J IMMUNOL, V177, P8560, DOI 10.4049/jimmunol.177.12.8560
   Strowig T, 2012, NATURE, V481, P278, DOI 10.1038/nature10759
   Tabas I, 2015, J CELL BIOL, V209, P13, DOI 10.1083/jcb.201412052
   Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5
   Tschopp J, 2010, NAT REV IMMUNOL, V10, P210, DOI 10.1038/nri2725
   Yu SY, 2017, INT J CARDIOL, V247, P11, DOI 10.1016/j.ijcard.2017.05.016
   Yu XH, 2013, CLIN CHIM ACTA, V424, P245, DOI 10.1016/j.cca.2013.06.006
   Yuan Y, 2012, PROTEIN CELL, V3, P173, DOI 10.1007/s13238-012-2025-6
   Zernecke A, 2008, ARTERIOSCL THROM VAS, V28, P1897, DOI 10.1161/ATVBAHA.107.161174
NR 77
TC 2
Z9 2
U1 3
U2 6
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD JAN 9
PY 2020
VL 10
AR 2927
DI 10.3389/fimmu.2019.02927
PG 15
WC Immunology
SC Immunology
GA KE9RZ
UT WOS:000508889200001
PM 31998284
OA DOAJ Gold, Green Published
DA 2020-12-15
ER

PT J
AU de Sant'Ana, LP
   Ribeiro, DJS
   Martins, AMA
   dos Santos, FN
   Correa, R
   Almeida, RD
   Eberlin, MN
   Maurice, CF
   Magalhaes, KG
AF de Sant'Ana, Livia Pimentel
   Ribeiro, Dalila Juliana S.
   Araujo Martins, Aline Maria
   dos Santos, Fabio Neves
   Correa, Rafael
   Almeida, Raquel das Neves
   Eberlin, Marcos Nogueira
   Maurice, Corinne F.
   Magalhaes, Kelly Grace
TI Absence of the Caspases 1/11 Modulates Liver Global Lipid Profile and
   Gut Microbiota in High-Fat-Diet-Induced Obese Mice
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE obesity; gut microbiota; high-fat diet; NAFLD; inflammasome
ID ADIPOSE-TISSUE INFLAMMATION; DISEASE; ACTIVATION; CAPACITY; SYSTEM;
   NAFLD
AB Obesity is a chronic disease with rising worldwide prevalence and largely associated with several other comorbidities, such as cancer, non-alcoholic fatty liver disease (NAFLD), and metabolic syndrome. Hepatic steatosis, a hallmark of NAFLD, is strongly correlated with obesity and has been correlated with changes in the gut microbiota, which can promote its development through the production of short-chain fatty acids (SCFAs) that regulate insulin resistance, bile acid, choline metabolism, and inflammation. Recent studies have suggested a controversial role for the inflammasome/caspase-1 in the development of obesity and non-alcoholic steatohepatitis (NASH). Here, we evaluated the role of inflammasome NLRP3 and caspases 1/11 in the establishment of obesity and hepatic steatosis in diet-induced obese mice, correlating them with the global lipid profile of the liver and gut microbiota diversity. After feeding wild-type, caspases 1/11, and NLRP3 knockout mice with a standard fat diet (SFD) or a high-fat diet (HFD), we found that the caspases 1/11 knockout mice, but not NLRP3 knockout mice, were more susceptible to HFD-induced obesity, and developed enhanced hepatic steatosis even under SFD conditions. Lipidomics analysis of the liver, assessed by MALDI-MS analysis, revealed that the HFD triggered a significant change in global lipid profile in the liver of WT mice compared to those fed an SFD, and this profile was modified by the lack of caspases 1/11 and NLRP3. The absence of caspases 1/11 was also correlated with an increased presence of triacylglycerol in the liver. Gut microbial diversity analysis, using 16S rRNA gene sequencing, showed that there was also an increase of Proteobacteria and a higher Firmicutes/Bacteroidetes ratio in the gut of caspases 1/11 knockout mice fed an HFD. Overall, mice without caspases 1/11 harbored gut bacterial phyla involved with weight gain, obesity, and hepatic steatosis. Taken together, our data suggest an important role for caspases 1/11 in the lipid composition of the liver and in the modulation of the gut microbial community composition. Our results further suggest that HFD-induced obesity and the absence of caspases 1/11 may regulate both lipid metabolism and gut microbial diversity, and therefore may be associated with NAFLD and obesity.
C1 [de Sant'Ana, Livia Pimentel; Ribeiro, Dalila Juliana S.; Correa, Rafael; Almeida, Raquel das Neves; Magalhaes, Kelly Grace] Univ Brasilia, Lab Immunol & Inflammat, Dept Cell Biol, Brasilia, DF, Brazil.
   [Araujo Martins, Aline Maria] Univ San Pablo CEU, Ctr Metabolom & Bioanal, CEMBIO, Madrid, Spain.
   [dos Santos, Fabio Neves] Univ Estadual Campinas, UNICAMP, Inst Chem, ThoMSon Mass Spectrometry Lab, Sao Paulo, Brazil.
   [Eberlin, Marcos Nogueira] Univ Prebiteriana Mackenzie, Dept Chem, Sao Paulo, Brazil.
   [Maurice, Corinne F.] McGill Univ, Dept Microbiol & Immunol, Montreal, PQ, Canada.
RP Magalhaes, KG (corresponding author), Univ Brasilia, Lab Immunol & Inflammat, Dept Cell Biol, Brasilia, DF, Brazil.
EM kellymagalhaes@unb.br
RI ; Magalhaes, Kelly Grace/A-6966-2010
OI Correa, Rafael/0000-0003-2989-2383; Eberlin, Marcos
   Nogueira/0000-0003-4868-0618; Magalhaes, Kelly Grace/0000-0002-7435-5272
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq) [312359/2016-0]; Canada Research Chair ProgramCanada Research
   Chairs; Canadian Foundation for InnovationCanada Foundation for
   Innovation; McGill University; Canadian Institutes for Health
   ResearchCanadian Institutes of Health Research (CIHR) [PJT-149098]; Sao
   Paulo Research Foundation (FAPESP)Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP) [2016/22577-6]
FX This research was funded by Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq -#312359/2016-0). CM was funded by the
   Canada Research Chair Program, the Canadian Foundation for Innovation,
   McGill University, and the Canadian Institutes for Health Research
   (PJT-149098). ME was funded by the Sao Paulo Research Foundation
   (FAPESP) (2016/22577-6).
CR Backhed F, 2004, P NATL ACAD SCI USA, V101, P15718, DOI 10.1073/pnas.0407076101
   Ballak DB, 2015, CYTOKINE, V75, P280, DOI 10.1016/j.cyto.2015.05.005
   Benedict M, 2017, WORLD J HEPATOL, V9, P715, DOI 10.4254/wjh.v9.i16.715
   BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911
   Campo L, 2019, J CLIN TRANSL HEPATO, V7, P56, DOI 10.14218/JCTH.2018.00008
   Caporaso JG, 2011, P NATL ACAD SCI USA, V108, P4516, DOI 10.1073/pnas.1000080107
   Chavez-Carbajal A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20020438
   Clarke SF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065790
   Clarke SF, 2012, GUT MICROBES, V3, P186, DOI 10.4161/gmic.20168
   Compare D, 2012, NUTR METAB CARDIOVAS, V22, P471, DOI 10.1016/j.numecd.2012.02.007
   David LA, 2014, NATURE, V505, P559, DOI 10.1038/nature12820
   Dixon LJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056100
   Elinav E, 2011, CELL, V145, P745, DOI 10.1016/j.cell.2011.04.022
   Exley MA, 2014, J ENDOCRINOL, V223, pR41, DOI 10.1530/JOE-13-0516
   Feldman AT, 2014, METHODS MOL BIOL, V1180, P31, DOI 10.1007/978-1-4939-1050-2_3
   Gonzalez-Muniesa P, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.34
   Goodrich JK, 2014, CELL, V159, P789, DOI 10.1016/j.cell.2014.09.053
   Henao-Mejia J, 2012, NATURE, V482, P179, DOI 10.1038/nature10809
   Kimura H, 2016, AM J PHYSIOL-ENDOC M, V311, pE881, DOI 10.1152/ajpendo.00174.2016
   Kleiner DE, 2005, HEPATOLOGY, V41, P1313, DOI 10.1002/hep.20701
   Krishan S, 2016, DIABETES METAB SYND, V10, pS77, DOI 10.1016/j.dsx.2016.01.034
   Krishnan S, 2018, CELL REP, V23, P1099, DOI 10.1016/j.celrep.2018.03.109
   Ley RE, 2005, P NATL ACAD SCI USA, V102, P11070, DOI 10.1073/pnas.0504978102
   Ley RE, 2008, SCIENCE, V320, P1647, DOI 10.1126/science.1155725
   Lopez-Velazquez JA, 2014, ANN HEPATOL, V13, P166, DOI 10.1016/S1665-2681(19)30879-8
   Ma JL, 2017, NUTRIENTS, V9, DOI 10.3390/nu9101124
   Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3
   Murphy EF, 2010, GUT, V59, P1635, DOI 10.1136/gut.2010.215665
   Mwaikono KS, 2016, BMC MICROBIOL, V16, DOI 10.1186/s12866-016-0758-8
   Perumpail BJ, 2017, WORLD J GASTROENTERO, V23, P8263, DOI 10.3748/wjg.v23.i47.8263
   REEVES PG, 1993, J NUTR, V123, P1939
   Riva A, 2016, DIGEST LIVER DIS, V48, pE268, DOI 10.1016/j.dld.2016.08.072
   Rowland I, 2018, EUR J NUTR, V57, P1, DOI 10.1007/s00394-017-1445-8
   Schnabl B, 2014, GASTROENTEROLOGY, V146, P1513, DOI 10.1053/j.gastro.2014.01.020
   Turnbaugh PJ, 2006, NATURE, V444, P1027, DOI 10.1038/nature05414
   Turnbaugh PJ, 2009, NATURE, V457, P480, DOI 10.1038/nature07540
   Vandanmagsar B, 2011, NAT MED, V17, P179, DOI 10.1038/nm.2279
   Wang BH, 2016, SCI REP-UK, V6, DOI 10.1038/srep32002
   Wang H, 2014, INT J OBESITY, V38, P152, DOI 10.1038/ijo.2013.59
   Wilson CH, 2018, CELL DEATH DIFFER, V25, P1010, DOI 10.1038/s41418-018-0111-x
   Wishart DS, 2013, NUCLEIC ACIDS RES, V41, pD801, DOI 10.1093/nar/gks1065
   Wree A, 2014, J MOL MED, V92, P1069, DOI 10.1007/s00109-014-1170-1
   Xia Jianguo, 2016, Curr Protoc Bioinformatics, V55, DOI 10.1002/cpbi.11
   Zhu LX, 2013, HEPATOLOGY, V57, P601, DOI 10.1002/hep.26093
NR 44
TC 0
Z9 0
U1 3
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD JAN 9
PY 2020
VL 10
AR 2926
DI 10.3389/fimmu.2019.02926
PG 13
WC Immunology
SC Immunology
GA KE9SC
UT WOS:000508889600001
PM 31998283
OA DOAJ Gold, Green Published
DA 2020-12-15
ER

PT J
AU Braz-De-Melo, HA
   Pasquarelli-do-Nascimento, G
   Correa, R
   Almeida, RD
   Santos, ID
   Prado, PS
   Picolo, V
   de Bem, AF
   Pizato, N
   Magalhaes, KG
AF Braz-De-Melo, Heloisa Antoniella
   Pasquarelli-do-Nascimento, Gabriel
   Correa, Rafael
   Almeida, Raquel das Neves
   Santos, Igor de Oliveira
   Prado, Paulo Sousa
   Picolo, Victor
   de Bem, Andreza Fabro
   Pizato, Nathalia
   Magalhaes, Kelly Grace
TI Potential neuroprotective and anti-inflammatory effects provided by
   omega-3 (DHA) against Zika virus infection in human SH-SY5Y cells
SO SCIENTIFIC REPORTS
LA English
DT Article
ID DOCOSAHEXAENOIC ACID; STEM-CELLS; BRAIN; OMEGA-3-FATTY-ACIDS;
   INFLAMMATION; APOPTOSIS; RETINA; IMPACT
AB Zika virus (ZIKV) has a strong tropism for the nervous system and has been related to post-infection neurological syndromes. Once neuronal cells are infected, the virus is capable of modulating cell metabolism, leading to neurotoxicity and cellular death. The negative effect of ZIKV in neuron cells has been characterized. However, the description of molecules capable of reversing these cytotoxic effects is still under investigation. In this context, it has been largely demonstrated that docosahexaenoic acid (DHA), an omega-3 polyunsaturated fatty acid, is highly neuroprotective. Here, we hypothesized that DHA's neuroprotective proprieties could have an influence on ZIKV-induced neurotoxicity in SH-SY5Y cells. Our data showed that pre-treatment of SH-SY5Y cells with DHA increased the cell viability and proliferation in ZIKV-infected cells. Moreover, DHA triggered an anti-inflammatory response in those infected cells. Besides, DHA was capable of restoring mitochondria function and number in ZIKV-infected SH-SY5Y cells. In addition, cells pre-treated with DHA prior to ZIKV infection presented a lower viral load at different times of infection. Taking together, these results demonstrated that DHA has a potential anti-inflammatory and neuroprotective effect against ZIKV infection in these neuron-like cells and could be a useful tool in the treatment against this virus.
C1 [Braz-De-Melo, Heloisa Antoniella; Pasquarelli-do-Nascimento, Gabriel; Correa, Rafael; Almeida, Raquel das Neves; Santos, Igor de Oliveira; Magalhaes, Kelly Grace] Univ Brasilia UnB, Dept Cell Biol, Lab Immunol & Inflammat, BR-70910900 Brasilia, DF, Brazil.
   [Prado, Paulo Sousa] Cent Lab Fed Dist LACEN, BR-70830010 Brasilia, DF, Brazil.
   [Picolo, Victor; de Bem, Andreza Fabro] Univ Brasilia UnB, Dept Physiol Sci, BR-70910900 Brasilia, DF, Brazil.
   [Pizato, Nathalia] Univ Brasilia UnB, Dept Nutr, BR-70910900 Brasilia, DF, Brazil.
RP Magalhaes, KG (corresponding author), Univ Brasilia UnB, Dept Cell Biol, Lab Immunol & Inflammat, BR-70910900 Brasilia, DF, Brazil.
EM kellymagalhaes@unb.br
RI de, Andreza/AAA-1523-2019; Magalhaes, Kelly Grace/A-6966-2010
OI de, Andreza/0000-0003-1090-5244; Magalhaes, Kelly
   Grace/0000-0002-7435-5272; Correa, Rafael/0000-0003-2989-2383; Braz de
   Melo, Heloisa Antoniella/0000-0003-3327-4633; Pizato,
   Nathalia/0000-0001-5858-7076; Pasquarelli do Nascimento,
   Gabriel/0000-0002-8329-343X
FU National Council for Scientific and Technological Development
   (CNPq)National Council for Scientific and Technological Development
   (CNPq) [312359/2016-0]; Fundacao de Amparo a Pesquisa do Distrito
   Federal (FapDF/PPSUS) [193.001.621/2016]; Welcome TrustWellcome Trust
   [24076*1*014]
FX We would like to thank our financial support provided by National
   Council for Scientific and Technological Development (CNPq
   #312359/2016-0), Fundacao de Amparo a Pesquisa do Distrito Federal
   (FapDF/PPSUS #193.001.621/2016) and Welcome Trust (24076*1*014).
CR Agapite J., 2009, AM PHYS SOC, V98, P813
   Agathocleous M, 2012, NAT CELL BIOL, V14, P859, DOI 10.1038/ncb2531
   Alpuche-Lazcano S. P., 2018, VIRUSES, V10, P1
   Anil E, 2007, P NUTR SOC, V66, P60, DOI 10.1017/S0029665107005307
   Bazan NG, 2005, BRAIN PATHOL, V15, P159
   Bazan NG, 2007, CURR OPIN CLIN NUTR, V10, P136, DOI 10.1097/MCO.0b013e32802b7030
   Bazan NG, 2013, NESTLE NUTR WORKS SE, V77, P121, DOI 10.1159/000351395
   Bennett M, 2016, MICROBIOL SPECTR, V4, DOI 10.1128/microbiolspec.MCHD-0035-2016
   Calder PC, 2010, NUTRIENTS, V2, P355, DOI 10.3390/nu2030355
   Croset M., 1996, AM SOC CLI NUT, V64, P577
   Culshaw A., 2018, F1000RESEARCH, V7, P1
   Devhare P, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.517
   Du XL, 2015, MOL MED REP, V12, P953, DOI 10.3892/mmr.2015.3482
   Dyall SC, 2015, FRONT AGING NEUROSCI, V7, DOI 10.3389/fnagi.2015.00052
   Florent S, 2006, J NEUROCHEM, V96, P385, DOI 10.1111/j.1471-4159.2005.03541.x
   He ZJ, 2018, J INFECT DIS, V217, P1942, DOI 10.1093/infdis/jiy129
   Husson M., 2016, J INFECTION, V4453, P1
   Jones G. J. B., 2017, SCI REPORTS, V159, P1
   Kalia M, 2013, J VIROL, V87, P148, DOI 10.1128/JVI.01399-12
   Kim HY, 2014, MIL MED, V179, P106, DOI 10.7205/MILMED-D-14-00162
   Kim Hee-Young, 2010, PROSTAGLANDINS LEUKO, V5, P379
   Kim HY, 2003, LIPIDS, V38, P453, DOI 10.1007/s11745-003-1083-z
   Lawrence T, 2007, INT J EXP PATHOL, V88, P85, DOI 10.1111/j.1365-2613.2006.00507.x
   Lee DY, 2015, EXP NEUROBIOL, V24, P177, DOI 10.5607/en.2015.24.3.177
   Leonelli M, 2011, BRAZ J MED BIOL RES, V44, P1088, DOI [10.1590/S0100-879X2011007500124, 10.1590/S0100-879X2011001100003]
   Li GB, 2017, J LIPID RES, V58, P1080, DOI [10.1194/jlr.m072587, 10.1194/jlr.M072587]
   Li HD, 2016, CELL STEM CELL, V19, P593, DOI 10.1016/j.stem.2016.08.005
   Liang QM, 2016, CELL STEM CELL, V19, P663, DOI 10.1016/j.stem.2016.07.019
   Losev Y, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39218-x
   Lowe R, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15010096
   Lum FM, 2017, CLIN INFECT DIS, V64, P914, DOI 10.1093/cid/ciw878
   Luplertlop N, 2017, J VECTOR DIS, V54, P207, DOI 10.4103/0972-9062.217611
   Martinot AJ, 2018, CELL, V173, P1111, DOI 10.1016/j.cell.2018.03.019
   Mead PS, 2018, CURR OPIN INFECT DIS, V31, P39, DOI 10.1097/QCO.0000000000000414
   Moore CA, 2017, JAMA PEDIATR, V171, P288, DOI 10.1001/jamapediatrics.2016.3982
   Muench Reed, 2018, AM J HYG, V27, P493
   Ojha CR, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02340
   Olmo IG, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01016
   Onorati M, 2016, CELL REP, V16, P2576, DOI 10.1016/j.celrep.2016.08.038
   Prado PS, 2018, MEM I O CRUZ, V113, P1
   Querques G, 2011, J NUTR METAB, V2011, DOI 10.1155/2011/748361
   Quicke KM, 2013, VIRUSES-BASEL, V5, P2643, DOI 10.3390/v5112643
   Rothan HA, 2019, MOL NEUROBIOL, V56, P2551, DOI 10.1007/s12035-018-1263-x
   Sakai C., 2017, PLOS ONE, V12, P1
   Souza B. S. F., 2016, SCI REPORTS, V6, P1
   Stefanik M, 2018, BMC NEUROSCI, V19, DOI 10.1186/s12868-018-0407-2
   Suphioglu C, 2010, FEBS LETT, V584, P612, DOI 10.1016/j.febslet.2009.12.013
   Xicoy H, 2017, MOL NEURODEGENER, V12, DOI 10.1186/s13024-017-0149-0
   Yan YQ, 2013, IMMUNITY, V38, P1154, DOI 10.1016/j.immuni.2013.05.015
NR 49
TC 4
Z9 4
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD DEC 27
PY 2019
VL 9
AR 20119
DI 10.1038/s41598-019-56556-y
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA KF6GA
UT WOS:000509337000027
PM 31882804
OA DOAJ Gold, Green Published
DA 2020-12-15
ER

PT J
AU Garcia-Hernandez, L
   Chao-Mujica, FJ
   de Souza, JMF
   Mol, AR
   Fontes, W
   Ricart, CA
   Musacchio, A
   de Sant'ana, LP
   Magalhaes, KG
   da Silva, IGM
   Bao, SN
   Desdin-Garcia, LF
   de Sousa, MV
AF Garcia-Hernandez, Liudy
   Chao-Mujica, Frank J.
   Ferreira de Souza, Jaques M.
   Mol, Alan R.
   Fontes, Wagner
   Ricart, Carlos A.
   Musacchio, Alexis
   de Sant'ana, Livia Pimentel
   Magalhaes, Kelly G.
   Martins da Silva, Ingrid G.
   Bao, Sonia N.
   Desdin-Garcia, Luis F.
   de Sousa, Marcelo, V
TI Proteomic analysis in cells treated with pristine carbon nano-onions and
   its subcellular localization
SO ADVANCES IN NATURAL SCIENCES-NANOSCIENCE AND NANOTECHNOLOGY
LA English
DT Article
DE proteomics; carbon nano-onions; keratinocyte cells; cellular uptake
ID NANOPARTICLE UPTAKE; CELLULAR UPTAKE; NANOTUBES; BIODEGRADATION;
   NANOMATERIALS; CYTOTOXICITY; PHAGOCYTOSIS; FLUORESCENCE; WEBGESTALT;
   MECHANISM
AB Nanoparticles toxicity and cellular uptake are substantial factors that regulate the utility of nanoparticles for biomedical applications in diagnostic imaging and therapy. In this work, the cellular uptake of pristine carbon nano-onions (CNOs) produced by submerged arc discharge was confirmed by transmission electron microscopy (TEM) analysis. Carbon nano-onions were localized within early and late endosomes of human keratinocyte cells. TEM images suggest the possible degradation of these structures, in late endosomes of keratinocyte cells after 24 h. Proteomic shotgun analysis revealed that carbon nano-onions cause statistically significant protein abundance changes in a total of 168 proteins. Most of the differentially expressed proteins are involved in biological processes such as metabolic, cellular and immune system processes. Treated cells showed increased expression of clathrin heavy chain 1, calnexin and isoforms beta/alpha, epsilon and sigma 14-3-3 protein, which are related to clathrin-mediated endocytosis. Thus changes in protein abundance concerning clathrin-mediated endocytosis may suggest this as a plausible way by which the carbon nano-onions intracellular traffic occurs.
C1 [Garcia-Hernandez, Liudy; Chao-Mujica, Frank J.; Desdin-Garcia, Luis F.] Ctr Technol Applicat & Nucl Dev CEADEN, Phys Dept, Havana, Cuba.
   [Ferreira de Souza, Jaques M.; Mol, Alan R.; Fontes, Wagner; Ricart, Carlos A.; de Sousa, Marcelo, V] Univ Brasilia, Brazilian Ctr Prot Res, Dept Cell Biol, Lab Prot Chem & Biochem, Brasilia, DF, Brazil.
   [Musacchio, Alexis] Ctr Genet Engn & Biotechnol, Syst Biol Dept, Havana, Cuba.
   [de Sant'ana, Livia Pimentel; Magalhaes, Kelly G.] Univ Brasilia, Dept Cell Biol, Lab Immunol & Inflammat, Brasilia, DF, Brazil.
   [Martins da Silva, Ingrid G.; Bao, Sonia N.] Univ Brasilia, Dept Cell Biol, Lab Electron Microscopy, Brasilia, DF, Brazil.
RP Garcia-Hernandez, L (corresponding author), Ctr Technol Applicat & Nucl Dev CEADEN, Phys Dept, Havana, Cuba.
EM liudy@ceaden.edu.cu
RI Fontes, Wagner/A-1771-2008; Valle de Sousa, Marcelo/H-1838-2016;
   Magalhaes, Kelly Grace/A-6966-2010
OI Fontes, Wagner/0000-0001-5140-8573; Musacchio,
   Alexis/0000-0001-6598-6067; Garcia Hernandez, Liudy/0000-0001-6260-7252;
   Valle de Sousa, Marcelo/0000-0002-2871-4430; Bao,
   Sonia/0000-0002-9873-3098; Chao-Mujica, Frank J./0000-0002-1809-5939;
   Magalhaes, Kelly Grace/0000-0002-7435-5272
FU ICGEB SMART Fellowship [S/CUB15-02]; Financiadora de Estudos e Projetos
   (FINEP/CT-INFRA)Ciencia Tecnologia e Inovacao (FINEP) [0439/2011,
   0694/2013];  [NAP-1-11-AENTA CITMA]
FX We would like to thank Laura Maria Garcia Rodriguez (CECMED,
   Havana-Cuba) for technical assistance in cell viability assay. We are
   grateful to the institutions and development agencies that support our
   work (project NAP-1-11-AENTA CITMA). This work was supported by ICGEB
   SMART Fellowship ID#S/CUB15-02 to L G H Funding was provided by
   Financiadora de Estudos e Projetos (FINEP/CT-INFRA, grants 0439/2011 and
   0694/2013) to M V S.
CR Alkilany AM, 2009, SMALL, V5, P701, DOI 10.1002/smll.200801546
   Allen BL, 2008, NANO LETT, V8, P3899, DOI 10.1021/nl802315h
   Allen BL, 2009, J AM CHEM SOC, V131, P17194, DOI 10.1021/ja9083623
   Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Bartelmess J, 2015, CHEM SOC REV, V44, P4672, DOI 10.1039/c4cs00306c
   Bartelmess J, 2014, BEILSTEIN J NANOTECH, V5, P1980, DOI 10.3762/bjnano.5.207
   Bhattacharya K, 2016, NANOMED-NANOTECHNOL, V12, P333, DOI 10.1016/j.nano.2015.11.011
   Chao- Mujica F J, 2019, ANALES ACAD CIENCIAS, V9, P1
   Chithrani BD, 2007, NANO LETT, V7, P1542, DOI 10.1021/nl070363y
   Chithrani BD, 2006, NANO LETT, V6, P662, DOI 10.1021/nl052396o
   Codorniu Pujals D, 2018, NUCLEUS, V64, P15
   Pujals DC, 2015, APPL PHYS A-MATER, V120, P1339, DOI 10.1007/s00339-015-9315-9
   d'Amora M, 2016, SCI REP-UK, V6, DOI 10.1038/srep33923
   Darias J, 2011, REV CUB FIS, V28, p1E80
   Ding LH, 2005, NANO LETT, V5, P2448, DOI 10.1021/nl051748o
   Efendiev R, 2005, J BIOL CHEM, V280, P16272, DOI 10.1074/jbc.M500486200
   Firmino M, 2018, J PROTEOMICS, V187, P182, DOI 10.1016/j.jprot.2018.07.018
   Frasconi M, 2015, CHEM-EUR J, V21, P19071, DOI 10.1002/chem.201503166
   Giordani S, 2014, J MATER CHEM B, V2, P7459, DOI 10.1039/c4tb01087f
   GOLDMAN R, 1977, EXP CELL RES, V104, P325, DOI 10.1016/0014-4827(77)90098-2
   Haniu H, 2010, TOXICOL APPL PHARM, V242, P256, DOI 10.1016/j.taap.2009.10.015
   Hernandez-Tabares L, 2018, ADV NAT SCI-NANOSCI, V9
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Ju L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084974
   Kammers Kai, 2015, EuPA Open Proteom, V7, P11
   Kotchey GP, 2013, ADV DRUG DELIVER REV, V65, P1921, DOI 10.1016/j.addr.2013.07.007
   Kotchey GP, 2011, ACS NANO, V5, P2098, DOI 10.1021/nn103265h
   KROTO HW, 1985, NATURE, V318, P162, DOI 10.1038/318162a0
   Lange H, 2003, CARBON, V41, P1617, DOI 10.1016/S0008-6223(03)00111-8
   Li HD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021678
   Marchesano V, 2015, NANOMATERIALS-BASEL, V5, P1331, DOI 10.3390/nano5031331
   Marco F., 2015, METHODS APPL FLUORES, V3
   Mi HY, 2013, NUCLEIC ACIDS RES, V41, pD377, DOI 10.1093/nar/gks1118
   Mi HY, 2009, METHODS MOL BIOL, V563, P123, DOI 10.1007/978-1-60761-175-2_7
   Nepomuceno RR, 1998, J IMMUNOL, V160, P1929
   Panariti A, 2012, NANOTECHNOL SCI APPL, V5, P87, DOI 10.2147/NSA.S25515
   Pelisch F, 2012, J BIOL CHEM, V287, P30789, DOI 10.1074/jbc.M112.390120
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   RYAN US, 1989, INFECT IMMUN, V57, P1356, DOI 10.1128/IAI.57.5.1356-1362.1989
   Sano N, 2001, NATURE, V414, P506, DOI 10.1038/35107141
   Santos CXC, 2009, J LEUKOCYTE BIOL, V86, P989, DOI 10.1189/jlb.0608354
   Shao N, 2007, NANOTECHNOLOGY, V18, DOI 10.1088/0957-4484/18/31/315101
   UGARTE D, 1992, NATURE, V359, P707, DOI 10.1038/359707a0
   Wang J, 2013, NUCLEIC ACIDS RES, V41, pW77, DOI 10.1093/nar/gkt439
   Wisniewski JR, 2009, NAT METHODS, V6, P359, DOI [10.1038/NMETH.1322, 10.1038/nmeth.1322]
   Witzmann FA, 2006, NANOMED-NANOTECHNOL, V2, P158, DOI 10.1016/j.nano.2006.07.005
   Xiao Y, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-351
   Xu BS, 2008, NEW CARBON MATER, V23, P289, DOI 10.1016/S1872-5805(09)60001-9
   Yuan JF, 2012, TOXICOL SCI, V126, P149, DOI 10.1093/toxsci/kfr332
   Zhang B, 2005, NUCLEIC ACIDS RES, V33, pW741, DOI 10.1093/nar/gki475
   Zhang YY, 2010, BIOMATERIALS, V31, P8465, DOI 10.1016/j.biomaterials.2010.07.060
   Zhao Y, 2011, J PHYS CHEM A, V115, P9536, DOI 10.1021/jp112324d
NR 52
TC 0
Z9 0
U1 2
U2 4
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 2043-6254
EI 2043-6262
J9 ADV NAT SCI-NANOSCI
JI Adv. Nat. Sci.-Nanosci Nanotechnol
PD SEP
PY 2019
VL 10
IS 3
AR 035011
DI 10.1088/2043-6254/ab3dfd
PG 10
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary;
   Physics, Applied
SC Science & Technology - Other Topics; Materials Science; Physics
GA KJ2BN
UT WOS:000511863200012
DA 2020-12-15
ER

PT J
AU Brand, GD
   Ramada, MHS
   Manickchand, JR
   Correa, R
   Ribeiro, DJS
   Santos, MA
   Vasconcelos, AG
   Abrao, FY
   Prates, MV
   Murad, AM
   Fh, JLC
   Leite, JRSA
   Magalhaes, KG
   Oliveira, AL
   Bloch, C
AF Brand, Guilherme D.
   Ramada, Marcelo H. S.
   Manickchand, Julia R.
   Correa, Rafael
   Ribeiro, Dalila J. S.
   Santos, Michele A.
   Vasconcelos, Andreanne G.
   Abrao, Fernando Y.
   Prates, Maura, V
   Murad, Andre M.
   Cardozo Fh, Jose L.
   Leite, Jose Roberto S. A.
   Magalhaes, Kelly G.
   Oliveira, Aline L.
   Bloch Jr, Carlos
TI Intragenic antimicrobial peptides (IAPs) from human proteins with potent
   antimicrobial and anti-inflammatory activity
SO PLOS ONE
LA English
DT Article
ID FROG; ULTRAVIOLET; IMMUNITY; INNATE; MODEL; LL-37
AB Following the treads of our previous works on the unveiling of bioactive peptides encrypted in plant proteins from diverse species, the present manuscript reports the occurrence of four proof-of-concept intragenic antimicrobial peptides in human proteins, named Hs IAPs. These IAPs were prospected using the software Kamal, synthesized by solid phase chemistry, and had their interactions with model phospholipid vesicles investigated by differential scanning calorimetry and circular dichroism. Their antimicrobial activity against bacteria, yeasts and filamentous fungi was determined, along with their cytotoxicity towards erythrocytes. Our data demonstrates that Hs IAPs are capable to bind model membranes while attaining alpha-helical structure, and to inhibit the growth of microorganisms at concentrations as low as 1 mu M. Hs02, a novel sixteen residue long internal peptide (KWAVRIIRKFIKGFIS-NH2) derived from the unconventional myosin 1h protein, was further investigated in its capacity to inhibit lipopolysaccharide-induced release of TNF-alpha in murine macrophages. Hs02 presented potent anti-inflammatory activity, inhibiting the release of TNF-alpha in LPS-primed cells at the lowest assayed concentration, 0.1 mu M. A three-dimensional solution structure of Hs02 bound to DPC micelles was determined by Nuclear Magnetic Resonance. Our work exemplifies how the human genome can be mined for molecules with biotechnological potential in human health and demonstrates that IAPs are actual alternatives to antimicrobial peptides as pharmaceutical agents or in their many other putative applications.
C1 [Brand, Guilherme D.; Manickchand, Julia R.] Univ Brasilia, Inst Quim, LSAB, Brasilia, DF, Brazil.
   [Ramada, Marcelo H. S.] Univ Catolica Brasilia, Programa Posgrad Ciencias Genom & Biotecnol, Brasilia, DF, Brazil.
   [Ramada, Marcelo H. S.] Univ Catolica Brasilia, Programa Posgrad Gerontol, Brasilia, DF, Brazil.
   [Ramada, Marcelo H. S.; Prates, Maura, V; Murad, Andre M.; Cardozo Fh, Jose L.; Bloch Jr, Carlos] Embrapa Recursos Genet & Biotecnol, LEM, Brasilia, DF, Brazil.
   [Correa, Rafael; Ribeiro, Dalila J. S.; Magalhaes, Kelly G.] Univ Brasilia, Inst Biol, Lab Imunol & Inflamacao, LIMI, Brasilia, DF, Brazil.
   [Santos, Michele A.; Oliveira, Aline L.] Univ Brasilia, Inst Quim, LRMN, Brasilia, DF, Brazil.
   [Vasconcelos, Andreanne G.; Leite, Jose Roberto S. A.] Univ Brasilia, Fac Med, NuPMIA, Nucleo Pesquisa Morfol & Imunol Aplicada, Campus Univ Darcy Ribeiro, Brasilia, DF, Brazil.
   [Abrao, Fernando Y.] FacUnicamps, Fac Farm, Goiania, Go, Brazil.
   [Cardozo Fh, Jose L.] Inst Matogrossense Algodao, Dept Fitopatol, Primavera Do Leste, MT, Brazil.
RP Brand, GD (corresponding author), Univ Brasilia, Inst Quim, LSAB, Brasilia, DF, Brazil.
EM gdbrand@unb.br
RI Brand, Guilherme/B-5603-2015; Ramada, Marcelo H.S./G-7543-2015; Prates,
   Maura/S-8399-2019; Oliveira, Aline/AAD-6671-2019; Bloch,
   Carlos/S-8375-2019; Magalhaes, Kelly G/A-6966-2010; Murad, Andre
   M/C-4459-2017; Oliveira, Aline L/D-2953-2012; Leite, Jose
   Roberto/H-9065-2013
OI Brand, Guilherme/0000-0002-1615-0009; Ramada, Marcelo
   H.S./0000-0001-9738-3412; Prates, Maura/0000-0002-0206-5890; Oliveira,
   Aline/0000-0002-6928-078X; Magalhaes, Kelly G/0000-0002-7435-5272;
   Murad, Andre M/0000-0002-7055-9462; Oliveira, Aline
   L/0000-0002-6928-078X; Correa, Rafael/0000-0003-2989-2383; Leite, Jose
   Roberto/0000-0002-1096-3236; Bloch Jr, Carlos/0000-0003-2799-6883; Yano
   Abrao, Fernando/0000-0002-0553-0946
FU Fundacao de amparo a pesquisa do DF (FAP-DF) [0193.000866/2015,
   0193.001566/2017]; Coordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior - Brasil (CAPES)CAPES [001]; Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq)National Council for
   Scientific and Technological Development (CNPq) [563712/2010-4,
   557761/2009-3]; Financiadora de Estudos e Projetos (FINEP)Ciencia
   Tecnologia e Inovacao (FINEP) [0110073600]
FX This work was supported by: GDB Fundacao de amparo a pesquisa do DF
   (FAP-DF, www.fap.df.gov.br/) grant 0193.000866/2015; ALO - Fundacao de
   amparo a pesquisa do DF (FAP-DF, www.fap.df.gov.br/) grant
   0193.001566/2017; MAS - Coordenacao de Aperfeicoamento de Pessoal de
   Nivel Superior - Brasil (CAPES, www.capes. gov. br/pt/) - Finance Code
   001; CB Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq, www.cnpq.br/) grants 563712/2010-4 and 557761/2009-3,
   Financiadora de Estudos e Projetos (FINEP, http://www.finep.gov.br/)
   grant 0110073600. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript..
CR [Anonymous], 2008, M38A2 CLSI, V28, P29
   Barbosa EA, 2015, RAPID COMMUN MASS SP, V29, P2061, DOI 10.1002/rcm.7313
   Bjorstad A, 2005, ANTIMICROB AGENTS CH, V49, P3889, DOI 10.1128/AAC.49.9.3889-3895.2005
   Brand GD, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19566-w
   Brand GD, 2002, J BIOL CHEM, V277, P49332, DOI 10.1074/jbc.M209289200
   Brand GD, 2007, ESTRATEGIAS PROSPECC
   Brand GD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045848
   Brunger AT, 2007, NAT PROTOC, V2, P2728, DOI 10.1038/nprot.2007.406
   Chan DI, 2006, BBA-BIOMEMBRANES, V1758, P1184, DOI 10.1016/j.bbamem.2006.04.006
   Chan W., 2000, FMOC SOLID PHASE PEP
   CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027
   Clinical and Laboratory Standards Institute (CLSI), 2008, M38A2 CLSI, P1
   CLSI, 2015, M07A10 CLSI, P1
   Conchillo-Sole O, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-65
   Conlon JM, 2004, BIOCHEM BIOPH RES CO, V320, P170, DOI 10.1016/j.bbrc.2004.05.141
   Dale CS, 2005, MEM I OSWALDO CRUZ, V100, P105, DOI 10.1590/S0074-02762005000900017
   den Brok MH, 2018, TRENDS IMMUNOL, V39, P380, DOI 10.1016/j.it.2018.01.012
   dos Santos RC, 2018, FOOD RES INT, V105, P184, DOI 10.1016/j.foodres.2017.10.045
   Duplantier AJ, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00143
   EISENBERG D, 1982, NATURE, V299, P371, DOI 10.1038/299371a0
   Flores SC, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-167
   Giuliani A, 2010, METHODS MOL BIOL, V618, P137, DOI 10.1007/978-1-60761-594-1_10
   Gronberg A, 2014, WOUND REPAIR REGEN, V22, P613, DOI 10.1111/wrr.12211
   Hancock REW, 2016, NAT REV IMMUNOL, V16, P321, DOI 10.1038/nri.2016.29
   Iorga A, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18051018
   Ivanov VT, 1997, BIOPOLYMERS, V43, P171
   Kahlenberg JM, 2013, J IMMUNOL, V191, P4895, DOI 10.4049/jimmunol.1302005
   KIRSCHENBAUM DM, 1975, ANAL BIOCHEM, V64, P186, DOI 10.1016/0003-2697(75)90420-0
   Lai YP, 2009, TRENDS IMMUNOL, V30, P131, DOI 10.1016/j.it.2008.12.003
   Lande R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6621
   Li LH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182057
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Nilsson M, 2008, MOL MICROBIOL, V67, P482, DOI 10.1111/j.1365-2958.2007.05974.x
   Norris M, 2016, J BIOMOL NMR, V65, P205, DOI 10.1007/s10858-016-0049-6
   Pahlman LI, 2013, THROMB HAEMOSTASIS, V109, P930, DOI 10.1160/TH12-10-0739
   Phelan M, 2009, INT DAIRY J, V19, P643, DOI 10.1016/j.idairyj.2009.06.001
   Ramada MHS, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13685-6
   Rieping W, 2007, BIOINFORMATICS, V23, P381, DOI 10.1093/bioinformatics/btl589
   Sato A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153130
   Seto GWJ, 2007, BBA-BIOMEMBRANES, V1768, P2787, DOI 10.1016/j.bbamem.2007.07.018
   Skinner SP, 2015, ACTA CRYSTALLOGR D, V71, P154, DOI 10.1107/S1399004714026662
   STEWART JCM, 1980, ANAL BIOCHEM, V104, P10, DOI 10.1016/0003-2697(80)90269-9
   Taylor D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081224
   Tsai C-J, 2008, PROTEIN SCI, V6, P24, DOI DOI 10.1002/PR0.5560060104
   Tsai CJ, 1998, FOLD DES, V3, pR71, DOI 10.1016/S1359-0278(98)00032-7
   Tsai CJ, 2000, P NATL ACAD SCI USA, V97, P12038, DOI 10.1073/pnas.97.22.12038
   Tsai CJ, 1997, PROTEIN SCI, V6, P1426, DOI 10.1002/pro.5560060707
   Vranken WF, 2005, PROTEINS, V59, P687, DOI 10.1002/prot.20449
   WADDELL WJ, 1956, J LAB CLIN MED, V48, P311
   Wang GS, 2014, PHARMACEUTICALS, V7, P545, DOI 10.3390/ph7050545
   WISHART DS, 1995, J BIOMOL NMR, V5, P67, DOI 10.1007/BF00227471
   Wuthrich K., NMR PROTEINS NUCL AC
   Yang D, 1999, SCIENCE, V286, P525, DOI 10.1126/science.286.5439.525
   Zelezetsky I, 2006, BBA-BIOMEMBRANES, V1758, P1436, DOI 10.1016/j.bbamem.2006.03.021
   Zhao G, 2006, PROTEIN SCI, V15, P1987, DOI 10.1110/ps.062286306
NR 55
TC 2
Z9 2
U1 1
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 6
PY 2019
VL 14
IS 8
AR e0220656
DI 10.1371/journal.pone.0220656
PG 20
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA IW5CU
UT WOS:000484997100029
PM 31386688
OA DOAJ Gold, Green Published
DA 2020-12-15
ER

PT J
AU Correa, LH
   Heyn, GS
   Magalhaes, KG
AF Correa, Luis Henrique
   Heyn, Gabriella Simoes
   Magalhaes, Kelly Grace
TI The Impact of the Adipose Organ Plasticity on Inflammation and Cancer
   Progression
SO CELLS
LA English
DT Review
DE brown adipose tissue; white adipose tissue; pink adipose tissue;
   browning; cancer
ID BROWN FAT; PPAR-GAMMA; MACROPHAGE POLARIZATION; INSULIN-RESISTANCE;
   TUMOR PROGRESSION; WEIGHT-LOSS; WHITE; OBESITY; TISSUE; ADIPOCYTES
AB Obesity is characterized by chronic and low-grade systemic inflammation, an increase of adipose tissue, hypertrophy, and hyperplasia of adipocytes. Adipose tissues can be classified into white, brown, beige and pink adipose tissues, which display different regulatory, morphological and functional characteristics of their adipocyte and immune cells. Brown and white adipocytes can play a key role not only in the control of energy homeostasis, or through the balance between energy storage and expenditure, but also by the modulation of immune and inflammatory responses. Therefore, brown and white adipocytes can orchestrate important immunological crosstalk that may deeply impact the tumor microenvironment and be crucial for cancer establishment and progression. Recent works have indicated that white adipose tissues can undergo a process called browning, in which an inducible brown adipocyte develops. In this review, we depict the mechanisms involved in the differential role of brown, white and pink adipocytes, highlighting their structural, morphological, regulatory and functional characteristics and correlation with cancer predisposition, establishment, and progression. We also discuss the impact of the increased adiposity in the inflammatory and immunological modulation. Moreover, we focused on the plasticity of adipocytes, describing the molecules produced and secreted by those cells, the modulation of the signaling pathways involved in the browning phenomena of white adipose tissue and its impact on inflammation and cancer.
C1 [Correa, Luis Henrique; Heyn, Gabriella Simoes; Magalhaes, Kelly Grace] Univ Brasilia, Dept Cell Biol, Lab Immunol & Inflammat, BR-70910900 Brasilia, DF, Brazil.
RP Magalhaes, KG (corresponding author), Univ Brasilia, Dept Cell Biol, Lab Immunol & Inflammat, BR-70910900 Brasilia, DF, Brazil.
EM kellymagalhaes@unb.br
OI Heyn, Gabriella Simoes/0000-0001-7120-1086; Correa, Luis
   Henrique/0000-0003-2825-0127
CR [Anonymous], 2018, NEOPLASIA, V20, P1161
   Apostoli AJ, 2014, INT J CANCER, V134, P1055, DOI 10.1002/ijc.28432
   Avgerinos KI, 2019, METABOLISM, V92, P121, DOI 10.1016/j.metabol.2018.11.001
   Balzola F., 2010, INFLAMM BOWEL DIS MO, V11, P77
   Bartelt A, 2014, NAT REV ENDOCRINOL, V10, P24, DOI 10.1038/nrendo.2013.204
   Beck GR, 2013, TRANSL RES, V161, P145, DOI 10.1016/j.trsl.2012.08.006
   Birks S, 2012, OBES REV, V13, P868, DOI 10.1111/j.1467-789X.2012.01010.x
   Boutens L, 2016, DIABETOLOGIA, V59, P879, DOI 10.1007/s00125-016-3904-9
   Brennan AM, 2006, NAT CLIN PRACT ENDOC, V2, P318, DOI 10.1038/ncpendmet0196
   Brestoff JR, 2015, CELL, V161, P146, DOI 10.1016/j.cell.2015.02.022
   Broeders EPM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0145049
   Calderon-dominguez M., 2016, PLOS ONE, V11, P1
   Caron A, 2018, NAT REV NEUROSCI, V19, P153, DOI 10.1038/nrn.2018.7
   Cinti S, 2001, P NUTR SOC, V60, P319, DOI 10.1079/PNS200192
   Cinti S, 2018, TRENDS ENDOCRIN MET, V29, P651, DOI 10.1016/j.tem.2018.05.007
   Correa LH, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01129
   Cui XB, 2017, J BIOMED RES, V31, P1, DOI 10.7555/JBR.31.20160101
   de Jesus LA, 2001, J CLIN INVEST, V108, P1379, DOI 10.1172/JCI200113803
   De Pergola G, 2013, J OBES, V2013, DOI 10.1155/2013/291546
   Chu DT, 2017, BIOCHIMIE, V138, P102, DOI 10.1016/j.biochi.2017.04.017
   Dirat B, 2011, CANCER RES, V71, P2455, DOI 10.1158/0008-5472.CAN-10-3323
   Fenzl A, 2014, HORM MOL BIOL CLIN I, V19, P25, DOI 10.1515/hmbci-2014-0022
   Fisher FM, 2012, GENE DEV, V26, P271, DOI 10.1101/gad.177857.111
   Giordano A, 2014, EUR J ENDOCRINOL, V170, pR159, DOI 10.1530/EJE-13-0945
   Goodwin PJ, 2015, ANNU REV MED, V66, P281, DOI 10.1146/annurev-med-051613-012328
   Hallberg M, 2008, MOL CELL BIOL, V28, P6785, DOI 10.1128/MCB.00504-08
   Handschin C, 2006, ENDOCR REV, V27, P728, DOI 10.1210/er.2006-0037
   Harms M, 2013, NAT MED, V19, P1252, DOI 10.1038/nm.3361
   Harms MJ, 2014, CELL METAB, V19, P593, DOI 10.1016/j.cmet.2014.03.007
   Himbert C, 2017, CANCER PREV RES, V10, P494, DOI 10.1158/1940-6207.CAPR-16-0322
   Hwang I, 2015, FASEB J, V29, P2397, DOI 10.1096/fj.14-265983
   Itoh N, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00107
   Kalinovich AV, 2017, BIOCHIMIE, V134, P127, DOI 10.1016/j.biochi.2017.01.007
   Kandul NP, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13100
   Kellen C., 2018, FRONT CELL NEUROSCI, V12, P1
   Kershaw E. E., 2018, J CLIN ENDOCR METAB, V89, P2548
   Kir S, 2016, TRENDS CANCER, V2, P461, DOI 10.1016/j.trecan.2016.07.005
   Kleiner S, 2012, P NATL ACAD SCI USA, V109, P9635, DOI 10.1073/pnas.1207287109
   Labbe SM, 2015, FRONT SYST NEUROSCI, V9, DOI 10.3389/fnsys.2015.00150
   Lauby-Secretan B, 2016, NEW ENGL J MED, V375, P794, DOI 10.1056/NEJMsr1606602
   Lee YH, 2014, EXP MOL MED, V46, DOI 10.1038/emm.2013.163
   Leone TC, 2005, PLOS BIOL, V3, P672, DOI 10.1371/journal.pbio.0030101
   Levental KR, 2009, CELL, V139, P891, DOI 10.1016/j.cell.2009.10.027
   Li C, 2018, TRANSL RES, V191, P29, DOI 10.1016/j.trsl.2017.10.004
   Lin JD, 2004, CELL, V119, P121, DOI 10.1016/j.cell.2004.09.013
   Liu DX, 2016, J CLIN INVEST, V126, P1704, DOI 10.1172/JCI83532
   Lo KA, 2013, BIOSCIENCE REP, V33, P711, DOI 10.1042/BSR20130046
   Bargut TCL, 2017, HORM MOL BIOL CLIN I, V31, DOI 10.1515/hmbci-2016-0051
   Luo JH, 2017, J CLIN ONCOL, V35, P1189, DOI [10.1200/jco.2016.70.5822, 10.1200/JCO.2016.70.5822]
   Maalouf G., 2019, J OBES, V2019, P1
   Martinez-Sanchez N, 2017, J ENDOCRINOL, V232, P351, DOI 10.1530/JOE-16-0425
   Miao J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7498
   Miao Y., 2016, SCI REPORTS, V6, P1
   Nedergaard J, 2005, BBA-MOL BASIS DIS, V1740, P293, DOI 10.1016/j.bbadis.2005.02.003
   Nieman KM, 2013, BBA-MOL CELL BIOL L, V1831, P1533, DOI 10.1016/j.bbalip.2013.02.010
   Nishimoto S, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1501332
   Noy R, 2014, IMMUNITY, V41, P49, DOI 10.1016/j.immuni.2014.06.010
   Nyasani E, 2019, ENDOCRINE, V63, P3, DOI 10.1007/s12020-018-1748-4
   Ohno H, 2012, CELL METAB, V15, P395, DOI 10.1016/j.cmet.2012.01.019
   Ortega-Molina A, 2012, CELL METAB, V15, P382, DOI 10.1016/j.cmet.2012.02.001
   Paino F, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.308
   Panina YA, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01656
   Park J, 2014, NAT REV ENDOCRINOL, V10, P455, DOI 10.1038/nrendo.2014.94
   Peng XR, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00174
   Petruzzelli M, 2014, CELL METAB, V20, P433, DOI 10.1016/j.cmet.2014.06.011
   Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5
   Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014
   Qiu YF, 2014, CELL, V157, P1292, DOI 10.1016/j.cell.2014.03.066
   Quail DF, 2019, NAT REV ENDOCRINOL, V15, P139, DOI 10.1038/s41574-018-0126-x
   Renehan AG, 2015, NAT REV CANCER, V15, P484, DOI 10.1038/nrc3967
   Ribeiro R, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-108
   Richard JE, 2017, AM J PHYSIOL-ENDOC M, V313, pE344, DOI 10.1152/ajpendo.00418.2016
   Risk T., 2016, CELL, V165, P111
   Rocha-Rodrigues S, 2016, LIFE SCI, V165, P100, DOI [10.1016/j.lfs.2016.09.023, 10.1016/j.lfs.2016.0]
   Rodriguez A, 2015, AM J PHYSIOL-ENDOC M, V309, pE691, DOI 10.1152/ajpendo.00297.2015
   Rogers NH, 2009, ENDOCRINOLOGY, V150, P2161, DOI 10.1210/en.2008-1405
   Rosenwald M, 2013, NAT CELL BIOL, V15, P659, DOI 10.1038/ncb2740
   Sa N., 2010, PLOS ONE, V5, P1
   Sanchez-Delgado G, 2015, ANN NUTR METAB, V67, P21, DOI 10.1159/000437173
   Santander AM, 2015, CANCERS, V7, P143, DOI 10.3390/cancers7010143
   Sarmento-Cabral A, 2017, SCI REP-UK, V7, DOI 10.1038/srep43537
   Schauer DP, 2017, OBESITY, V25, pS52, DOI 10.1002/oby.22002
   Schugar RC, 2017, CELL REP, V19, P2451, DOI 10.1016/j.celrep.2017.05.077
   Seale P, 2007, CELL METAB, V6, P38, DOI 10.1016/j.cmet.2007.06.001
   Seale P, 2011, J CLIN INVEST, V121, P96, DOI 10.1172/JCI44271
   Sica A, 2008, SEMIN CANCER BIOL, V18, P349, DOI 10.1016/j.semcancer.2008.03.004
   Singh R., 2014, FRONT CELL DEV BIOL, V2, P1
   Srivastava S, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.00038
   Stanford KI, 2015, DIABETES, V64, P2361, DOI 10.2337/db15-0227
   Stolarczyk E, 2017, CURR OPIN PHARMACOL, V37, P35, DOI 10.1016/j.coph.2017.08.006
   Su F, 2019, ONCOGENE, V38, P1979, DOI 10.1038/s41388-018-0558-8
   Suarez-Zamorano N, 2015, NAT MED, V21, P1497, DOI 10.1038/nm.3994
   Szentirmai E., 2017, SCI REP, V7, P1
   Tahergorabi Z, 2016, CELL BIOCHEM FUNCT, V34, P533, DOI 10.1002/cbf.3229
   Tamucci KA, 2018, PROTEIN CELL, V9, P152, DOI 10.1007/s13238-017-0434-2
   Tanaka M, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5982
   Uddin S, 2011, INT J CLIN EXP PATHO, V4, P637
   Uldry M, 2006, CELL METAB, V3, P333, DOI 10.1016/j.cmet.2006.04.002
   Vaitkus JA, 2017, EXP BIOL MED, V242, P473, DOI 10.1177/1535370216683282
   Varela L, 2012, EMBO REP, V13, P1079, DOI 10.1038/embor.2012.174
   Vargovic P, 2011, FEBS LETT, V585, P2279, DOI 10.1016/j.febslet.2011.06.001
   Vernochet C, 2009, MOL CELL BIOL, V29, P4714, DOI 10.1128/MCB.01899-08
   Vitali A, 2012, J LIPID RES, V53, P619, DOI 10.1194/jlr.M018846
   Walden TB, 2012, AM J PHYSIOL-ENDOC M, V302, pE19, DOI 10.1152/ajpendo.00249.2011
   Wankhade UD, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/2365609
   Weiner J., 2016, SCI REP, V6, P1
   Weisberg SP, 2006, J CLIN INVEST, V116, P115, DOI 10.1172/JCI24335
   Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246
   Wilson-Fritch L, 2004, J CLIN INVEST, V114, P1281, DOI 10.1172/JCI200421752
   Wu J, 2013, GENE DEV, V27, P234, DOI 10.1101/gad.211649.112
   Xu M, 2018, PANCREAS, V47, P158, DOI [10.1097/MPA.0000000000000974, 10.1097/mpa.0000000000000974]
   Zhao YR, 2003, BIOCHEM BIOPH RES CO, V300, P247, DOI 10.1016/S0006-291X(02)02838-3
   Zhu Y, 2016, CELL METAB, V24, P420, DOI 10.1016/j.cmet.2016.08.005
   Zhuang GQ, 2012, CIRCULATION, V125, P2892, DOI 10.1161/CIRCULATIONAHA.111.087817
NR 114
TC 12
Z9 12
U1 0
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4409
J9 CELLS-BASEL
JI Cells
PD JUL
PY 2019
VL 8
IS 7
AR 662
DI 10.3390/cells8070662
PG 18
WC Cell Biology
SC Cell Biology
GA IN8AC
UT WOS:000478902000065
PM 31262098
OA DOAJ Gold, Green Published
DA 2020-12-15
ER

PT J
AU Pizato, N
   Kiffer, LFMV
   Luzete, BC
   Assumpcao, JAF
   Correa, LH
   de Melo, HAB
   de Sant'Ana, LP
   Ito, MK
   Magalhaes, KG
AF Pizato, Nathalia
   Melo Vasconcelos Kiffer, Larissa Fernanda
   Luzete, Beatriz Christina
   Fagundes Assumpcao, Jose Antonio
   Correa, Luis Henrique
   Braz de Melo, Heloisa Antoniella
   de Sant'Ana, Livia Pimentel
   Ito, Marina Kiyomi
   Magalhaes, Kelly Grace
TI Omega 3-DHA and Delta-Tocotrienol Modulate Lipid Droplet Biogenesis and
   Lipophagy in Breast Cancer Cells: The Impact in Cancer Aggressiveness
SO NUTRIENTS
LA English
DT Article
DE docosahexaenoic acid (DHA); delta-tocotrienol (Delta-T3); lipid
   droplets; lipophagy; breast cancer
ID HUMAN HEPATOCELLULAR-CARCINOMA; POLYUNSATURATED FATTY-ACIDS; VITAMIN-E;
   DOCOSAHEXAENOIC ACID; GAMMA-TOCOTRIENOL; TRIGLYCERIDE ACCUMULATION;
   INDUCED APOPTOSIS; UP-REGULATION; AUTOPHAGY; METABOLISM
AB Omega 3-docosahexaenoic acid (DHA) and vitamin E Delta-tocotrienol (Delta-T3) are extensively studied as protective nutrients against cancer development. Little is known about the biological mechanisms targeted by these bioactive molecules on lipid droplet (LD) biogenesis, an important breast cancer aggressiveness marker, and the occurrence of lipophagy in breast cancer cells. The aim of this study was to investigate the effect of DHA, Delta-T3 and DHA plus Delta-T3 co-treatment in LD biogenesis and lipophagy process in triple negative breast cancer cell line MDA-MB-231. Cells were treated with 50 mu M DHA and/or 5 mu M Delta-T3. Our results demonstrated that DHA can trigger an increase in LD biogenesis and co-treatment with Delta-T3 was able to reduce this LD biogenesis. In addition, we showed that a higher cytoplasmic LD content is associated with a higher breast cancer cells malignance and proliferation. Reduction of cytoplasmic LD content by silencing ADRP (adipose differentiation-related protein), a structural LD protein, also decreased cell proliferation in MDA-MB-231 cells. Treatment with DHA and Delta-T3 alone or co-treatment did not reduce cell viability. Moreover, we showed here that DHA can trigger lipophagy in MDA-MB-231 cells and DHA plus Delta-T3 co-treatment was able to enhance this lipophagy process. Our findings demonstrated that co-treatment with DHA plus Delta-T3 in MDA-MB-231 cells could reduce LD biogenesis and potentiate lipophagy in these cells, possibly having a positive impact to inhibit breast cancer malignancy. Therefore, suitable doses of DHA and Delta-T3 vitamin E isoform supplementation can be a prominent tool in therapeutic treatments against breast cancer.
C1 [Pizato, Nathalia; Melo Vasconcelos Kiffer, Larissa Fernanda; Luzete, Beatriz Christina; Ito, Marina Kiyomi] Univ Brasilia, Dept Nutr, UnB, BR-70910900 Brasilia, DF, Brazil.
   [Melo Vasconcelos Kiffer, Larissa Fernanda; Luzete, Beatriz Christina; Fagundes Assumpcao, Jose Antonio; Correa, Luis Henrique; Braz de Melo, Heloisa Antoniella; de Sant'Ana, Livia Pimentel; Magalhaes, Kelly Grace] Univ Brasilia, Dept Cell Biol, Lab Immunol & Inflammat, UnB, BR-70910900 Brasilia, DF, Brazil.
RP Magalhaes, KG (corresponding author), Univ Brasilia, Dept Cell Biol, Lab Immunol & Inflammat, UnB, BR-70910900 Brasilia, DF, Brazil.
EM pizatonat@unb.br; larissa.vasconcelos94@gmail.com;
   biachristinaa@gmail.com; zeassumpcao@gmail.com;
   henrique.costacorrea@gmail.com; heloisa.antoniella@gmail.com;
   liviapsdourado@gmail.com; marinakito@gmail.com; kellymagalhaes@unb.br
RI Assumpcao, Jose AF/P-6588-2018; Magalhaes, Kelly Grace/A-6966-2010
OI Assumpcao, Jose AF/0000-0002-2836-1583; Pizato,
   Nathalia/0000-0001-5858-7076; Correa, Luis Henrique/0000-0003-2825-0127;
   Magalhaes, Kelly Grace/0000-0002-7435-5272; Braz de Melo, Heloisa
   Antoniella/0000-0003-3327-4633
FU Fundacao de Apoio a Pesquisa do Distrito Federal FAP-DFNational Council
   for Scientific and Technological Development (CNPq)
FX This research was funded by Fundacao de Apoio a Pesquisa do Distrito
   Federal FAP-DF.
CR Abramczyk H, 2015, ANALYST, V140, P2224, DOI 10.1039/c4an01875c
   Abramczyk H, 2012, PROG BIOPHYS MOL BIO, V108, P74, DOI 10.1016/j.pbiomolbio.2011.10.004
   Accioly MT, 2008, CANCER RES, V68, P1732, DOI 10.1158/0008-5472.CAN-07-1999
   Aggarwal BB, 2010, BIOCHEM PHARMACOL, V80, P1613, DOI 10.1016/j.bcp.2010.07.043
   Ahsan H, 2014, NUTR METAB, V11, DOI 10.1186/1743-7075-11-52
   Almeida JL, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.1002476
   Ambrosio MR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044315
   Tran AT, 2015, EUR J NUTR, V54, P265, DOI 10.1007/s00394-014-0707-y
   Antalis CJ, 2011, CLIN EXP METASTAS, V28, P733, DOI 10.1007/s10585-011-9405-9
   Baenke F, 2013, DIS MODEL MECH, V6, P1353, DOI 10.1242/dmm.011338
   Blanckaert V, 2015, INT J ONCOL, V46, P2649, DOI 10.3892/ijo.2015.2936
   Blanckaert V, 2010, INT J ONCOL, V36, P737, DOI 10.3892/ijo_00000549
   Bozza PT, 2010, PROSTAG LEUKOTR ESS, V82, P243, DOI 10.1016/j.plefa.2010.02.005
   Burdeos GC, 2014, FOOD FUNCT, V5, P2221, DOI [10.1039/c4fo00463a, 10.1039/C4FO00463A]
   Burdeos GC, 2012, LIPIDS, V47, P471, DOI 10.1007/s11745-012-3659-0
   Cardenas E, 2013, BIOCHEM PHARMACOL, V86, P845, DOI 10.1016/j.bcp.2013.07.018
   Chavez Kathryn J, 2010, Breast Dis, V32, P35, DOI 10.3233/BD-2010-0307
   Cheng G, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-285
   Chitraju C, 2012, J LIPID RES, V53, P2141, DOI 10.1194/jlr.M028902
   Cohen BC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121645
   Cruz ALS, 2019, MOL CELL BIOL, V39, DOI 10.1128/MCB.00374-18
   Currie E, 2013, CELL METAB, V18, P153, DOI 10.1016/j.cmet.2013.05.017
   D'Andrea S, 2016, BIOCHIMIE, V120, P17, DOI 10.1016/j.biochi.2015.07.010
   Dai XF, 2017, J CANCER, V8, P3131, DOI 10.7150/jca.18457
   Dupont N, 2014, CURR BIOL, V24, P609, DOI 10.1016/j.cub.2014.02.008
   El-Mashtoly SF, 2015, ANAL CHEM, V87, P7297, DOI 10.1021/acs.analchem.5b01431
   Fabian CJ, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0571-6
   Falagan-Lotsch P, 2015, J MICROBIOL METH, V118, P31, DOI 10.1016/j.mimet.2015.08.010
   Galan JA, 2008, TOXICON, V51, P1186, DOI 10.1016/j.toxicon.2008.02.004
   Ghoncheh Mahshid, 2016, Asian Pac J Cancer Prev, V17, P43
   Giovannelli P, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00492
   Golubkov Vladislav, 2003, Angiogenesis, V6, P213, DOI 10.1023/B:AGEN.0000021396.47009.b0
   Guieze R, 2015, HEMATOL REP, V7, P90, DOI 10.4081/hr.2015.6043
   Jarc E, 2018, DATA BRIEF, V18, P234, DOI 10.1016/j.dib.2018.03.033
   Jarc E, 2018, BBA-MOL CELL BIOL L, V1863, P247, DOI 10.1016/j.bbalip.2017.12.006
   Jiang ZY, 2011, J IMMUNOL, V186, P1173, DOI 10.4049/jimmunol.1002342
   Kaini RR, 2012, PROSTATE, V72, P1412, DOI 10.1002/pros.22489
   Kang KS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010296
   Kline K, 2004, J NUTR, V134, p3458S, DOI 10.1093/jn/134.12.3458S
   Koizume S, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17091430
   Kolar S, 2011, CANCER-AM CANCER SOC, V117, P5294, DOI 10.1002/cncr.26205
   Komatsu M, 2005, J CELL BIOL, V169, P425, DOI 10.1083/jcb.200412022
   Krahmer N, 2013, EMBO MOL MED, V5, P973, DOI 10.1002/emmm.201100671
   Kuo CY, 2018, CANCER COMMUN, V38, DOI 10.1186/s40880-018-0317-9
   Lecchi C, 2013, RES VET SCI, V94, P246, DOI 10.1016/j.rvsc.2012.09.019
   Lettiero B, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23726-3
   Lim SW, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-469
   Listenberger LL, 2003, P NATL ACAD SCI USA, V100, P3077, DOI 10.1073/pnas.0630588100
   Liu JJ, 2014, NUTRIENTS, V6, P5184, DOI 10.3390/nu6115184
   Liu K, 2013, CELL DEATH DIFFER, V20, P3, DOI 10.1038/cdd.2012.63
   Loganathan R, 2013, CELL PROLIFERAT, V46, P203, DOI 10.1111/cpr.12014
   Maan M, 2018, BIOCHEM BIOPH RES CO, V504, P582, DOI 10.1016/j.bbrc.2018.02.097
   Marme F, 2015, BREAST CARE, V10, P159, DOI 10.1159/000433622
   Mathew R, 2011, CURR OPIN GENET DEV, V21, P113, DOI 10.1016/j.gde.2010.12.008
   Mei S, 2011, J PHARMACOL EXP THER, V339, P487, DOI 10.1124/jpet.111.184341
   Merendino N, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/310186
   Mitra R, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3589-6
   Mitra R, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-540
   Mizushima N, 2010, NAT CELL BIOL, V12, P823, DOI 10.1038/ncb0910-823
   Muller L, 2010, MOL NUTR FOOD RES, V54, P731, DOI 10.1002/mnfr.200900399
   Nakagawa H, 2018, CANCERS, V10, DOI 10.3390/cancers10110447
   Niso-Santano M, 2015, EMBO J, V34, P1025, DOI 10.15252/embj.201489363
   Olzmann JA, 2019, NAT REV MOL CELL BIO, V20, P137, DOI 10.1038/s41580-018-0085-z
   Peh HY, 2016, PHARMACOL THERAPEUT, V162, P152, DOI 10.1016/j.pharmthera.2015.12.003
   Pereira Leanne, 2012, Int J Cell Biol, V2012, P931956, DOI 10.1155/2012/931956
   Petan T, 2018, MOLECULES, V23, DOI 10.3390/molecules23081941
   Pettersen K, 2016, FREE RADICAL BIO MED, V90, P158, DOI 10.1016/j.freeradbiomed.2015.11.018
   Pizato N, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20422-0
   Pol A, 2014, J CELL BIOL, V204, P635, DOI 10.1083/jcb.201311051
   Rabinowitz JD, 2010, SCIENCE, V330, P1344, DOI 10.1126/science.1193497
   Rajendran P, 2011, BRIT J PHARMACOL, V163, P283, DOI 10.1111/j.1476-5381.2010.01187.x
   Rak S, 2014, ANALYST, V139, P3407, DOI 10.1039/c4an00412d
   Ramdas P, 2011, CANCER GENOM PROTEOM, V8, P19
   Shen GM, 2015, MOL MED REP, V12, P8055, DOI 10.3892/mmr.2015.4488
   SHIN S, 2013, BIOMED RES INT, V2013, DOI DOI 10.1155/2013/568671
   Singh R, 2009, NATURE, V458, P1131, DOI 10.1038/nature07976
   Siveen KS, 2014, ONCOTARGET, V5, P1897, DOI 10.18632/oncotarget.1876
   Stone WL, 2004, ANN NY ACAD SCI, V1031, P223, DOI 10.1196/annals.1331.022
   Strouch MJ, 2011, J SURG RES, V165, P75, DOI 10.1016/j.jss.2009.04.022
   Sun HG, 2011, CARCINOGENESIS, V32, P1518, DOI 10.1093/carcin/bgr132
   Sun SN, 2013, INT J CLIN EXP PATHO, V6, P281
   Sunami Y, 2018, CANCERS, V10, DOI 10.3390/cancers10010003
   Tirinato L, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/1656053
   Tiwari RV, 2014, EXP BIOL MED, V239, P33, DOI 10.1177/1535370213511022
   Uto-Kondo H, 2009, J NUTR, V139, P51, DOI 10.3945/jn.108.096131
   Walch L, 2015, DEV CELL, V32, P657, DOI 10.1016/j.devcel.2015.03.008
   Wang C, 2015, INT J CLIN EXP MED, V8, P15648
   White E, 2015, J CLIN INVEST, V125, P42, DOI 10.1172/JCI73941
   Wong RSY, 2012, NUTR REV, V70, P483, DOI 10.1111/j.1753-4887.2012.00512.x
   Wright HJ, 2017, P NATL ACAD SCI USA, V114, pE6556, DOI 10.1073/pnas.1703791114
   Wu M, 2005, INT J CANCER, V117, P340, DOI 10.1002/ijc.21238
   Xiong AL, 2012, MOL NUTR FOOD RES, V56, P923, DOI 10.1002/mnfr.201200027
   Xu HN, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3431714
   Xue ML, 2017, MOL MED REP, V16, P978, DOI 10.3892/mmr.2017.6678
   Yue PYK, 2010, J BIOMOL SCREEN, V15, P427, DOI 10.1177/1087057110361772
   Zhang CC, 2015, ARCH MED SCI, V11, P1081, DOI 10.5114/aoms.2015.54865
NR 96
TC 4
Z9 4
U1 0
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6643
J9 NUTRIENTS
JI Nutrients
PD JUN
PY 2019
VL 11
IS 6
AR 1199
DI 10.3390/nu11061199
PG 18
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA II1AJ
UT WOS:000474936700005
PM 31141912
OA DOAJ Gold, Green Published
DA 2020-12-15
ER

PT J
AU Magalhaes, KG
   Luna-Gomes, T
   Mesquita-Santos, F
   Correa, R
   Assuncao, LS
   Atella, GC
   Weller, PF
   Bandeira-Melo, C
   Bozza, PT
AF Magalhaes, Kelly G.
   Luna-Gomes, Tatiana
   Mesquita-Santos, Fabio
   Correa, Rafael
   Assuncao, Leonardo Santos
   Atella, Georgia Correa
   Weller, Peter F.
   Bandeira-Melo, Christianne
   Bozza, Patricia T.
TI Schistosomal Lipids Activate Human Eosinophils via Toll-Like Receptor 2
   and PGD(2) Receptors: 15-LO Role in Cytokine Secretion
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE eosinophil; PGD(2); lipids; schistosoma; TLR; LPC; TGF beta; eoxin
ID PROSTAGLANDIN-D SYNTHASE; HEPATIC STELLATE CELLS; TGF-BETA; MANSONI;
   EXPRESSION; D-2; DP; INFECTION; PATHWAY; LYSOPHOSPHATIDYLCHOLINE
AB Parasite-derived lipids may play important roles in host-pathogen interactions and immune evasion mechanisms. Remarkable accumulation of eosinophils is a characteristic feature of inflammation associated with parasitic disease, especially caused by helminthes. Infiltrating eosinophils are implicated in the pathogenesis of helminth infection by virtue of their capacity to release an array of tissue-damaging and immunoregulatory mediators. However, the mechanisms involved in the activation of human eosinophils by parasite-derived molecules are not clear. Here we investigated the effects and mechanisms of schistosomal lipids-induced activation of human eosinophils. Our results showed that stimulation of human eosinophils in vitro with total lipid extracts from adult worms of S. mansoni induced direct activation of human eosinophils, eliciting lipid droplet biogenesis, synthesis of leukotriene (LT) C-4 and eoxin (EX) C-4 (14,15 LTC4) and secretion of eosinophil pre-formed TGF beta. We demonstrated that main eosinophil activating components within S. mansoni lipid extract are schistosomal-derived lysophosphatidylcholine (LPC) and prostaglandin (PG)D-2. Moreover, TLR2 is up-regulated in human eosinophils upon stimulation with schistosomal lipids and pre-treatment with anti-TLR2 inhibited both schistosomal lipids- and LPC-, but not PGD(2)-, induced lipid droplet biogenesis and EXC4 synthesis within eosinophils, indicating that TLR2 mediates LPC-driven human eosinophil activation. By employing PGD(2) receptor antagonists, we demonstrated that DP1 receptors are also involved in various parameters of human eosinophil activation induced by schistosomal lipids, but not by schistosomal LPC. In addition, schistosomal lipids and their active components PGD(2) and LPC, triggered 15-LO dependent production of EXC4 and secretion of TGF beta. Taken together, our results showed that schistosomal lipids contain at least two components-LPC and PGD(2)-that are capable of direct activation of human eosinophils acting on distinct eosinophil-expressed receptors, noticeably TLR2 as well as DP1, trigger human eosinophil activation characterized by production/secretion of pro-inflammatory and immunoregulatory mediators.
C1 [Magalhaes, Kelly G.; Assuncao, Leonardo Santos; Bozza, Patricia T.] Fiocruz MS, Inst Oswaldo Cruz, Lab Imunofarmacol, Rio De Janeiro, Brazil.
   [Magalhaes, Kelly G.; Correa, Rafael] Univ Brasilia UnB, Lab Imunol & Inflamacao, Brasilia, DF, Brazil.
   [Luna-Gomes, Tatiana; Mesquita-Santos, Fabio; Bandeira-Melo, Christianne] Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, Lab Inflamacao, Rio De Janeiro, Brazil.
   [Luna-Gomes, Tatiana] Univ Estado Rio de Janeiro, Inst Aplicacao Fernando Rodrigues da Silveira, Dept Ciencias Nat, Rio De Janeiro, Brazil.
   [Mesquita-Santos, Fabio] Ctr Univ Zona Oeste, Unidade Farm, Lab Pesquisas Anal Clin, Rio De Janeiro, Brazil.
   [Atella, Georgia Correa] Univ Fed Rio de Janeiro, Lab Bioquim Lipideos & Lipoproteinas, Rio De Janeiro, Brazil.
   [Weller, Peter F.] Harvard Med Sch, Allergy & Inflammat, Boston, MA USA.
RP Bozza, PT (corresponding author), Fiocruz MS, Inst Oswaldo Cruz, Lab Imunofarmacol, Rio De Janeiro, Brazil.; Bandeira-Melo, C (corresponding author), Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, Lab Inflamacao, Rio De Janeiro, Brazil.
EM cbmelo@biof.ufrj.br; pbozza@ioc.fiocruz.br
RI Magalhaes, Kelly G/A-6966-2010; de Melo, Christianne
   Bandeira/B-7724-2009; Magalhaes, Kelly Grace/L-6081-2019; Atella,
   Georgia/AAK-7897-2020
OI Magalhaes, Kelly G/0000-0002-7435-5272; de Melo, Christianne
   Bandeira/0000-0003-3305-3865; Magalhaes, Kelly
   Grace/0000-0002-7435-5272; Bozza, Patricia/0000-0001-8349-9529; Correa,
   Rafael/0000-0003-2989-2383
FU Conselho Nacional de Pesquisa (CNPq, Brazil)National Council for
   Scientific and Technological Development (CNPq); Fundacao de Amparo a
   Pesquisa do Rio de Janeiro (FAPERJ, Brazil)Carlos Chagas Filho
   Foundation for Research Support of the State of Rio de Janeiro (FAPERJ);
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES,
   Brazil)CAPES; National Institute of HealthUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USA
   [R37AI020241]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R37AI020241, R37AI020241, R37AI020241,
   R37AI020241] Funding Source: NIH RePORTER
FX This work was supported by Conselho Nacional de Pesquisa (CNPq, Brazil),
   Fundacao de Amparo a Pesquisa do Rio de Janeiro (FAPERJ, Brazil),
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES,
   Brazil) and National Institute of Health (R37AI020241).
CR Amorim NRT, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02139
   Angeli V, 2001, J EXP MED, V193, P1135, DOI 10.1084/jem.193.10.1135
   Archambault AS, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0202424
   Assuncao LS, 2017, BBA-MOL CELL BIOL L, V1862, P246, DOI 10.1016/j.bbalip.2016.11.006
   Bandeira-Melo C, 2002, J EXP MED, V196, P841, DOI 10.1084/jem.20020516
   Bandeira-Melo C, 2017, METHODS MOL BIOL, V1554, P127, DOI 10.1007/978-1-4939-6759-9_6
   Bozza PT, 2011, PROSTAG LEUKOTR ESS, V85, P205, DOI 10.1016/j.plefa.2011.04.020
   Bozza PT, 2009, BBA-MOL CELL BIOL L, V1791, P540, DOI 10.1016/j.bbalip.2009.01.005
   Bozza PT, 1997, J EXP MED, V186, P909, DOI 10.1084/jem.186.6.909
   Bozza PT, 1998, J LEUKOCYTE BIOL, V64, P563
   da Silva GT, 2016, EXP PARASITOL, V167, P124, DOI 10.1016/j.exppara.2016.06.001
   Elovic AE, 1998, J IMMUNOL, V160, P6121
   Esser J, 2010, J ALLERGY CLIN IMMUN, V126, P1032, DOI 10.1016/j.jaci.2010.06.039
   Feltenmark S, 2008, P NATL ACAD SCI USA, V105, P680, DOI 10.1073/pnas.0710127105
   Freire-de-Lima CG, 2006, J BIOL CHEM, V281, P38376, DOI 10.1074/jbc.M605146200
   FURLONG ST, 1988, EXP PARASITOL, V65, P222, DOI 10.1016/0014-4894(88)90126-9
   Gerashchenko D, 1998, J NEUROCHEM, V71, P937
   Giera M, 2018, ANAL CHIM ACTA, V1037, P107, DOI 10.1016/j.aca.2017.11.058
   Herve M, 2003, EUR J IMMUNOL, V33, P2764, DOI 10.1002/eji.200324143
   Kamdem SD, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02781
   Klion AD, 2004, J ALLERGY CLIN IMMUN, V113, P30, DOI 10.1016/j.jaci.2003.10.050
   Kostenis E, 2006, TRENDS MOL MED, V12, P148, DOI 10.1016/j.molmed.2006.02.005
   Luna-Gomes T, 2011, J IMMUNOL, V187, P6518, DOI 10.4049/jimmunol.1101806
   Magalhaes KG, 2010, J INFECT DIS, V202, P1369, DOI 10.1086/656477
   Melo RCN, 2011, METHODS MOL BIOL, V689, P149, DOI 10.1007/978-1-60761-950-5_9
   Mesquita-Santos FP, 2011, BRIT J PHARMACOL, V162, P1674, DOI 10.1111/j.1476-5381.2010.01086.x
   Mohri I, 2007, J NEUROPATH EXP NEUR, V66, P469, DOI 10.1097/01.jnen.0000240472.43038.27
   Nantel F, 2004, PROSTAG OTH LIPID M, V73, P87, DOI 10.1016/j.prostaglandins.2003.12.002
   Paiva LA, 2010, BBA-MOL CELL BIOL L, V1801, P1341, DOI 10.1016/j.bbalip.2010.08.014
   Paiva LA, 2015, PROSTAG LEUKOTR ESS, V95, P57, DOI 10.1016/j.plefa.2015.01.004
   Pearce EJ, 2002, NAT REV IMMUNOL, V2, P499, DOI 10.1038/nri843
   Peinhaupt M, 2017, FRONT MED-LAUSANNE, V4, DOI 10.3389/fmed.2017.00104
   Rothenberg ME, 2006, ANNU REV IMMUNOL, V24, P147, DOI 10.1146/annurev.immunol.24.021605.090720
   Rumbley CA, 1999, J IMMUNOL, V162, P1003
   Sabin EA, 1996, J EXP MED, V184, P1871, DOI 10.1084/jem.184.5.1871
   Sachs-Olsen C, 2010, J ALLERGY CLIN IMMUN, V126, P859, DOI 10.1016/j.jaci.2010.07.015
   Secor WE, 1998, PROSTAG OTH LIPID M, V56, P291, DOI 10.1016/S0090-6980(98)00059-8
   Serhan CN, 2015, BBA-MOL CELL BIOL L, V1851, P397, DOI 10.1016/j.bbalip.2014.08.006
   Serhan CN, 2011, CHEM REV, V111, P5922, DOI 10.1021/cr100396c
   SHER A, 1990, J IMMUNOL, V145, P3911
   SIGAL E, 1993, J LIPID MEDIATOR, V6, P75
   Strandmark J, 2016, CRIT REV IMMUNOL, V36, P193, DOI 10.1615/CritRevImmunol.2016018726
   Swartz JM, 2006, BLOOD, V108, P2420, DOI 10.1182/blood-2006-04-015933
   van der Kleij D, 1999, INFECT IMMUN, V67, P5946, DOI 10.1128/IAI.67.11.5946-5950.1999
   van der Kleij D, 2003, EUR J IMMUNOL, V33, P2953, DOI 10.1002/eji.200324340
   van der Kleij D, 2002, J BIOL CHEM, V277, P48122, DOI 10.1074/jbc.M206941200
   Van Hellemond JJ, 2006, INT J PARASITOL, V36, P691, DOI 10.1016/j.ijpara.2006.01.007
   Wahl SM, 1997, KIDNEY INT, V51, P1370, DOI 10.1038/ki.1997.187
   Weller PF, 2017, NAT REV IMMUNOL, V17, P746, DOI 10.1038/nri.2017.95
   Wen YS, 2007, ENDOCRINOLOGY, V148, P1313, DOI 10.1210/en.2006-0665
   Wong CK, 2007, AM J RESP CELL MOL, V37, P85, DOI 10.1165/rcmb.2006-0457OC
   WONG DTW, 1991, BLOOD, V78, P2702
   Wright DH, 2000, BRIT J PHARMACOL, V131, P1537, DOI 10.1038/sj.bjp.0703688
   Yoo S, 2013, CURR NEUROPHARMACOL, V11, P664, DOI 10.2174/1570159X11311060009
   Zhou SX, 2018, MOL MED REP, V17, P2366, DOI 10.3892/mmr.2017.8102
NR 55
TC 6
Z9 6
U1 0
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD JAN 25
PY 2019
VL 9
AR 3161
DI 10.3389/fimmu.2018.03161
PG 11
WC Immunology
SC Immunology
GA HJ0JB
UT WOS:000456844800001
PM 30740113
OA DOAJ Gold, Green Published
DA 2020-12-15
ER

PT J
AU Pinheiro, WO
   Fascineli, ML
   Farias, GR
   Horst, FH
   de Andrade, LR
   Correa, LH
   Magalhaes, KG
   Sousa, MH
   de Almeida, MC
   Azevedo, RB
   Lacava, ZGM
AF Pinheiro, Willie O.
   Fascineli, Maria L.
   Farias, Gabriel R.
   Horst, Frederico H.
   de Andrade, Laise Rodrigues
   Correa, Luis Henrique
   Magalhaes, Kelly Grace
   Sousa, Marcelo Henrique
   de Almeida, Marcos C.
   Azevedo, Ricardo B.
   Lacava, Zulmira G. M.
TI The influence of female mice age on biodistribution and biocompatibility
   of citrate-coated magnetic nanoparticles
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Article
DE elderly; nanotoxicity; maghemite nanoparticles; superparamagnetic iron
   oxide nanoparticles; SPIO; nano-safety; inductively coupled plasma
   optical emission spectrometry; ICP-OES
ID IRON-OXIDE NANOPARTICLES; ALBUMIN-BOUND PACLITAXEL; ELDERLY-PATIENTS;
   DRUG-DELIVERY; BREAST-CANCER; LIVER; RESONANCE; EXPOSURE; FLUIDS;
   NANOTOXICITY
AB Background: Magnetic nanoparticles (MNPs) have been successfully tested for several purposes in medical applications. However, knowledge concerning the effects of nanostructures on elderly organisms is remarkably scarce.
   Purpose: To fill part of this gap, this work aimed to investigate biocompatibility and biodistribution aspects of magnetic nanoparticles coated with citrate (NpCit) in both elderly and young healthy mice.
   Methods: NpCit (2.4 mg iron) was administered intraperitoneally, and its toxicity was evaluated for 28 days through clinical, biochemical, hematological, and histopathological examinations. In addition, its biodistribution was evaluated by spectrometric (inductively coupled plasma optical emission spectrometry) and histological methods.
   Results: NpCit presented age-dependent effects, inducing very slight and temporary biochemical and hematological changes in young animals. These changes were even weaker than the effects of the aging process, especially those related to the hematological data, tumor necrosis factor alpha, and nitric oxide levels. On the other hand, NpCit showed a distinct set of results in the elderly group, sometimes reinforcing (decrease of lymphocytes and increase of monocytes) and sometimes opposing (erythrocyte parameters and cytokine levels) the aging changes. Leukocyte changes were still observed on the 28th day after treatment in the elderly group. Slight evidence of a decrease in liver and immune functions was detected in elderly mice treated or not treated with NpCit. It was noted that tissue damage or clinical changes related to aging or to the NpCit treatment were not observed. As detected for aging, the pattern of iron biodistribution was significantly different after NpCit administration: extra iron was detected until the 28th day, but in different organs of elderly (liver and kidneys) and young (spleen, liver, and lungs) mice.
   Conclusion: Taken together, the data show NpCit to be a stable and reasonably biocompatible sample, especially for young mice, and thus appropriate for biomedical applications. The data showed important differences after NpCit treatment related to the animals' age, and this emphasizes the need for further studies in older animals to appropriately extend the benefits of nanotechnology to the elderly population.
C1 [Pinheiro, Willie O.; Fascineli, Maria L.; Farias, Gabriel R.; Horst, Frederico H.; de Andrade, Laise Rodrigues; de Almeida, Marcos C.; Azevedo, Ricardo B.; Lacava, Zulmira G. M.] Univ Brasilia, CNANO, Inst Biol Sci, Dept Genet & Morphol, BR-70910900 Brasilia, DF, Brazil.
   [Pinheiro, Willie O.; Lacava, Zulmira G. M.] Univ Brasilia, Fac Med, Postgrad Program Mol Pathol, BR-70910900 Brasilia, DF, Brazil.
   [Correa, Luis Henrique; Magalhaes, Kelly Grace] Univ Brasilia, Dept Cell Biol, Lab Immunol & Inflammat, BR-70910900 Brasilia, DF, Brazil.
   [Sousa, Marcelo Henrique] Univ Brasilia, Fac Ceilandia, Green Nanotechnol Grp, BR-72220900 Brasilia, DF, Brazil.
RP Lacava, ZGM (corresponding author), Univ Brasilia, CNANO, Inst Biol Sci, Dept Genet & Morphol, BR-70910900 Brasilia, DF, Brazil.
EM zulmira@unb.br
RI Magalhaes, Kelly G/A-6966-2010; Magalhaes, Kelly Grace/L-6081-2019;
   Sousa, Marcelo Henrique/AAM-3003-2020; Sousa, Marcelo
   Henrique/D-5420-2012
OI Magalhaes, Kelly G/0000-0002-7435-5272; Magalhaes, Kelly
   Grace/0000-0002-7435-5272; Sousa, Marcelo Henrique/0000-0003-1210-8329;
   Andrade, Laise/0000-0003-2390-3539; Farias, Gabriel/0000-0002-0770-1956;
   Horst, Frederico/0000-0002-3696-0033; Correa, Luis
   Henrique/0000-0003-2825-0127; Pinheiro, Willie/0000-0001-6396-3953
FU Coordination for Further Training of Graduate Staff (CAPES)CAPES;
   Brazilian National Council for Technological and Scientific Development
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Foundation to Support Research in the Federal District
   (FAPDF)National Council for Scientific and Technological Development
   (CNPq); Network of Nanobiotechnology CON-NANO (CAPES); National
   Institute of Science and Technology in Nanobiotechnology
   (INCT-Nanobiotecnologia); Center for Nanoscience and Nanobiotechnology
   of the University of Brasilia (CNANOUnB); University of Brasilia
   (DPP-UnB)
FX We acknowledge Dr Emilia CO Lima from the Federal University of Goias,
   Goiania, GO, Brazil, for providing the NpCit sample, the Coordination
   for Further Training of Graduate Staff (CAPES), the Brazilian National
   Council for Technological and Scientific Development (CNPq), the
   Foundation to Support Research in the Federal District (FAPDF), the
   Network of Nanobiotechnology CON-NANO (CAPES), the National Institute of
   Science and Technology in Nanobiotechnology (INCT-Nanobiotecnologia),
   the Center for Nanoscience and Nanobiotechnology of the University of
   Brasilia (CNANOUnB), and the Dean of Research and Post-Graduation of the
   University of Brasilia (DPP-UnB) for financial support.
CR ALMERSJO O, 1968, ANN SURG, V167, P9, DOI 10.1097/00000658-196801000-00002
   AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915
   Bonadio RS, 2017, NANOMEDICINE-UK, V12, P2637, DOI 10.2217/nnm-2017-0241
   BRUCE R, 1958, BRIT MED J, V2, P1125, DOI 10.1136/bmj.2.5105.1125
   BUSKE N, 1984, COLLOID SURFACE, V12, P195, DOI 10.1016/0166-6622(84)80099-2
   Calero M, 2015, J NANOBIOTECHNOL, V13, DOI 10.1186/s12951-015-0073-9
   Cançado Rodolfo D., 2007, Rev. Bras. Hematol. Hemoter., V29, P316, DOI 10.1590/S1516-84842007000300025
   Candido N., 2014, J NANOMED NANOTECHNO, V5, P1
   Cassim SM, 2011, PROC SPIE, V7901, DOI 10.1117/12.876514
   CHALIFOUX A, 1969, CAN J COMPARAT MED, V33, P178
   Chaves SB, 2002, IEEE T MAGN, V38, P3231, DOI 10.1109/TMAG.2002.802495
   Chen Z, 2008, ENVIRON SCI TECHNOL, V42, P8985, DOI 10.1021/es800975u
   Crielaard BJ, 2017, NAT REV DRUG DISCOV, V16, P400, DOI 10.1038/nrd.2016.248
   da Silva AC, 2010, EINSTEIN-SAO PAULO, V8, P361, DOI 10.1590/S1679-45082010RW1757
   DEWAR HA, 1958, BRIT MED J, V2, P1121, DOI 10.1136/bmj.2.5105.1121
   Estevanato L, 2011, INT J NANOMED, V6, P1709, DOI 10.2147/IJN.S21323
   Ewers I, 2008, EINSTEIN-SAO PAULO, V6, P13
   Farrugia A, 2010, TRANSFUS MED REV, V24, P53, DOI 10.1016/j.tmrv.2009.09.005
   Feng QY, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19628-z
   Gate L, 2017, TOXICOL LETT, V265, P61, DOI 10.1016/j.toxlet.2016.11.009
   Grotto Helena Z. W., 2010, Rev. Bras. Hematol. Hemoter., V32, P08
   Habib S, 2011, INDIAN J CLIN BIOCHE, V26, P3, DOI 10.1007/s12291-011-0108-4
   Haley B, 2008, UROL ONCOL-SEMIN ORI, V26, P57, DOI 10.1016/j.urolonc.2007.03.015
   Han XY, 2018, J NANOSCI NANOTECHNO, V18, P879, DOI 10.1166/jnn.2018.14110
   Hasty P, 2002, SCIENCE, V296, P1250, DOI 10.1126/science.1071808
   Herrera DA, 2019, EXPERT OPIN PHARMACO, V20, P95, DOI 10.1080/14656566.2018.1546290
   Ivkov R, 2013, INT J HYPERTHER, V29, P703, DOI 10.3109/02656736.2013.857434
   Jenkins EO, 2014, ONCOLOGIST, V19, P1076, DOI 10.1634/theoncologist.2014-0184
   Kaur P, 2016, INT J HYPERTHER, V32, P76, DOI 10.3109/02656736.2015.1120889
   Kim J, 2008, MECH AGEING DEV, V129, P322, DOI 10.1016/j.mad.2008.02.011
   Kossatz S, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0576-1
   Kuckelhaus S, 2003, J APPL PHYS, V93, P6707, DOI 10.1063/1.1558665
   Kuckelhaus S, 2005, J APPL PHYS, V97, DOI 10.1063/1.1852311
   Lacava LM, 2002, J MAGN MAGN MATER, V252, P367, DOI 10.1016/S0304-8853(02)00654-6
   Lacava ZGM, 1999, J MAGN MAGN MATER, V201, P431, DOI 10.1016/S0304-8853(99)00002-5
   Lee WM, 2003, SEMIN LIVER DIS, V23, P217
   Li JS, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19469-w
   Li Y, 2014, INT J MOL SCI, V15, P3671, DOI 10.3390/ijms15033671
   Mohammadi Z, 2017, DRUG RES, V67, P211, DOI 10.1055/s-0042-122136
   Morais PC, 2006, THIN SOLID FILMS, V515, P266, DOI 10.1016/j.tsf.2005.12.079
   Nallathamby PD, 2015, NANOSCALE, V7, P6545, DOI 10.1039/c4nr06441k
   Neves WP, 2017, J CANC SCI THER, V9, P392
   Okuma Y, 2016, CANCER CHEMOTH PHARM, V78, P383, DOI 10.1007/s00280-016-3092-9
   Orucevic A, 2015, CANCERS, V7, P1472, DOI 10.3390/cancers7030846
   Pernodet N, 2006, SMALL, V2, P766, DOI 10.1002/smll.200500492
   Pulchinelli Junior Alvaro, 2012, J. Bras. Patol. Med. Lab., V48, P169, DOI 10.1590/S1676-24442012000300004
   Quimby FW, 2007, MOUSE BIOMEDICAL RES, VIII, P171, DOI DOI 10.1016/B978-012369454-6/50060-1
   Rodrigues D, 2017, NANOTOXICOLOGY, V11, P256, DOI 10.1080/17435390.2017.1291865
   Sadeghiani N, 2005, IEEE T MAGN, V41, P4108, DOI 10.1109/TMAG.2005.855334
   Scharf A, 2013, ACS NANO, V7, P10695, DOI 10.1021/nn403443r
   Sharma A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23317-2
   Sharma A, 2013, MOL NEUROBIOL, V48, P386, DOI 10.1007/s12035-013-8500-0
   Sheedfar F, 2013, AGING CELL, V12, P950, DOI 10.1111/acel.12128
   Shibuya S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109288
   Shrestha S, 2016, J MATER CHEM B, V4, P245, DOI 10.1039/c5tb02007g
   Sousa MH, 2011, MICROCHEM J, V97, P182, DOI 10.1016/j.microc.2010.09.002
   Steichen SD, 2013, EUR J PHARM SCI, V48, P416, DOI 10.1016/j.ejps.2012.12.006
   SUTHERLAND RJ, 1989, VET CLIN N AM-SMALL, V19, P899, DOI 10.1016/S0195-5616(89)50104-9
   Szigeti K, 2018, CONTRAST MEDIA MOL I, DOI 10.1155/2018/2023604
   Thrall M.A., 2007, HEMATOLOGIA BIOQUIMI, P259
   Valerio MR, 2017, J CANC THER, V8, P933
   Wei YY, 2016, NANOIMPACT, V3-4, P1, DOI 10.1016/j.impact.2016.09.003
   Whitehead JC, 2014, J GERONTOL A-BIOL, V69, P621, DOI 10.1093/gerona/glt136
   Wu W, 2016, NANOSCALE, V8, P19421, DOI 10.1039/c6nr07542h
   Zhang Y, 2016, ADV MATER, V28, P1387, DOI 10.1002/adma.201503893
   Zheng Q, 2012, J BIOMED RES, V26, P159, DOI 10.7555/JBR.26.20110106
NR 66
TC 1
Z9 1
U1 0
U2 3
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2019
VL 14
BP 3375
EP 3388
DI 10.2147/IJN.S197888
PG 14
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
SC Science & Technology - Other Topics; Pharmacology & Pharmacy
GA HX8CR
UT WOS:000467633900002
PM 31123402
OA DOAJ Gold, Green Published
DA 2020-12-15
ER

PT J
AU de Campos, TA
   Goncalves, LF
   Magalhaes, KG
   Martins, VD
   Pappas, GJ
   Peirano, G
   Pitout, JDD
   Goncalves, GB
   Furlan, JPR
   Stehling, EG
   Pitondo-Silva, A
AF de Campos, Tatiana Amabile
   Goncalves, Laura Fernandes
   Magalhaes, Kelly Grace
   Martins, Vicente de Paulo
   Pappas Junior, Georgios Joannis
   Peirano, Gisele
   Pitout, Johann D. D.
   Goncalves, Guilherme Bartolomeu
   Rueda Furlan, Joao Pedro
   Stehling, Eliana Guedes
   Pitondo-Silva, Andre
TI A Fatal Bacteremia Caused by Hypermucousviscous KPC-2 Producing
   Extensively Drug-Resistant K64-ST11 Klebsiella pneumoniae in Brazil
SO FRONTIERS IN MEDICINE
LA English
DT Article
DE Klebsiella pneumoniae; hypermucousviscous; KPC-2; XDR; ST11; virulence;
   antimicrobial resistance
ID ANTIMICROBIAL RESISTANCE; ENTEROBACTERIACEAE; HYPERVIRULENT; SEPSIS
AB We report a fatal bacteremia caused by Klebsiella pneumoniae in a 60-70-year-old patient from Brazil. The genomic analysis of three isolates (from blood culture, nasal and anal swabs) showed that the bacteremia was caused by a KPC-2 producing extensively drug-resistant K64-ST11 hypermucousviscous K. pneumoniae (hmKP) harboring several virulence and antimicrobial resistance genes. Although the isolates did not present virulence markers associated with hypervirulent K. pneumoniae (hvKP), they showed invasion and toxicity to epithelial Hep-2 cells; resistance to cell microbicidal mechanisms; and blood and human serum survival, evidencing their pathogenic potential. This study highlights the risk of infection caused by hmKp strains not characterized as hvKP as well as the clinical implications and difficulty of treatment, especially in elderly or immunocompromised patients.
C1 [de Campos, Tatiana Amabile; Goncalves, Laura Fernandes; Magalhaes, Kelly Grace; Martins, Vicente de Paulo; Pappas Junior, Georgios Joannis] Univ Brasilia, Inst Biol Sci, Dept Cell Biol, Brasilia, DF, Brazil.
   [Peirano, Gisele; Pitout, Johann D. D.] Univ Calgary, Dept Pathol & Lab Med, Calgary, AB, Canada.
   [Goncalves, Guilherme Bartolomeu; Rueda Furlan, Joao Pedro; Stehling, Eliana Guedes] Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto, Dept Clin Toxicol & Bromatol Anal, Ribeirao Preto, Brazil.
   [Pitondo-Silva, Andre] Univ Ribeirao Preto, Sch Dent, Ribeirao Preto, Brazil.
RP de Campos, TA (corresponding author), Univ Brasilia, Inst Biol Sci, Dept Cell Biol, Brasilia, DF, Brazil.
EM tatianadecampos@unb.br
RI Pappas, Georgios J./N-8071-2019; Magalhaes, Kelly G/A-6966-2010; de
   paulo martins, vicente/H-7182-2019; Furlan, Joao Pedro
   Rueda/A-7552-2018; Furlan, Joao Pedro Rueda/W-7724-2019; Stehling,
   Eliana G/I-1171-2015; Magalhaes, Kelly Grace/L-6081-2019; Pitout,
   Johann/AAA-3790-2020
OI Pappas, Georgios J./0000-0002-1100-976X; Magalhaes, Kelly
   G/0000-0002-7435-5272; de paulo martins, vicente/0000-0001-7611-861X;
   Furlan, Joao Pedro Rueda/0000-0003-2516-1129; Furlan, Joao Pedro
   Rueda/0000-0003-2516-1129; Stehling, Eliana G/0000-0002-4362-3203;
   Magalhaes, Kelly Grace/0000-0002-7435-5272; 
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo-FAPESPFundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2013/22581-5];
   Fundacao de Apoio ao Desenvolvimento Cientifico e Tecnologico do
   Hospital Universitario de Brasilia-FAHUB [01/2015]
FX We are thankful for the financial support from Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo-FAPESP [grant number 2013/22581-5] and
   Fundacao de Apoio ao Desenvolvimento Cientifico e Tecnologico do
   Hospital Universitario de Brasilia-FAHUB [grant number 01/2015]. We also
   would like to thank John Carpenter (Ribeirao Preto, SP, Brazil) for the
   English revision.
CR Ahmad TA, 2012, VACCINE, V30, P2411, DOI 10.1016/j.vaccine.2011.11.027
   Araujo BF, 2018, J MED MICROBIOL, V67, P523, DOI 10.1099/jmm.0.000711
   Arena F, 2017, VIRULENCE, V8, P1900, DOI 10.1080/21505594.2017.1286439
   Bi WZ, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01230
   Bialek-Davenet S, 2014, EMERG INFECT DIS, V20, P1812, DOI 10.3201/eid2011.140206
   Biberg CA, 2015, BRAZ J MICROBIOL, V46, P501, DOI 10.1590/S1517-838246246220140174
   Carattoli A, 2014, ANTIMICROB AGENTS CH, V58, P3895, DOI 10.1128/AAC.02412-14
   Catalan-Najera JC, 2017, VIRULENCE, V8, P1111, DOI 10.1080/21505594.2017.1317412
   Carrigan SD, 2004, CLIN CHEM, V50, P1301, DOI 10.1373/clinchem.2004.032144
   Clinical and Laboratory Standards Institute [CLSI], 2016, M100S26 CLSI
   Dallenne C, 2010, J ANTIMICROB CHEMOTH, V65, P490, DOI 10.1093/jac/dkp498
   DeLeo FR, 2017, ANTIMICROB AGENTS CH, V61, DOI 10.1128/AAC.02533-16
   Doyle D, 2012, J CLIN MICROBIOL, V50, P3877, DOI 10.1128/JCM.02117-12
   Favre-Bonte S, 1999, INFECT IMMUN, V67, P554, DOI 10.1128/IAI.67.2.554-561.1999
   Fry DE, 2013, SCIENTIFICA, V2013, DOI 10.1155/2013/896297
   Girometti N, 2014, MEDICINE, V93, P298, DOI 10.1097/MD.0000000000000111
   Jacobs DM, 2017, ANN CLIN MICROB ANTI, V16, DOI 10.1186/s12941-017-0249-2
   Krapp F, 2018, OPEN FORUM INFECT DI, V5, DOI 10.1093/ofid/ofy074
   Lee CR, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00483
   Llobet E, 2008, MICROBIOL-SGM, V154, P3877, DOI 10.1099/mic.0.2008/022301-0
   Magiorakos AP, 2012, CLIN MICROBIOL INFEC, V18, P268, DOI 10.1111/j.1469-0691.2011.03570.x
   Sampaio JLM, 2016, BRAZ J MICROBIOL, V47, P31, DOI 10.1016/j.bjm.2016.10.002
   Nurk S, 2013, J COMPUT BIOL, V20, P714, DOI 10.1089/cmb.2013.0084
   Paczosa MK, 2016, MICROBIOL MOL BIOL R, V80, P629, DOI 10.1128/MMBR.00078-15
   Podnos YD, 2002, CLIN INFECT DIS, V35, P62, DOI 10.1086/340866
   Shon AS, 2013, VIRULENCE, V4, P107, DOI 10.4161/viru.22718
   Lopes ACS, 2016, MICROB PATHOGENESIS, V96, P15, DOI 10.1016/j.micpath.2016.04.018
   Struve C, 2015, MBIO, V6, DOI 10.1128/mBio.00630-15
   Versalovic James, 1994, Methods in Molecular and Cellular Biology, V5, P25
   Wilksch JJ, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002204
   Zankari E, 2012, J ANTIMICROB CHEMOTH, V67, P2640, DOI 10.1093/jac/dks261
   Zhao F, 2015, J INFECT DEV COUNTR, V9, P1016, DOI 10.3855/jidc.6679
NR 32
TC 7
Z9 7
U1 0
U2 3
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-858X
J9 FRONT MED-LAUSANNE
JI Front. Med.
PD SEP 21
PY 2018
VL 5
AR 265
DI 10.3389/fmed.2018.00265
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA GU5MX
UT WOS:000445331500001
PM 30298131
OA DOAJ Gold, Green Published
DA 2020-12-15
ER

PT J
AU Almeida, RD
   Racine, T
   Magalhaes, KG
   Kobinger, GP
AF Almeida, Raquel das Neves
   Racine, Trina
   Magalhaes, Kelly G.
   Kobinger, Gary P.
TI Zika Virus Vaccines: Challenges and Perspectives
SO VACCINES
LA English
DT Review
DE zika virus; flaviviruses; vaccines; animal models; immunopathology;
   immune responses; challenge; clinical trials
ID FLAVIVIRUS INFECTION ENHANCEMENT; ANTIBODY-DEPENDENT ENHANCEMENT;
   JAPANESE ENCEPHALITIS VACCINE; DENGUE VIRUS; DNA VACCINE; PROTEIN NS1;
   PHASE-III; IMMUNOGENICITY; SAFETY; PROTECTION
AB Zika virus is an arbovirus that has rapidly spread within the Americas since 2014, presenting a variety of clinical manifestations and neurological complications resulting in congenital malformation, microcephaly, and possibly, in male infertility. These significant clinical manifestations have led investigators to develop several candidate vaccines specific to Zika virus. In this review we describe relevant targets for the development of vaccines specific for Zika virus, the development status of various vaccine candidates and their different platforms, as well as their clinical progression.
C1 [Almeida, Raquel das Neves; Magalhaes, Kelly G.] Univ Brasilia, Lab Immunol & Inflammat, BR-70910900 Brasilia, DF, Brazil.
   [Racine, Trina; Kobinger, Gary P.] Univ Laval, CHU Quebec, Ctr Rech Infectiol, Quebec City, PQ G1V 4G2, Canada.
   [Racine, Trina; Kobinger, Gary P.] Univ Manitoba, Dept Med Microbiol, Winnipeg, MB R3E 0J9, Canada.
   [Kobinger, Gary P.] Univ Manitoba, Dept Immunol, Winnipeg, MB R3E 0T5, Canada.
   [Kobinger, Gary P.] Univ Laval, Dept Microbiol Infectiol & Immunol, Quebc, PQ G1V 0A6, Canada.
   [Kobinger, Gary P.] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.
RP Kobinger, GP (corresponding author), Univ Laval, CHU Quebec, Ctr Rech Infectiol, Quebec City, PQ G1V 4G2, Canada.; Kobinger, GP (corresponding author), Univ Manitoba, Dept Med Microbiol, Winnipeg, MB R3E 0J9, Canada.; Kobinger, GP (corresponding author), Univ Manitoba, Dept Immunol, Winnipeg, MB R3E 0T5, Canada.; Kobinger, GP (corresponding author), Univ Laval, Dept Microbiol Infectiol & Immunol, Quebc, PQ G1V 0A6, Canada.; Kobinger, GP (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.
EM raquel.das-neves-almeida.1@ulaval.ca;
   trina.racine@crchudequebec.ulaval.ca; kellymagalhaes@gmail.com;
   Gary.Kobinger@crchudequebec.ulaval.ca
RI Magalhaes, Kelly Grace/L-6081-2019; Magalhaes, Kelly G/A-6966-2010
OI Magalhaes, Kelly Grace/0000-0002-7435-5272; Magalhaes, Kelly
   G/0000-0002-7435-5272; Racine, Trina/0000-0001-6370-8661
CR Agarwal A., 2016, SCIENCE, V353, P1
   Ahlers LRH, 2018, FRONT CELL INFECT MI, V8, DOI 10.3389/fcimb.2018.00096
   Araujo AQC, 2016, BRAIN, V139, P2122, DOI 10.1093/brain/aww158
   Astill J, 2018, VACCINE, V36, P3908, DOI 10.1016/j.vaccine.2018.05.093
   Bardina SV, 2017, SCIENCE, V356, P175, DOI 10.1126/science.aal4365
   Barrett ADT, 2009, CURR OPIN IMMUNOL, V21, P308, DOI 10.1016/j.coi.2009.05.018
   Besnard M, 2014, EUROSURVEILLANCE, V19, P13, DOI 10.2807/1560-7917.ES2014.19.13.20751
   Boigard H, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005608
   Brault AC, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15039-8
   Castanha PMS, 2017, J INFECT DIS, V215, P781, DOI 10.1093/infdis/jiw638
   Chahal JS, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00193-w
   Committee G. A. W, SAF IMM PREGN
   Costa SM, 2006, VACCINE, V24, P4562, DOI 10.1016/j.vaccine.2005.08.022
   Dai LP, 2016, CELL HOST MICROBE, V19, P696, DOI 10.1016/j.chom.2016.04.013
   Dawes BE, 2016, NPJ VACCINES, V1, DOI 10.1038/npjvaccines.2016.7
   de Cassan SC, 2011, J IMMUNOL, V187, P2602, DOI 10.4049/jimmunol.1101004
   Dejnirattisai W, 2016, NAT IMMUNOL, V17, P1102, DOI 10.1038/ni.3515
   Desai SK, 2017, AM J STEM CELLS, V6, P13
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4
   Dubaut JP, 2017, J ASSIST REPROD GEN, V34, P1237, DOI 10.1007/s10815-017-0988-1
   Egloff MP, 2002, EMBO J, V21, P2757, DOI 10.1093/emboj/21.11.2757
   Emanuel J, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29401-x
   Foy BD, 2011, EMERG INFECT DIS, V17, P880, DOI 10.3201/eid1705.101939
   Franco LD, 2017, J BIOMED SCI, V24, DOI 10.1186/s12929-017-0395-z
   Gaudinski MR, 2018, LANCET, V391, P552, DOI 10.1016/S0140-6736(17)33105-7
   GOLLINS SW, 1985, J GEN VIROL, V66, P1969, DOI 10.1099/0022-1317-66-9-1969
   GOLLINS SW, 1984, J GEN VIROL, V65, P1261, DOI 10.1099/0022-1317-65-8-1261
   Goo L, 2018, VIROLOGY, V515, P191, DOI 10.1016/j.virol.2017.12.032
   Goo L, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006178
   Griffin BD, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15743
   Guy B, 2010, VACCINE, V28, P632, DOI 10.1016/j.vaccine.2009.09.098
   Haddow AD, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005083
   Hadinegoro SR, 2015, NEW ENGL J MED, V373, P1195, DOI 10.1056/NEJMoa1506223
   Halstead SB, 2003, ADV VIRUS RES, V60, P421, DOI 10.1016/S0065-3527(03)60011-4
   Hasson Sidgi Syed Anwer Abdo, 2015, Asian Pacific Journal of Tropical Biomedicine, V5, P344, DOI 10.1016/S2221-1691(15)30366-X
   Heinz FX, 2017, MICROBIOL MOL BIOL R, V81, DOI [10.1128/MMBR.00055-16, 10.1128/mmbr.00055-16]
   Heukelbach J, 2016, J INFECT DEV COUNTR, V10, P116, DOI 10.3855/jidc.8217
   Hilgenfeld R, 2016, EMBO J, V35, P2631, DOI 10.15252/embj.201695871
   Ishikawa T, 2014, VACCINE, V32, P1326, DOI 10.1016/j.vaccine.2014.01.040
   Kawiecki AB, 2016, J INFECT DIS, V214, P1357, DOI 10.1093/infdis/jiw377
   Kim E, 2016, EBIOMEDICINE, V13, P315, DOI 10.1016/j.ebiom.2016.09.028
   Kindhauser MK, 2016, B WORLD HEALTH ORGAN, V94, P675, DOI 10.2471/BLT.16.171082
   KLIKS S, 1990, AIDS RES HUM RETROV, V6, P993, DOI 10.1089/aid.1990.6.993
   Kuhn RJ, 2002, CELL, V108, P717, DOI 10.1016/S0092-8674(02)00660-8
   Kutzler MA, 2008, NAT REV GENET, V9, P776, DOI 10.1038/nrg2432
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Larocca RA, 2016, NATURE, V536, P474, DOI 10.1038/nature18952
   Lessler J, 2016, SCIENCE, V353, DOI 10.1126/science.aaf8160
   Li SH, 2013, J VIROL, V87, P5812, DOI 10.1128/JVI.02806-12
   Liang HB, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194860
   Lim SP, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005737
   Lin YS, 2011, EXP BIOL MED, V236, P515, DOI 10.1258/ebm.2011.010339
   Lyons A, 2007, VACCINE, V25, P3445, DOI 10.1016/j.vaccine.2006.12.046
   Mahalingam S, 2017, LANCET INFECT DIS, V17, P686, DOI 10.1016/S1473-3099(17)30340-7
   Makhluf H, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6010007
   Martins KAO, 2016, EBIOMEDICINE, V3, P67, DOI 10.1016/j.ebiom.2015.11.041
   Maslow JN, 2017, VACCINE, V35, P5437, DOI 10.1016/j.vaccine.2017.02.015
   Matsui K, 2010, J GEN VIROL, V91, P2249, DOI 10.1099/vir.0.021220-0
   Miyazaki C, 2014, CLIN VACCINE IMMUNOL, V21, P188, DOI 10.1128/CVI.00377-13
   Modis Y, 2003, P NATL ACAD SCI USA, V100, P6986, DOI 10.1073/pnas.0832193100
   Modjarrad K, 2018, LANCET, V391, P563, DOI 10.1016/S0140-6736(17)33106-9
   Monath T.P., 2005, EXPERT REV VACCINES, DOI [10.1136/bmj.324.7335.439, DOI 10.1136/BMJ.324.7335.439]
   Monath TP, 2011, NEW ENGL J MED, V364, P1326, DOI 10.1056/NEJMoa1009303
   Monath TP, 2010, VACCINE, V28, P3827, DOI 10.1016/j.vaccine.2010.03.023
   Monath TP, 2002, VACCINE, V20, P1004, DOI 10.1016/S0264-410X(01)00457-1
   Morrison C, 2016, NAT REV DRUG DISCOV, V15, P521, DOI 10.1038/nrd.2016.159
   Mukhopadhyay S, 2005, NAT REV MICROBIOL, V3, P13, DOI 10.1038/nrmicro1067
   Munjal A, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01469
   Mutebi JP, 2004, EMERG INFECT DIS, V10, P1657
   Muthumani K, 2016, NPJ VACCINES, V1, DOI 10.1038/npjvaccines.2016.21
   Oehler E, 2014, EUROSURVEILLANCE, V19, DOI [0.2807/1560-7917.es2014.19.9.20720, DOI 10.2807/1560-7917.ES2014.19.9.20720]
   Ozkurt Z, 2017, EURASIAN J MED, V49, P142, DOI 10.5152/eurasianjmed.2017.17147
   Pardi N, 2017, NATURE, V543, P248, DOI 10.1038/nature21428
   Priyamvada L, 2016, P NATL ACAD SCI USA, V113, P7852, DOI 10.1073/pnas.1607931113
   Rastogi M, 2016, VIROL J, V13, DOI 10.1186/s12985-016-0590-7
   Richner JM, 2017, CELL, V170, P273, DOI 10.1016/j.cell.2017.06.040
   Richner JM, 2017, CELL, V168, P1114, DOI 10.1016/j.cell.2017.02.017
   Roehrig JT, 2013, VIROLOGY, V441, P114, DOI 10.1016/j.virol.2013.03.011
   Sen Kwek S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03337-2
   Shan C, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00737-8
   Shan C, 2017, NAT MED, V23, P763, DOI 10.1038/nm.4322
   Smit JM, 2011, VIRUSES-BASEL, V3, P160, DOI 10.3390/v3020160
   Sun GY, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170462
   Sun HY, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010054
   Suwanmanee S, 2017, J MICROBIOL, V55, P81, DOI 10.1007/s12275-017-6494-4
   Tauber E, 2007, LANCET, V370, P1847, DOI 10.1016/S0140-6736(07)61780-2
   Tebas Pablo, 2017, N Engl J Med, DOI 10.1056/NEJMoa1708120
   To A, 2018, MSPHERE, V3, DOI 10.1128/mSphere.00576-17
   Villar L, 2015, NEW ENGL J MED, V372, P113, DOI 10.1056/NEJMoa1411037
   Wan SW, 2013, J FORMOS MED ASSOC, V112, P3, DOI 10.1016/j.jfma.2012.11.006
   Wang Z, 2004, GENE THER, V11, P711, DOI 10.1038/sj.gt.3302213
   Wu SF, 2003, VACCINE, V21, P3919, DOI 10.1016/S0264-410X(03)00310-4
   Yang ML, 2017, SCI REP-UK, V7, DOI 10.1038/srep43829
   Zhang XC, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9110338
   Zhao BY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14762
   Zhou ZH, 2014, CURR OPIN VIROL, V5, P111, DOI 10.1016/j.coviro.2014.04.001
   Zhu Z, 2016, EMERG MICROBES INFEC, V5, DOI 10.1038/emi.2016.48
NR 97
TC 11
Z9 11
U1 0
U2 6
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-393X
J9 VACCINES-BASEL
JI Vaccines
PD SEP
PY 2018
VL 6
IS 3
AR 62
DI 10.3390/vaccines6030062
PG 13
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA GY1ZR
UT WOS:000448337100001
PM 30217027
OA DOAJ Gold, Green Published
DA 2020-12-15
ER

PT J
AU Pizato, N
   Luzete, BC
   Kiffer, LFMV
   Correa, LH
   Santos, ID
   Assumpcao, JAF
   Ito, MK
   Magalhaes, KG
AF Pizato, Nathalia
   Luzete, Beatriz Christina
   Melo Vasconcelos Kiffer, Larissa Fernanda
   Correa, Luis Henrique
   Santos, Igor de Oliveira
   Fagundes Assumpcao, Jose Antonio
   Ito, Marina Kiyomi
   Magalhaes, Kelly Grace
TI Omega-3 docosahexaenoic acid induces pyroptosis cell death in
   triplenegative breast cancer cells (vol 8, 2018)
SO SCIENTIFIC REPORTS
LA English
DT Correction
C1 [Pizato, Nathalia; Luzete, Beatriz Christina; Melo Vasconcelos Kiffer, Larissa Fernanda; Ito, Marina Kiyomi] Univ Brasilia, Dept Nutr, BR-70910900 Brasilia, DF, Brazil.
   [Correa, Luis Henrique; Santos, Igor de Oliveira; Fagundes Assumpcao, Jose Antonio; Magalhaes, Kelly Grace] Univ Brasilia, Lab Immunol & Inflammat, BR-70910900 Brasilia, DF, Brazil.
RP Magalhaes, KG (corresponding author), Univ Brasilia, Lab Immunol & Inflammat, BR-70910900 Brasilia, DF, Brazil.
EM kellymagalhaes@unb.br
RI Magalhaes, Kelly G/A-6966-2010; Assumpcao, Jose AF/P-6588-2018;
   Magalhaes, Kelly Grace/L-6081-2019
OI Magalhaes, Kelly G/0000-0002-7435-5272; Assumpcao, Jose
   AF/0000-0002-2836-1583; Magalhaes, Kelly Grace/0000-0002-7435-5272;
   SANTOS, IGOR/0000-0001-6036-6694
FU FAPDF
FX "This research is supported by funding agency FAPDF."
CR Pizato N, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20422-0
NR 1
TC 4
Z9 4
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JUN 22
PY 2018
VL 8
AR 9775
DI 10.1038/s41598-018-27850-y
PG 1
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA GK3MD
UT WOS:000436048800001
PM 29930250
OA DOAJ Gold, Green Published
DA 2020-12-15
ER

PT J
AU Pizato, N
   Luzete, BC
   Kiffer, LFMV
   Correa, LH
   Santos, ID
   Assumpcao, JAF
   Ito, MK
   Magalhaes, KG
AF Pizato, Nathalia
   Luzete, Beatriz Christina
   Melo Vasconcelos Kiffer, Larissa Fernanda
   Correa, Luis Henrique
   Santos, Igor de Oliveira
   Fagundes Assumpcao, Jose Antonio
   Ito, Marina Kiyomi
   Magalhaes, Kelly Grace
TI Omega-3 docosahexaenoic acid induces pyroptosis cell death in
   triple-negative breast cancer cells
SO SCIENTIFIC REPORTS
LA English
DT Article
ID NLRP3 INFLAMMASOME ACTIVATION; ARACHIDONIC-ACID; PORE FORMATION;
   GASDERMIN D; APOPTOSIS; PROLIFERATION; INHIBITION; MECHANISM; CASPASES;
   PATHWAYS
AB The implication of inflammation in pathophysiology of several type of cancers has been under intense investigation. Omega-3 fatty acids can modulate inflammation and present anticancer effects, promoting cancer cell death. Pyroptosis is an inflammation related cell death and so far, the function of docosahexaenoic acid (DHA) in pyroptosis cell death has not been described. This study investigated the role of DHA in triggering pyroptosis activation in breast cancer cells. MDA-MB-231 breast cancer cells were supplemented with DHA and inflammation cell death was analyzed. DHA-treated breast cancer cells triggered increased caspase-1and gasdermin D activation, enhanced IL-1 ss secretion, translocated HMGB1 towards the cytoplasm, and membrane pore formation when compared to untreated cells, suggesting DHA induces pyroptosis programmed cell death in breast cancer cells. Moreover, caspase-1 inhibitor (YVAD) could protect breast cancer cells from DHA-induced pyroptotic cell death. In addition, membrane pore formation showed to be a lysosomal damage and ROS formation-depended event in breast cancer cells. DHA triggered pyroptosis cell death in MDA-MB-231by activating several pyroptosis markers in these cells. This is the first study that shows the effect of DHA triggering pyroptosis programmed cell death in breast cancer cells and it could improve the understanding of the omega-3 supplementation during breast cancer treatment.
C1 [Pizato, Nathalia; Luzete, Beatriz Christina; Melo Vasconcelos Kiffer, Larissa Fernanda; Ito, Marina Kiyomi] Univ Brasilia, Dept Nutr, BR-70910900 Brasilia, DF, Brazil.
   [Correa, Luis Henrique; Santos, Igor de Oliveira; Fagundes Assumpcao, Jose Antonio; Magalhaes, Kelly Grace] Univ Brasilia, Lab Immunol & Inflammat, BR-70910900 Brasilia, DF, Brazil.
RP Magalhaes, KG (corresponding author), Univ Brasilia, Lab Immunol & Inflammat, BR-70910900 Brasilia, DF, Brazil.
EM kellymagalhaes@unb.br
RI Magalhaes, Kelly Grace/L-6081-2019; Assumpcao, Jose AF/P-6588-2018;
   Magalhaes, Kelly G/A-6966-2010
OI Magalhaes, Kelly Grace/0000-0002-7435-5272; Assumpcao, Jose
   AF/0000-0002-2836-1583; Magalhaes, Kelly G/0000-0002-7435-5272; Pizato,
   Nathalia/0000-0001-5858-7076; SANTOS, IGOR/0000-0001-6036-6694; Correa,
   Luis Henrique/0000-0003-2825-0127
CR Alfonso-Loeches S, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00216
   Badve S, 2011, MODERN PATHOL, V24, P157, DOI 10.1038/modpathol.2010.200
   Baig S, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2015.275
   Bauernfeind FG, 2009, J IMMUNOL, V183, P787, DOI 10.4049/jimmunol.0901363
   Bell CW, 2006, AM J PHYSIOL-CELL PH, V291, pC1318, DOI 10.1152/ajpcell.00616.2005
   Bergsbaken T, 2009, NAT REV MICROBIOL, V7, P99, DOI 10.1038/nrmicro2070
   Bizjak M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01801-5
   Blanckaert V, 2010, INT J ONCOL, V36, P737, DOI 10.3892/ijo_00000549
   Blander JM, 2014, NAT REV IMMUNOL, V14, P601, DOI 10.1038/nri3720
   Brown MD, 2010, BRIT J CANCER, V102, P403, DOI 10.1038/sj.bjc.6605481
   Cabral M., 2015, PHYSL REP, V3, P1
   Cao W., 2012, PLOS ONE, V7, P1
   Cao Y, 2000, P NATL ACAD SCI USA, V97, P11280, DOI 10.1073/pnas.200367597
   Corsetto PA, 2011, LIPIDS HEALTH DIS, V10, DOI 10.1186/1476-511X-10-73
   Degterev A, 2005, NAT CHEM BIOL, V1, P112, DOI 10.1038/nchembio711
   Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045
   Ding JJ, 2016, NATURE, V535, P111, DOI 10.1038/nature18590
   Doitsh G, 2014, NATURE, V505, P509, DOI 10.1038/nature12940
   Fernandes-Alnemri T, 2007, CELL DEATH DIFFER, V14, P1590, DOI 10.1038/sj.cdd.4402194
   Fink SL, 2006, CELL MICROBIOL, V8, P1812, DOI 10.1111/j.1462-5822.2006.00751.x
   Fuchs Y, 2015, NAT REV MOL CELL BIO, V16, P329, DOI 10.1038/nrm3999
   Grootjans S, 2017, CELL DEATH DIFFER, V24, P1184, DOI 10.1038/cdd.2017.65
   Holliday DL, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2889
   Hornung V, 2008, NAT IMMUNOL, V9, P847, DOI 10.1038/ni.1631
   Kang KS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010296
   Karamanou K, 2017, SCI REP-UK, V7, DOI 10.1038/srep45138
   Kayagaki N, 2015, NATURE, V526, P666, DOI 10.1038/nature15541
   Kim N., 2015, NON SMALL CELL LUNG, V2015
   Lamkanfi M, 2010, J IMMUNOL, V185, P4385, DOI 10.4049/jimmunol.1000803
   Lebeaupin C, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.248
   Lee EJ, 2014, BBA-MOL CELL BIOL L, V1841, P190, DOI 10.1016/j.bbalip.2013.10.006
   Li X, 2015, PATHOG DIS, V73, DOI 10.1093/femspd/ftu024
   Li Y, 2013, TOXICOL APPL PHARM, V272, P37, DOI 10.1016/j.taap.2013.05.031
   Liedtke C, 2008, J CLIN ONCOL, V26, P1275, DOI 10.1200/JCO.2007.14.4147
   Lin J, 2013, NANOSCALE RES LETT, V8, DOI 10.1186/1556-276X-8-170
   Lin QR, 2016, TOXICOL APPL PHARM, V292, P56, DOI 10.1016/j.taap.2015.12.027
   Linkermann A, 2014, NEW ENGL J MED, V370, P455, DOI 10.1056/NEJMra1310050
   Liu X, 2016, NATURE, V535, P153, DOI 10.1038/nature18629
   Magna M, 2014, MOL MED, V20, P138, DOI 10.2119/molmed.2013.00164
   Man S. M., 2015, CELL RES, V3, P1
   Mansara PP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136542
   Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3
   Miao EA, 2010, NAT IMMUNOL, V11, P1136, DOI 10.1038/ni.1960
   Morris GJ, 2007, CANCER-AM CANCER SOC, V110, P876, DOI 10.1002/cncr.22836
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Munoz-Planillo R, 2013, IMMUNITY, V38, P1142, DOI 10.1016/j.immuni.2013.05.016
   Pender-Cudlip MC, 2013, CANCER SCI, V104, P760, DOI 10.1111/cas.12129
   Rebe C, 2015, MOL CELL ONCOL, V2, DOI 10.4161/23723548.2014.970094
   Roy J, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0273-z
   Sagulenko V, 2013, CELL DEATH DIFFER, V20, P1149, DOI 10.1038/cdd.2013.37
   Sborgi L, 2016, EMBO J, V35, P1766, DOI 10.15252/embj.201694696
   Shi JJ, 2015, NATURE, V526, P660, DOI 10.1038/nature15514
   Shin S., 2013, BIOMED RES INT, V2013
   Sollberger G, 2012, J IMMUNOL, V188, P1992, DOI 10.4049/jimmunol.1101620
   Wang SL, 2014, J BIOL CHEM, V289, P30075, DOI 10.1074/jbc.M114.578781
   Weinlich R, 2017, NAT REV MOL CELL BIO, V18, P127, DOI 10.1038/nrm.2016.149
   Williams-Bey Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097957
   Willingham SB, 2007, CELL HOST MICROBE, V2, P147, DOI 10.1016/j.chom.2007.07.009
   Wree A, 2014, HEPATOLOGY, V59, P898, DOI 10.1002/hep.26592
   Xiong AL, 2012, MOL NUTR FOOD RES, V56, P923, DOI 10.1002/mnfr.201200027
   Xu Yi, 2014, Biomed J, V37, P112, DOI 10.4103/2319-4170.131378
   Xue ML, 2014, J NUTR BIOCHEM, V25, P104, DOI 10.1016/j.jnutbio.2013.09.008
   Yan YQ, 2013, IMMUNITY, V38, P1154, DOI 10.1016/j.immuni.2013.05.015
   Yang CS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7115
   ZYCHLINSKY A, 1992, NATURE, V358, P167, DOI 10.1038/358167a0
NR 65
TC 50
Z9 55
U1 1
U2 13
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JAN 31
PY 2018
VL 8
AR 1952
DI 10.1038/s41598-018-20422-0
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FU2EW
UT WOS:000423663100031
PM 29386662
OA DOAJ Gold, Green Published
DA 2020-12-15
ER

PT J
AU Almeida, CM
   Nascimento, GP
   Magalhaes, KG
   Iglesias, BA
   Gatto, CC
AF Almeida, Carolane M.
   Nascimento, Gabriel P.
   Magalhaes, Kelly G.
   Iglesias, Bernardo A.
   Gatto, Claudia C.
TI Crystal structures, DNA-binding ability and influence on cellular
   viability of gold(I) complexes of thiosemicarbazones
SO JOURNAL OF COORDINATION CHEMISTRY
LA English
DT Article
DE Gold(I) complexes; thiosemicarbazones; crystal structures; cellular
   viability; DNA-binding
ID ANTITUMOR-ACTIVITY; PD-II; COPPER; CYTOTOXICITY; METALS; AU
AB The present study reports the synthesis and crystal structure of four novel gold(I) complexes with di-2-pyridyl ketone N(4)-ethylthiosemicarbazone (L-1) and 2-acetylfuran-4-methyl-3-thiosemicarbazone (L-2). All the gold(I) complexes were observed with monodentate thiosemicarbazones and exhibited gold(I) ions with linear geometries, bound to a sulfur atom of the ligand and a halogen ion (Br- or Cl-). The crystal structures of gold complexes with Br- and thiosemicarbazone are the first examples reported. Interestingly, 2[AuBr(HL1)]2Br was observed to have a AuAu length of 3.155(8) angstrom, and this distance suggests an unusual AuAu interaction in the solid state. The ability of the thiosemicarbazones and the corresponding gold(I) complexes to bind to DNA was studied by UV-vis and emission spectroscopy. The effect on cell viability of the compounds was evaluated against human breast cancer cell lines. The results show that the gold(I) complexes exhibit more potent inhibition of tumor growth than the free ligands.
   [GRAPHICS]
   .
C1 [Almeida, Carolane M.; Gatto, Claudia C.] Univ Brasilia, Inst Chem, Lab Inorgan Synth & Crystallog, Campus Univ Darcy Ribeiro, Brasilia, DF, Brazil.
   [Nascimento, Gabriel P.; Magalhaes, Kelly G.] Univ Brasilia, Inst Biol, Dept Cellular Biol, Lab Immunol & Inflammat, Brasilia, DF, Brazil.
   [Iglesias, Bernardo A.] Univ Fed Santa Maria, Dept Chem, Lab Mat Inorgan, Santa Maria, RS, Brazil.
RP Gatto, CC (corresponding author), Univ Brasilia, Inst Chem, Lab Inorgan Synth & Crystallog, Campus Univ Darcy Ribeiro, Brasilia, DF, Brazil.
EM ccgatto@gmail.com
RI Gatto, Claudia Cristina/I-9924-2014; Magalhaes, Kelly Grace/L-6081-2019;
   Magalhaes, Kelly G/A-6966-2010
OI Gatto, Claudia Cristina/0000-0002-3736-6861; Magalhaes, Kelly
   Grace/0000-0002-7435-5272; Magalhaes, Kelly G/0000-0002-7435-5272;
   Pasquarelli do Nascimento, Gabriel/0000-0002-8329-343X
CR ADAMS HN, 1982, Z ANORG ALLG CHEM, V485, P65, DOI 10.1002/zaac.19824850107
   Ali MA, 2011, POLYHEDRON, V30, P1478, DOI 10.1016/j.poly.2011.02.048
   Andrezalova L, 2017, J ORGANOMET CHEM, V827, P67, DOI 10.1016/j.jorganchem.2016.11.007
   Beraldo H, 2004, QUIM NOVA, V27, P461, DOI 10.1590/S0100-40422004000300017
   Bisceglie F, 2015, J INORG BIOCHEM, V152, P10, DOI 10.1016/j.jinorgbio.2015.08.008
   Borges RHU, 1997, J INORG BIOCHEM, V65, P267, DOI 10.1016/S0162-0134(96)00142-0
   Brammer L, 2003, DALTON T, P3145, DOI 10.1039/b303006g
   Brandenburg K., 2004, CRYSTAL IMPACT GBR
   Castineiras A, 2012, DALTON T, V41, P13486, DOI 10.1039/c2dt31753b
   Castineiras A, 2012, CRYST GROWTH DES, V12, P1432, DOI 10.1021/cg2015435
   Duan CY, 1996, J CHEM SOC DALTON, P3485, DOI 10.1039/dt9960003485
   Farrugia LJ, 1997, J APPL CRYSTALLOGR, V30, P565, DOI DOI 10.1107/S0021889897003117
   Farrugia LJ, 2012, J APPL CRYSTALLOGR, V45, P849, DOI 10.1107/S0021889812029111
   Garcia Santos I., 2004, DALTON T, V<bold>76</bold>, P677, DOI [10.1039/B312978&#x00A0;K, DOI 10.1039/B312978&#X00A0;K]
   Gatto CC, 2017, SUPRAMOL CHEM, V29, P296, DOI 10.1080/10610278.2016.1227440
   Gatto CC, 2015, ACTA CRYSTALLOGR E, V71, P1070, DOI 10.1107/S2056989015015480
   Ibrahim AA, 2014, DALTON T, V43, P3850, DOI 10.1039/c3dt53032a
   IMW SMART and SAINT, 1999, AR DET CONTR INT SOF
   Indoria S, 2015, EUR J INORG CHEM, P5106, DOI 10.1002/ejic.201500618
   Kalaivani P, 2015, INORG CHIM ACTA, V438, P264, DOI 10.1016/j.ica.2015.08.031
   Koskinen L, 2014, CRYST GROWTH DES, V14, P1989, DOI 10.1021/cg500102c
   Kowol CR, 2010, DALTON T, V39, P704, DOI 10.1039/b919119b
   Lessa JA, 2011, J INORG BIOCHEM, V105, P1729, DOI 10.1016/j.jinorgbio.2011.09.008
   Li CK, 2004, INORG CHEM, V43, P7421, DOI 10.1021/ic049094u
   Lobana TS, 2011, DALTON T, V40, P3219, DOI 10.1039/c0dt01291b
   Lobana TS, 1997, J CHEM SOC DALTON, P4289, DOI 10.1039/a703726k
   Maia PID, 2017, DALTON T, V46, P2559, DOI 10.1039/c6dt04307k
   Maia PID, 2012, INORG CHEM, V51, P1604, DOI 10.1021/ic201905t
   Medici S, 2015, COORDIN CHEM REV, V284, P329, DOI 10.1016/j.ccr.2014.08.002
   Mishra V, 2016, J ORGANOMET CHEM, V813, P103, DOI 10.1016/j.jorganchem.2016.04.013
   Ott I, 2009, COORDIN CHEM REV, V253, P1670, DOI 10.1016/j.ccr.2009.02.019
   Padhye S, 2005, INORG CHEM, V44, P1154, DOI 10.1021/ic048214v
   Palanimuthu D, 2013, J MED CHEM, V56, P722, DOI 10.1021/jm300938r
   Richardson DR, 2006, J MED CHEM, V49, P6510, DOI 10.1021/jm0606342
   Samia LBP, 2016, BIOMETALS, V29, P515, DOI 10.1007/s10534-016-9933-5
   Schmidbaur H, 2008, CHEM SOC REV, V37, P1931, DOI 10.1039/b708845k
   Schmidbaur H, 2014, CHEM SOC REV, V43, P345, DOI 10.1039/c3cs60251f
   Schmidbaur H, 2012, CHEM SOC REV, V41, P370, DOI 10.1039/c1cs15182g
   Shaw CF, 1999, CHEM REV, V99, P2589, DOI 10.1021/cr980431o
   Sheldrick G., 1997, SADABS PROGRAM EMPIR
   Sheldrick G.M., 1997, SHELXS 97
   Sheldrick GM, 2008, ACTA CRYSTALLOGR A, V64, P112, DOI 10.1107/S0108767307043930
   Strekowski L, 2007, MUTAT RES-FUND MOL M, V623, P3, DOI 10.1016/j.mrfmmm.2007.03.008
   Swearingen JK, 2001, TRANSIT METAL CHEM, V26, P252, DOI 10.1023/A:1007139022915
   Tan SJ, 2010, FUTURE MED CHEM, V2, P1591, DOI [10.4155/fmc.10.234, 10.4155/FMC.10.234]
NR 45
TC 5
Z9 5
U1 0
U2 9
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0095-8972
EI 1029-0389
J9 J COORD CHEM
JI J. Coord. Chem.
PY 2018
VL 71
IS 4
BP 502
EP 519
DI 10.1080/00958972.2018.1435869
PG 18
WC Chemistry, Inorganic & Nuclear
SC Chemistry
GA FZ4JA
UT WOS:000427557300002
DA 2020-12-15
ER

PT J
AU de Castro, RJA
   Siqueira, IM
   Jeronimo, MS
   Basso, AMM
   Veloso, PHD
   Magalhaes, KG
   Leonhardt, LC
   de Oliveira, SAM
   Burgel, PH
   Tavares, AH
   Bocca, AL
AF Araujo de Castro, Raffael Junio
   Siqueira, Isaque Medeiros
   Jeronimo, Marcio Sousa
   Moreschi Basso, Angelina Maria
   de Holanda Veloso Junior, Paulo Henrique
   Magalhaes, Kelly Grace
   Leonhardt, Luiza Chaves
   Machado de Oliveira, Stephan Alberto
   Burgel, Pedro Henrique
   Tavares, Aldo Henrique
   Bocca, Anamelia Lorenzetti
TI The Major Chromoblastomycosis Etiologic Agent Fonsecaea pedrosoi
   Activates the NLRP3 Inflammasome
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE NLRP3 inflammasome; Fonsecaea pedrosoi; chromoblastomycosis; hyphae;
   macrophages; dendritic cells
ID PATTERN-RECOGNITION RECEPTOR; HOST-DEFENSE; DENDRITIC CELLS;
   FINE-STRUCTURE; NITRIC-OXIDE; DECTIN-2; MACROPHAGES; IL-1-BETA;
   INDUCTION; DIFFERENTIATION
AB Fonsecaea pedrosoi is the main etiologic agent of chromoblastomycosis (CBM), one of the most prevalent subcutaneous mycosis in tropical and subtropical countries. CBM is a poorly characterized chronic infection that commonly starts after transcutaneous inoculation of conidia and saprophytic hyphae of F. pedrosoi. Recently, we have shown that unlike conidia, hyphae and muriform cells (the parasitic morphotype) of F. pedrosoi promotes an intense inflammatory response pattern in vivo, which comprises the production of an inflammasome-derived cytokine, IL-1 beta. Nonetheless, the mechanisms underlying IL-1 beta production and maturation upon F. pedrosoi infection and its functional output in the course of CBM remains unknown. We show here that F. pedrosoi hyphae, differently from conidia, induce IL-1 beta secretion in both bone marrow-derived dendritic cells and macrophages. Using inhibitors and knockout cells, we demonstrated that the mechanisms underlying IL-1 beta production by hyphae-infected macrophages were dependent on dectin-1, -2, and -3 receptors and the Syk-NF-kappa B signaling pathway. Furthermore, F. pedrosoi promoted a NLRP3-dependent inflammasome activation, which required potassium efflux, reactive oxygen species production, phagolysosomal acidification, and cathepsin B release as triggers. IL-1 beta processing and release was mediated primarily by caspase-1 and, to a lesser extent, by caspase-8-dependent cleavage. Finally, we showed using a murine CBM model that F. pedrosoi elicits a NLRP3-regulated IL-1 beta and interleukin-18 release in vivo, but without NLRP3 inflammasome activation interfering in the course of the experimental infection.
C1 [Araujo de Castro, Raffael Junio; Siqueira, Isaque Medeiros; Jeronimo, Marcio Sousa; Moreschi Basso, Angelina Maria; de Holanda Veloso Junior, Paulo Henrique; Leonhardt, Luiza Chaves; Machado de Oliveira, Stephan Alberto; Burgel, Pedro Henrique; Tavares, Aldo Henrique; Bocca, Anamelia Lorenzetti] Univ Brasilia, Inst Biol Sci, Dept Cellular Biol, Lab Appl Immunol, Brasilia, DF, Brazil.
   [Magalhaes, Kelly Grace] Univ Brasilia, Inst Biol Sci, Dept Cellular Biol, Lab Immunol & Inflammat, Brasilia, DF, Brazil.
RP Bocca, AL (corresponding author), Univ Brasilia, Inst Biol Sci, Dept Cellular Biol, Lab Appl Immunol, Brasilia, DF, Brazil.
EM albocca@unb.br
RI Magalhaes, Kelly G/A-6966-2010; Magalhaes, Kelly Grace/L-6081-2019; de
   Castro, Raffael Junio Araujo/G-4353-2018; TAVARES, ALDO
   HENRIQUE/L-5662-2015; Burgel, Pedro Henrique Miranda/AAX-2047-2020;
   Bocca, Anamelia Lorenzetti/K-4758-2018
OI Magalhaes, Kelly G/0000-0002-7435-5272; Magalhaes, Kelly
   Grace/0000-0002-7435-5272; de Castro, Raffael Junio
   Araujo/0000-0002-5207-8892; Bocca, Anamelia
   Lorenzetti/0000-0003-3323-5300; TAVARES, ALDO
   HENRIQUE/0000-0003-0579-3380
FU Fundacao de Apoio a Pesquisa do Distrito Federal (FAPDF)National Council
   for Scientific and Technological Development (CNPq) [193.00805/2015];
   Conselho Nacional de Pesquisa (CNPq)National Council for Scientific and
   Technological Development (CNPq) [302752/2015-3]; Coordenacao de
   Aperfeicoamentoc de Pessoal de Nivel Superior (CAPES)
FX Funding for this research was provided by Fundacao de Apoio a Pesquisa
   do Distrito Federal (FAPDF Project 193.00805/2015), Conselho Nacional de
   Pesquisa (CNPq Project 302752/2015-3) for financial support and
   Coordenacao de Aperfeicoamentoc de Pessoal de Nivel Superior (CAPES) for
   graduate students' grants.
CR AHRENS J, 1989, AM J TROP MED HYG, V40, P651, DOI 10.4269/ajtmh.1989.40.651
   Bauernfeind F, 2013, EMBO MOL MED, V5, P814, DOI 10.1002/emmm.201201771
   Bauernfeind F, 2012, J IMMUNOL, V189, P4175, DOI 10.4049/jimmunol.1201516
   Bauernfeind F, 2011, J IMMUNOL, V187, P613, DOI 10.4049/jimmunol.1100613
   Bauernfeind FG, 2009, J IMMUNOL, V183, P787, DOI 10.4049/jimmunol.0901363
   Bocca AL, 2006, MYCOPATHOLOGIA, V161, P195, DOI 10.1007/s11046-005-0228-6
   Bonifaz A, 2001, MYCOSES, V44, P1, DOI 10.1046/j.1439-0507.2001.00613.x
   Chang TH, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006485
   Chen MK, 2015, J IMMUNOL, V195, P4962, DOI 10.4049/jimmunol.1500865
   Sousa MD, 2011, CELL HOST MICROBE, V9, P436, DOI 10.1016/j.chom.2011.04.005
   Dong BL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114113
   Erwig LP, 2016, NAT REV MICROBIOL, V14, P163, DOI 10.1038/nrmicro.2015.21
   ESTERRE P, 1993, VIRCHOWS ARCH A, V422, P285, DOI 10.1007/BF01608337
   FARBIARZ SR, 1990, J MED VET MYCOL, V28, P373
   Feriotti C, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00786
   Gantner BN, 2003, J EXP MED, V197, P1107, DOI 10.1084/jem.20021787
   Gringhuis SI, 2012, NAT IMMUNOL, V13, P246, DOI 10.1038/ni.2222
   Gringhuis SI, 2009, NAT IMMUNOL, V10, P203, DOI 10.1038/ni.1692
   Gross O, 2009, NATURE, V459, P433, DOI 10.1038/nature07965
   Guarda G, 2011, J IMMUNOL, V186, P2529, DOI 10.4049/jimmunol.1002720
   Guo CQ, 2014, MICROBES INFECT, V16, P845, DOI 10.1016/j.micinf.2014.08.013
   Hardison SE, 2012, NAT IMMUNOL, V13, P817, DOI 10.1038/ni.2369
   Hayakawa M, 2006, SCAND J IMMUNOL, V64, P382, DOI 10.1111/j.1365-3083.2006.01804.x
   He Y, 2013, J IMMUNOL, V190, P334, DOI 10.4049/jimmunol.1202737
   Hise AG, 2009, CELL HOST MICROBE, V5, P487, DOI 10.1016/j.chom.2009.05.002
   Hohl TM, 2005, PLOS PATHOG, V1, P232, DOI 10.1371/journal.ppat.0010030
   Jo EK, 2016, CELL MOL IMMUNOL, V13, P148, DOI 10.1038/cmi.2015.95
   Joly S, 2009, J IMMUNOL, V183, P3578, DOI 10.4049/jimmunol.0901323
   Kalantari P, 2014, CELL REP, V6, P196, DOI 10.1016/j.celrep.2013.12.014
   Karki R, 2015, CELL HOST MICROBE, V17, P357, DOI 10.1016/j.chom.2015.01.006
   Ketelut-Carneiro N, 2015, J IMMUNOL, V194, P4507, DOI 10.4049/jimmunol.1402321
   Kistowska M, 2014, EXP DERMATOL, V23, P884, DOI 10.1111/exd.12552
   Lei GW, 2013, CELL RES, V23, P965, DOI 10.1038/cr.2013.49
   Li H, 2013, PROTEIN CELL, V4, P529, DOI 10.1007/s13238-013-2127-9
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Luther K, 2007, CELL MICROBIOL, V9, P368, DOI 10.1111/j.1462-5822.2006.00796.x
   Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022-1759(98)00204-X
   Mao LM, 2014, INFECT IMMUN, V82, P882, DOI 10.1128/IAI.01097-13
   Martinez RL, 2007, CLIN DERMATOL, V25, P188, DOI 10.1016/j.clindermatol.2006.05.007
   MCGINNIS MR, 1987, ARCH DERMATOL, V123, P1300, DOI 10.1001/archderm.123.10.1300
   Mencacci A., 2000, Current Pharmaceutical Biotechnology, V1, P235, DOI 10.2174/1389201003378924
   Minotto R, 2017, J CUTAN PATHOL, V44, P915, DOI 10.1111/cup.13014
   Munoz-Planillo R, 2013, IMMUNITY, V38, P1142, DOI 10.1016/j.immuni.2013.05.016
   Netea MG, 2015, CELL METAB, V21, P513, DOI 10.1016/j.cmet.2015.03.012
   Queiroz-Telles F, 2017, CLIN MICROBIOL REV, V30, P233, DOI 10.1128/CMR.00032-16
   Queiroz-Telles F, 2015, REV INST MED TROP SP, V57, P46, DOI 10.1590/S0036-46652015000700009
   Queiroz-Telles F, 2009, MED MYCOL, V47, P3, DOI 10.1080/13693780802538001
   Rozental S, 1996, J MED VET MYCOL, V34, P323
   ROZENTAL S, 1994, MYCOPATHOLOGIA, V126, P85, DOI 10.1007/BF01146200
   Said-Sadier N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010008
   Saijo S, 2010, IMMUNITY, V32, P681, DOI 10.1016/j.immuni.2010.05.001
   Salgado Claudio Guedes, 2004, Rev. Inst. Med. trop. S. Paulo, V46, P33, DOI 10.1590/S0036-46652004000100006
   Santos ALS, 2007, FEMS MICROBIOL REV, V31, P570, DOI 10.1111/j.1574-6976.2007.00077.x
   Schroder K, 2010, CELL, V140, P821, DOI 10.1016/j.cell.2010.01.040
   Siqueira IM, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005461
   Tavares AH, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004948
   Tavares AH, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002595
   de Sousa MDT, 2006, SCAND J IMMUNOL, V64, P595, DOI 10.1111/j.1365-3083.2006.01846.x
   Tomalka J, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002379
   van de Veerdonk FL, 2015, IMMUNOL REV, V265, P172, DOI 10.1111/imr.12280
   Vonk AG, 2006, J INFECT DIS, V193, P1419, DOI 10.1086/503363
   WALTER P, 1982, VIRCHOWS ARCH A, V397, P203, DOI 10.1007/BF00442390
   Wang HF, 2016, INFECT IMMUN, V84, P635, DOI 10.1128/IAI.01263-15
   Wellington M, 2014, EUKARYOT CELL, V13, P329, DOI 10.1128/EC.00336-13
   Wellington M, 2013, MBIO, V4, DOI 10.1128/mBio.00433-12
   Wen HT, 2013, IMMUNITY, V39, P432, DOI 10.1016/j.immuni.2013.08.037
   Wevers BA, 2014, CELL HOST MICROBE, V15, P494, DOI 10.1016/j.chom.2014.03.008
   Wuthrich M, 2015, EUR J IMMUNOL, V45, P2542, DOI 10.1002/eji.201545591
   Yoshikawa FSY, 2016, INNATE IMMUN-LONDON, V22, P316, DOI 10.1177/1753425916645392
   Zhu LL, 2013, IMMUNITY, V39, P324, DOI 10.1016/j.immuni.2013.05.017
NR 70
TC 3
Z9 3
U1 0
U2 3
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD NOV 20
PY 2017
VL 8
AR 1572
DI 10.3389/fimmu.2017.01572
PG 16
WC Immunology
SC Immunology
GA FN0PI
UT WOS:000415680100001
OA DOAJ Gold, Green Published
DA 2020-12-15
ER

PT J
AU Correa, LH
   Dourado, LPS
   Magalhaes, KG
AF Correa, Luis Henrique
   Sant'ana Dourado, Livia Pimentel
   Magalhaes, Kelly Grace
TI Featuring adipocytes secretion as pharmacological target for adjuvant
   immunotherapy against breast cancer
SO JOURNAL FOR IMMUNOTHERAPY OF CANCER
LA English
DT Meeting Abstract
C1 [Correa, Luis Henrique; Sant'ana Dourado, Livia Pimentel; Magalhaes, Kelly Grace] Univ Brasilia, Brasilia, DF, Brazil.
EM kellymagalhaes@gmail.com
RI Magalhaes, Kelly Grace/L-6081-2019; Magalhaes, Kelly G/A-6966-2010
OI Magalhaes, Kelly Grace/0000-0002-7435-5272; Magalhaes, Kelly
   G/0000-0002-7435-5272
CR Alderton GK, 2015, NAT REV CANCER, V15, P513, DOI [10.1038/nrc4013, 10.1038/nrc4005]
NR 1
TC 0
Z9 0
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2051-1426
J9 J IMMUNOTHER CANCER
JI J. Immunother. Cancer
PD NOV 7
PY 2017
VL 5
SU 2
MA P371
PG 1
WC Oncology; Immunology
SC Oncology; Immunology
GA VI0ZY
UT WOS:000460207200151
OA DOAJ Gold
DA 2020-12-15
ER

PT J
AU Assumpcao, JAF
   Magalhaes, KG
   Correa, JR
AF Fagundes Assumpcao, Jose Antonio
   Magalhaes, Kelly Grace
   Correa, Jose Raimundo
TI The role of ppary and autophagy in ros production, lipid droplets
   biogenesis and its involvement with colorectal cancer cells modulation
   (vol 17, 82, 2017)
SO CANCER CELL INTERNATIONAL
LA English
DT Correction
C1 [Fagundes Assumpcao, Jose Antonio; Magalhaes, Kelly Grace; Correa, Jose Raimundo] Univ Brasilia, Dept Biol Celular, Inst Ciencias Biol, Brasilia, DF, Brazil.
RP Correa, JR (corresponding author), Univ Brasilia, Dept Biol Celular, Inst Ciencias Biol, Brasilia, DF, Brazil.
EM correa@unb.br
RI Assumpcao, Jose AF/P-6588-2018; Magalhaes, Kelly Grace/L-6081-2019;
   Magalhaes, Kelly G/A-6966-2010
OI Assumpcao, Jose AF/0000-0002-2836-1583; Magalhaes, Kelly
   Grace/0000-0002-7435-5272; Magalhaes, Kelly G/0000-0002-7435-5272;
   Correa, Jose/0000-0003-2752-5395
CR Assumpcao JAF, 2017, CANCER CELL INT, V17, DOI 10.1186/s12935-017-0451-5
NR 1
TC 2
Z9 2
U1 0
U2 4
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2867
J9 CANCER CELL INT
JI Cancer Cell Int.
PD NOV 2
PY 2017
VL 17
AR 99
DI 10.1186/s12935-017-0463-1
PG 1
WC Oncology
SC Oncology
GA FL8ZO
UT WOS:000414540000001
PM 29118672
OA DOAJ Gold, Green Published
DA 2020-12-15
ER

PT J
AU Paixao, EMD
   Oliveira, ACD
   Pizato, N
   Muniz-Junqueira, MI
   Magalhaes, KG
   Nakano, EY
   Ito, MK
AF da Silva Paixao, Elemarcia Martins
   Oliveira, Ana Carolina De M.
   Pizato, Nathalia
   Muniz-Junqueira, Maria Imaculada
   Magalhaes, Kelly G.
   Nakano, Eduardo Yoshio
   Ito, Marina K.
TI The effects of EPA and DHA enriched fish oil on nutritional and
   immunological markers of treatment naive breast cancer patients: a
   randomized double-blind controlled trial
SO NUTRITION JOURNAL
LA English
DT Article
DE Breast cancer; N-3 fatty acids; Fish oil; Immunonutrition; Cytokines;
   Eicosapentaenoic acid (EPA)
ID EICOSAPENTAENOIC ACID; SUPPLEMENT; ROLES; BLOOD
AB Background: We evaluated the effects of eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids enriched fish oil (FO) on nutritional and immunological parameters of treatment naive breast cancer patients.
   Methods: In a randomized double blind controlled trial, the FO group (FG) patients were supplemented with 2 g/day of FO concentrate containing 1.8 g of n-3 fatty acids during 30 days. The placebo group (PG) received 2 g/day of mineral oil. At baseline and after the intervention, plasma levels of n-3 fatty acids, dietary intake, weight, body composition, biochemical and immunological markers were assessed.
   Results: At the end of the intervention period, no between group differences were observed regarding anthropometric parameters. There was a significant increase in the plasma phospholipid EPA (p = 0.004), DHA (p = 0.007) of the FG patients. In FG patients the percentages of peripheral blood CD4(+) T lymphocytes and serum high sensitivity C-reactive protein (hsCRP) levels were maintained while in PG patients there was a significant increase in hsCRP (p = 0.024). We also observed a significant reduction in the percentage of CD4(+) T lymphocytes in the peripheral blood (p = 0.042) of PG patients. No changes in serum proinflammatory cytokine and prostaglandin E-2 levels were observed.
   Conclusions: Supplementation of newly diagnosed breast cancer patients with EPA and DHA led to a significant change in the composition of plasma fatty acids, maintained the level of CD4(+) T cells and serum levels of hsCRP, suggestive of a beneficial effect on the immune system and less active inflammatory response.
C1 [da Silva Paixao, Elemarcia Martins; Oliveira, Ana Carolina De M.; Pizato, Nathalia; Ito, Marina K.] Univ Brasilia, Post Grad Program Human Nutr, BR-70910900 Brasilia, DF, Brazil.
   [Muniz-Junqueira, Maria Imaculada] Univ Brasilia, Lab Cellular Immunol, Dept Pathol, Fac Med, BR-70910900 Brasilia, DF, Brazil.
   [Magalhaes, Kelly G.] Univ Brasilia, Lab Immunol & Inflammat, Dept Cell Biol, Inst Biol, BR-70910900 Brasilia, DF, Brazil.
   [Nakano, Eduardo Yoshio] Univ Brasilia, Dept Stat, BR-70910900 Brasilia, DF, Brazil.
RP Paixao, EMD (corresponding author), Univ Brasilia, Post Grad Program Human Nutr, BR-70910900 Brasilia, DF, Brazil.
EM e.paixao@yahoo.com.br
RI Magalhaes, Kelly Grace/L-6081-2019; Muniz-Junqueira, M. I./W-9622-2019;
   Nakano, Eduardo Y/G-1660-2011; Magalhaes, Kelly G/A-6966-2010
OI Magalhaes, Kelly Grace/0000-0002-7435-5272; Muniz-Junqueira, M.
   I./0000-0002-9006-4619; Nakano, Eduardo Y/0000-0002-9071-8512;
   Magalhaes, Kelly G/0000-0002-7435-5272; Pizato,
   Nathalia/0000-0001-5858-7076
FU Federal District Research Foundation (FAPDF) [0193.000.557/2009];
   Coordination for the Improvement of Higher Education Personnel (CAPES),
   BrazilCAPES
FX This work was supported by the Federal District Research Foundation
   (FAPDF: process number 0193.000.557/2009) and Coordination for the
   Improvement of Higher Education Personnel (CAPES), Brazil.
CR Bagga D, 1997, J NATL CANCER I, V89, P1123, DOI 10.1093/jnci/89.15.1123
   Barbosa-Silva MCG, 2005, AM J CLIN NUTR, V82, P49
   Boomsma MF, 2010, J SURG ONCOL, V102, P640, DOI 10.1002/jso.21662
   Bougnoux P, 2009, BRIT J CANCER, V101, P1978, DOI 10.1038/sj.bjc.6605441
   Brunner E, 2000, BIOMETRICAL J, V42, P663, DOI 10.1002/1521-4036(200010)42:6<663::AID-BIMJ663>3.0.CO;2-7
   Calder P. C., 2015, BIOCHIM BIOPHYS ACTA, V1851, P469, DOI [10.1016/j.bbalip.2014.08.01025149823, DOI 10.1016/J.BBALIP.2014.08.010]
   Calder PC, 2002, BRIT J NUTR, V87, pS31, DOI 10.1079/BJN2001455
   Campbell MJ, 2005, BREAST CANCER RES TR, V91, P163, DOI 10.1007/s10549-004-7048-0
   Christie WW, 2003, METHOD SEPARATION SI, P105
   Du Clos TW, 2004, IMMUNOL RES, V30, P261, DOI 10.1385/IR:30:3:261
   Faber J, 2013, CLIN NUTR, V32, P338, DOI 10.1016/j.clnu.2012.09.009
   Fawzy MS, 2013, GENE, V527, P601, DOI 10.1016/j.gene.2013.06.007
   FOLCH J, 1957, J BIOL CHEM, V226, P497
   Ghoreishi Z, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-355
   Goldberg JE, 2010, CURR DRUG TARGETS, V11, P1133
   Goldfarb Y, 2006, Breast Dis, V26, P99
   Gomez-Candela C, 2011, NUTR HOSP, V26, P1385, DOI [10.3305/nh.2011.26.6.5349, 10.1590/S0212-16112011000600028]
   Mansara Prakash, 2015, J Med Case Rep, V9, P148, DOI 10.1186/s13256-015-0619-3
   Mantovani G, 2006, CANCER EPIDEM BIOMAR, V15, P1030, DOI 10.1158/1055-9965.EPI-05-0538
   MCCLUSKEY DR, 1983, BRIT J CANCER, V47, P307, DOI 10.1038/bjc.1983.41
   Mocellin MC, 2016, CLIN NUTR, V35, P359, DOI 10.1016/j.clnu.2015.04.013
   Nicolaou A, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00075
   Sallusto F, 2016, ANNU REV IMMUNOL, V34, P317, DOI 10.1146/annurev-immunol-032414-112056
   Sanchez-Lara K, 2014, CLIN NUTR, V33, P1017, DOI 10.1016/j.clnu.2014.03.006
   Schreiber RD, 2011, SCIENCE, V331, P1565, DOI 10.1126/science.1203486
   Serini S, 2016, NUTR RES REV, V29, P102, DOI 10.1017/S0954422416000044
   Sicking I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111306
   Taylor LA, 2010, SUPPORT CARE CANCER, V18, P159, DOI 10.1007/s00520-009-0640-4
   Velentzis LS, 2011, BREAST CANCER RES TR, V128, P473, DOI 10.1007/s10549-010-1238-8
   Wang ZK, 2012, CANCER IMMUNOL IMMUN, V61, P911, DOI 10.1007/s00262-011-1158-4
   West AL, 2016, BRIT J NUTR, V116, P788, DOI 10.1017/S0007114516002713
   WHITFORD P, 1992, EUR J CANCER, V28A, P350, DOI 10.1016/S0959-8049(05)80052-8
   World Health Organization, 1998, WHO TECHN REP SER
   Xiong AL, 2012, MOL NUTR FOOD RES, V56, P923, DOI 10.1002/mnfr.201200027
   Zheng JS, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f3706
NR 35
TC 18
Z9 19
U1 0
U2 10
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1475-2891
J9 NUTR J
JI Nutr. J.
PD OCT 23
PY 2017
VL 16
AR 71
DI 10.1186/s12937-017-0295-9
PG 11
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA FK7IY
UT WOS:000413680300002
PM 29061183
OA DOAJ Gold, Green Published
DA 2020-12-15
ER

PT J
AU Correa, LH
   Correa, R
   Farinasso, CM
   Dourado, LPD
   Magalhaes, KG
AF Correa, Luis Henrique
   Correa, Rafael
   Farinasso, Cecilia Menezes
   de Sant'Ana Dourado, Livia Pimentel
   Magalhaes, Kelly Grace
TI Adipocytes and Macrophages interplay in the Orchestration of Tumor
   Microenvironment: New implications in Cancer Progression
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Review
DE adipocytes; cancer; tumor microenvironment; obesity; inflammation;
   tumor-associated macrophages; tumor-associated adipocytes; macrophage
   polarization
ID ADIPOSE-TISSUE MACROPHAGES; MONOCYTE CHEMOATTRACTANT PROTEIN-1; CELL
   LUNG-CANCER; BREAST-CANCER; M1 MACROPHAGES; M2-POLARIZED MACROPHAGES;
   NEGATIVE REGULATOR; SIGNAL TRANSDUCER; M2 POLARIZATION; INFLAMMATION
AB Inflammation has been known as one of the main keys to the establishment and progression of cancers. Chronic low-grade inflammation is also a strategic condition that underlies the causes and development of metabolic syndrome and obesity. Moreover, obesity has been largely related to poor prognosis of tumors by modulating tumor microenvironment with secretion of several inflammatory mediators by tumor-associated adipocytes (TAAs), which can modulate and recruit tumor-associated macrophages. Thus, the understanding of cellular and molecular mechanisms that underlay and link inflammation, obesity, and cancer is crucial to identify potential targets that interfere with this important route. Knowledge about the exact role of each component of the tumor microenvironment is not yet fully understood, but the new insights in literature highlight the essential role of adipocytes and macrophages interplay as key factor to determine the fate of cancer progression. In this review article, we focus on the functions of adipocytes and macrophages orchestrating cellular and molecular mechanisms that lead to inflammatory modulation in tumor microenvironment, which will be crucial to cancer establishment. We also emphasized the mechanisms by which the tumor promotes itself by recruiting and polarizing macrophages, discussing the role of adipocytes in this process. In addition, we discuss here the newest possible anticancer therapeutic treatments aiming to retard the development of the tumor based on what is known about cancer, adipocyte, and macrophage polarization.
C1 [Correa, Luis Henrique; Correa, Rafael; Farinasso, Cecilia Menezes; de Sant'Ana Dourado, Livia Pimentel; Magalhaes, Kelly Grace] Univ Brasilia, Dept Cell Biol, Lab Immunol & Inflammat, Brasilia, DF, Brazil.
RP Magalhaes, KG (corresponding author), Univ Brasilia, Dept Cell Biol, Lab Immunol & Inflammat, Brasilia, DF, Brazil.
EM kellymagalhaes@unb.br
RI Magalhaes, Kelly Grace/L-6081-2019; Magalhaes, Kelly G/A-6966-2010
OI Magalhaes, Kelly Grace/0000-0002-7435-5272; Magalhaes, Kelly
   G/0000-0002-7435-5272; Correa, Luis Henrique/0000-0003-2825-0127;
   Correa, Rafael/0000-0003-2989-2383
CR Adjei IM, 2015, J FUNCT BIOMATER, V6, P81, DOI 10.3390/jfb6010081
   Afsharimani B, 2011, CANCER METAST REV, V30, P225, DOI 10.1007/s10555-011-9285-0
   Alizadeh AM, 2012, EUR J PHARMACOL, V689, P226, DOI 10.1016/j.ejphar.2012.06.016
   Andarawewa KL, 2005, CANCER RES, V65, P10862, DOI 10.1158/0008-5472.CAN-05-1231
   Arenberg DA, 2000, CANCER IMMUNOL IMMUN, V49, P63, DOI 10.1007/s002620050603
   Arendt LM, 2013, CANCER RES, V73, P6080, DOI 10.1158/0008-5472.CAN-13-0926
   Arpin CC, 2016, MOL CANCER THER, V15, P794, DOI 10.1158/1535-7163.MCT-15-0003
   Azenshtein E, 2002, CANCER RES, V62, P1093
   Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0
   Bianchini F, 2007, PROSTAG OTH LIPID M, V83, P320, DOI 10.1016/j.prostaglandins.2007.03.003
   Biswas SK, 2006, BLOOD, V107, P2112, DOI 10.1182/blood-2005-01-0428
   Boutens L, 2016, DIABETOLOGIA, V59, P879, DOI 10.1007/s00125-016-3904-9
   Brockstedt DG, 2004, P NATL ACAD SCI USA, V101, P13832, DOI 10.1073/pnas.0406035101
   Cai X, 2012, J MOL CELL BIOL, V4, P341, DOI 10.1093/jmcb/mjs044
   Chang CI, 2001, CANCER RES, V61, P1100
   Chanmee T, 2014, CANCERS, V6, P1670, DOI 10.3390/cancers6031670
   Chen EP, 2011, PROSTAG OTH LIPID M, V96, P14, DOI 10.1016/j.prostaglandins.2011.08.005
   Chen PW, 2013, INT REV CEL MOL BIO, V301, P1, DOI 10.1016/B978-0-12-407704-1.00001-4
   Chen P, 2011, TOXICOLOGY, V282, P122, DOI 10.1016/j.tox.2011.01.018
   Chen WK, 2016, ONCOTARGET, V7, P78726, DOI 10.18632/oncotarget.12807
   Chen YN, 2002, INT J CANCER, V100, P158, DOI 10.1002/ijc.10479
   Cheng FD, 2003, IMMUNITY, V19, P425, DOI 10.1016/S1074-7613(03)00232-2
   Colegio OR, 2014, NATURE, V513, P559, DOI 10.1038/nature13490
   Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007
   Dalmas E, 2011, TRENDS IMMUNOL, V32, P307, DOI 10.1016/j.it.2011.04.008
   Deng T, 2016, ANNU REV PATHOL-MECH, V11, P421, DOI 10.1146/annurev-pathol-012615-044359
   Dihanich S, 2012, BIOCHEM SOC T, V40, P1090, DOI 10.1042/BST20120127
   Dirat B, 2011, CANCER RES, V71, P2455, DOI 10.1158/0008-5472.CAN-10-3323
   Dirat B, 2010, ENDOCR DEV, V19, P45, DOI 10.1159/000316896
   Dominguez-Soto A, 2014, J IMMUNOL, V193, P5181, DOI 10.4049/jimmunol.1303375
   Drake CG, 2014, NAT REV CLIN ONCOL, V11, P24, DOI 10.1038/nrclinonc.2013.208
   Duan ZF, 2006, CLIN CANCER RES, V12, P5055, DOI 10.1158/1078-0432.CCR-06-0861
   Essandoh K, 2016, SHOCK, V46, P122, DOI 10.1097/SHK.0000000000000604
   Giordano C, 2016, ONCOTARGET, V7, P1262, DOI 10.18632/oncotarget.6014
   Gordon S, 2005, NAT REV IMMUNOL, V5, P953, DOI 10.1038/nri1733
   Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025
   Gu L, 2000, NATURE, V404, P407, DOI 10.1038/35006097
   Gunasekaran MK, 2013, CYTOKINE, V64, P103, DOI 10.1016/j.cyto.2013.07.017
   Heusinkveld M, 2011, J IMMUNOL, V187, P1157, DOI 10.4049/jimmunol.1100889
   Hsieh CC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147161
   Imtiyaz HZ, 2010, CURR TOP MICROBIOL, V345, P105, DOI 10.1007/82_2010_74
   Italiani P, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00514
   Iyengar NM, 2016, J CLIN ONCOL, V34, P4270, DOI 10.1200/JCO.2016.67.4283
   Jia XM, 2014, BREAST CANCER RES TR, V148, P291, DOI 10.1007/s10549-014-3164-7
   Kanda H, 2006, J CLIN INVEST, V116, P1494, DOI 10.1172/JCI26498
   Khabbazi S, 2015, SCI REP-UK, V5, DOI 10.1038/srep11389
   Kim KY, 2006, J IMMUNOL, V176, P5958, DOI 10.4049/jimmunol.176.10.5958
   Kim YJ, 2012, J GASTROEN HEPATOL, V27, P1004, DOI 10.1111/j.1440-1746.2012.07108.x
   Lewis CE, 2006, CANCER RES, V66, P605, DOI 10.1158/0008-5472.CAN-05-4005
   Li HZ, 2015, ONCOTARGET, V6, P29637, DOI 10.18632/oncotarget.4936
   Li KF, 2016, INT J ONCOL, V48, P2479, DOI 10.3892/ijo.2016.3483
   Lin EY, 2001, J EXP MED, V193, P727, DOI 10.1084/jem.193.6.727
   Liu CY, 2013, LAB INVEST, V93, P844, DOI 10.1038/labinvest.2013.69
   Liu LX, 2012, J THORAC ONCOL, V7, P1091, DOI 10.1097/JTO.0b013e3182542752
   Lizotte PH, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/onci.28926
   Lu S, 2014, INT J BIOL SCI, V10, P415, DOI 10.7150/ijbs.8002
   Mamessier E, 2011, J CLIN INVEST, V121, P3609, DOI 10.1172/JCI45816
   Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5
   Mantovani A, 2011, EUR J IMMUNOL, V41, P2522, DOI 10.1002/eji.201141894
   Mayi TH, 2012, J BIOL CHEM, V287, P21904, DOI 10.1074/jbc.M111.315200
   Mazumder A, 2013, EMBO REP, V14, P1008, DOI 10.1038/embor.2013.149
   Duong MN, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0569-0
   Mizutani K, 2009, NEOPLASIA, V11, P1235, DOI 10.1593/neo.09988
   Mocan T, 2015, J CANCER, V6, P583, DOI 10.7150/jca.11567
   Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448
   Motrescu ER, 2008, BIOL CHEM, V389, P1037, DOI 10.1515/BC.2008.110
   Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008
   NEGUS RPM, 1995, J CLIN INVEST, V95, P2391, DOI 10.1172/JCI117933
   Nimmerjahn F, 2008, ANNU REV IMMUNOL, V26, P513, DOI 10.1146/annurev.immunol.26.021607.090232
   Nishimoto S, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1501332
   Noel W, 2004, TRENDS PARASITOL, V20, P126, DOI 10.1016/j.pt.2004.01.004
   Noy R, 2014, IMMUNITY, V41, P49, DOI 10.1016/j.immuni.2014.06.010
   Ostman A, 2012, NAT MED, V18, P1332, DOI 10.1038/nm.2938
   Park J, 2014, NAT REV ENDOCRINOL, V10, P455, DOI 10.1038/nrendo.2014.94
   Perise-Barrios AJ, 2015, NANOSCALE, V7, P3857, DOI 10.1039/c4nr04038d
   Qian BZ, 2011, NATURE, V475, P222, DOI 10.1038/nature10138
   Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014
   Qian BZ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006562
   Qin T, 2015, TOXICOL APPL PHARM, V286, P112, DOI 10.1016/j.taap.2015.03.021
   Qin YY, 2016, CANCER CELL INT, V16, DOI 10.1186/s12935-016-0300-y
   Rauh Rolf, 2007, Chin Med, V2, P8
   Riabov V, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00075
   Rogers NH, 2009, ENDOCRINOLOGY, V150, P2161, DOI 10.1210/en.2008-1405
   Roszer T, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/816460
   Said N, 2011, J CLIN INVEST, V121, P132, DOI 10.1172/JCI42912
   Saito H, 2012, GASTRIC CANCER, V15, P27, DOI 10.1007/s10120-011-0059-8
   Santander AM, 2015, CANCERS, V7, P143, DOI 10.3390/cancers7010143
   Sartipy P, 2003, P NATL ACAD SCI USA, V100, P7265, DOI 10.1073/pnas.1133870100
   Seno H, 2002, CANCER RES, V62, P506
   Shang D, 2016, SCI REP-UK, V6, DOI 10.1038/srep32180
   Shang Xiao-yu, 2002, Yaoxue Xuebao, V37, P798
   Shiri Sadaf, 2015, Asian Pac J Cancer Prev, V16, P3917
   Sica A, 2008, SEMIN CANCER BIOL, V18, P349, DOI 10.1016/j.semcancer.2008.03.004
   Sica A, 2007, J CLIN INVEST, V117, P1155, DOI 10.1172/JCI31422
   Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643
   Silver DL, 2004, CANCER RES, V64, P3550, DOI 10.1158/0008-5472.CAN-03-3959
   Sinha P, 2005, J IMMUNOL, V174, P636, DOI 10.4049/jimmunol.174.2.636
   Spear P, 2012, J IMMUNOL, V188, P6389, DOI 10.4049/jimmunol.1103019
   Spencer M, 2010, AM J PHYSIOL-ENDOC M, V299, pE1016, DOI 10.1152/ajpendo.00329.2010
   Suganami T, 2010, J LEUKOCYTE BIOL, V88, P33, DOI 10.1189/jlb.0210072
   Sun Y, 2016, ONCOGENE, V35, P4321, DOI 10.1038/onc.2015.494
   Takaishi K, 2010, CANCER SCI, V101, P2128, DOI 10.1111/j.1349-7006.2010.01652.x
   Thomou T, 2017, NATURE, V542, P450, DOI 10.1038/nature21365
   Tsai CS, 2007, INT J RADIAT ONCOL, V68, P499, DOI 10.1016/j.ijrobp.2007.01.041
   Turley SJ, 2015, NAT REV IMMUNOL, V15, P669, DOI 10.1038/nri3902
   Vendramini-Costa DB, 2012, CURR PHARM DESIGN, V18, P3831
   Verreck FAW, 2004, P NATL ACAD SCI USA, V101, P4560, DOI 10.1073/pnas.0400983101
   Wang N, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00614
   Weisberg SP, 2006, J CLIN INVEST, V116, P115, DOI 10.1172/JCI24335
   Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246
   Williams CB, 2016, NPJ BREAST CANCER, V2, DOI 10.1038/npjbcancer.2015.25
   Yeh CB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031055
   Yu H, 2007, NAT REV IMMUNOL, V7, P41, DOI 10.1038/nri1995
   Zeyda M, 2007, IMMUNOL LETT, V112, P61, DOI 10.1016/j.imlet.2007.07.003
   Zhang J, 2014, ONCOTARGET, V5, P9664, DOI 10.18632/oncotarget.1856
   Zhang XW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065896
   Zhao HX, 2014, TOXICOL APPL PHARM, V279, P311, DOI 10.1016/j.taap.2014.07.001
   Zhao YR, 2003, BIOCHEM BIOPH RES CO, V300, P247, DOI 10.1016/S0006-291X(02)02838-3
   Zhao Y, 2015, MOL CARCINOGEN, V54, pE81, DOI 10.1002/mc.22182
   Zhou N, 2015, J CANCER, V6, P1049, DOI 10.7150/jca.12501
   Zhou N, 2015, INT J MOL SCI, V16, P11966, DOI 10.3390/ijms160611966
   Ziech D, 2011, MUTAT RES-FUND MOL M, V711, P167, DOI 10.1016/j.mrfmmm.2011.02.015
NR 122
TC 28
Z9 29
U1 1
U2 14
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD SEP 19
PY 2017
VL 8
AR 1129
DI 10.3389/fimmu.2017.01129
PG 12
WC Immunology
SC Immunology
GA FH3PI
UT WOS:000411061300001
PM 28970834
OA DOAJ Gold, Green Published
DA 2020-12-15
ER

PT J
AU Assumpcao, JAF
   Magalhaes, KG
   Correa, JR
AF Fagundes Assumpcao, Jose Antonio
   Magalhaes, Kelly Grace
   Correa, Jose Raimundo
TI The role of ppar gamma and autophagy in ros production, lipid droplets
   biogenesis and its involvement with colorectal cancer cells modulation
SO CANCER CELL INTERNATIONAL
LA English
DT Article
DE Colorectal cancer; Autophagy; PPAR; ROS; Lipid bodies; Cancer stem cells
ID ACTIVATED RECEPTOR-GAMMA; TUMOR-SUPPRESSOR; UP-REGULATION; INHIBITION;
   MTOR; INFLAMMATION; APOPTOSIS; PTEN; AGONISTS; STRESS
AB Background: In cancer cells, autophagy can act as both tumor suppressor, when autophagic event eliminates cellular contends which exceeds the cellular capacity of regenerate promoting cell death, and as a pro-survival agent removing defective organelles and proteins and helping well-established tumors to maintain an accelerated metabolic state while still dealing with harsh conditions, such as inflammation. Many pathways can coordinate the autophagic process and one of them involves the transcription factors called PPARs, which also regulate cellular differentiation, proliferation and survival. The PPAR. activation and autophagy initiation seems to be interrelated in a variety of cell types.
   Methods: Caco-2 cells were submitted to treatment with autophagy and PPAR gamma modulators and the relationship between both pathways was determined by western blotting and confocal microscopy. The effects of such modulations on Caco-2 cells, such as lipid bodies biogenesis, cell death, proliferation, cell cycle, ROS production and cancer stem cells profiling were analyzed by flow cytometry.
   Results: PPAR. and autophagy pathways seem to be overlap in Caco-2 cells, modulating each other in different ways and determining the lipid bodies biogenesis. In general, inhibition of autophagy by 3-MA leaded to reduced cell proliferation, cell cycle arrest and, ultimately, cell death by apoptosis. In agreement with these results, ROS production was increased in 3-MA treated cells. Autophagy also seems to play an important role in cancer stem cells profiling. Rapamycin and 3-MA induced epithelial and mesenchymal phenotypes, respectively.
   Conclusions: This study helps to elucidate in which way the induction or inhibition of these pathways regulate each other and affect cellular properties, such as ROS production, lipid bodies biogenesis and cell survive. We also consolidate autophagy as a key factor for colorectal cancer cells survival in vitro, pointing out a potential side effect of autophagic inhibition as a therapeutic application for this disease and demonstrate a novel regulation of PPAR. expression by inhibition of PI3K III.
C1 [Fagundes Assumpcao, Jose Antonio; Magalhaes, Kelly Grace; Correa, Jose Raimundo] Univ Brasilia, Inst Ciencias Biol, Dept Biol Celular, Brasilia, DF, Brazil.
RP Assumpcao, JAF (corresponding author), Univ Brasilia, Inst Ciencias Biol, Dept Biol Celular, Brasilia, DF, Brazil.
EM zeassumpcao@gmail.com
RI Magalhaes, Kelly Grace/L-6081-2019; Assumpcao, Jose AF/P-6588-2018;
   Magalhaes, Kelly G/A-6966-2010; Correa, Jose R/K-6270-2012
OI Magalhaes, Kelly Grace/0000-0002-7435-5272; Assumpcao, Jose
   AF/0000-0002-2836-1583; Magalhaes, Kelly G/0000-0002-7435-5272; Correa,
   Jose R/0000-0003-2752-5395
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq-Brazil)National Council for Scientific and Technological
   Development (CNPq)
FX Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq-Brazil).
CR Accioly MT, 2008, CANCER RES, V68, P1732, DOI 10.1158/0008-5472.CAN-07-1999
   Aires V, 2014, MOL NUTR FOOD RES, V58, P1785, DOI 10.1002/mnfr.201300962
   Arico S, 2001, J BIOL CHEM, V276, P35243, DOI 10.1074/jbc.C100319200
   Bhutia SK, 2013, ADV CANCER RES, V118, P61, DOI 10.1016/B978-0-12-407173-5.00003-0
   Blas-Garcia A, 2010, HEPATOLOGY, V52, P115, DOI 10.1002/hep.23647
   Bordonaro M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115068
   Bozza PT, 2010, PROSTAG LEUKOTR ESS, V82, P243, DOI 10.1016/j.plefa.2010.02.005
   Burchert A, 2005, LEUKEMIA, V19, P1774, DOI 10.1038/sj.leu.2403898
   Cabrera MC, 2015, WORLD J STEM CELLS, V7, P27, DOI 10.4252/wjsc.v7.i1.27
   Cerquetti L, 2011, EXP CELL RES, V317, P1397, DOI 10.1016/j.yexcr.2011.02.014
   Chateau D, 2005, J CELL PHYSIOL, V202, P767, DOI 10.1002/jcp.20173
   Chen XS, 2013, MOL CANCER RES, V11, P1269, DOI 10.1158/1541-7786.MCR-13-0212
   Chen YQ, 2011, J CELL SCI, V124, P161, DOI 10.1242/jcs.064576
   Coppede F, 2014, WORLD J GASTROENTERO, V20, P943, DOI 10.3748/wjg.v20.i4.943
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Errafiy R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083318
   Fang F, 2015, ONCOL LETT, V9, P1439, DOI 10.3892/ol.2015.2849
   Ferlay J, 2013, GLOBOCAN 2012 V1 0 C
   FUCCI A, 2012, PPAR RES, DOI DOI 10.1155/2012/242498
   Garza-Trevino EN, 2015, CANCER CELL INT, V15, DOI 10.1186/s12935-015-0163-7
   Geremia A, 2014, AUTOIMMUN REV, V13, P3, DOI 10.1016/j.autrev.2013.06.004
   Gibson SB, 2013, METHOD ENZYMOL, V528, P217, DOI 10.1016/B978-0-12-405881-1.00013-6
   Girnun G, 2009, GASTROENTEROLOGY, V136, P1157, DOI 10.1053/j.gastro.2009.02.022
   Gracz AD, 2013, STEM CELLS, V31, P2024, DOI 10.1002/stem.1391
   Grivennikov SI, 2013, SEMIN IMMUNOPATHOL, V35, P229, DOI 10.1007/s00281-012-0352-6
   Hafner C, 2005, CURR CANCER DRUG TAR, V5, P393, DOI 10.2174/1568009054863591
   Jewell JL, 2013, TRENDS BIOCHEM SCI, V38, P233, DOI 10.1016/j.tibs.2013.01.004
   Jiang PD, 2014, CELL RES, V24, P69, DOI 10.1038/cr.2013.161
   Kang JH, 2012, J BIOL CHEM, V287, P15661, DOI 10.1074/jbc.M112.358473
   Koehler BC, 2014, WORLD J GASTROENTERO, V20, P1923, DOI 10.3748/wjg.v20.i8.1923
   Lamark Trond, 2012, Int J Cell Biol, V2012, P736905, DOI 10.1155/2012/736905
   Lee SJ, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/327167
   Lei YL, 2015, MED RES REV, V35, P306, DOI 10.1002/med.21330
   Lin CF, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/787924
   Liu K, 2013, CELL DEATH DIFFER, V20, P3, DOI 10.1038/cdd.2012.63
   Mahmood DFD, 2011, J BIOL CHEM, V286, P28858, DOI 10.1074/jbc.M111.273292
   Manninen P, 2013, J CROHNS COLITIS, V7, P551
   Muller G, 2008, BRIT J PHARMACOL, V154, P901, DOI 10.1038/bjp.2008.146
   Nicoli ER, 2014, ROM J MORPHOL EMBRYO, V55, P57
   Oliveira LR, 2014, HEAD NECK-J SCI SPEC, V36, P1718, DOI 10.1002/hed.23527
   Park JI, 2012, PPAR RES, V2012, DOI 10.1155/2012/876418
   Patel L, 2001, CURR BIOL, V11, P764, DOI 10.1016/S0960-9822(01)00225-1
   Pellerito O, 2014, APOPTOSIS, V19, P1029, DOI 10.1007/s10495-014-0985-0
   Randall-Demllo S, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00301
   Rao S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4056
   Roelofs HMJ, 2014, BMC GASTROENTEROL, V14, DOI 10.1186/1471-230X-14-1
   Ryoo HD, 2012, COLD SPRING HARB PER, V4, P1
   Schaaf MBE, 2013, RADIOTHER ONCOL, V108, P529, DOI 10.1016/j.radonc.2013.06.015
   Schonewolf CA, 2014, WORLD J GASTRO ONCOL, V6, P74, DOI 10.4251/wjgo.v6.i3.74
   Sekiya M, 2008, BIOCHEM BIOPH RES CO, V375, P602, DOI 10.1016/j.bbrc.2008.08.068
   Selvakumaran M, 2013, CLIN CANCER RES, V19, P2995, DOI 10.1158/1078-0432.CCR-12-1542
   Shi CS, 2012, NAT IMMUNOL, V13, P255, DOI 10.1038/ni.2215
   Shi Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051076
   Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI [10.3322/caac.21208, 10.3322/caac.21254]
   Song MS, 2012, NAT REV MOL CELL BIO, V13, P283, DOI 10.1038/nrm3330
   Sreevalsan S, 2013, CURR COLORECT CANC R, V9, P350, DOI 10.1007/s11888-013-0190-5
   Tanida I, 2011, ANTIOXID REDOX SIGN, V14, P2201, DOI 10.1089/ars.2010.3482
   Vaiopoulos AG, 2014, BBA-MOL BASIS DIS, V1842, P971, DOI 10.1016/j.bbadis.2014.02.006
   Vaiopoulos AG, 2013, J MOL MED, V91, P1029, DOI 10.1007/s00109-013-1045-x
   Wang JF, 2014, WORLD J GASTROENTERO, V20, P4106, DOI 10.3748/wjg.v20.i14.4106
   Weng JR, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/935675
   Yan S, 2014, CANCER GENE THER, V21, P188, DOI 10.1038/cgt.2014.16
   Yang Q, 2007, CELL RES, V17, P666, DOI 10.1038/cr.2007.64
   Yang ZNJ, 2011, MOL CANCER THER, V10, P1533, DOI 10.1158/1535-7163.MCT-11-0047
   Zhang HH, 2015, CANCER LETT, V356, P781, DOI 10.1016/j.canlet.2014.10.029
   Zhang KJ, 2014, WORLD J GASTROENTERO, V20, P4167, DOI 10.3748/wjg.v20.i15.4167
   Zhang W, 2006, CANCER BIOL THER, V5, P1008, DOI 10.4161/cbt.5.8.2887
   Zhang Y, 2012, ONCOL REP, V27, P1599, DOI 10.3892/or.2012.1681
   Zhao H, 2014, BBA-GEN SUBJECTS, V1840, P545, DOI 10.1016/j.bbagen.2013.09.005
   Zheng Hai-yang, 2012, Cancer Biology Medicine, V9, P105, DOI 10.3969/j.issn.2095-3941.2012.02.004
   Zhou J, 2009, INT J BIOCHEM CELL B, V41, P2334, DOI 10.1016/j.biocel.2009.06.007
NR 71
TC 9
Z9 10
U1 0
U2 5
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1475-2867
J9 CANCER CELL INT
JI Cancer Cell Int.
PD SEP 15
PY 2017
VL 17
AR 82
DI 10.1186/s12935-017-0451-5
PG 12
WC Oncology
SC Oncology
GA FG9YP
UT WOS:000410796400001
PM 28932171
OA DOAJ Gold, Green Published
DA 2020-12-15
ER

PT J
AU Borges, TKS
   Alves, EAR
   Vasconcelos, HAR
   Carneiro, FP
   Nicola, AM
   Magalhaes, KG
   Muniz-Junqueira, MI
AF Borges, Tatiana K. S.
   Alves, Erica A. R.
   Vasconcelos, Henda A. R.
   Carneiro, Fabiana P.
   Nicola, Andre M.
   Magalhaes, Kelly G.
   Muniz-Junqueira, Maria Imaculada
TI Differences in the modulation of reactive species, lipid bodies,
   cyclooxygenase-2, 5-lipoxygenase and PPAR-gamma in cerebral
   malaria-susceptible and resistant mice
SO IMMUNOBIOLOGY
LA English
DT Article
DE Eicosanoids; Hydrogen peroxide; Inflammatory response; Lipid bodies;
   Malaria; Nitric oxide; PPAR-gamma
ID PROLIFERATOR-ACTIVATED RECEPTORS; PLASMODIUM-FALCIPARUM MALARIA; INNATE
   IMMUNE-RESPONSE; NITRIC-OXIDE SYNTHASE; NECROSIS-FACTOR-ALPHA;
   NF-KAPPA-B; IMMUNOMODULATORY THERAPY; PROSTAGLANDIN E-2; PATHOGENESIS;
   MACROPHAGES
AB Proinflammatory responses are associated with the severity of cerebral malaria. NO, H2O2, eicosanoid and PPAR-gamma are involved in proinflammatory responses, but regulation of these factors is unclear in malaria. This work aimed to compare the expression of eicosanoid-forming-enzymes in cerebral malaria-susceptible CBA and C57BL/6 and -resistant BALB/c mice. Mice were infected with Plasmodium berghei ANKA, and the survival rates and parasitemia curves were assessed. On the sixth day post-infection, cyclooxygenase-2 and 5-lipoxygenase in brain sections were assessed by immunohistochemistry, and, NO, H2O2, lipid bodies, and PPAR-gamma expression were assessed in peritoneal macrophages. The C57BL/6 had more severe disease with a lower survival time, higher parasitemia and lower production of plasmodicidal NO and H2O2 molecules than BALB/c. Enhanced COX-2 and 5-LOX expression were observed in brain tissue cells and vessels from C57BL/6 mice, and these mice expressed higher constitutive PPAR-gamma levels. There was no translocation of PPAR-gamma from cytoplasm to nucleus in macrophages from these mice. CBA mice had enhanced COX-2 expression in brain tissue cells and vessels and also lacked PPAR-gamma cytoplasm-to-nucleus translocation. The resistant BALB/c mice presented higher survival time, lower parasitemia and higher NO and H2O2 production on the sixth day post-infection. These mice did not express either COX-2 or 5-LOX in brain tissue cells and vessels. Our data showed that besides the high parasite burden and lack of microbicidal molecules, an imbalance with high COX-2 and 5-LOX eicosanoid expression and a lack of regulatory PPAR-gamma cytoplasm-to-nucleus translocation in macrophages were observed in mice that develop cerebral malaria. (C) 2016 Elsevier GmbH. All rights reserved.
C1 [Borges, Tatiana K. S.; Alves, Erica A. R.; Vasconcelos, Henda A. R.; Nicola, Andre M.; Muniz-Junqueira, Maria Imaculada] Univ Brasilia, Fac Med, Lab Cellular Immunol Pathol, Campus Darcy Ribeiro, BR-70910900 Brasilia, DF, Brazil.
   [Alves, Erica A. R.] Rene Rachou Res Ctr, Lab Cellular & Mol Immunol, BR-30190002 Belo Horizonte, MG, Brazil.
   [Vasconcelos, Henda A. R.] Minist Hlth Republ Angola, Natl Direct Publ Hlth, Luanda, Angola.
   [Carneiro, Fabiana P.] Univ Brasilia, Fac Med, Pathol Lab, Pathol, Campus Darcy Ribeiro, BR-70910900 Brasilia, DF, Brazil.
   [Magalhaes, Kelly G.] Univ Brasilia, Inst Biol, Dept Cellular Biol, Lab Immunol & Inflammat, Campus Darcy Ribeiro, BR-70910900 Brasilia, DF, Brazil.
RP Muniz-Junqueira, MI (corresponding author), Univ Brasilia, Fac Med, Lab Cellular Immunol Pathol, Campus Darcy Ribeiro, BR-70910900 Brasilia, DF, Brazil.
EM mimjunqueira@unb.br
RI Muniz-Junqueira, M. I./W-9622-2019; Magalhaes, Kelly G/A-6966-2010;
   Magalhaes, Kelly Grace/L-6081-2019; Nicola, Andre Moraes/B-3434-2008
OI Muniz-Junqueira, M. I./0000-0002-9006-4619; Magalhaes, Kelly
   G/0000-0002-7435-5272; Magalhaes, Kelly Grace/0000-0002-7435-5272;
   Nicola, Andre Moraes/0000-0001-8656-5835
FU CAPES (Molecular Pathology, University of Brasilia, Brazil); Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq),
   BrazilNational Council for Scientific and Technological Development
   (CNPq) [308985/2013-3]; Fundacao de Apoio a Pesquisa do Distrito Federal
   (FAPDF), BrazilNational Council for Scientific and Technological
   Development (CNPq) [193.000.021/2012]
FX Tatiana Karla Borges and Erica Alessandra Rocha Alves were supported by
   CAPES (Molecular Pathology, University of Brasilia, Brazil). Maria
   Imaculada Muniz-Junqueira is an investigator supported by the Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), Brazil
   (process number 308985/2013-3). This research was partially supported by
   a grant from Fundacao de Apoio a Pesquisa do Distrito Federal (FAPDF),
   Brazil (193.000.021/2012). The authors used a copy-editing service for
   language revision. We thank Dr. David Lima Duarte for reviewing the
   statistical analyses. We thank Andreia Cristina Gonsalves Cascaes,
   Danilo Corazza, Marcelo Henrique de Novoa Netto, Simone Schmil, Daniela
   Aquino, Mayara G C de Oliveira and Luciana Magalhdes, as well as all
   technical staff, for their assistance with the experiments and animal
   care. We thank Mrs. Fernanda Muniz Junqueira Ottoni and Mrs. Jack-
   elline Cavalcante do Nascimento Borges for the excellent work in image
   processing.
CR ALVES MFC, 1992, MEM I OSWALDO CRUZ, V87, P331, DOI 10.1590/S0074-02761992000700055
   Anyona SB, 2013, BIOCHEM BIOPH RES CO, V436, P585, DOI 10.1016/j.bbrc.2013.05.089
   Baker PRS, 2009, FREE RADICAL BIO MED, V46, P989, DOI 10.1016/j.freeradbiomed.2008.11.021
   Balachandar S, 2011, EUR J CLIN MICROBIOL, V30, P483, DOI 10.1007/s10096-010-1122-9
   Ball HJ, 2004, J INFECT DIS, V189, P751, DOI 10.1086/381503
   Blanquart C, 2003, J STEROID BIOCHEM, V85, P267, DOI 10.1016/S0960-0760(03)00214-0
   Boggild AK, 2009, CLIN INFECT DIS, V49, P841, DOI 10.1086/605431
   Bozza PT, 2011, PROSTAG LEUKOTR ESS, V85, P205, DOI 10.1016/j.plefa.2011.04.020
   Bozza PT, 2009, BBA-MOL CELL BIOL L, V1791, P540, DOI 10.1016/j.bbalip.2009.01.005
   Burry RW, 2011, J HISTOCHEM CYTOCHEM, V59, P6, DOI 10.1369/jhc.2010.956920
   Clark IA, 2003, MALARIA J, V2, DOI 10.1186/1475-2875-2-6
   Deininger MH, 2000, J NEUROIMMUNOL, V106, P198, DOI 10.1016/S0165-5728(00)00187-9
   Delerive P, 2001, J ENDOCRINOL, V169, P453, DOI 10.1677/joe.0.1690453
   Dorovini-Zis K, 2011, AM J PATHOL, V178, P2146, DOI 10.1016/j.ajpath.2011.01.016
   Gerritsen ME, 1996, CARDIOVASC RES, V32, P720, DOI 10.1016/0008-6363(96)00072-7
   Gil-de-Gomez L, 2013, J IMMUNOL, V190, P5169, DOI 10.4049/jimmunol.1203494
   Gramaglia I, 2006, NAT MED, V12, P1417, DOI 10.1038/nm1499
   GRAU GE, 1989, P NATL ACAD SCI USA, V86, P5572, DOI 10.1073/pnas.86.14.5572
   Hanum S, 2003, INT IMMUNOL, V15, P633, DOI 10.1093/intimm/dxg065
   Idro R, 2010, PEDIATR RES, V68, P267, DOI 10.1203/00006450-201011001-00524
   Keller CC, 2006, J INFECT DIS, V193, P1384, DOI 10.1086/503047
   Kim SF, 2011, NITRIC OXIDE-BIOL CH, V25, P255, DOI 10.1016/j.niox.2011.07.002
   Lou J, 2001, CLIN MICROBIOL REV, V14, P810, DOI 10.1128/CMR.14.4.810-820.2001
   Maitland K, 2004, ACTA TROP, V90, P131, DOI 10.1016/j.actatropica.2003.11.010
   Maneerat Y, 2000, HISTOPATHOLOGY, V37, P269, DOI 10.1046/j.1365-2559.2000.00989.x
   Lapouble OMM, 2015, REV PANAM SALUD PUBL, V38, P300
   Morgan MJ, 2011, CELL RES, V21, P103, DOI 10.1038/cr.2010.178
   Moussaud S, 2010, J NEUROSCI METH, V187, P243, DOI 10.1016/j.jneumeth.2010.01.017
   Muniz-Junqueira M. I., 2007, Antibiotiques, V9, P164, DOI 10.1016/S1294-5501(07)91375-8
   Muniz-Junqueira MI, 2007, CURR CLIN PHARMACOL, V2, P59, DOI 10.2174/157488407779422285
   Muniz-Junqueira MI, 2005, ACTA TROP, V94, P128, DOI 10.1016/j.actatropica.2005.03.002
   Muniz-Junqueira MI, 2003, CLIN DIAGN LAB IMMUN, V10, P1096, DOI 10.1128/CDLI.10.6.1096-1102.2003
   Muniz-Junqueira MI, 2001, CELL IMMUNOL, V208, P73, DOI 10.1006/cimm.2001.1770
   Paxinos G., 2008, MOUSE BRAIN STEREOTA
   Perkins DJ, 2005, J INFECT DIS, V191, P1548, DOI 10.1086/429332
   Alves EAR, 2015, INT IMMUNOPHARMACOL, V24, P314, DOI 10.1016/j.intimp.2014.12.025
   Rogerio AP, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/595694
   Schofield L, 2005, NAT REV IMMUNOL, V5, P722, DOI 10.1038/nri1686
   Serghides L, 2001, J IMMUNOL, V166, P6742, DOI 10.4049/jimmunol.166.11.6742
   Serghides L, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003980
   Serghides L, 2012, PPAR RES, V2012, P1, DOI 10.1155/2012/513865
   Serghides L, 2009, J INFECT DIS, V199, P1536, DOI 10.1086/598222
   Shryock N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061882
   Torra IP, 2001, CURR OPIN LIPIDOL, V12, P245, DOI 10.1097/00041433-200106000-00002
   Warrell DA, 1999, PARASSITOLOGIA, VOL 41, NOS 1-3, SEPTEMBER 1999, P287
   Weigel G, 1997, THROMB RES, V87, P363, DOI 10.1016/S0049-3848(97)00140-0
   World Health Organization, 2015, WORLD MALARIA REPORT
   Wymann MP, 2008, NAT REV MOL CELL BIO, V9, P162, DOI 10.1038/nrm2335
   Xiao LH, 1999, AM J TROP MED HYG, V60, P668, DOI 10.4269/ajtmh.1999.60.668
   Ye JP, 2008, BIOCHEM BIOPH RES CO, V374, P405, DOI 10.1016/j.bbrc.2008.07.068
NR 50
TC 4
Z9 4
U1 0
U2 3
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 0171-2985
J9 IMMUNOBIOLOGY
JI Immunobiology
PD APR
PY 2017
VL 222
IS 4
BP 604
EP 619
DI 10.1016/j.imbio.2016.11.010
PG 16
WC Immunology
SC Immunology
GA EO8SP
UT WOS:000396960500002
PM 27887739
DA 2020-12-15
ER

PT J
AU Azevedo, CS
   Guido, BC
   Pereira, JL
   Nolasco, DO
   Correa, R
   Magalhaes, KG
   Motta, FN
   Santana, JM
   Grellier, P
   Bastos, IMD
AF Azevedo, Clenia S.
   Guido, Bruna C.
   Pereira, Jhonata L.
   Nolasco, Diego O.
   Correa, Rafael
   Magalhaes, Kelly G.
   Motta, Flavia N.
   Santana, Jaime M.
   Grellier, Philippe
   Bastos, Izabela M. D.
TI Revealing a Novel Otubain-Like Enzyme from Leishmania infantum with
   Deubiquitinating Activity toward K48-Linked Substrate
SO FRONTIERS IN CHEMISTRY
LA English
DT Article
DE leishmania; deubiquitination; cysteine protease; molecular dynamic;
   site-directed mutagenesis; otubain
ID PLASMODIUM-FALCIPARUM; UBIQUITIN LIGASE; SPECIFICITY; INFECTION;
   PARASITES; PROTEINS; GENE; CODE; A20; IKK
AB Deubiquitinating enzymes (DUBs) play an important role in regulating a variety of eukaryotic processes. In this context, exploring the role of deubiquitination in Leishmania infanturn could be a promising alternative to search new therapeutic targets for leishmaniasis. Here we present the first characterization of a DUB from L. infanturn, otubain (OtuLi), and its localization within parasite. The recombinant OtuLi (rOtuLi) showed improved activity on lysine 48 (K48)-linked over K63-linked tetra-ubiquitin (Ub) and site-directed mutations on amino acids close to the catalytic site (F82) or involved in Ub interaction (L265 and F182) caused structural changes as shown by molecular dynamics, resulting in a reduction or loss of enzyme activity, respectively. Furthermore, rOtuLi stimulates lipid droplet biogenesis (an inflammatory marker) and induces IL-6 and TNF-alpha secretion in peritoneal macrophages, both proinflammatory cytokines. Our findings suggest that OtuLi is a cytoplasmic enzyme with K48-linked substrate specificity that could play a part in proinflammatory response in stimulated murine macrophages.
C1 [Azevedo, Clenia S.; Pereira, Jhonata L.; Motta, Flavia N.; Santana, Jaime M.; Bastos, Izabela M. D.] Univ Brasilia, Dept Cell Biol, Pathogen Host Interface Lab, Brasilia, DF, Brazil.
   [Guido, Bruna C.] Univ Brasilia, Dept Cell Biol, Lab Electron Microscopy, Brasilia, DF, Brazil.
   [Nolasco, Diego O.] Univ Catolica Brasilia, Phys Course, Brasilia, DF, Brazil.
   [Nolasco, Diego O.] Univ Catolica Brasilia, Programa Posgrad Ciencias Genom & Biotecnol, Brasilia, DF, Brazil.
   [Correa, Rafael; Magalhaes, Kelly G.] Univ Brasilia, Dept Cell Biol, Lab Immunol & Inflammat, Brasilia, DF, Brazil.
   [Motta, Flavia N.] Univ Brasilia, Fac Ceilandia, Brasilia, DF, Brazil.
   [Grellier, Philippe] Sorbonne Univ, Museum Natl Hist Nat, CNRS, UMR 7245, Paris, France.
RP Bastos, IMD (corresponding author), Univ Brasilia, Dept Cell Biol, Pathogen Host Interface Lab, Brasilia, DF, Brazil.
EM dourado@unb.br
RI Magalhaes, Kelly G/A-6966-2010; Magalhaes, Kelly Grace/L-6081-2019;
   Nolasco, Diego O/O-6743-2014; Guido, Bruna C/D-7790-2013
OI Magalhaes, Kelly G/0000-0002-7435-5272; Magalhaes, Kelly
   Grace/0000-0002-7435-5272; Nolasco, Diego O/0000-0001-7931-5475; Candido
   Guido, Bruna/0000-0001-6397-1259; Correa, Rafael/0000-0003-2989-2383;
   Bastos, Izabela/0000-0002-2785-4255
FU INCE (Institutos Nacionais de Ciencia e Tecnologia) [465771/2014-9];
   CAPES (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior) -
   COFECUB [723/11]; CNPq (Conselho Nacional de Ciencia e
   Tecnologia)National Council for Scientific and Technological Development
   (CNPq) [303675/2015-2, 307186/2013-0]; FAPDF (Fundacao de Apoio a
   Pesquisa do Distrito Federal)National Council for Scientific and
   Technological Development (CNPq) [193.001.076/2015, 193.000.822/2015];
   IDEX Sorbonne Universites (SUPER)
FX This work was supported by INCE (Institutos Nacionais de Ciencia e
   Tecnologia) grant number: 465771/2014-9, CAPES (Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior) - COFECUB grant number:
   723/11, CNPq (Conselho Nacional de Ciencia e Tecnologia) grant number:
   303675/2015-2 and 307186/2013-0. FAPDF (Fundayao de Apoio a Pesquisa do
   Distrito Federal) grant numbers: 193.001.076/2015 and 193.000.822/2015.
   MCT/CNPq/ENDCT/FAPs/MEC/CAPES/PRO-CENTROOESTE. FINEP and by the an
   international mobility grant from IDEX Sorbonne Universites (SUPER).
CR Alcolea Pedro J, 2010, BMC Genomics, V11, P31, DOI 10.1186/1471-2164-11-31
   Altun M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0115344
   Alvar J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035671
   Artavanis-Tsakonas K, 2006, MOL MICROBIOL, V61, P1187, DOI 10.1111/j.1365-2958.2006.05307.x
   Berendsen H. J. C., 1981, INTERMOLECULAR FORCE, P331, DOI DOI 10.1007/978-94-015-7658-1_21
   BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118
   Bozza PT, 2007, PHARMACOL THERAPEUT, V113, P30, DOI 10.1016/j.pharmthera.2006.06.006
   Brooks BR, 2009, J COMPUT CHEM, V30, P1545, DOI 10.1002/jcc.21287
   Choi CM, 2001, J INVEST DERM SYMP P, V6, P175, DOI 10.1046/j.0022-202x.2001.00038.x
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   Doil C, 2009, CELL, V136, P435, DOI 10.1016/j.cell.2008.12.041
   Edelmann MJ, 2009, BIOCHEM J, V418, P379, DOI 10.1042/BJ20081318
   Florenta I, 2000, FEBS LETT, V484, P246, DOI 10.1016/S0014-5793(00)02170-0
   Frickel EM, 2007, CELL MICROBIOL, V9, P1601, DOI 10.1111/j.1462-5822.2007.00896.x
   Furtado AR, 2013, CELL MICROBIOL, V15, P2064, DOI 10.1111/cmi.12171
   Gack MU, 2007, NATURE, V446, P916, DOI 10.1038/nature05732
   Harhay MO, 2011, TRENDS PARASITOL, V27, P403, DOI 10.1016/j.pt.2011.04.001
   Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425
   Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H
   Hunt P, 2007, MOL MICROBIOL, V65, P27, DOI 10.1111/j.1365-2958.2007.05753.x
   Husnjak K, 2012, ANNU REV BIOCHEM, V81, P291, DOI 10.1146/annurev-biochem-051810-094654
   Hutchins AP, 2013, MOL BIOL EVOL, V30, P1172, DOI 10.1093/molbev/mst022
   Ju HL, 2014, PARASITOL INT, V63, P580, DOI 10.1016/j.parint.2014.03.005
   Kayagaki N, 2007, SCIENCE, V318, P1628, DOI 10.1126/science.1145918
   KING RC, 1988, BIOESSAYS, V8, P18, DOI 10.1002/bies.950080106
   Kobets T, 2012, CURR MED CHEM, V19, P1443, DOI 10.2174/092986712799828300
   Komander D, 2012, ANNU REV BIOCHEM, V81, P203, DOI 10.1146/annurev-biochem-060310-170328
   Komander D, 2009, NAT REV MOL CELL BIO, V10, P550, DOI 10.1038/nrm2731
   Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148
   Lazaridis T, 1999, PROTEINS, V35, P133, DOI 10.1002/(SICI)1097-0134(19990501)35:2<133::AID-PROT1>3.0.CO;2-N
   Makarova KS, 2000, TRENDS BIOCHEM SCI, V25, P50, DOI 10.1016/S0968-0004(99)01530-3
   McConville MJ, 2002, MICROBIOL MOL BIOL R, V66, P122, DOI 10.1128/MMBR.66.1.122-154.2002
   MIYAMOTO S, 1992, J COMPUT CHEM, V13, P952, DOI 10.1002/jcc.540130805
   Nanao MH, 2004, EMBO REP, V5, P783, DOI 10.1038/sj.embor.7400201
   Nijman SMB, 2005, CELL, V123, P773, DOI 10.1016/j.cell.2005.11.007
   Pearson RD, 1996, CLIN INFECT DIS, V22, P1, DOI 10.1093/clinids/22.1.1
   Pereira RV, 2015, PARASITOL RES, V114, P2835, DOI 10.1007/s00436-015-4484-1
   Pronk S, 2013, BIOINFORMATICS, V29, P845, DOI 10.1093/bioinformatics/btt055
   Rabhi S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148640
   Rodrigues V, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1412-x
   Soares L, 2004, NAT IMMUNOL, V5, P45, DOI 10.1038/ni1017
   Srivastav S, 2012, J IMMUNOL, V189, P924, DOI 10.4049/jimmunol.1102845
   Stewart GS, 2009, CELL, V136, P420, DOI 10.1016/j.cell.2008.12.042
   Swatek KN, 2016, CELL RES, V26, P399, DOI 10.1038/cr.2016.39
   TURK B, 1995, BIOL CHEM H-S, V376, P225, DOI 10.1515/bchm3.1995.376.4.225
   Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597
   Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794
   Xu M, 2009, MOL CELL, V36, P302, DOI 10.1016/j.molcel.2009.10.002
   Yau R, 2016, NAT CELL BIOL, V18, P579, DOI 10.1038/ncb3358
NR 49
TC 5
Z9 5
U1 0
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
   SWITZERLAND
SN 2296-2646
J9 FRONT CHEM
JI Front. Chem.
PD MAR 23
PY 2017
VL 5
AR 13
DI 10.3389/fchem.2017.00013
PG 11
WC Chemistry, Multidisciplinary
SC Chemistry
GA EP1LU
UT WOS:000397147200001
PM 28386537
OA DOAJ Gold, Green Published
DA 2020-12-15
ER

PT J
AU Portugal, B
   Motta, FN
   Correa, AF
   Nolasco, DO
   de Almeida, H
   Magalhaes, KG
   Atta, ALV
   Vieira, FD
   Bastos, IMD
   Santana, JM
AF Portugal, Brina
   Motta, Flavia N.
   Correa, Andre F.
   Nolasco, Diego O.
   de Almeida, Hugo
   Magalhaes, Kelly G.
   Atta, Ana L. V.
   Vieira, Francisco D.
   Bastos, Izabela M. D.
   Santana, Jaime M.
TI Mycobacterium tuberculosis Prolyl Oligopeptidase Induces In vitro
   Secretion of Proinflammatory Cytokines by Peritoneal Macrophages
SO FRONTIERS IN MICROBIOLOGY
LA English
DT Article
DE tuberculosis; Mycobacterium tuberculosis; protease; serine protease;
   prolyl oligopeptidase; proinflammatory cytokines; molecular dynamic;
   fluorescence spectroscopy
ID PARTICLE MESH EWALD; TRYPANOSOMA-CRUZI; ENDOPEPTIDASE ACTIVITY;
   DENDRITIC CELLS; INTRABACTERIAL PH; PROTEIN; IMMUNITY; ENZYME;
   INTERLEUKIN-6; PURIFICATION
AB Tuberculosis (TB) is a disease that leads to death over 1 million people per year worldwide and the biological mediators of this pathology are poorly established, preventing the implementation of effective therapies to improve outcomes in TB. Host-bacterium interaction is a key step to TB establishment and the proteases produced by these microorganisms seem to facilitate bacteria invasion, migration and host immune response evasion. We presented, for the first time, the identification, biochemical characterization, molecular dynamics (MDs) and immunomodulatory properties of a prolyl oligopeptidase (POP) from Mycobacterium tuberculosis (POPMt). POP is a serine protease that hydrolyzes substrates with high specificity for proline residues and has already been characterized as virulence factor in infectious diseases. POPMt reveals catalytic activity upon N-Suc-Gly-Pro-Leu-Gly-Pro-AMC, a recognized POP substrate, with optimal activity at pH 7.5 and 37 degrees C. The enzyme presents K-M and K-cat/K-M values of 108 mu M and 21.838 mM(-1) s(-1), respectively. MDs showed that POPMt structure is similar to that of others POPs, which consists of a cylindrical architecture divided into an alpha/beta hydrolase catalytic domain and a beta-propeller domain. Finally, POPMt was capable of triggering in vitro secretion of proinflammatory cytokines by peritoneal macrophages, an event dependent on POPMt intact structure. Our data suggests that POPMt may contribute to an inflammatory response during M. tuberculosis infection.
C1 [Portugal, Brina; Motta, Flavia N.; Correa, Andre F.; de Almeida, Hugo; Bastos, Izabela M. D.; Santana, Jaime M.] Univ Brasilia, Dept Cell Biol, Pathogen Host Interface Lab, Brasilia, DF, Brazil.
   [Motta, Flavia N.] Univ Brasilia, Fac Ceilandia, Brasilia, DF, Brazil.
   [Correa, Andre F.] Univ Fed Goias, Inst Patol Trop & Saude Publ, Goiania, Go, Brazil.
   [Nolasco, Diego O.] Univ Catolica Brasilia, Phys Course, Brasilia, DF, Brazil.
   [Nolasco, Diego O.] Univ Catolica Brasilia, Postgrad Program Genom Sci & Biotechnol, Brasilia, DF, Brazil.
   [Magalhaes, Kelly G.] Univ Brasilia, Dept Cell Biol, Lab Immunol & Inflammat, Brasilia, DF, Brazil.
   [Atta, Ana L. V.; Vieira, Francisco D.] Lab Cent Saude Publ Dist Fed, Brasilia, DF, Brazil.
RP Bastos, IMD; Santana, JM (corresponding author), Univ Brasilia, Dept Cell Biol, Pathogen Host Interface Lab, Brasilia, DF, Brazil.
EM dourado@unb.br; jsantana@unb.br
RI Magalhaes, Kelly G/A-6966-2010; Magalhaes, Kelly Grace/L-6081-2019;
   Nolasco, Diego O/O-6743-2014
OI Magalhaes, Kelly G/0000-0002-7435-5272; Magalhaes, Kelly
   Grace/0000-0002-7435-5272; Nolasco, Diego O/0000-0001-7931-5475; Bastos,
   Izabela/0000-0002-2785-4255; de Almeida Silva, Hugo/0000-0003-3773-3251
FU CAPES-COFECUBCAPES [723/11]; CNPqNational Council for Scientific and
   Technological Development (CNPq); MCTI/CNPq/FNDCT/PRO-CENTRO-OESTE
   [407730/2013-3]; FAPDF; FINEPCiencia Tecnologia e Inovacao (FINEP)
FX This work was supported by CAPES-COFECUB No 723/11, CNPq,
   MCTI/CNPq/FNDCT/PRO-CENTRO-OESTE 407730/2013-3, FAPDF, FINEP.
CR Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389
   BAKKER AV, 1990, BIOCHEM J, V271, P559, DOI 10.1042/bj2710559
   Balcewicz-Sablinska MK, 1998, J IMMUNOL, V161, P2636
   Bastos IMD, 2005, BIOCHEM J, V388, P29, DOI 10.1042/BJ20041049
   Bastos IMD, 2010, MICROBES INFECT, V12, P457, DOI 10.1016/j.micinf.2010.02.007
   Berendsen H. J. C., 1981, INTERMOLECULAR FORCE, P331, DOI DOI 10.1007/978-94-015-7658-1_21
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Chackerian AA, 2002, INFECT IMMUN, V70, P4501, DOI 10.1128/IAI.70.8.4501-4509.2002
   CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
   Clay H, 2008, IMMUNITY, V29, P283, DOI 10.1016/j.immuni.2008.06.011
   Cooper AM, 2012, CURR OPIN IMMUNOL, V24, P431, DOI 10.1016/j.coi.2012.04.008
   CORNISHBOWDEN A, 1976, PRINCIPLES ENZYME KI
   Correa AF, 2014, INFECT IMMUN, V82, P5154, DOI 10.1128/IAI.02304-14
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   de Almeida H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072402
   Elkington PT, 2011, EUR RESPIR J, V38, P456, DOI 10.1183/09031936.00015411
   ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117
   Fajtova P, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003827
   Fogel N, 2015, TUBERCULOSIS, V95, P527, DOI 10.1016/j.tube.2015.05.017
   Gaggar Amit, 2010, Open Respir Med J, V4, P32, DOI 10.2174/1874306401004020032
   Galimi R, 2011, EUR REV MED PHARMACO, V15, P365
   Gerszten RE, 1999, NATURE, V398, P718
   Goldberg MF, 2014, MICROBIOL SPECTR, V2, DOI 10.1128/microbiolspec.MGM2-0005-2013
   Grellier P, 2001, J BIOL CHEM, V276, P47078, DOI 10.1074/jbc.M106017200
   Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H
   Hess B, 2008, J CHEM THEORY COMPUT, V4, P435, DOI 10.1021/ct700301q
   HOLT PG, 1987, IMMUNOLOGY, V62, P349
   Jayaraman P, 2013, J IMMUNOL, V190, P4196, DOI 10.4049/jimmunol.1202688
   Jayaraman P, 2010, J EXP MED, V207, P2343, DOI 10.1084/jem.20100687
   Joyeau R, 2000, EUR J MED CHEM, V35, P257, DOI 10.1016/S0223-5234(00)00118-5
   Juffermans NP, 2000, J INFECT DIS, V182, P888, DOI 10.1086/315750
   Kabashima T, 1998, ARCH BIOCHEM BIOPHYS, V358, P141, DOI 10.1006/abbi.1998.0836
   KANATANI A, 1993, J BIOCHEM, V113, P790, DOI 10.1093/oxfordjournals.jbchem.a124120
   Kaushik S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026251
   KOIDA M, 1976, J BIOL CHEM, V251, P7593
   Korb VC, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17030131
   Ladel CH, 1997, INFECT IMMUN, V65, P4843, DOI 10.1128/IAI.65.11.4843-4849.1997
   Lakowicz J.R., 2004, PRINCIPLES FLUORESCE
   Lebrun I, 2009, MINI-REV MED CHEM, V9, P820, DOI 10.2174/138955709788452603
   Lun SC, 2007, J BIOL CHEM, V282, P18348, DOI 10.1074/jbc.M700035200
   Maes M, 2001, PSYCHONEUROENDOCRINO, V26, P17, DOI 10.1016/S0306-4530(00)00032-9
   Maes M, 1998, PSYCHONEUROENDOCRINO, V23, P485, DOI 10.1016/S0306-4530(98)00020-1
   MAES M, 1995, PSYCHIAT RES, V58, P217, DOI 10.1016/0165-1781(95)02698-V
   Mantle D, 1996, CLIN CHIM ACTA, V249, P129, DOI 10.1016/0009-8981(96)06282-1
   Martinez AN, 2013, J INFECT DIS, V207, P1253, DOI 10.1093/infdis/jit037
   Master SS, 2008, CELL HOST MICROBE, V3, P224, DOI 10.1016/j.chom.2008.03.003
   Mayer-Barber KD, 2010, J IMMUNOL, V184, P3326, DOI 10.4049/jimmunol.0904189
   Mihret A, 2013, J INFECTION, V66, P357, DOI 10.1016/j.jinf.2012.11.005
   Morty RE, 2005, FEBS LETT, V579, P2191, DOI 10.1016/j.febslet.2005.03.014
   Motta FN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030431
   Mukherjee S, 2009, BIOPHYS CHEM, V141, P94, DOI 10.1016/j.bpc.2009.01.002
   Nagabhushanam V, 2003, J IMMUNOL, V171, P4750, DOI 10.4049/jimmunol.171.9.4750
   O'Reilly PJ, 2009, J NEUROIMMUNOL, V217, P51, DOI 10.1016/j.jneuroim.2009.09.020
   Orme IM, 1999, IMMUNOL TODAY, V20, P307, DOI 10.1016/S0167-5699(98)01438-8
   Peters W, 2004, J IMMUNOL, V172, P7647, DOI 10.4049/jimmunol.172.12.7647
   Peters W, 2001, P NATL ACAD SCI USA, V98, P7958, DOI 10.1073/pnas.131207398
   POKALSKY C, 1995, J BIOL CHEM, V270, P3809, DOI 10.1074/jbc.270.8.3809
   Qiu YQ, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002984
   Raju RM, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002511
   Rea D, 2006, CELL BIOCHEM BIOPHYS, V44, P349, DOI 10.1385/CBB:44:3:349
   Reiley WW, 2008, P NATL ACAD SCI USA, V105, P10961, DOI 10.1073/pnas.0801496105
   Rengarajan J, 2008, P NATL ACAD SCI USA, V105, P264, DOI 10.1073/pnas.0710601105
   Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3
   Roberts DM, 2013, FUTURE MICROBIOL, V8, P621, DOI [10.2217/FMB.13.25, 10.2217/fmb.13.25]
   Sada-Ovalle I, 2012, J IMMUNOL, V189, P5896, DOI 10.4049/jimmunol.1200990
   Santana JM, 1997, BIOCHEM J, V325, P129, DOI 10.1042/bj3250129
   Saunders BM, 2000, INFECT IMMUN, V68, P3322, DOI 10.1128/IAI.68.6.3322-3326.2000
   SERTL K, 1986, J EXP MED, V163, P436, DOI 10.1084/jem.163.2.436
   Shan L, 2005, P NATL ACAD SCI USA, V102, P3599, DOI 10.1073/pnas.0408286102
   Shan L, 2004, BIOCHEM J, V383, P311, DOI 10.1042/BJ20040907
   Shan L, 2002, SCIENCE, V297, P2275, DOI 10.1126/science.1074129
   Sia JK, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/747543
   Sodenkamp J, 2012, IMMUNOBIOLOGY, V217, P996, DOI 10.1016/j.imbio.2012.01.015
   Solovic I, 2010, EUR RESPIR J, V36, P1185, DOI 10.1183/09031936.00028510
   Szeltner Z, 2000, J BIOL CHEM, V275, P15000, DOI 10.1074/jbc.M000942200
   SZWAJCERDEY E, 1992, J BACTERIOL, V174, P2454, DOI 10.1128/jb.174.8.2454-2459.1992
   Tenorio-Laranga J, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0404-7
   Tenorio-Laranga J, 2013, BIOCHEM PHARMACOL, V85, P1783, DOI 10.1016/j.bcp.2013.04.018
   Tenorio-Laranga J, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-23
   Usuki H, 2009, BBA-PROTEINS PROTEOM, V1794, P1673, DOI 10.1016/j.bbapap.2009.07.024
   Vandal OH, 2008, NAT MED, V14, P849, DOI 10.1038/nm.1795
   Vandal OH, 2009, J BACTERIOL, V191, P625, DOI 10.1128/JB.00932-08
   Vendeville S, 1999, CHEM PHARM BULL, V47, P194, DOI 10.1248/cpb.47.194
   Eswar Narayanan, 2006, Curr Protoc Bioinformatics, VChapter 5, pUnit, DOI [10.1002/cpps.20, 10.1002/cpbi.3, 10.1002/0471140864.ps0209s50, 10.1002/0471250953.bi0506s15]
   Wells JM, 2015, MATRIX BIOL, V44-46, P122, DOI 10.1016/j.matbio.2015.01.016
   WILK S, 1983, J NEUROCHEM, V41, P69, DOI 10.1111/j.1471-4159.1983.tb11815.x
   Williams RSB, 2000, TRENDS PHARMACOL SCI, V21, P61, DOI 10.1016/S0165-6147(99)01428-5
   Williams RSB, 1999, EMBO J, V18, P2734, DOI 10.1093/emboj/18.10.2734
   Wolf AJ, 2008, J EXP MED, V205, P105, DOI 10.1084/jem.20071367
   World Health Organization, 2015, GLOB TUB REP
   YOSHIMOTO T, 1991, J BIOCHEM-TOKYO, V110, P873, DOI 10.1093/oxfordjournals.jbchem.a123682
   YOSHIMOTO T, 1987, J PHARMACOBIO-DYNAM, V10, P730, DOI 10.1248/bpb1978.10.730
   YOSHIMOTO T, 1980, J BIOL CHEM, V255, P4786
   YOSHIMOTO T, 1988, J BIOCHEM, V104, P622, DOI 10.1093/oxfordjournals.jbchem.a122522
   Zhao N, 2015, ACS CHEM BIOL, V10, P364, DOI 10.1021/cb500746z
   Zhao QJ, 2011, CRIT REV EUKAR GENE, V21, P347, DOI 10.1615/CritRevEukarGeneExpr.v21.i4.50
NR 96
TC 3
Z9 4
U1 0
U2 7
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-302X
J9 FRONT MICROBIOL
JI Front. Microbiol.
PD FEB 7
PY 2017
VL 8
AR 155
DI 10.3389/fmicb.2017.00155
PG 13
WC Microbiology
SC Microbiology
GA EJ9QN
UT WOS:000393561500001
PM 28223969
OA DOAJ Gold, Green Published
DA 2020-12-15
ER

PT J
AU Assuncao, LS
   Magalhaes, KG
   Carneiro, AB
   Molinaro, R
   Almeida, PE
   Atella, GC
   Castro-Faria-Neto, HC
   Bozza, PT
AF Assuncao, Leonardo Santos
   Magalhaes, Kelly G.
   Carneiro, Alan Brito
   Molinaro, Raphael
   Almeida, Patricia E.
   Atella, Georgia C.
   Castro-Faria-Neto, Hugo C.
   Bozza, Patricia T.
TI Schistosomal-derived lysophosphatidylcholine triggers M2 polarization of
   macrophages through PPAR gamma dependent mechanisms
SO BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
LA English
DT Article
DE Lysophosphatidylcholine; Macrophage; PPARgamma; Parasites; S. mansoni
ID NITRIC-OXIDE PRODUCTION; ALTERNATIVE ACTIVATION; CYTOKINE PRODUCTION;
   LIPID-METABOLISM; HUMAN-MONOCYTES; T-CELLS; MANSONI; INFECTION;
   RESPONSES; PHENOTYPE
AB Mansonic schistosomiasis is a disease caused by the trematode Schistosoma mansoni, endemic to tropical countries. S. mansoni infection induces the formation of granulomas and potent polarization of Th2-type immune response. There is great interest in understanding the mechanisms used by this parasite that causes a modulation of the immune system. Recent studies from our group demonstrated that lipids of S. mansoni, including lysophosphatidylcholine (LPC) have immunomodulatory activity. In the present study, our aim was to investigate the role of lipids derived from S. mansoni in the activation and polarization of macrophages and to characterize the mechanisms involved in this process. Peritoneal macrophages obtained from wild type C57BL/6mice or bone marrow derived macrophages were stimulated in vitro with lipids extracted from adult worms of S. mansoni. We demonstrated that total schistosomal-derived lipids as well as purified LPC induced alternatively activated macrophages/M2 profile observed by increased expression of arginase-1, mannose receptor, Chi313, TGF beta and production of IL-10 and PGE(2) 24 h after stimulation. The involvement of the nuclear receptor PPAR gamma in macrophage response against LPC was investigated. Through Western blot and immunofluorescence confocal microscopy we demonstrated that schistosomal-derived LPC induces increased expression of PPAR gamma in macrophages. The LPC-induced increased expression of arginase-1 were significantly inhibited by the PPAR-gamma antagonist GW9662. Together, these results demonstrate an immunomodulatory role of schistosomal-derived LPC in activating macrophages to a profile of the type M2 through PPAR gamma-dependent mechanisms, indicating a novel pathway for macrophage polarization triggered by parasite-derived LPC with potential implications to disease pathogenesis. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Assuncao, Leonardo Santos; Magalhaes, Kelly G.; Carneiro, Alan Brito; Molinaro, Raphael; Almeida, Patricia E.; Castro-Faria-Neto, Hugo C.; Bozza, Patricia T.] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Imunofarmacol, Av Brasil 4365, BR-21045900 Rio De Janeiro, RJ, Brazil.
   [Magalhaes, Kelly G.] Univ Brasilia UNB, Lab Imunol & Inflamacao, Brasilia, DF, Brazil.
   [Almeida, Patricia E.] Univ Fed Juiz De Fora, Lab Biol Celular, Juiz De Fora, MG, Brazil.
   [Atella, Georgia C.] Univ Fed Rio de Janeiro, Inst Bioquim Med Leopoldo de Meis, Programa Biol Mol & Biotecnol, Lab Bioquim Lipidios & Lipoprot, Rio De Janeiro, RJ, Brazil.
   [Atella, Georgia C.] Inst Nacl Ciencia & Tecnol Entomol Mol, Rio De Janeiro, Brazil.
RP Bozza, PT (corresponding author), Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Imunofarmacol, Av Brasil 4365, BR-21045900 Rio De Janeiro, RJ, Brazil.
EM pbozza@ioc.fiocruz.br
RI Atella, Georgia/AAK-7897-2020; Magalhaes, Kelly G/A-6966-2010;
   Magalhaes, Kelly Grace/L-6081-2019
OI Magalhaes, Kelly G/0000-0002-7435-5272; Magalhaes, Kelly
   Grace/0000-0002-7435-5272; Almeida, Patricia Elaine
   de/0000-0002-9081-8601; Bozza, Patricia/0000-0001-8349-9529
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq) [439894/2016-6, 306365/2014-6]; Fundacao de Amparo a Pesquisa do
   Estado do Rio de Janeiro (FAPERJ)Carlos Chagas Filho Foundation for
   Research Support of the State of Rio de Janeiro (FAPERJ)
   [E-26/201.379/2014]; Fundacao de Amparo a Pesquisa do Estado de Minas
   Gerais (FAPEMIG)Minas Gerais State Research Foundation (FAPEMIG)
   [APQ00894-13]
FX The parasites were kindly provided by Dr. Marcelo Pelajo, from Pathology
   lab, FIOCRUZ-RJ-Brazil. The authors thank Mileane de Souza Busch for
   technical support with schistosomal LPC purification. This work was
   supported by grants from Conselho Nacional de Desenvolvimento Cientifico
   e Tecnologico (CNPq) (439894/2016-6; 306365/2014-6), Fundacao de Amparo
   a Pesquisa do Estado do Rio de Janeiro (FAPERJ) (E-26/201.379/2014) and
   Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG)
   (APQ00894-13).
CR Almeida PE, 2014, BBA-MOL CELL BIOL L, V1841, P97, DOI 10.1016/j.bbalip.2013.10.008
   Almeida PE, 2012, PPAR RES, V2012, DOI 10.1155/2012/383829
   Almeida PE, 2009, J IMMUNOL, V183, P1337, DOI 10.4049/jimmunol.0900365
   Anthony BJ, 2012, PPAR RES, V2012, DOI 10.1155/2012/128068
   Barron L, 2011, EUR J IMMUNOL, V41, P2509, DOI 10.1002/eji.201141869
   Barron L, 2011, AM J PHYSIOL-GASTR L, V300, pG723, DOI 10.1152/ajpgi.00414.2010
   BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911
   Bouhlel MA, 2007, CELL METAB, V6, P137, DOI 10.1016/j.cmet.2007.06.010
   Cardoso LS, 2010, CLIN EXP IMMUNOL, V160, P266, DOI 10.1111/j.1365-2249.2009.04084.x
   Carneiro AB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076233
   CAULFIELD JP, 1985, J CELL BIOL, V101, P158, DOI 10.1083/jcb.101.1.158
   CHAN MM, 2012, PPAR RES, DOI DOI 10.1155/2012/796235
   Chang CI, 1998, AM J PHYSIOL-HEART C, V274, pH342
   Cooke A, 1999, PARASITE IMMUNOL, V21, P169, DOI 10.1046/j.1365-3024.1999.00213.x
   CORRALIZA IM, 1994, J IMMUNOL METHODS, V174, P231, DOI 10.1016/0022-1759(94)90027-2
   de Jesus AR, 2002, J INFECT DIS, V185, P98, DOI 10.1086/324668
   Fu CL, 2015, FASEB J, V29, P193, DOI 10.1096/fj.14-259572
   FURLONG ST, 1988, EXP PARASITOL, V65, P222, DOI 10.1016/0014-4894(88)90126-9
   GOLAN DE, 1986, J CELL BIOL, V103, P819, DOI 10.1083/jcb.103.3.819
   Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978
   Gordon S, 2010, IMMUNITY, V32, P593, DOI 10.1016/j.immuni.2010.05.007
   Hasegawa H, 2011, BIOCHEM BIOPH RES CO, V415, P526, DOI 10.1016/j.bbrc.2011.10.119
   Herbert DR, 2004, IMMUNITY, V20, P623, DOI 10.1016/S1074-7613(04)00107-4
   Hesse M, 2004, J IMMUNOL, V172, P3157, DOI 10.4049/jimmunol.172.5.3157
   Hesse M, 2001, J IMMUNOL, V167, P6533, DOI 10.4049/jimmunol.167.11.6533
   Hong CW, 2010, J IMMUNOL, V184, P4401, DOI 10.4049/jimmunol.0902814
   Hovsepian E, 2012, PPAR RES, V2012, DOI 10.1155/2012/528435
   Huang JT, 1999, NATURE, V400, P378
   Ka MB, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00500
   Kim EA, 2009, J MATERN-FETAL NEO M, V22, P325, DOI 10.1080/14767050802556075
   King CH, 2005, LANCET, V365, P1561, DOI 10.1016/S0140-6736(05)66457-4
   Lin P, 2005, J IMMUNOL, V174, P2981, DOI 10.4049/jimmunol.174.5.2981
   Loke P, 2007, J IMMUNOL, V179, P3926, DOI 10.4049/jimmunol.179.6.3926
   MacKenzie KF, 2013, J IMMUNOL, V190, P565, DOI 10.4049/jimmunol.1202462
   Magalhaes KG, 2010, J INFECT DIS, V202, P1369, DOI 10.1086/656477
   Matsumoto T, 2007, CURR MED CHEM, V14, P3209, DOI 10.2174/092986707782793899
   MEHTA D, 1990, AM REV RESPIR DIS, V142, P157, DOI 10.1164/ajrccm/142.1.157
   Mesquita RD, 2008, INFECT IMMUN, V76, P5543, DOI 10.1128/IAI.00683-08
   Montenegro SML, 1999, J INFECT DIS, V179, P1502, DOI 10.1086/314748
   Munder M, 1999, J IMMUNOL, V163, P3771
   Na YR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063451
   Noel W, 2004, TRENDS PARASITOL, V20, P126, DOI 10.1016/j.pt.2004.01.004
   Odegaard JI, 2007, NATURE, V447, P1116, DOI 10.1038/nature05894
   Odegaard JI, 2011, ANNU REV PATHOL-MECH, V6, P275, DOI 10.1146/annurev-pathol-011110-130138
   Okano M, 1999, J IMMUNOL, V163, P6712
   Prokazova NV, 1998, BIOCHEMISTRY-MOSCOW+, V63, P31
   QUINN MT, 1988, P NATL ACAD SCI USA, V85, P2805, DOI 10.1073/pnas.85.8.2805
   RABINI RA, 1994, DIABETES, V43, P915, DOI 10.2337/diabetes.43.7.915
   Radu CG, 2004, P NATL ACAD SCI USA, V101, P245, DOI 10.1073/pnas.2536801100
   Rios FJ, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/198193
   ROGERS MV, 1987, MOL BIOCHEM PARASIT, V22, P273, DOI 10.1016/0166-6851(87)90058-2
   Seo JW, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/235797
   Silva-Neto Mario A C, 2012, J Parasitol Res, V2012, P625838, DOI 10.1155/2012/625838
   STEINBERG D, 1989, NEW ENGL J MED, V320, P915
   Thomas PG, 2003, J IMMUNOL, V171, P5837, DOI 10.4049/jimmunol.171.11.5837
   Tounsi N, 2015, INT IMMUNOPHARMACOL, V25, P1, DOI 10.1016/j.intimp.2015.01.006
   van der Werf MJ, 2003, ACTA TROP, V86, P125, DOI 10.1016/S0001-706X(03)00029-9
   Van Hellemond JJ, 2006, INT J PARASITOL, V36, P691, DOI 10.1016/j.ijpara.2006.01.007
   Vannella KM, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004372
   Wilson S, 2007, TROP MED INT HEALTH, V12, P1442, DOI 10.1111/j.1365-3156.2007.01950.x
   Wolfs IMJ, 2014, FASEB J, V28, P288, DOI 10.1096/fj.13-235911
   Wynn TA, 2004, IMMUNOL REV, V201, P156, DOI 10.1111/j.0105-2896.2004.00176.x
   Wynn TA, 1998, J IMMUNOL, V160, P4473
   Yan JJ, 2004, NAT MED, V10, P161, DOI 10.1038/nm989
   Yang LV, 2005, BLOOD, V105, P1127, DOI 10.1182/blood-2004-05-1916
   YUAN YP, 1995, BLOOD, V86, P4166, DOI 10.1182/blood.V86.11.4166.bloodjournal86114166
   Zaccone P, 2009, EUR J IMMUNOL, V39, P1098, DOI 10.1002/eji.200838871
NR 67
TC 23
Z9 23
U1 0
U2 9
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1388-1981
EI 1879-2618
J9 BBA-MOL CELL BIOL L
JI Biochim. Biophys. Acta Mol. Cell Biol. Lipids
PD FEB
PY 2017
VL 1862
IS 2
BP 246
EP 254
DI 10.1016/j.bbalip.2016.11.006
PG 9
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA EJ0KU
UT WOS:000392898100011
PM 27871882
DA 2020-12-15
ER

PT J
AU Caixeta, AV
   Romeiro, LAS
   Magalhaes, KG
AF Veloso Caixeta, A.
   Soares Romeiro, L. A.
   Grace Magalhaes, K.
TI Characterization of the antitumor and immunomodulatory properties of new
   HDAC inhibitors as targeted anti-cancer drugs
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT International Congress of Immunology (ICI)
CY AUG 21-26, 2016
CL Melbourne, AUSTRALIA
C1 [Veloso Caixeta, A.; Grace Magalhaes, K.] Univ Brasilia, Lab Immunol & Inflammat, Brasilia, DF, Brazil.
   [Soares Romeiro, L. A.] Univ Brasilia, Lab Dev & Therapeut Innovat, Brasilia, DF, Brazil.
RI Magalhaes, Kelly Grace/L-6081-2019; Magalhaes, Kelly G/A-6966-2010;
   Romeiro, Luiz A S/U-3607-2017
OI Magalhaes, Kelly Grace/0000-0002-7435-5272; Magalhaes, Kelly
   G/0000-0002-7435-5272; Romeiro, Luiz A S/0000-0001-5679-0820
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2980
EI 1521-4141
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD AUG
PY 2016
VL 46
SU 1
SI SI
MA 139
BP 185
EP 185
PG 1
WC Immunology
SC Immunology
GA DW4KA
UT WOS:000383610400373
DA 2020-12-15
ER

PT J
AU Gimenez, G
   Belaunzaran, ML
   Magalhaes, KG
   Poncini, CV
   Lammel, EM
   Cappa, SMG
   Bozza, PT
   Isola, ELD
AF Gimenez, G.
   Belaunzaran, M. L.
   Magalhaes, K. G.
   Poncini, C. V.
   Lammel, E. M.
   Gonzalez Cappa, S. M.
   Bozza, P. T.
   Isola, E. L. D.
TI Involvement of TLR6 in the induction of COX-2, PGE(2) and IL-10 in
   macrophages by lipids from virulent S2P and attenuated R1A Babesia bovis
   strains
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Lipids; Babesia bovis; TLR6; Macrophages
ID PARASITE; CELLS; RECOGNITION; RESPONSES; IMMUNITY; INNATE
AB Toll like receptors (TLRs) are involved in the modulation of diverse host genes expression through a complex network of signalling events that allow for an appropriate response to a microbial pathogen. In the present work we used TLR6KO mice in order to study the role of TLR6 in the immune discrimination of lipids from two Babesia bovis strains, attenuated R1A (L-A) and virulent S2P (L-V), and the consequent macrophage activation. We demonstrated that TLR6 is required for lipid body induction in murine peritoneal macrophages by both L-A and L-V. Interestingly, as regards IL-10 and COX-2/PGE(2) pathway induction by L-A and L-V, we observed differences in the biological effects produced by these lipid extracts. Our results indicate a role of TLR6 in the down-modulation of these immunoregulators only in the case of L-A, whereas this receptor was not implicated in pro-inflammatory TNF alpha, IL-6 and KC release induced by L-A. Remarkably, L-V did not exert the down-modulatory effect observed for L-A, supporting the notion that L-A and L-V possess different lipid composition that could correlate with the polar pathogenic effect of both B. bovis strains. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Gimenez, G.; Belaunzaran, M. L.; Poncini, C. V.; Lammel, E. M.; Gonzalez Cappa, S. M.; Isola, E. L. D.] UBA, Fac Med, CONICET, Inst Invest Microbiol & Parasitol Med, Paraguay 2155 Piso 13,C1121ABG, Buenos Aires, DF, Argentina.
   [Magalhaes, K. G.] Univ Brasilia, Inst Biol, Dept Biol Celular, Lab Imunol & Inflamacao, BR-70910900 Brasilia, DF, Brazil.
   [Bozza, P. T.] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Imunofarmacol, Rio De Janeiro, Brazil.
RP Gimenez, G (corresponding author), UBA, Fac Med, CONICET, Inst Invest Microbiol & Parasitol Med, Paraguay 2155 Piso 13,C1121ABG, Buenos Aires, DF, Argentina.
EM paradife@fmed.uba.ar
RI Magalhaes, Kelly G/A-6966-2010; Magalhaes, Kelly Grace/L-6081-2019
OI Magalhaes, Kelly G/0000-0002-7435-5272; Magalhaes, Kelly
   Grace/0000-0002-7435-5272; Bozza, Patricia/0000-0001-8349-9529; poncini,
   carolina/0000-0003-3419-8062
FU Agencia Nacional de Promocion Cientifica y Tecnologica (FONCYT),
   ArgentinaANPCyTFONCyT; Consejo Nacional de Investigaciones Cientificas y
   Tecnicas (CONICET), ArgentinaConsejo Nacional de Investigaciones
   Cientificas y Tecnicas (CONICET); Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq), BrazilNational Council for Scientific
   and Technological Development (CNPq); Fundacao de Amparo a Pesquisa do
   Estado do Rio de Janeiro (FAPERJ), BrazilCarlos Chagas Filho Foundation
   for Research Support of the State of Rio de Janeiro (FAPERJ)
FX We are indebted to Dr. I. Echaide (Instituto Nacional de Tecnologia
   Agropecuaria, Rafaela, Santa Fe, Argentina) for providing B. bovis
   cultures and to Dr. S. Akira (Department of Host Defense, Research
   Institute for Microbial Disease, Osaka, Japan) for providing the TLR6KO
   mice. This work was supported by Agencia Nacional de Promocion
   Cientifica y Tecnologica (FONCYT) and Consejo Nacional de
   Investigaciones Cientificas y Tecnicas (CONICET), Argentina and from
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) and
   Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ),
   Brazil.
CR Akira S, 2003, J BIOL CHEM, V278, P38105, DOI 10.1074/jbc.R300028200
   Anziani O. S., 1993, Revista de Medicina Veterinaria (Buenos Aires), V74, P47
   Arcanjo AF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124888
   Baravalle ME, 2012, VET PARASITOL, V190, P391, DOI 10.1016/j.vetpar.2012.06.037
   Bock R, 2004, PARASITOLOGY, V129, pS247, DOI 10.1017/S0031182004005190
   Bozza PT, 2011, PROSTAG LEUKOTR ESS, V85, P205, DOI 10.1016/j.plefa.2011.04.020
   Brown WC, 2001, VET PARASITOL, V101, P233, DOI 10.1016/S0304-4017(01)00569-6
   D'Avila H, 2011, J INFECT DIS, V204, P951, DOI 10.1093/infdis/jir432
   Florin-Christensen M, 2014, PARASITOLOGY, V141, P1563, DOI 10.1017/S0031182014000961
   Gimenez G, 2013, PARASITOLOGY, V140, P530, DOI 10.1017/S003118201200193X
   Gimenez G, 2010, MOL IMMUNOL, V47, P747, DOI 10.1016/j.molimm.2009.10.014
   GOODGER BV, 1990, INT J PARASITOL, V20, P685, DOI 10.1016/0020-7519(90)90129-B
   Guillemi E, 2013, INFECT GENET EVOL, V14, P214, DOI 10.1016/j.meegid.2012.12.005
   MANGOLD AJ, 1993, VET PARASITOL, V51, P143, DOI 10.1016/0304-4017(93)90205-2
   Mattos KA, 2011, J IMMUNOL, V187, P2548, DOI 10.4049/jimmunol.1101344
   Mount A, 2013, EXPERT REV VACCINES, V12, P733, DOI 10.1586/14760584.2013.811185
   Norimine J, 2003, INFECT IMMUN, V71, P5021, DOI 10.1128/IAI.71.9.5021-5032.2003
   Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497
   Quesniaux VJ, 2004, J IMMUNOL, V172, P4425, DOI 10.4049/jimmunol.172.7.4425
   Shoda LKM, 2000, INFECT IMMUN, V68, P5139, DOI 10.1128/IAI.68.9.5139-5145.2000
   Stewart C.R., 2010, NAT IMMUNOL, V22
   Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3
   Werling D, 2006, VET IMMUNOL IMMUNOP, V112, P2, DOI 10.1016/j.vetimm.2006.03.007
NR 23
TC 4
Z9 4
U1 0
U2 5
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD JUN 15
PY 2016
VL 223
BP 127
EP 132
DI 10.1016/j.vetpar.2016.04.033
PG 6
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA DN8GM
UT WOS:000377317200022
PM 27198789
DA 2020-12-15
ER

PT J
AU Siqueira, IM
   Fraga, CLF
   Amaral, AC
   Souza, ACO
   Jeronimo, MS
   Correa, JR
   Magalhaes, KG
   Inacio, CA
   Ribeiro, AM
   Burguel, PH
   Felipe, MS
   Tavares, AH
   Bocca, AL
AF Siqueira, Isaque Medeiros
   Falcomer Fraga, Cecilia Livia
   Amaral, Andre Correa
   Oliveira Souza, Ana Camila
   Jeronimo, Marcio Souza
   Correa, Jose Raimundo
   Magalhaes, Kelly Grace
   Inacio, Carlos Antonio
   Ribeiro, Alice Melo
   Burguel, Pedro Henrique
   Felipe, Maria Sueli
   Tavares, Aldo Henrique
   Bocca, Anamelia Lorenzetti
TI Distinct patterns of yeast cell morphology and host responses induced by
   representative strains of Paracoccidioides brasiliensis (Pb18) and
   Paracoccidioides lutzii (Pb01)
SO MEDICAL MYCOLOGY
LA English
DT Article
DE Paracoccidioidomycosis; Paracoccidioides lutzii; Paracoccidioides
   brasiliensis; morphological patterns; host-fungal interaction
ID HUMAN MONOCYTES; RESISTANT MICE; IN-VITRO; MACROPHAGES; CYTOKINES;
   BINDING; ALPHA; GAMMA; SPP.; TLR2
AB Paracoccidioidomycosis (PCM) is a systemic mycosis, widespread in Latin America. PCM is a granulomatous disease characterized by a polymorphism of lesions depending on the pathogen's virulence, the immune status of the host and its genetic susceptibility. The thermodimorphic fungus Paracoccidioides brasiliensis was considered the only etiologic agent of PCM, yet recent works have shown significant genetic diversity among different strains of P. brasiliensis. Therefore, it has been proposed for a new species within the Paracoccidioides genus, named Paracoccidioides lutzii. To better understand the fungus-host interactions elicited by strains Pb01 and Pb18 as key representatives of P. lutzii and P. brasiliensis, respectively, we carried out studies to investigate differences in morphology, induced immune response, virulence and pathology between these two Paracoccidioides species. Our results demonstrate distinct patterns of host-parasite interaction and pathology caused by Pb18 and Pb01. These results open up new fronts for new clinical studies, which may result in significant consequences for the diagnosis and treatment of PCM. Considering that our results cannot be extended to all strains of both species, more studies about the virulence among Paracoccioides must be explored in the future.
C1 [Siqueira, Isaque Medeiros; Falcomer Fraga, Cecilia Livia; Oliveira Souza, Ana Camila; Jeronimo, Marcio Souza; Burguel, Pedro Henrique] Univ Brasilia, Fac Med, Mol Pathol Postgrad Program, BR-70910900 Brasilia, DF, Brazil.
   [Amaral, Andre Correa] Univ Fed Goias, Inst Trop Pathol & Publ Hlth, Biotechnol, Jatai, Go, Brazil.
   [Correa, Jose Raimundo; Magalhaes, Kelly Grace; Ribeiro, Alice Melo; Felipe, Maria Sueli; Tavares, Aldo Henrique; Bocca, Anamelia Lorenzetti] Univ Brasilia, Inst Biol, Asa Norte, BR-70910900 Brasilia, DF, Brazil.
   [Inacio, Carlos Antonio] Univ Fed Rural Rio de Janeiro, Dept Entomol & Plant Pathol, Inst Biol, Rio De Janeiro, Brazil.
   [Felipe, Maria Sueli] Univ Catolica Brasilia, Genom Sci & Biotechnol Postgrad Program, Brasilia, DF, Brazil.
RP Bocca, AL (corresponding author), Univ Brasilia, Inst Biol, Asa Norte, BR-70910900 Brasilia, DF, Brazil.
EM albocca@unb.br
RI Magalhaes, Kelly G/A-6966-2010; Correa, Jose R/K-6270-2012; Amaral,
   Andre/A-7936-2015; Souza, Ana Camila Oliveira/J-2061-2014; Felipe, Maria
   Sueli/L-6260-2016; TAVARES, ALDO HENRIQUE/L-5662-2015; Magalhaes, Kelly
   Grace/L-6081-2019; Bocca, Anamelia Lorenzetti/K-4758-2018
OI Magalhaes, Kelly G/0000-0002-7435-5272; Correa, Jose
   R/0000-0003-2752-5395; Souza, Ana Camila Oliveira/0000-0002-9639-1207;
   Felipe, Maria Sueli/0000-0003-4347-6853; Magalhaes, Kelly
   Grace/0000-0002-7435-5272; Correa Amaral, Andre/0000-0001-9516-8970;
   TAVARES, ALDO HENRIQUE/0000-0003-0579-3380; Bocca, Anamelia
   Lorenzetti/0000-0003-3323-5300
FU Fundacao de Apoio a Pesquisa do Distrito Federal (FAPDF)National Council
   for Scientific and Technological Development (CNPq); Conselho Nacional
   de Pesquisa (CNPq)National Council for Scientific and Technological
   Development (CNPq); Decanato de Pesquisa e Pos-Graduacao da Universidade
   de Brasilia (DPP/UnB); CAPESCAPES
FX The authors would like to thank the Fundacao de Apoio a Pesquisa do
   Distrito Federal (FAPDF), Conselho Nacional de Pesquisa (CNPq) and
   Decanato de Pesquisa e Pos-Graduacao da Universidade de Brasilia
   (DPP/UnB) for financial support, and CAPES for graduate student grants.
   The authors would also like to thank the Electron Microscopy Laboratory
   at the Biology Institute of the University of Brasilia and Viviane
   Monteiro Leal for technical support.
CR Acorci-Valerio MJ, 2010, SCAND J IMMUNOL, V71, P99, DOI 10.1111/j.1365-3083.2009.02351.x
   Balderramas HA, 2014, CYTOKINE, V67, P36, DOI 10.1016/j.cyto.2014.02.004
   Benard G, 2008, MYCOPATHOLOGIA, V165, P209, DOI 10.1007/s11046-007-9065-0
   Bocca AL, 1998, J IMMUNOL, V161, P3056
   Calcagno AM, 1998, J CLIN MICROBIOL, V36, P1733, DOI 10.1128/JCM.36.6.1733-1736.1998
   Calich VLG, 1998, BRAZ J MED BIOL RES, V31, P615, DOI 10.1590/S0100-879X1998000500003
   Calvi SA, 2003, MICROBES INFECT, V5, P107, DOI 10.1016/S1286-4579(02)00078-3
   Carmo JPM, 2006, MED MYCOL, V44, P363, DOI 10.1080/13693780500536885
   Carrero LL, 2008, FUNGAL GENET BIOL, V45, P605, DOI 10.1016/j.fgb.2008.02.002
   Costa DL, 2007, MICROBIOL IMMUNOL, V51, P73, DOI 10.1111/j.1348-0421.2007.tb03892.x
   Neto BRD, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-254
   De Oliveira HC, 2015, FRONT MICROBIOL, V6
   Tavares AHFP, 2007, MICROBES INFECT, V9, P583, DOI 10.1016/j.micinf.2007.01.024
   Felipe MSS, 2005, J BIOL CHEM, V280, P24706, DOI 10.1074/jbc.M500625200
   Gegembauer G, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002986
   Gonzalez A, 2000, INFECT IMMUN, V68, P2546, DOI 10.1128/IAI.68.5.2546-2552.2000
   GREEN LC, 1981, SCIENCE, V212, P56, DOI 10.1126/science.6451927
   Grossklaus DD, 2013, MICROBES INFECT, V15, P347, DOI 10.1016/j.micinf.2012.12.002
   Gu L, 2000, NATURE, V404, P407, DOI 10.1038/35006097
   Hogan LH, 1996, CLIN MICROBIOL REV, V9, P469, DOI 10.1128/CMR.9.4.469
   Kurokawa CS, 2007, MICROBIOL IMMUNOL, V51, P421, DOI 10.1111/j.1348-0421.2007.tb03929.x
   Leitao NP, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003111
   Lenhard-Vidal A, 2013, MYCOPATHOLOGIA, V176, P345, DOI 10.1007/s11046-013-9698-0
   Longo LVG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063372
   Loures FV, 2009, J IMMUNOL, V183, P1279, DOI 10.4049/jimmunol.0801599
   Bailao EFLC, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002856
   Lutz A, 1908, BRAS MED, V22, P121
   Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022-1759(98)00204-X
   Machado GC, 2013, MEM I OSWALDO CRUZ, V108, P637, DOI 10.1590/0074-0276108052013016
   Marques SA, 2012, CLIN DERMATOL, V30, P610, DOI 10.1016/j.clindermatol.2012.01.006
   Matute DR, 2006, MOL BIOL EVOL, V23, P65, DOI 10.1093/molbev/msj008
   Molinari-Madlum EEWI, 1999, MED MYCOL, V37, P269, DOI 10.1046/j.1365-280X.1999.00230.x
   Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683
   Moreira AP, 2008, MYCOPATHOLOGIA, V166, P17, DOI 10.1007/s11046-007-9046-3
   Moreira AP, 2010, CELL IMMUNOL, V263, P196, DOI 10.1016/j.cellimm.2010.03.016
   Nuutila J, 2005, CYTOM PART A, V65A, P93, DOI 10.1002/cyto.a.20139
   Parente AFA, 2015, MICROBES INFECT, V17, P575, DOI 10.1016/j.micinf.2015.03.012
   Fortes MRP, 2011, AN BRAS DERMATOL, V86, P516, DOI 10.1590/S0365-05962011000300014
   Pina A, 2008, J LEUKOCYTE BIOL, V83, P1088, DOI 10.1189/jlb.1107738
   Popi AF, 2002, CELL IMMUNOL, V218, P87, DOI 10.1016/S0008-8749(02)00576-2
   Ramos-E-Silva M, 2008, DERMATOL CLIN, V26, P257, DOI 10.1016/j.det.2007.11.005
   RAPONI G, 1993, ANTIMICROB AGENTS CH, V37, P1958, DOI 10.1128/AAC.37.9.1958
   Restrepo A, 2001, MED MYCOL, V39, P233, DOI 10.1080/714031028
   Romani L, 2004, NAT REV IMMUNOL, V4, P11, DOI 10.1038/nri1255
   SCHINDLER R, 1990, BLOOD, V75, P40
   SINGERVERMES LM, 1992, J MED VET MYCOL, V30, P261
   Siqueira KZ, 2009, MED MYCOL, V47, P259, DOI 10.1080/13693780802244204
   SOARES CMA, 1995, J CLIN MICROBIOL, V33, P505, DOI 10.1128/JCM.33.2.505-507.1995
   Mendes-Giannini MJS, 2006, MICROBES INFECT, V8, P1550, DOI 10.1016/j.micinf.2006.01.012
   Tavares AH, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002595
   Teixeira MD, 2014, MED MYCOL, V52, P19, DOI 10.3109/13693786.2013.794311
   Teixeira MM, 2009, MOL PHYLOGENET EVOL, V52, P273, DOI 10.1016/j.ympev.2009.04.005
   Theodoro RC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037694
   Torres I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068434
   Tristao GB, 2015, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00761
   VICENTINI AP, 1994, INFECT IMMUN, V62, P1465, DOI 10.1128/IAI.62.4.1465-1469.1994
NR 56
TC 11
Z9 11
U1 0
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1369-3786
EI 1460-2709
J9 MED MYCOL
JI Med. Mycol.
PD FEB
PY 2016
VL 54
IS 2
BP 177
EP 188
DI 10.1093/mmy/myv072
PG 12
WC Infectious Diseases; Mycology; Veterinary Sciences
SC Infectious Diseases; Mycology; Veterinary Sciences
GA DD5SW
UT WOS:000369985700010
PM 26384386
OA Bronze
DA 2020-12-15
ER

PT J
AU Barbosa, CDDS
   Correa, JR
   Medeiros, GA
   Barreto, G
   Magalhaes, KG
   de Oliveira, AL
   Spencer, J
   Rodrigues, MO
   Neto, BAD
AF Barbosa, Cintya D'Angelis do E. S.
   Correa, Jose R.
   Medeiros, Gisele A.
   Barreto, Gabrielle
   Magalhaes, Kelly G.
   de Oliveira, Aline L.
   Spencer, John
   Rodrigues, Marcelo O.
   Neto, Brenno A. D.
TI Carbon Dots (C-dots) from Cow Manure with Impressive Subcellular
   Selectivity Tuned by Simple Chemical Modification
SO CHEMISTRY-A EUROPEAN JOURNAL
LA English
DT Article
DE carbon dots; cell imaging; fluorescence; functionalized c-dots; nucleoli
ID FLUORESCENCE IMAGING PROBES; ONE-STEP SYNTHESIS; QUANTUM DOTS;
   PHOTOLUMINESCENCE; COMPLEXES; CELLS; BENZOTHIADIAZOLE; NANOPARTICLES;
   NUCLEOLI; GRAPHENE
AB Improved cellular selectivity for nucleoli staining was achieved by simple chemical modification of carbon dots (C-dots) synthesized from waste carbon sources such as cow manure (or from glucose). The C-dots were characterized and functionalized (amine-passivated) with ethylenediamine, affording amide bonds that resulted in bright green fluorescence. The new modified C-dots were successfully applied as selective live-cell fluorescence imaging probes with impressive subcellular selectivity and the ability to selectively stain nucleoli in breast cancer cell lineages (MCF-7). The C-dots were also tested in four other cellular models and showed the same cellular selection in live-cell imaging experiments.
C1 [Barbosa, Cintya D'Angelis do E. S.; Barreto, Gabrielle; Rodrigues, Marcelo O.] LIMA Lab Inorgan & Mat, BR-70904970 Brasilia, DF, Brazil.
   [Correa, Jose R.; Medeiros, Gisele A.; Magalhaes, Kelly G.; de Oliveira, Aline L.; Neto, Brenno A. D.] Univ Brasilia, Lab Med & Technol Chem, Inst Chem, UnB, BR-70904970 Brasilia, DF, Brazil.
   [Spencer, John] Univ Sussex, Dept Chem, Sch Life Sci, Brighton BN1 9QJ, E Sussex, England.
RP Rodrigues, MO (corresponding author), LIMA Lab Inorgan & Mat, Campus Univ Darcy Ribeiro,POB 4478, BR-70904970 Brasilia, DF, Brazil.
EM marcelozohio@unb.br; brenno.ipi@gmail.com
RI Medeiros, Gisele A/D-9560-2018; Correa, Jose R/K-6270-2012; Rodrigues,
   Marcelo Oliveira O/J-6367-2014; Magalhaes, Kelly G/A-6966-2010;
   Magalhaes, Kelly Grace/L-6081-2019; Oliveira, Aline/AAD-6671-2019;
   BARBOSA, CINTYA D A E S/I-9248-2018; Oliveira, Aline L/D-2953-2012;
   BARBOSA, CINTYA/AAO-4063-2020; SPENCER, John/P-5492-2019; Neto, Brenno
   A. D./I-4579-2012; Rodrigues, Marcelo Oliveira/V-5902-2019; spencer,
   john/C-2156-2008
OI Correa, Jose R/0000-0003-2752-5395; Rodrigues, Marcelo Oliveira
   O/0000-0003-0684-3618; Magalhaes, Kelly G/0000-0002-7435-5272;
   Magalhaes, Kelly Grace/0000-0002-7435-5272; Oliveira,
   Aline/0000-0002-6928-078X; BARBOSA, CINTYA D A E S/0000-0003-2620-8240;
   Oliveira, Aline L/0000-0002-6928-078X; BARBOSA,
   CINTYA/0000-0003-2620-8240; SPENCER, John/0000-0001-5231-8836; Neto,
   Brenno A. D./0000-0003-3783-9283; Rodrigues, Marcelo
   Oliveira/0000-0003-0684-3618; spencer, john/0000-0001-5231-8836
FU CAPESCAPES; FAPDF; FINATEC; CNPqNational Council for Scientific and
   Technological Development (CNPq); INCT-Inami; FACEPE [APT-0859-1.06/08];
   LabMIC(UFG); DPP-UnBand SMSdrug.net; Engineering and Physical Sciences
   Research CouncilEngineering & Physical Sciences Research Council (EPSRC)
   [EP/I037229/1] Funding Source: researchfish
FX The authors gratefully acknowledge CAPES, FAPDF, FINATEC, CNPq,
   INCT-Inami, FACEPE(APT-0859-1.06/08), LabMIC(UFG), DPP-UnBand
   SMSdrug.net for partial financial support. B.A.D.N. also thanks the
   INCT-Transcend group.
CR Anilkumar P, 2011, NANOSCALE, V3, P2023, DOI 10.1039/c0nr00962h
   [Anonymous], 2007, ANGEW CHEM, V119, P6593
   Cao L, 2007, J AM CHEM SOC, V129, P11318, DOI 10.1021/ja073527l
   Chandra S, 2011, NANOSCALE, V3, P1533, DOI 10.1039/c0nr00735h
   Ding CQ, 2014, ACCOUNTS CHEM RES, V47, P20, DOI 10.1021/ar400023s
   Diniz JR, 2013, INORG CHEM, V52, P10199, DOI 10.1021/ic4017678
   HAUGLAND RP, 2005, GUIDE FLUORESCENT PR
   Kelly KF, 2013, ACCOUNTS CHEM RES, V46, P4, DOI 10.1021/ar300121q
   Kong WQ, 2014, J MATER CHEM B, V2, P5077, DOI 10.1039/c4tb00579a
   Leary DJ, 2004, MOL BIOL CELL, V15, P281
   Li LL, 2013, NANOSCALE, V5, P4015, DOI 10.1039/c3nr33849e
   Liu CJ, 2011, J MATER CHEM, V21, P13163, DOI 10.1039/c1jm12744f
   Liu HP, 2007, ANGEW CHEM INT EDIT, V46, P6473, DOI 10.1002/anie.200701271
   Liu SS, 2014, J MATER CHEM C, V2, P6477, DOI 10.1039/c4tc00636d
   Luo PJG, 2014, RSC ADV, V4, P10791, DOI 10.1039/c3ra47683a
   Luo PJG, 2013, J MATER CHEM B, V1, P2116, DOI 10.1039/c3tb00018d
   Mota AAR, 2014, CHEM SCI, V5, P3995, DOI 10.1039/c4sc01785d
   Neto BAD, 2007, ORG LETT, V9, P4001, DOI 10.1021/ol701708y
   Neto BAD, 2013, RSC ADV, V3, P5291, DOI 10.1039/c2ra21995f
   Neto BAD, 2012, J BRAZIL CHEM SOC, V23, P770, DOI 10.1590/S0103-50532012000400024
   Neto BAD, 2012, RSC ADV, V2, P1524, DOI 10.1039/c1ra00701g
   Piatkevich KD, 2010, P NATL ACAD SCI USA, V107, P5369, DOI 10.1073/pnas.0914365107
   Ray SC, 2009, J PHYS CHEM C, V113, P18546, DOI 10.1021/jp905912n
   Song YC, 2012, J MATER CHEM, V22, P12568, DOI 10.1039/c2jm31582c
   Sun YP, 2006, J AM CHEM SOC, V128, P7756, DOI 10.1021/ja062677d
   Thorp-Greenwood FL, 2012, NEW J CHEM, V36, P64, DOI 10.1039/c1nj20662a
   Xu Y, 2013, CHEM-EUR J, V19, P2276, DOI 10.1002/chem.201203641
   Yang J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064849
   Yang YH, 2012, CHEM COMMUN, V48, P380, DOI 10.1039/c1cc15678k
   Yu JH, 2006, J AM CHEM SOC, V128, P2294, DOI 10.1021/ja056303g
   Zhou JG, 2007, J AM CHEM SOC, V129, P744, DOI 10.1021/ja0669070
NR 31
TC 52
Z9 52
U1 9
U2 152
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 0947-6539
EI 1521-3765
J9 CHEM-EUR J
JI Chem.-Eur. J.
PD MAR 23
PY 2015
VL 21
IS 13
BP 5055
EP 5060
DI 10.1002/chem.201406330
PG 6
WC Chemistry, Multidisciplinary
SC Chemistry
GA CE9CB
UT WOS:000352140000024
PM 25693878
DA 2020-12-15
ER

PT J
AU Silva, ON
   Fensterseifer, ICM
   Rodrigues, EA
   Holanda, HHS
   Novaes, NRF
   Cunha, JPA
   Rezende, TMB
   Magalhaes, KG
   Moreno, SE
   Jeronimo, MS
   Bocca, AL
   Francoa, OL
AF Silva, Osmar N.
   Fensterseifer, Isabel C. M.
   Rodrigues, Elaine A.
   Holanda, Hortencia H. S.
   Novaes, Natasha R. F.
   Cunha, Junia P. A.
   Rezende, Taia M. B.
   Magalhaes, Kelly G.
   Moreno, Susana E.
   Jeronimo, Marcio S.
   Bocca, Anamelia L.
   Francoa, Octavio L.
TI Clavanin A Improves Outcome of Complications from Different Bacterial
   Infections
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID PEPTIDE ANTIBIOTIC CLAVANIN; ANTIMICROBIAL PEPTIDES; WOUND INFECTIONS;
   UNITED-STATES; SEVERE SEPSIS; EPIDEMIOLOGY; MECHANISMS; TRIAL; LL-37;
   CARE
AB The rapid increase in the incidence of multidrug-resistant infections today has led to enormous interest in antimicrobial peptides (AMPs) as suitable compounds for developing unusual antibiotics. In this study, clavanin A, an antimicrobial peptide previously isolated from the marine tunicate Styela clava, was selected as a purposeful molecule that could be used in controlling infection and further synthesized. Clavanin A was in vitro evaluated against Staphylococcus aureus and Escherichia coli as well as toward L929 mouse fibroblasts and skin primary cells (SPCs). Moreover, this peptide was challenged here in an in vivo wound and sepsis model, and the immune response was also analyzed. Despite displaying clear in vitro antimicrobial activity toward Gram-positive and - negative bacteria, clavanin A showed no cytotoxic activities against mammalian cells, and in acute toxicity tests, no adverse reaction was observed at any of the concentrations. Moreover, clavanin A significantly reduced the S. aureus CFU in an experimental wound model. This peptide also reduced the mortality of mice infected with E. coli and S. aureus by 80% compared with that of control animals (treated with phosphate-buffered saline [PBS]): these data suggest that clavanin A prevents the start of sepsis and thereby reduces mortality. These data suggest that clavanin A is an AMP that could improve the development of novel peptide-based strategies for the treatment of wound and sepsis infections.
C1 [Silva, Osmar N.; Francoa, Octavio L.] Univ Fed Juiz de Fora, Inst Biol Sci, Dept Biol, Juiz De Fora, MG, Brazil.
   [Fensterseifer, Isabel C. M.; Francoa, Octavio L.] Univ Brasilia, Mol Pathol Post Grad Program, Brasilia, DF, Brazil.
   [Fensterseifer, Isabel C. M.; Rodrigues, Elaine A.; Holanda, Hortencia H. S.; Novaes, Natasha R. F.; Cunha, Junia P. A.; Rezende, Taia M. B.; Moreno, Susana E.; Francoa, Octavio L.] Univ Catolica Brasilia, Programa Posgrad Ciencias Genom & Biotecnol, Ctr Anal Proteom & Bioquim, Brasilia, DF, Brazil.
   [Rezende, Taia M. B.] Univ Catolica Brasilia, Curso Odontol, Brasilia, DF, Brazil.
   [Magalhaes, Kelly G.] Univ Brasilia, Inst Biol Sci, Lab Immunol & Inflammat, Dept Cellular Biol, Brasilia, DF, Brazil.
   [Jeronimo, Marcio S.; Bocca, Anamelia L.] Univ Brasilia, Dept Cellular Biol, Inst Biol Sci, Brasilia, DF, Brazil.
   [Francoa, Octavio L.] Univ Catolica Dom Bosco, Posgrad Biotecnol, S Inova, Campo Grande, MS, Brazil.
RP Francoa, OL (corresponding author), Univ Fed Juiz de Fora, Inst Biol Sci, Dept Biol, Juiz De Fora, MG, Brazil.
EM ocfranco@gmail.com
RI Magalhaes, Kelly G/A-6966-2010; Rezende, Taia M B/D-3732-2015; Franco,
   Octavio L/T-3020-2017; Silva, Osmar N./B-3183-2012; Magalhaes, Kelly
   Grace/L-6081-2019; Bocca, Anamelia Lorenzetti/K-4758-2018
OI Magalhaes, Kelly G/0000-0002-7435-5272; Rezende, Taia M
   B/0000-0002-4148-0659; Silva, Osmar N./0000-0003-2148-131X; Magalhaes,
   Kelly Grace/0000-0002-7435-5272; Franco, Octavio/0000-0001-9546-0525;
   Bocca, Anamelia Lorenzetti/0000-0003-3323-5300
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES)CAPES; Fundacao de Amparo a Pesquisa do Distrito Federal (FAPDF);
   Universidade Catolica de Brasilia (UCB)UCB Pharma SA; Universidade
   Federal de Juiz de Fora (UFJF)
FX This work was supported by Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq), Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (CAPES), Fundacao de Amparo a Pesquisa do
   Distrito Federal (FAPDF), Universidade Catolica de Brasilia (UCB), and
   Universidade Federal de Juiz de Fora (UFJF).
CR AHMAD I, 1995, BBA-BIOMEMBRANES, V1237, P109, DOI 10.1016/0005-2736(95)00087-J
   Angus DC, 2000, JAMA-J AM MED ASSOC, V283, P1723, DOI 10.1001/jama.283.13.1723
   Angus DC, 2001, CRIT CARE MED, V29, P1303, DOI 10.1097/00003246-200107001-00035
   Carriel-Gomes MC, 2007, MEM I OSWALDO CRUZ, V102, P469, DOI 10.1590/S0074-02762007005000028
   Chalekson CP, 2003, J TRAUMA, V54, P770, DOI 10.1097/01.TA.0000047047.79701.6D
   Cirioni O, 2006, ANTIMICROB AGENTS CH, V50, P1672, DOI 10.1128/AAC.50.5.1672-1679.2006
   Jacobsen F, 2005, J ANTIMICROB CHEMOTH, V55, P735, DOI 10.1093/jac/dki067
   Johansson J, 1998, J BIOL CHEM, V273, P3718, DOI 10.1074/jbc.273.6.3718
   Lee IH, 1997, INFECT IMMUN, V65, P2898, DOI 10.1128/IAI.65.7.2898-2903.1997
   Lee IH, 1997, FEBS LETT, V400, P158, DOI 10.1016/S0014-5793(96)01374-9
   Lee Young Shin, 2011, Antimicrob Agents Chemother, V55, P1296, DOI 10.1128/AAC.00948-10
   LEHRER RI, 1993, ANNU REV IMMUNOL, V11, P105, DOI 10.1146/annurev.iy.11.040193.000541
   Levi M, 1999, NEW ENGL J MED, V341, P586, DOI 10.1056/NEJM199908193410807
   Lima TB, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1155/2011/309390
   Lipsky BA, 2008, CLIN INFECT DIS, V47, P1537, DOI 10.1086/593185
   Lopez-Abarrategui C, 2012, BIOCHIMIE, V94, P968, DOI 10.1016/j.biochi.2011.12.016
   MAGGIORA LL, 1992, J MED CHEM, V35, P3727, DOI 10.1021/jm00099a001
   Malmsten M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016400
   Marti-Carvajal AJ, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004388.pub6
   McGwire BS, 2003, J INFECT DIS, V188, P146, DOI 10.1086/375747
   MCRIPLEY RJ, 1976, ANTIMICROB AGENTS CH, V10, P38, DOI 10.1128/AAC.10.1.38
   Murray CJL, 2007, LANCET, V370, P109, DOI 10.1016/S0140-6736(07)61064-2
   Namas R, 2012, J CRIT CARE, V27, DOI 10.1016/j.jcrc.2011.05.025
   Navon-Venezia S, 2002, ANTIMICROB AGENTS CH, V46, P689, DOI 10.1128/AAC.46.3.689-694.2002
   O'Dell ML, 1998, AM FAM PHYSICIAN, V57, P2424
   OHSAKI Y, 1992, CANCER RES, V52, P3534
   Qiu XQ, 2003, NAT BIOTECHNOL, V21, P1480, DOI 10.1038/nbt913
   Rinaldi AC, 2002, BIOCHEM J, V368, P91, DOI 10.1042/BJ20020806
   Rittirsch D, 2008, NAT REV IMMUNOL, V8, P776, DOI 10.1038/nri2402
   Silva ON, 2012, BIOPOLYMERS, V98, P322, DOI 10.1002/bip.22071
   Silva ON, 2011, FRONT MICROBIOL, V2, DOI 10.3389/fmicb.2011.00232
   Steinstraesser L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039373
   Van Amersfoort ES, 2003, CLIN MICROBIOL REV, V16, P379, DOI 10.1128/CMR.16.3.379-414.2003
   van Kan EJM, 2003, BIOCHEMISTRY-US, V42, P11366, DOI 10.1021/bi0349017
   van Kan EJM, 2003, BBA-BIOMEMBRANES, V1615, P84, DOI 10.1016/S0005-2736(03)00233-5
   van Kan EJM, 2001, BIOCHEMISTRY-US, V40, P6398, DOI 10.1021/bi0028136
   Vincent JL, 2006, CRIT CARE MED, V34, P344, DOI 10.1097/01.CCM.0000194725.48928.3A
   Watson RS, 2003, AM J RESP CRIT CARE, V167, P695, DOI 10.1164/rccm.200207-682OC
   Wiegand I, 2008, NAT PROTOC, V3, P163, DOI 10.1038/nprot.2007.521
   Zaleski KJ, 2006, ANTIMICROB AGENTS CH, V50, P3856, DOI 10.1128/AAC.00082-06
   Zhang ZG, 2006, J CELL SCI, V119, P1886, DOI 10.1242/jcs.02921
NR 41
TC 18
Z9 18
U1 0
U2 13
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
EI 1098-6596
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD MAR
PY 2015
VL 59
IS 3
BP 1625
EP 1631
DI 10.1128/AAC.03732-14
PG 7
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA CF4VF
UT WOS:000352550000031
PM 25547358
OA Bronze, Green Published
DA 2020-12-15
ER

PT J
AU Alves, EAR
   de Miranda, MG
   Borges, TK
   Magalhaes, KG
   Muniz-Junqueira, MI
AF Rocha Alves, Erica Alessandra
   de Miranda, Marthina Gomes
   Borges, Tatiana Karla
   Magalhaes, Kelly Grace
   Muniz-Junqueira, Maria Imaculada
TI Anti-HIV drugs, lopinavir/ritonavir and atazanavir, modulate innate
   immune response triggered by Leishmania in macrophages: The role of
   NF-kappa B and PPAR-gamma
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE Lopinavir/ritonavir; Atazanavir; Leishmania; Cytokines; PPAR-gamma;
   RelB/NF kappa B
ID HUMAN-IMMUNODEFICIENCY-VIRUS; PROTEASE INHIBITORS; CUTANEOUS
   LEISHMANIASIS; VISCERAL LEISHMANIASIS; INTRACELLULAR SURVIVAL;
   TNF-ALPHA; AMAZONENSIS; INFECTION; MICE; ACTIVATION
AB This study evaluated the influence of HIV protease inhibitors lopinavir/ritonavir (LPV/RTV) and atazanavir (ATV) on macrophage functions during their first interaction with Leishmania. Macrophages from BALB/c mice treated for 10 days with LPV/RTV and ATV, infected or not in vitro with L. (L.) amazonensis, were used to investigate the effects of these drugs on infection index, leishmanicidal capacity, cytokine production and PPAR-gamma and RelB expression. LPV/RTV and ATV treatments significantly increased the infection index and the percentage of Leishmania-infected macrophages compared to untreated infected macrophages. There was no correlated increase in the production of NO and H2O2 leishmanicidal molecules. Promastigotes derived from Leishmania-infected macrophages from LPV/RIV and ATV-treated BALB/c mice had an in vitro growth 45.1% and 56.4% higher in groups treated with LPV/RTV and ATV than with PBS in culture. ATV treatment reduced IL-12p70 and IL-10 secretion in Leishmania-infected macrophages, but had no effect on IL-23 and TNF production. LPV reduced IL-10 and had no effect on IL-12p70, TNF and IL-23 secretion. ATV treatment decreased PPAR-gamma expression in Leishmania-infected macrophages compared to untreated infected macrophages. In addition, LPV/RTV, but not ATV, reduced RelB cytoplasm-to-nucleus translocation in Leishmania-infected macrophages. Results showed that LPV/RTV and ATV HIV protease inhibitors were able to modulate innate defense mechanisms against Leishmania via different intracellular pathways. Although HIV protease inhibitors are highly efficient to control the Human Immunodeficiency Virus, these drugs might also influence the course of leishmaniasis in HIV-Leishmania-co-infected individuals. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Rocha Alves, Erica Alessandra; de Miranda, Marthina Gomes; Borges, Tatiana Karla; Muniz-Junqueira, Maria Imaculada] Univ Brasilia, Cellular Immunol Lab, Fac Med, Area Pathol, BR-70910900 Brasilia, DF, Brazil.
   [Rocha Alves, Erica Alessandra] Rene Rachou Res Ctr, Lab Cellular & Mol Immunol, Belo Horizonte, MG, Brazil.
   [Magalhaes, Kelly Grace] Univ Brasilia, Lab Immunol & Inflammat, Dept Cell Biol, Inst Biol, BR-70910900 Brasilia, DF, Brazil.
RP Muniz-Junqueira, MI (corresponding author), Univ Brasilia, Cellular Immunol Lab, Fac Med, Campus Darcy Ribeiro, BR-70910900 Brasilia, DF, Brazil.
EM erica.alves@cpqrr.flocruz.br; marthina.gomes@gmail.com;
   tatianakarlab@gmail.com; kellymagalhaes@unb.br;
   mimjunqueira@yahoo.com.br
RI Muniz-Junqueira, M. I./W-9622-2019; Magalhaes, Kelly G/A-6966-2010;
   Magalhaes, Kelly Grace/L-6081-2019
OI Muniz-Junqueira, M. I./0000-0002-9006-4619; Magalhaes, Kelly
   G/0000-0002-7435-5272; Magalhaes, Kelly Grace/0000-0002-7435-5272
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq),
   BrazilNational Council for Scientific and Technological Development
   (CNPq) [308985/2013-3]
FX Maria Imaculada Muniz-Junqueira is an investigator supported by the
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq),
   Brazil (process number 308985/2013-3). Erica Alessandra Rocha Alves,
   Marthina Gomes de Miranda and Tatiana Karla Borges were supported by
   CAPES (Molecular Pathology, University of Brasilia, Brazil). The authors
   used a copy-editing service for language revision.
CR Alleva DG, 2002, J LEUKOCYTE BIOL, V71, P677
   Almeida TF, 2012, PARASITE IMMUNOL, V34, P492, DOI 10.1111/j.1365-3024.2012.01384.x
   Alvar J, 2008, CLIN MICROBIOL REV, V21, P334, DOI 10.1128/CMR.00061-07
   Rodrigues MZA, 2011, CLIN VACCINE IMMUNOL, V18, P1765, DOI 10.1128/CVI.00076-11
   Andre P, 1998, P NATL ACAD SCI USA, V95, P13120, DOI 10.1073/pnas.95.22.13120
   Andreani G, 2012, CURR OPIN HIV AIDS, V7, P276, DOI 10.1097/COH.0b013e32835211e9
   Balestieri FMP, 2002, MICROBES INFECT, V4, P23, DOI 10.1016/S1286-4579(01)01505-2
   Ghosn EEB, 2010, P NATL ACAD SCI USA, V107, P2568, DOI 10.1073/pnas.0915000107
   Castellano LR, 2009, HUM IMMUNOL, V70, P383, DOI 10.1016/j.humimm.2009.01.007
   Chrusciak-Talhari A, 2009, AM J TROP MED HYG, V81, P559, DOI 10.4269/ajtmh.2009.09-0077
   Cota GF, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001153
   Cruz I, 2006, INDIAN J MED RES, V123, P357
   de Saldanha RR, 2012, T ROY SOC TROP MED H, V106, P596, DOI 10.1016/j.trstmh.2012.07.001
   Delerive P, 2001, J ENDOCRINOL, V169, P453, DOI 10.1677/joe.0.1690453
   Demarchi IG, 2012, PARASITOL INT, V61, P538, DOI 10.1016/j.parint.2012.04.006
   Detels R, 1998, JAMA-J AM MED ASSOC, V280, P1497, DOI 10.1001/jama.280.17.1497
   Dressman J, 2003, J CLIN INVEST, V111, P389, DOI 10.1172/JCI200316261
   Ezra N, 2010, J GLOB INFECT DIS, V2, P248, DOI 10.4103/0974-777X.68528
   Farias LHS, 2013, J INFECT DIS, V207, P537, DOI 10.1093/infdis/jis689
   GREEN LC, 1981, P NATL ACAD SCI-BIOL, V78, P7764, DOI 10.1073/pnas.78.12.7764
   Gruber A, 2001, J BIOL CHEM, V276, P47840, DOI 10.1074/jbc.M105582200
   Hadad N, 2007, CLIN VACCINE IMMUNOL, V14, P1515, DOI 10.1128/CVI.00130-07
   Kawasaki Y, 2002, J BIOL CHEM, V277, P27559, DOI 10.1074/jbc.M202879200
   Kiss M, 2013, J ALLERGY CLIN IMMUN, V132, P264, DOI 10.1016/j.jaci.2013.05.044
   Kuckelhaus CS, 2011, EXP PARASITOL, V127, P658, DOI 10.1016/j.exppara.2010.12.003
   Lagathu C, 2007, ANTIVIR THER, V12, P489
   Laufs H, 2002, INFECT IMMUN, V70, P826, DOI 10.1128/IAI.70.2.826-835.2002
   Lopez-Velez R, 2003, ANN TROP MED PARASIT, V97, P143, DOI 10.1179/000349803225002615
   Macedo-Silva ST, 2011, MOL BIOL INT, V2011
   McComsey GA, 2012, AIDS, V26, P1371, DOI 10.1097/QAD.0b013e328354f4fb
   Nathoo S, 2003, LANCET, V362, P1039, DOI 10.1016/S0140-6736(03)14414-5
   Noursadeghi M, 2008, J IMMUNOL METHODS, V329, P194, DOI 10.1016/j.jim.2007.10.015
   Padigel UM, 2003, J IMMUNOL, V171, P3705, DOI 10.4049/jimmunol.171.7.3705
   PICK E, 1981, J IMMUNOL METHODS, V46, P211, DOI 10.1016/0022-1759(81)90138-1
   Pokorna J, 2009, VIRUSES-BASEL, V1, P1209, DOI 10.3390/v1031209
   Prive C, 2000, EUR J IMMUNOL, V30, P2235, DOI 10.1002/1521-4141(2000)30:8&lt;2235::AID-IMMU2235&gt;3.0.CO;2-9
   Prot M, 2006, ANTIMICROB AGENTS CH, V50, P3998, DOI 10.1128/AAC.00625-06
   Santos LO, 2013, CURR MED CHEM, V20, P3116
   Santos LO, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004918
   Savoia D, 2005, INT J ANTIMICROB AG, V26, P92, DOI 10.1016/j.ijantimicag.2005.04.003
   Singh VK, 2004, BIOCHEM BIOPH RES CO, V322, P1086, DOI [10.1016/j.bbrc.2004.08.016, 10.1016/j.bbrc.2004.08.020]
   Stewart CR, 2010, NAT IMMUNOL, V11, P155, DOI 10.1038/ni.1836
   Trudel N, 2008, J INFECT DIS, V198, P1292, DOI 10.1086/592280
   Von Stebut E, 2007, EUR J DERMATOL, V17, P115, DOI 10.1684/ejd.2007.0122
   Wanasen N, 2008, IMMUNOL RES, V41, P15, DOI 10.1007/s12026-007-8012-y
   Weih F, 1997, J IMMUNOL, V158, P5211
   Whelan KT, 2003, EUR J IMMUNOL, V33, P2520, DOI 10.1002/eji.200323646
   Yang ZY, 2007, J IMMUNOL, V178, P1077, DOI 10.4049/jimmunol.178.2.1077
   Ye JP, 2008, BIOCHEM BIOPH RES CO, V374, P405, DOI 10.1016/j.bbrc.2008.07.068
NR 49
TC 8
Z9 10
U1 0
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1567-5769
EI 1878-1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD FEB
PY 2015
VL 24
IS 2
BP 314
EP 324
DI 10.1016/j.intimp.2014.12.025
PG 11
WC Immunology; Pharmacology & Pharmacy
SC Immunology; Pharmacology & Pharmacy
GA CC2OD
UT WOS:000350183600023
PM 25545854
DA 2020-12-15
ER

PT J
AU Lazzari, AM
   de Oliveira, MVS
   Moreti, B
   Guimaraes, G
   Krug, F
   Noleto, G
   de Mesquita, AJ
   Magalhaes, KG
   Bocca, AL
   Neves, JP
AF Lazzari, Andrea Maria
   Snel de Oliveira, Marilia Viviane
   Moreti, Bruno
   Guimaraes, Gabriela
   Krug, Fernanda
   Noleto, Giovana
   de Mesquita, Albenones Jose
   Magalhaes, Kelly Grace
   Bocca, Anamelia Lorenzetti
   Neves, Jairo Pereira
TI Interleukin-1 beta production and severity of mastitis post-inoculation
   of Staphylococcus aureus in the mammary gland of bovines and bubalines
SO CIENCIA RURAL
LA Portuguese
DT Article
DE buffaloes; cows; cytokine; innate immunity; induced mastitis
ID INTRAMAMMARY INFECTION; DAIRY-COWS; NEUTROPHIL; DIAGNOSIS; CYTOKINE
AB This study aimed to analyze in cows and buffaloes, submitted to mastitis induced by inoculation of S. aureus, the concentration of the pro-inflammatory cytokine interleukin-1beta (IL-1 beta), the somatic cell count (SCC), and their correlation with some parameters of local and systemic response to inflammation. The animals had one mammary gland inoculated and the inflammatory process was monitored by milk culture, SCC, IL-1 beta measurement in the milk evaluation of the gland appearance/consistency, milk secretion appearance (localized response to inflammation) and rectal temperature measurement (systemic response to inflammation). There was increase in the levels of IL-1 beta, SCC, and both local and systemic inflammatory response, in bovine and bubaline species. The production kinetics of the cytokine was different between the two species (P<0.05). Buffaloes showed a faster increase but achieved lower levels of interleukin-1beta, when compared to cows. Both species reached similar maximum counts (P>0.05) of SC/milk mL, with different concentrations (P<0.05) of IL-1 beta/mL. The parameters used to verify the local response to inflammation showed higher mean scores in bovine specie. Positive correlation between IL-1 beta concentration in the milk SCC and parameters used to analyze the severity of mastitis was verified only in the bovine specie. The results evidenced that the kinetics of IL-1 beta production was different in the bovine and bubaline species, and demonstrated that the buffaloes developed a milder inflammatory process with faster recovery of the parameters used for mastitis severity evaluation.
C1 [Lazzari, Andrea Maria; Snel de Oliveira, Marilia Viviane; Moreti, Bruno; Guimaraes, Gabriela; Krug, Fernanda; Noleto, Giovana] UPIS, Dept Vet Med, BR-70390125 Brasilia, DF, Brazil.
   [de Mesquita, Albenones Jose] Univ Fed Goias, Dept Vet Med, Goiania, Go, Brazil.
   [Magalhaes, Kelly Grace; Bocca, Anamelia Lorenzetti] Univ Brasilia, Dept Biol Celular, Brasilia, DF, Brazil.
   [Neves, Jairo Pereira] Univ Brasilia, Fac Agron & Med Vet, Brasilia, DF, Brazil.
RP Lazzari, AM (corresponding author), UPIS, Dept Vet Med, BR-70390125 Brasilia, DF, Brazil.
EM lazzari@upis.br
RI Magalhaes, Kelly Grace/L-6081-2019; Magalhaes, Kelly G/A-6966-2010;
   Bocca, Anamelia Lorenzetti/K-4758-2018
OI Magalhaes, Kelly Grace/0000-0002-7435-5272; Magalhaes, Kelly
   G/0000-0002-7435-5272; Bocca, Anamelia Lorenzetti/0000-0003-3323-5300
CR Alluwaimi AM, 2004, RES VET SCI, V77, P211, DOI 10.1016/j.rvsc.2004.04.006
   Andersen S, 2010, J DAIRY SCI, V93, P2966, DOI 10.3168/jds.2009-2726
   Atalla H, 2009, VET MICROBIOL, V137, P326, DOI 10.1016/j.vetmic.2009.01.027
   Bannerman DD, 2004, CLIN DIAGN LAB IMMUN, V11, P463, DOI 10.1128/CDLI.11.3.463-472.2004
   Contreras GA, 2011, J MAMMARY GLAND BIOL, V16, P339, DOI 10.1007/s10911-011-9234-0
   GALIERO G., 2000, BUBALUS BUBALIS, P26
   Lam TJGM, 1996, J AM VET MED ASSOC, V208, P1705
   Martins Filho L. P., 2007, Ars Veterinaria, V23, P75
   Mehrzad J, 2005, VET RES, V36, P101, DOI 10.1051/vetres:2004055
   Merle R, 2007, J DAIRY RES, V74, P174, DOI 10.1017/S002202990600238X
   Ote I, 2011, VET MICROBIOL, V153, P285, DOI 10.1016/j.vetmic.2011.05.042
   Paape MJ, 2003, VET RES, V34, P597, DOI 10.1051/vetres:2003024
   Rainard P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063471
   Sahoo G, 1998, COMP IMMUNOL MICROB, V21, P319, DOI 10.1016/S0147-9571(97)00029-5
   Schukken YH, 2003, VET RES, V34, P579, DOI 10.1051/vetres:2003028
   Sordillo LM, 1997, J DAIRY SCI, V80, P1851, DOI 10.3168/jds.S0022-0302(97)76121-6
   Watson CJ, 2011, J REPROD IMMUNOL, V88, P124, DOI 10.1016/j.jri.2010.11.006
   Wenz JR, 2010, J DAIRY SCI, V93, P2458, DOI 10.3168/jds.2009-2819
NR 18
TC 0
Z9 0
U1 0
U2 7
PU UNIV FEDERAL SANTA MARIA
PI SANTA MARIA
PA CIDADE UNIV, BAIRRO CAMOBI, SANTA MARIA, RS 97105-900, BRAZIL
SN 0103-8478
EI 1678-4596
J9 CIENC RURAL
JI Cienc. Rural
PD OCT
PY 2014
VL 44
IS 10
BP 1816
EP 1822
DI 10.1590/0103-8478cr20130726
PG 7
WC Agronomy
SC Agriculture
GA AS0IP
UT WOS:000343961400018
OA DOAJ Gold, Green Published
DA 2020-12-15
ER

PT J
AU Burgel, PHM
   Saavedra, PH
   Magalhaes, KG
   Cordero, RJ
   Zamboni, DS
   Tavares, AH
   Albuquerque, P
   Casadevall, A
   Bocca, AL
AF Buergel, P. H. M.
   Saavedra, P. H.
   Magalhaes, K. G.
   Cordero, R. J.
   Zamboni, D. S.
   Tavares, A. H.
   Albuquerque, P.
   Casadevall, A.
   Bocca, A. L.
TI Differences between acapsular and encapsulated strain of Cryptococcus
   neoformans in NLRP3 inflammasome-dependent activation
SO MYCOSES
LA English
DT Meeting Abstract
C1 [Buergel, P. H. M.; Saavedra, P. H.; Magalhaes, K. G.; Tavares, A. H.; Albuquerque, P.; Bocca, A. L.] Univ Brasilia UnB, Brasilia, DF, Brazil.
   [Cordero, R. J.] Univ Fed Rio de Janeiro, Rio de Janeiro, Brazil.
   [Zamboni, D. S.] USP Ribeirao Preto, Ribeirao Preto, Brazil.
   [Casadevall, A.] Albert Einstein Coll Med, New York, NY USA.
RI Burgel, Pedro Henrique Miranda/AAX-2047-2020; Albuquerque,
   Patricia/H-1403-2011; Magalhaes, Kelly Grace/L-6081-2019; Magalhaes,
   Kelly G/A-6966-2010
OI Albuquerque, Patricia/0000-0001-8160-7784; Magalhaes, Kelly
   Grace/0000-0002-7435-5272; Magalhaes, Kelly G/0000-0002-7435-5272
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0933-7407
EI 1439-0507
J9 MYCOSES
JI Mycoses
PD MAY
PY 2014
VL 57
SU 1
SI SI
BP 81
EP 82
PG 2
WC Dermatology; Mycology
SC Dermatology; Mycology
GA AG0FL
UT WOS:000335090600173
DA 2020-12-15
ER

PT J
AU Gomes, AF
   Magalhaes, KG
   Rodrigues, RM
   de Carvalho, L
   Molinaro, R
   Bozza, PT
   Barbosa, HS
AF Gomes, Alessandra F.
   Magalhaes, Kelly G.
   Rodrigues, Renata M.
   de Carvalho, Lais
   Molinaro, Raphael
   Bozza, Patricia T.
   Barbosa, Helene S.
TI Toxoplasma gondii-skeletal muscle cells interaction increases lipid
   droplet biogenesis and positively modulates the production of IL-12,
   IFN-g and PGE(2)
SO PARASITES & VECTORS
LA English
DT Article
DE Toxoplasma gondii; Lipid droplets; Skeletal muscle cells;
   Prostaglandin-E-2; Cytokines
ID PROSTAGLANDIN E-2; INTRACELLULAR DOMAINS; HOST-CELLS; IN-VIVO; PARASITE;
   BODIES; MACROPHAGES; EXPRESSION; INFECTION; RECEPTOR
AB Background: The interest in the mechanisms involved in Toxoplasma gondii lipid acquisition has steadily increased during the past few decades, but it remains not completely understood. Here, we investigated the biogenesis and the fate of lipid droplets (LD) of skeletal muscle cells (SkMC) during their interaction with T. gondii by confocal and electron microscopy. We also evaluated whether infected SkMC modulates the production of prostaglandin E-2 (PGE(2)), cytokines interleukin-12 (IL-12) and interferon-gamma (INF-g), and also the cyclooxygenase-2 (COX-2) gene induction.
   Methods: Primary culture of skeletal muscle cells were infected with tachyzoites of T. gondii and analysed by confocal microscopy for observation of LD. Ultrastructural cytochemistry was also used for lipid and sarcoplasmatic reticulum (SR) detection. Dosage of cytokines (IL-12 and INF-g) by ELISA technique and enzyme-linked immunoassay (EIA) for PGE(2) measurement were employed. The COX-2 gene expression analysis was performed by real time reverse transcriptase polymerase chain reaction (qRT-PCR).
   Results: We demonstrated that T. gondii infection of SkMC leads to increase in LD number and area in a time course dependent manner. Moreover, the ultrastructural analysis demonstrated that SR and LD are in direct contact with parasitophorous vacuole membrane (PVM), within the vacuolar matrix, around it and interacting directly with the membrane of parasite, indicating that LD are recruited and deliver their content inside the parasitophorous vacuole (PV) in T. gondii-infected SkMC. We also observed a positive modulation of the production of IL-12 and IFN-g, increase of COX-2 mRNA levels in the first hour of T. gondii-SkMC interaction and an increase of prostaglandin E-2 (PGE(2)) synthesis from 6 h up to 48 h of infection.
   Conclusions: Taken together, the close association between SR and LD with PV could represent a source of lipids as well as other nutrients for the parasite survival, and together with the increased levels of IL-12, INF-g and inflammatory indicators PGE(2) and COX-2 might contribute to the establishment and maintenance of chronic phase of the T. gondii infection in muscle cell.
C1 [Gomes, Alessandra F.; Rodrigues, Renata M.; Barbosa, Helene S.] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Biol Estrutural, Rio De Janeiro, Brazil.
   [Magalhaes, Kelly G.] Univ Brasilia, Lab Imunol & Inflamacao, Brasilia, DF, Brazil.
   [de Carvalho, Lais] Univ Estado Rio de Janeiro, Dept Histol & Embriol, Lab Cultura Celulas, BR-20550011 Rio De Janeiro, Brazil.
   [Molinaro, Raphael; Bozza, Patricia T.] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Imunofarmacol, Rio De Janeiro, Brazil.
RP Barbosa, HS (corresponding author), Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Biol Estrutural, Rio De Janeiro, Brazil.
EM helene@ioc.fiocruz.br
RI Magalhaes, Kelly Grace/L-6081-2019; Magalhaes, Kelly G/A-6966-2010
OI Magalhaes, Kelly Grace/0000-0002-7435-5272; Magalhaes, Kelly
   G/0000-0002-7435-5272; Barbosa, Helene/0000-0002-5672-5444; Carvalho,
   Lais/0000-0002-1790-3674; Bozza, Patricia/0000-0001-8349-9529
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do
   Rio de Janeiro (FAPERJ)Carlos Chagas Filho Foundation for Research
   Support of the State of Rio de Janeiro (FAPERJ); Universidade do Estado
   do Rio de Janeiro (UERJ); Fundacao Oswaldo Cruz (Programa Estrategico de
   Apoio a Pesquisa em Saude - PAPES VI); Pronex - Programa de Apoio a
   Nucleos de Excelencia - CNPq/FAPERJ; Instituto Oswaldo Cruz/Fiocruz
FX The authors thank Carlos Alberto Bizarro Rodrigues from
   Farmanguinhos/Fiocruz for the production of interferential microscopy
   images for the aid with confocal microscopy. We are grateful to Sandra
   Maria de Oliveira Souza and Genesio Lopes de Faria for technical
   assistance. This work was supported by grants from Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq), Fundacao Carlos Chagas
   Filho de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ),
   Universidade do Estado do Rio de Janeiro (UERJ), Fundacao Oswaldo Cruz
   (Programa Estrategico de Apoio a Pesquisa em Saude - PAPES VI), Pronex -
   Programa de Apoio a Nucleos de Excelencia - CNPq/FAPERJ and Instituto
   Oswaldo Cruz/Fiocruz.
CR Almeida PE, 2009, J IMMUNOL, V183, P1337, DOI 10.4049/jimmunol.0900365
   Andrade E. F., 2001, Journal of Submicroscopic Cytology and Pathology, V33, P337
   ANGERMULLER S, 1982, HISTOCHEM J, V14, P823, DOI 10.1007/BF01033631
   Barbosa HS, 2005, J PARASITOL, V91, P182, DOI 10.1645/GE-276R
   BETZ M, 1991, J IMMUNOL, V146, P108
   Blader IJ, 2001, J BIOL CHEM, V276, P24223, DOI 10.1074/jbc.M100951200
   Bozza PT, 2009, BBA-MOL CELL BIOL L, V1791, P540, DOI 10.1016/j.bbalip.2009.01.005
   Caceres N, 2009, TUBERCULOSIS, V89, P175, DOI 10.1016/j.tube.2008.11.001
   Caffaro CE, 2011, EUKARYOT CELL, V10, P1095, DOI 10.1128/EC.00002-11
   Canedo-Solares I, 2013, PARASITOL RES, V112, P3029, DOI 10.1007/s00436-013-3476-2
   Charron AJ, 2002, J CELL SCI, V115, P3049
   Cheng M, 2008, AM J PHYSIOL-CELL PH, V294, pC1183, DOI 10.1152/ajpcell.00568.2007
   Cocchiaro JL, 2008, P NATL ACAD SCI USA, V105, P9379, DOI 10.1073/pnas.0712241105
   Coppens I, 2006, CELL MICROBIOL, V8, P1, DOI 10.1111/j.1462-5822.2005.00647.x
   Coppens I, 2000, J CELL BIOL, V149, P167, DOI 10.1083/jcb.149.1.167
   D'Avila H, 2008, INT IMMUNOPHARMACOL, V8, P1308, DOI 10.1016/j.intimp.2008.01.035
   D'Avila H, 2006, J IMMUNOL, V176, P3087, DOI 10.4049/jimmunol.176.5.3087
   D'Avila H, 2011, J INFECT DIS, V204, P951, DOI 10.1093/infdis/jir432
   da Silva MDF, 2008, MOL BIOSYST, V4, P824, DOI 10.1039/b800520f
   Dedieu S, 2004, EXP CELL RES, V292, P187, DOI 10.1016/j.yexcr.2003.08.014
   Ferreira-da-Silva MD, 2009, MEM I OSWALDO CRUZ, V104, P196, DOI 10.1590/S0074-02762009000200012
   Ferreira-da-Silva MD, 2009, INT J MED MICROBIOL, V299, P381, DOI 10.1016/j.ijmm.2008.10.002
   FranziniArmstrong C, 1997, PHYSIOL REV, V77, P699
   GAZZINELLI RT, 1994, J IMMUNOL, V153, P2533
   GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0
   Goldszmid RS, 2009, J EXP MED, V206, P399, DOI 10.1084/jem.20082108
   Gomes AF, 2011, BMC MICROBIOL, V11, DOI 10.1186/1471-2180-11-110
   Guimaraes EV, 2008, J PARASITOL, V94, P72, DOI 10.1645/GE-1273.1
   Guimaraes EV, 2009, MEM I OSWALDO CRUZ, V104, P170, DOI 10.1590/S0074-02762009000200007
   Gupta N, 2005, J BIOL CHEM, V280, P16345, DOI 10.1074/jbc.M501523200
   Jackson KE, 2004, MOL MICROBIOL, V54, P109, DOI 10.1111/j.1365-2958.2004.04284.x
   Laliberte J, 2008, CELL MOL LIFE SCI, V65, P1900, DOI 10.1007/s00018-008-7556-x
   Lang C, 2007, PARASITOL RES, V100, P191, DOI 10.1007/s00436-006-0306-9
   Liu XL, 2003, J PHARMACOL EXP THER, V304, P63, DOI 10.1124/jpet.102.043406
   LOCKE M, 1983, J HISTOCHEM CYTOCHEM, V31, P1019, DOI 10.1177/31.8.6190856
   Martin S, 2006, NAT REV MOL CELL BIO, V7, P373, DOI 10.1038/nrm1912
   Matowicka-Karna J, 2009, CLIN DEV IMMUNOL, DOI 10.1155/2009/374696
   Mattos KA, 2011, CELL MICROBIOL, V13, P259, DOI 10.1111/j.1462-5822.2010.01533.x
   Melo RCN, 2003, TISSUE CELL, V35, P59, DOI 10.1016/S0040-8166(02)00105-2
   Moreno JM, 2002, IMMUNOLOGY, V106, P257, DOI 10.1046/j.1365-2567.2002.01403.x
   Nickdel MB, 2001, INFECT IMMUN, V69, P1044, DOI 10.1128/IAI.69.2.1044-1052.2001
   Nielsen S, 2008, CURR OPIN PHARMACOL, V8, P346, DOI 10.1016/j.coph.2008.02.005
   Nishikawa Y, 2011, J VET MED SCI, V73, P633, DOI 10.1292/jvms.10-0496
   Pacheco P, 2002, J IMMUNOL, V169, P6498, DOI 10.4049/jimmunol.169.11.6498
   Pedersen BK, 2007, J APPL PHYSIOL, V103, P1093, DOI 10.1152/japplphysiol.00080.2007
   Peng BW, 2008, PARASITOL RES, V102, P1043, DOI 10.1007/s00436-007-0873-4
   Portugal LR, 2008, MICROBES INFECT, V10, P276, DOI 10.1016/j.micinf.2007.12.001
   Puzianowska-Kuznicka M, 2009, AGEING RES REV, V8, P160, DOI 10.1016/j.arr.2009.05.002
   REMINGTON JS, 1965, NEW ENGL J MED, V273, P1308, DOI 10.1056/NEJM196512092732404
   RENZ H, 1988, J IMMUNOL, V141, P2388
   Rossi D, 2008, TRAFFIC, V9, P1044, DOI 10.1111/j.1600-0854.2008.00717.x
   Russell DG, 2009, NAT IMMUNOL, V10, P943, DOI 10.1038/ni.1781
   SchartonKersten TM, 1996, J IMMUNOL, V157, P4045
   Silva NM, 2009, EXP PARASITOL, V123, P65, DOI 10.1016/j.exppara.2009.05.011
   Sinai Anthony P., 2008, V47, P155
   Sivaramakrishnan V, 2009, CHEM-BIOL INTERACT, V180, P353, DOI 10.1016/j.cbi.2009.02.004
   Skariah S, 2010, PARASITOL RES, V107, P253, DOI 10.1007/s00436-010-1899-6
   Takacs AC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045440
   Tauchi-Sato K, 2002, J BIOL CHEM, V277, P44507, DOI 10.1074/jbc.M207712200
   Tenter AM, 2000, INT J PARASITOL, V30, P1217, DOI 10.1016/S0020-7519(00)00124-7
   van der Meer-Janssen YPM, 2010, PROG LIPID RES, V49, P1, DOI 10.1016/j.plipres.2009.07.003
   Zhang XF, 2007, MOL BIOL REP, V34, P199, DOI 10.1007/s11033-007-9085-3
NR 62
TC 23
Z9 24
U1 0
U2 8
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1756-3305
J9 PARASITE VECTOR
JI Parasites Vectors
PD JAN 23
PY 2014
VL 7
AR 47
DI 10.1186/1756-3305-7-47
PG 13
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA AF3WF
UT WOS:000334642400002
PM 24457118
OA DOAJ Gold, Green Published
DA 2020-12-15
ER

PT J
AU Almeida, PE
   Roque, NR
   Magalhaes, KG
   Mattos, KA
   Teixeira, L
   Maya-Monteiro, C
   Almeida, CJ
   Castro-Faria-Neto, HC
   Ryffel, B
   Quesniaux, VFJ
   Bozza, PT
AF Almeida, Patricia E.
   Roque, Natalia R.
   Magalhaes, Kelly G.
   Mattos, Katherine A.
   Teixeira, Livia
   Maya-Monteiro, Clarissa
   Almeida, Cecilia J.
   Castro-Faria-Neto, Hugo C.
   Ryffel, Bernhard
   Quesniaux, Valerie F. J.
   Bozza, Patricia T.
TI Differential TLR2 downstream signaling regulates lipid metabolism and
   cytokine production triggered by Mycobacterium bovis BCG infection
SO BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
LA English
DT Article
DE Nuclear receptor; TLR; Lipid droplet; CD36; PPARgamma
ID MACROPHAGE-GENE-EXPRESSION; INNATE IMMUNE-SYSTEM; B SCAVENGER RECEPTOR;
   HEPATITIS-C VIRUS; NF-KAPPA-B; PATTERN-RECOGNITION; NUCLEAR RECEPTORS;
   DENDRITIC CELLS; SCHWANN-CELLS; PPAR-GAMMA
AB The nuclear receptor PPAR gamma acts as a key modulator of lipid metabolism, inflammation and pathogenesis in BCG-infected macrophages. However, the molecular mechanisms involved in PPAR gamma expression and functions during infection are not completely understood. Here, we investigate signaling pathways triggered by TLR2, the involvement of co-receptors and lipid rafts in the mechanism of PPAR gamma expression, lipid body formation and cytokine synthesis in macrophages during BCG infection. BCG induces NF-kappa B activation and increased PPAR gamma expression in a TLR2-dependent manner. Furthermore, BCG-triggered increase of lipid body biogenesis was inhibited by the PPAR gamma antagonist GW9662, but not by the NF-kappa B inhibitor JSH-23. In contrast, KC/CXCL1 production was largely dependent on NF-KB but not on PPAR gamma. BCG infection induced increased expression of CD36 in macrophages in vitro. Moreover, CD36 co-immunoprecipitates with TLR2 in BCG-infected macrophages, suggesting its interaction with TLR2 in BCG signaling. Pretreatment with CD36 neutralizing antibodies significantly inhibited PPAR gamma expression, lipid body formation and PGE2 production induced by BCG. Involvement of CD36 in lipid body formation was further confirmed by decreased BCG-induced lipid body formation in CD36 deficient macrophages. Similarly, CD14 and CD11b/CD18 blockage also inhibited BCG-induced lipid body formation, whereas TNF-alpha synthesis was not affected. Disruption of rafts recapitulates the latter result, inhibiting lipid body formation, but not TNF-alpha synthesis in BCG-infected macrophages. In conclusion, our results suggest that CD36-TLR2 cooperation and signaling compartmentalization within rafts, divert host response signaling through PPAR gamma-dependent and NF-kappa B-independent pathways, leading to increased macrophage lipid accumulation and down-modulation of macrophage response. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Almeida, Patricia E.; Roque, Natalia R.; Magalhaes, Kelly G.; Teixeira, Livia; Maya-Monteiro, Clarissa; Almeida, Cecilia J.; Castro-Faria-Neto, Hugo C.; Bozza, Patricia T.] Fundacao Oswaldo Cruz, Lab Imunofarmacol, Inst Oswaldo Cruz, BR-21045900 Rio De Janeiro, RJ, Brazil.
   [Mattos, Katherine A.] Fundacao Oswaldo Cruz, Lab Microbiol Celular, Inst Oswaldo Cruz, BR-21045900 Rio De Janeiro, RJ, Brazil.
   [Almeida, Patricia E.] Univ Fed Juiz de Fora, Lab Biol Celular, Juiz De Fora, MG, Brazil.
   [Ryffel, Bernhard; Quesniaux, Valerie F. J.] CNRS, UMR7355, F-45071 Orleans, France.
   [Ryffel, Bernhard; Quesniaux, Valerie F. J.] Univ Orleans, F-45067 Orleans, France.
   [Magalhaes, Kelly G.] Univ Brasilia, UNB, Lab Imunol & Inflamacao, Brasilia, DF, Brazil.
RP Bozza, PT (corresponding author), Fundacao Oswaldo Cruz, Lab Imunofarmacol, Inst Oswaldo Cruz, Av Brasil 4365, BR-21045900 Rio De Janeiro, RJ, Brazil.
EM pbozza@ioc.fiocruz.br
RI Magalhaes, Kelly G/A-6966-2010; Magalhaes, Kelly Grace/L-6081-2019
OI Magalhaes, Kelly G/0000-0002-7435-5272; Magalhaes, Kelly
   Grace/0000-0002-7435-5272; Teixeira, Livia/0000-0002-6227-3202; Almeida,
   Patricia Elaine de/0000-0002-9081-8601; Bozza,
   Patricia/0000-0001-8349-9529
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq/Brazil)National Council for Scientific and Technological
   Development (CNPq); PAPES-FIOCRUZ; PRONEX (MCT, Brazil); Fundacao de
   Amparo Pesquisa do Estado do Rio de Janeiro (FAPERJ, Brazil)Carlos
   Chagas Filho Foundation for Research Support of the State of Rio de
   Janeiro (FAPERJ); French National Center for Scientific Research
   (CNRS)Centre National de la Recherche Scientifique (CNRS); CNRS/FIOCRUZ
   [24201]; Guggenheim Foundation
FX This work was funded by Conselho Nacional de Desenvolvimento Cientifico
   e Tecnologico (CNPq/Brazil), PAPES-FIOCRUZ, PRONEX (MCT, Brazil),
   Fundacao de Amparo Pesquisa do Estado do Rio de Janeiro (FAPERJ,
   Brazil), French National Center for Scientific Research (CNRS),
   CNRS/FIOCRUZ 2009 project No. 24201, and Guggenheim Foundation.
CR Almeida PE, 2012, PPAR RES, V2012, DOI 10.1155/2012/383829
   Almeida PE, 2009, J IMMUNOL, V183, P1337, DOI 10.4049/jimmunol.0900365
   Anes E, 2003, NAT CELL BIOL, V5, P793, DOI 10.1038/ncb1036
   ARMSTRONG JA, 1975, J EXP MED, V142, P1, DOI 10.1084/jem.142.1.1
   Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5
   Boulant S, 2007, J GEN VIROL, V88, P2204, DOI 10.1099/vir.0.82898-0
   Chawla A, 2001, NAT MED, V7, P48
   Collot-Teixeira S, 2007, CARDIOVASC RES, V75, P468, DOI 10.1016/j.cardiores.2007.03.010
   Court N, 2010, J IMMUNOL, V184, P7057, DOI 10.4049/jimmunol.1000164
   Cruz D, 2008, J CLIN INVEST, V118, P2917, DOI 10.1172/JCI34189
   D'Avila H, 2008, CELL MICROBIOL, V10, P2589, DOI 10.1111/j.1462-5822.2008.01233.x
   D'Avila H, 2008, INT IMMUNOPHARMACOL, V8, P1308, DOI 10.1016/j.intimp.2008.01.035
   D'Avila H, 2007, INFECT IMMUN, V75, P1507, DOI 10.1128/IAI.01326-06
   D'Avila H, 2006, J IMMUNOL, V176, P3087, DOI 10.4049/jimmunol.176.5.3087
   D'Avila H, 2011, J INFECT DIS, V204, P951, DOI 10.1093/infdis/jir432
   de Mattos KA, 2012, MEM I OSWALDO CRUZ, V107, P156, DOI 10.1590/S0074-02762012000900023
   Desreumaux P, 2001, J EXP MED, V193, P827, DOI 10.1084/jem.193.7.827
   Drage MG, 2009, CELL IMMUNOL, V258, P29, DOI 10.1016/j.cellimm.2009.03.008
   Febbraio M, 2001, J CLIN INVEST, V108, P785, DOI 10.1172/JCI200114006
   Flo TH, 2000, J IMMUNOL, V164, P2064, DOI 10.4049/jimmunol.164.4.2064
   Flo TH, 2002, J BIOL CHEM, V277, P35489, DOI 10.1074/jbc.M201366200
   Gatfield J, 2000, SCIENCE, V288, P1647, DOI 10.1126/science.288.5471.1647
   Hajishengallis G, 2006, CELL MICROBIOL, V8, P1557, DOI 10.1111/j.1462-5822.2006.00730.x
   Hawkes M, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-299
   Hoebe K, 2005, NATURE, V433, P523, DOI 10.1038/nature03253
   Kang JY, 2009, IMMUNITY, V31, P873, DOI 10.1016/j.immuni.2009.09.018
   Kim MJ, 2010, EMBO MOL MED, V2, P258, DOI 10.1002/emmm.201000079
   Kleinnijenhuis J, 2011, CLIN DEV IMMUNOL, DOI 10.1155/2011/405310
   Mahajan S, 2012, J IMMUNOL, V188, P5593, DOI 10.4049/jimmunol.1103038
   Mattos KA, 2011, J IMMUNOL, V187, P2548, DOI 10.4049/jimmunol.1101344
   Mattos KA, 2011, CELL MICROBIOL, V13, P259, DOI 10.1111/j.1462-5822.2010.01533.x
   Mattos KA, 2010, J LEUKOCYTE BIOL, V87, P371, DOI 10.1189/jlb.0609433
   Miyanari Y, 2007, NAT CELL BIOL, V9, P1089, DOI 10.1038/ncb1631
   Moore KJ, 2000, J IMMUNOL, V165, P4272, DOI 10.4049/jimmunol.165.8.4272
   Muzio M, 1998, J EXP MED, V187, P2097, DOI 10.1084/jem.187.12.2097
   Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3
   Neyrolles O, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000043
   Nicholson AC, 2001, ANN NY ACAD SCI, V947, P224
   Nilsen NJ, 2008, J LEUKOCYTE BIOL, V84, P280, DOI 10.1189/jlb.0907656
   Ogawa S, 2005, CELL, V122, P707, DOI 10.1016/j.cell.2005.06.029
   Organization W.H., 2011, WHOHTMTB201116, P258
   Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497
   PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0
   Peyron P, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000204
   Pfeiffer A, 2001, EUR J IMMUNOL, V31, P3153, DOI 10.1002/1521-4141(200111)31:11<3153::AID-IMMU3153>3.0.CO;2-0
   Rajaram MVS, 2010, J IMMUNOL, V185, P929, DOI 10.4049/jimmunol.1000866
   Russell DG, 2011, IMMUNOL REV, V240, P252, DOI 10.1111/j.1600-065X.2010.00984.x
   Russell DG, 2002, J CELL BIOL, V158, P421, DOI 10.1083/jcb.200205034
   Ryffel B., 2006, NOVART FDN SYMP, V279, P139
   Ryffel Bernhard, 2006, Novartis Found Symp, V279, P127
   Samsa MM, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000632
   Shin HM, 2004, FEBS LETT, V571, P50, DOI 10.1016/j.febslet.2004.06.056
   Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052
   Stewart CR, 2010, NAT IMMUNOL, V11, P155, DOI 10.1038/ni.1836
   Strapagiel D, 2008, FOLIA HISTOCHEM CYTO, V46, P353, DOI 10.2478/v10042-008-0044-1
   Stuart LM, 2005, J CELL BIOL, V170, P477, DOI 10.1083/jcb.200501113
   Szatmari I, 2008, EMBO J, V27, P2353, DOI 10.1038/emboj.2008.160
   Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3
   Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5
   Triantafilou M, 2007, CELL MICROBIOL, V9, P2030, DOI 10.1111/j.1462-5822.2007.00935.x
   Triantafilou M, 2006, J BIOL CHEM, V281, P31002, DOI 10.1074/jbc.M602794200
   Vasselon T, 2004, J IMMUNOL, V173, P7401, DOI 10.4049/jimmunol.173.12.7401
   Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1
   Yoshimura A, 1999, J IMMUNOL, V163, P1
NR 64
TC 35
Z9 38
U1 0
U2 16
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1388-1981
EI 1879-2618
J9 BBA-MOL CELL BIOL L
JI Biochim. Biophys. Acta Mol. Cell Biol. Lipids
PD JAN
PY 2014
VL 1841
IS 1
BP 97
EP 107
DI 10.1016/j.bbalip.2013.10.008
PG 11
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA 282DX
UT WOS:000329151600011
PM 24120921
DA 2020-12-15
ER

PT J
AU Tavares, AH
   Magalhaes, KG
   Almeida, RD
   Correa, R
   Burgel, PH
   Bocca, AL
AF Tavares, Aldo Henrique
   Magalhaes, Kelly Grace
   Almeida, Raquel Das Neves
   Correa, Rafael
   Burgel, Pedro Henrique
   Bocca, Anamelia Lorenzetti
TI NLRP3 Inflammasome Activation by Paracoccidioides brasiliensis
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID DENDRITIC CELLS; NALP3 INFLAMMASOME; ANTIINFLAMMATORY CYTOKINES;
   PATTERN-RECOGNITION; CANDIDA-ALBICANS; HUMAN MONOCYTES; NITRIC-OXIDE;
   IN-VITRO; INNATE; IMMUNITY
AB Paracoccidioides brasiliensis is the etiologic agent of paracoccidioidomycosis (PCM), the most prevalent systemic mycosis that is geographically confined to Latin America. The pro-inflammatory cytokine IL-1 that is mainly derived from the activation of the cytoplasmic multiprotein complex inflammasome is an essential host factor against opportunistic fungal infections; however, its role in infection with a primary fungal pathogen, such as P. brasiliensis, is not well understood. In this study, we found that murine bone marrow-derived dendritic cells responded to P. brasiliensis yeast cells infection by releasing IL-1 in a spleen tyrosine kinase (Syk), caspase-1 and NOD-like receptor (NLR) family member NLRP3 dependent manner. In addition, P. brasiliensis-induced NLRP3 inflammasome activation was dependent on potassium (K+) efflux, reactive oxygen species production, phagolysosomal acidification and cathepsin B release. Finally, using mice lacking the IL-1 receptor, we demonstrated that IL-1 signaling has an important role in killing P. brasiliensis by murine macrophages. Altogether, our results demonstrate that the NLRP3 inflammasome senses and responds to P. brasiliensis yeast cells infection and plays an important role in host defense against this fungus.
   Author Summary Paracoccidioidomycosis is a systemic disease that has an important mortality and morbidity impact in Latin America. It mainly affects rural workers of Argentina, Colombia, Venezuela and Brazil. Upon host infection, one of the most important aspects that contribute to the disease outcome is the initial interaction of the Paracoccidioides brasiliensis fungus with the phagocytic cells and the induction of the inflammatory process. Among several inflammatory mediators, the cytokine interleukin-1 is of pivotal importance in this complex process. Here, we demonstrate that P. brasiliensis is sensed by the NLRP3 inflammasome, a cytoplasmatic multiprotein complex that lead to the processing and secretion of IL-1. In addition, we described the intracellular perturbations that may be associated with NLRP3 activation such as potassium efflux, production of reactive oxygen species, and lysosomal damage. Finally, our work provides evidence for the protective role of IL-1 during fungal infection of murine macrophages.
C1 [Tavares, Aldo Henrique] Univ Brasilia, Fac Ceilandia, Brasilia, DF, Brazil.
   [Tavares, Aldo Henrique; Burgel, Pedro Henrique; Bocca, Anamelia Lorenzetti] Univ Brasilia, Lab Imunol Aplicada, Dept Biol Celular, Inst Biol, Brasilia, DF, Brazil.
   [Magalhaes, Kelly Grace; Almeida, Raquel Das Neves; Correa, Rafael] Univ Brasilia, Inst Biol, Dept Biol Celular, Lab Imunol & Inflamacao, Brasilia, DF, Brazil.
RP Tavares, AH (corresponding author), Univ Brasilia, Fac Ceilandia, Brasilia, DF, Brazil.
EM atavares@unb.br
RI Magalhaes, Kelly Grace/L-6081-2019; Burgel, Pedro Henrique
   Miranda/AAX-2047-2020; TAVARES, ALDO HENRIQUE/L-5662-2015; Magalhaes,
   Kelly G/A-6966-2010; Bocca, Anamelia Lorenzetti/K-4758-2018
OI Magalhaes, Kelly Grace/0000-0002-7435-5272; Magalhaes, Kelly
   G/0000-0002-7435-5272; TAVARES, ALDO HENRIQUE/0000-0003-0579-3380;
   Correa, Rafael/0000-0003-2989-2383; Bocca, Anamelia
   Lorenzetti/0000-0003-3323-5300
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPQ)National Council for Scientific and Technological Development
   (CNPq); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES)CAPES; Fundacao de Amparo a Pesquisa do Distrito Federal (FAP-DF)
FX The authors thank the Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPQ), Coordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior (CAPES) and Fundacao de Amparo a Pesquisa do Distrito Federal
   (FAP-DF) for financial support. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Bauernfeind F, 2013, EMBO MOL MED, V5, P814, DOI 10.1002/emmm.201201771
   Bauernfeind F, 2012, J IMMUNOL, V189, P4175, DOI 10.4049/jimmunol.1201516
   Bauernfeind F, 2011, J IMMUNOL, V187, P613, DOI 10.4049/jimmunol.1100613
   Bauernfeind FG, 2009, J IMMUNOL, V183, P787, DOI 10.4049/jimmunol.0901363
   Bellocchio S, 2004, J IMMUNOL, V172, P3059, DOI 10.4049/jimmunol.172.5.3059
   Bonfim CV, 2009, MED MYCOL, V47, P722, DOI 10.3109/13693780802641425
   Brown GD, 2011, ANNU REV IMMUNOL, V29, P1, DOI 10.1146/annurev-immunol-030409-101229
   BRUMMER E, 1988, J IMMUNOL, V140, P2786
   BRUMMER E, 1993, CLIN MICROBIOL REV, V6, P89, DOI 10.1128/CMR.6.2.89-117.1993
   Cassel SL, 2008, P NATL ACAD SCI USA, V105, P9035, DOI 10.1073/pnas.0803933105
   Chen C, 2012, PLOS ONE, V7
   de Veerdonk FLV, 2011, TRENDS IMMUNOL, V32, P110, DOI 10.1016/j.it.2011.01.003
   Dias MFRG, 2004, MICROSC MICROANAL, V10, P215, DOI 10.1017/S1431927604040061
   Diniz SN, 2004, J LEUKOCYTE BIOL, V75, P649, DOI 10.1189/jlb.0803371
   Tavares AHFP, 2007, MICROBES INFECT, V9, P583, DOI 10.1016/j.micinf.2007.01.024
   Fremond CM, 2007, J IMMUNOL, V179, P1178, DOI 10.4049/jimmunol.179.2.1178
   Gantner BN, 2003, J EXP MED, V197, P1107, DOI 10.1084/jem.20021787
   Calich VLG, 2008, MYCOPATHOLOGIA, V165, P223, DOI 10.1007/s11046-007-9048-1
   Gildea LA, 2005, INFECT IMMUN, V73, P6803, DOI 10.1128/IAI.73.10.6803-6811.2005
   Gonzalez A, 2000, INFECT IMMUN, V68, P2546, DOI 10.1128/IAI.68.5.2546-2552.2000
   Goodridge HS, 2009, J IMMUNOL, V182, P1146, DOI 10.4049/jimmunol.182.2.1146
   Gringhuis SI, 2012, NAT IMMUNOL, V13, P246, DOI 10.1038/ni.2222
   Gross O, 2009, NATURE, V459, P433, DOI 10.1038/nature07965
   Guarda G, 2011, J IMMUNOL, V186, P2529, DOI 10.4049/jimmunol.1002720
   Halle A, 2008, NAT IMMUNOL, V9, P857, DOI 10.1038/ni.1636
   HAVELL EA, 1992, J IMMUNOL, V148, P1486
   He XB, 2010, J IMMUNOL, V184, P5743, DOI 10.4049/jimmunol.0903937
   He Y, 2013, J IMMUNOL, V190, P334, DOI 10.4049/jimmunol.1202737
   Hise AG, 2009, CELL HOST MICROBE, V5, P487, DOI 10.1016/j.chom.2009.05.002
   Hornung V, 2008, NAT IMMUNOL, V9, P847, DOI 10.1038/ni.1631
   Joly S, 2009, J IMMUNOL, V183, P3578, DOI 10.4049/jimmunol.0901323
   Kang TB, 2013, IMMUNITY, V38, P27, DOI 10.1016/j.immuni.2012.09.015
   Kankkunen P, 2010, J IMMUNOL, V184, P6335, DOI 10.4049/jimmunol.0903019
   Kurokawa CS, 2007, MICROBIOL IMMUNOL, V51, P421, DOI 10.1111/j.1348-0421.2007.tb03929.x
   Lamkanfi M, 2009, J CELL BIOL, V187, P61, DOI 10.1083/jcb.200903124
   Lazarevic V, 2008, CELL HOST MICROBE, V3, P199, DOI 10.1016/j.chom.2008.03.006
   Lei GW, 2013, CELL RES, V23, P965, DOI 10.1038/cr.2013.49
   LeibundGut-Landmann S, 2012, CURR OPIN IMMUNOL, V24, P449, DOI 10.1016/j.coi.2012.04.007
   Li H, 2013, PROTEIN CELL, V4, P529, DOI 10.1007/s13238-013-2127-9
   LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5
   Loures FV, 2011, INFECT IMMUN, V79, P2470, DOI 10.1128/IAI.00375-10
   Loures FV, 2010, INFECT IMMUN, V78, P1078, DOI 10.1128/IAI.01198-09
   Loures FV, 2009, J IMMUNOL, V183, P1279, DOI 10.4049/jimmunol.0801599
   Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022-1759(98)00204-X
   Mariathasan S, 2006, NATURE, V440, P228, DOI 10.1038/nature04515
   Martinez FO, 2009, ANNU REV IMMUNOL, V27, P451, DOI 10.1146/annurev.immunol.021908.132532
   Master SS, 2008, CELL HOST MICROBE, V3, P224, DOI 10.1016/j.chom.2008.03.003
   Menino Joao Filipe, 2013, PLoS Negl Trop Dis, V7, pe2317, DOI 10.1371/journal.pntd.0002317
   Nascimento FRF, 2002, J IMMUNOL, V168, P4593, DOI 10.4049/jimmunol.168.9.4593
   Netea MG, 2009, BLOOD, V113, P2324, DOI 10.1182/blood-2008-03-146720
   Newman SL, 2005, INFECT IMMUN, V73, P770, DOI 10.1128/IAI.73.2.770-777.2005
   Pelegrin P, 2009, EMBO J, V28, P2114, DOI 10.1038/emboj.2009.163
   Peracoli MTS, 2003, MICROBES INFECT, V5, P413, DOI 10.1016/S1286-4579(03)00040-6
   Pina A, 2013, INFECT IMMUN, V81, P1064, DOI 10.1128/IAI.00736-12
   Prado M, 2009, MEM I OSWALDO CRUZ, V104, P513, DOI 10.1590/S0074-02762009000300019
   Dias MFRG, 2008, MED MYCOL, V46, P241, DOI 10.1080/13693780701824411
   Restrepo A, 2012, CURR FUNGAL INFECT R, V6, P303, DOI 10.1007/s12281-012-0114-x
   Romani L, 2011, NAT REV IMMUNOL, V11, P275, DOI 10.1038/nri2939
   Said-Sadier N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010008
   San-Blas G, 2002, MED MYCOL, V40, P225, DOI 10.1080/mmy.40.3.225.242
   San-Blas G, 2011, REV IBEROAM MICOL, V28, P1, DOI 10.1016/j.riam.2010.11.004
   SANBLAS G, 1993, J MED VET MYCOL, V31, P99
   Sharp FA, 2009, P NATL ACAD SCI USA, V106, P870, DOI 10.1073/pnas.0804897106
   Strasser JE, 1999, J IMMUNOL, V162, P6148
   Tavares AH, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001459
   van de Veerdonk FL, 2008, CURR OPIN MICROBIOL, V11, P305, DOI 10.1016/j.mib.2008.06.002
NR 66
TC 34
Z9 34
U1 0
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD DEC
PY 2013
VL 7
IS 12
AR e2595
DI 10.1371/journal.pntd.0002595
PG 11
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 282JU
UT WOS:000329168100025
PM 24340123
OA DOAJ Gold, Green Published
DA 2020-12-15
ER

PT J
AU Kasmar, AG
   Van Rhijn, I
   Magalhaes, KG
   Young, DC
   Cheng, TY
   Turner, MT
   Schiefner, A
   Kalathur, RC
   Wilson, IA
   Bhati, M
   Gras, S
   Birkinshaw, RW
   Tan, LL
   Rossjohn, J
   Shires, J
   Jakobsen, S
   Altman, JD
   Moody, DB
AF Kasmar, Anne G.
   Van Rhijn, Ildiko
   Magalhaes, Kelly G.
   Young, David C.
   Cheng, Tan-Yun
   Turner, Marie T.
   Schiefner, Andre
   Kalathur, Ravi C.
   Wilson, Ian A.
   Bhati, Mugdha
   Gras, Stephanie
   Birkinshaw, Richard W.
   Tan, Li L.
   Rossjohn, Jamie
   Shires, John
   Jakobsen, Soren
   Altman, John D.
   Moody, D. Branch
TI Cutting Edge: CD1a Tetramers and Dextramers Identify Human
   Lipopeptide-Specific T Cells Ex Vivo
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID ANTIGEN; REPERTOIRE; RECOGNITION; RECEPTORS; REVEALS; GENES
AB Human CD1a mediates foreign Ag recognition by a T cell clone, but the nature of possible TCR interactions with CD1a/lipid are unknown. After incubating CD1a with a mycobacterial lipopeptide Ag, dideoxymycobactin (DDM), we identified and measured binding to a recombinant TCR (TRAV3/TRBV3-1, K-D of approximate to 100 mu M). Detection of ternary CD1a/lipid/TCR interactions enabled development of CD1a tetramers and CD1a multimers with carbohydrate backbones (dextramers), which specifically stained T cells using a mechanism that was dependent on the precise stereochemistry of the peptide backbone and was blocked with a soluble TCR. Furthermore, sorting of human T cells from unrelated tuberculosis patients for bright DDM-dextramer staining allowed recovery of T cells that were activated by CD1a and DDM. These studies demonstrate that the mechanism of T cell activation by lipopeptides occurs via ternary interactions of CD1a/Ag/TCR. Furthermore, these studies demonstrate the existence of lipopeptide-specific T cells in humans ex vivo.
C1 [Kasmar, Anne G.; Van Rhijn, Ildiko; Magalhaes, Kelly G.; Young, David C.; Cheng, Tan-Yun; Moody, D. Branch] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Rheumatol Immunol & Allergy, Boston, MA 02115 USA.
   [Van Rhijn, Ildiko] Univ Utrecht, Fac Vet Med, Dept Infect Dis & Immunol, NL-3584 CL Utrecht, Netherlands.
   [Turner, Marie T.] Lemuel Shattuck Hosp, TB Treatment Unit, Jamaica Plain, MA 02130 USA.
   [Schiefner, Andre; Kalathur, Ravi C.; Wilson, Ian A.] Scripps Res Inst, Dept Integrat Struct & Computat Biol, La Jolla, CA 92037 USA.
   [Wilson, Ian A.] Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA.
   [Bhati, Mugdha; Gras, Stephanie; Birkinshaw, Richard W.; Tan, Li L.; Rossjohn, Jamie] Monash Univ, Dept Biochem & Mol Biol, Sch Biomed Sci, Clayton, Vic 3800, Australia.
   [Rossjohn, Jamie] Cardiff Univ, Sch Med, Inst Infect & Immun, Cardiff CF14 4XN, S Glam, Wales.
   [Shires, John; Altman, John D.] Emory Vaccine Ctr, Atlanta, GA 30329 USA.
   [Jakobsen, Soren] Immudex, DK-2100 Copenhagen, Denmark.
RP Moody, DB (corresponding author), Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, Smith Bldg,Room 514,1 Jimmy Fund Way, Boston, MA 02115 USA.
EM bmoody@partners.org
RI Kalathur, Ravi/L-7696-2016; Magalhaes, Kelly G/A-6966-2010; Magalhaes,
   Kelly Grace/L-6081-2019; Rossjohn, Jamie/F-9032-2013; Birkinshaw,
   Richard/AAC-7809-2019; gras, stephanie/C-8307-2013
OI Kalathur, Ravi/0000-0003-1669-9277; Magalhaes, Kelly
   G/0000-0002-7435-5272; Magalhaes, Kelly Grace/0000-0002-7435-5272;
   Rossjohn, Jamie/0000-0002-2020-7522; Birkinshaw,
   Richard/0000-0003-1825-0182; kalathur, ravi/0000-0002-4889-8003; Van
   Rhijn, Ildiko/0000-0002-1446-5701; gras, stephanie/0000-0001-7416-038X;
   Tan, Li Lynn/0000-0003-0606-4446; Schiefner, Andre/0000-0001-5215-4122;
   jakobsen, soren nyboe/0000-0002-2227-8615
FU Howard Hughes Medical Institute KwaZulu-Natal Research Institute for
   Tuberculosis and HIV; Harvard University Global Health Initiative;
   Burroughs Wellcome Fund Program in Translational ResearchBurroughs
   Wellcome Fund; National Institutes of HealthUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USA [T-32
   AI 007306-22, T-32 AR 007530-23, K08 AI089858, R01 AI49313, R01
   AR048632, R01 A1042266]; Nederlands Wetenschappelijk Onderzoek [Meervoud
   836.08.001]; Australian Research CouncilAustralian Research Council;
   National Health and Medical Research Council AustraliaNational Health
   and Medical Research Council of Australia; NATIONAL INSTITUTE OF ALLERGY
   AND INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [T32AI007306, R01AI049313,
   T32AI007306, K08AI089858, T32AI007306, T32AI007306, T32AI007306,
   R01AI049313, T32AI007306, T32AI007306, T32AI007306, T32AI007306,
   T32AI007306, T32AI007306, T32AI007306, T32AI007306, T32AI007306,
   R01AI049313, R01AI049313, R01AI049313, T32AI007306, T32AI007306,
   T32AI007306, T32AI007306, R01AI049313, T32AI007306, R01AI049313,
   R01AI049313, T32AI007306, T32AI007306, R01AI049313, T32AI007306,
   R01AI049313, R01AI049313, R01AI049313, T32AI007306, R01AI049313,
   T32AI007306, T32AI007306, T32AI007306, K08AI089858, T32AI007306,
   K08AI089858, T32AI007306, T32AI007306, K08AI089858, T32AI007306,
   R01AI049313, R01AI049313, T32AI007306, R01AI049313, T32AI007306,
   T32AI007306, R01AI049313, R01AI049313, K08AI089858, R01AI049313] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND
   MUSCULOSKELETAL AND SKIN DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)
   [T32AR007530, T32AR007530, T32AR007530, T32AR007530, T32AR007530,
   T32AR007530, T32AR007530, T32AR007530, R01AR048632, T32AR007530,
   R01AR048632, T32AR007530, R01AR048632, R01AR048632, R01AR048632,
   T32AR007530, R01AR048632, T32AR007530, T32AR007530, R01AR048632,
   T32AR007530, R01AR048632, T32AR007530, R01AR048632, R01AR048632,
   T32AR007530, T32AR007530, T32AR007530, R01AR048632, T32AR007530,
   R01AR048632, T32AR007530, T32AR007530, R01AR048632, T32AR007530,
   R01AR048632, R01AR048632, T32AR007530, T32AR007530, R01AR048632,
   T32AR007530, T32AR007530, T32AR007530, T32AR007530, T32AR007530,
   R01AR048632, R01AR048632, T32AR007530, T32AR007530, T32AR007530,
   T32AR007530, T32AR007530, T32AR007530, T32AR007530] Funding Source: NIH
   RePORTER
FX This work was supported by grants from the Howard Hughes Medical
   Institute KwaZulu-Natal Research Institute for Tuberculosis and HIV (to
   A. G. K. and D. B. M.), the Harvard University Global Health Initiative
   (to A. G. K.), the Burroughs Wellcome Fund Program in Translational
   Research (to D. B. M.), as well as by National Institutes of Health
   Grants T-32 AI 007306-22, T-32 AR 007530-23, K08 AI089858 (to A. G. K.),
   R01 AI49313, R01 AR048632 (to D. B. M.), and R01 A1042266 (to I. A. W.)
   and a grant from the Nederlands Wetenschappelijk Onderzoek (Meervoud
   836.08.001) (to I. V. R.). S. G. is supported by an Australian Research
   Council Future Fellowship. J.R. is supported by a National Health and
   Medical Research Council Australia Fellowship.
CR Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94
   Batard P, 2006, J IMMUNOL METHODS, V310, P136, DOI 10.1016/j.jim.2006.01.006
   Bedel R, 2012, NAT IMMUNOL, V13, P705, DOI 10.1038/ni.2347
   Benlagha K, 2000, J EXP MED, V191, P1895, DOI 10.1084/jem.191.11.1895
   de Jong A, 2010, NAT IMMUNOL, V11, P1102, DOI 10.1038/ni.1956
   Gras S, 2009, IMMUNITY, V30, P193, DOI 10.1016/j.immuni.2008.11.011
   Gumperz JE, 2002, J EXP MED, V195, P625, DOI 10.1084/jem.20011786
   Karadimitris A, 2001, P NATL ACAD SCI USA, V98, P3294, DOI 10.1073/pnas.051604498
   Kasmar AG, 2011, J EXP MED, V208, P1741, DOI 10.1084/jem.20110665
   Lee PT, 2002, J EXP MED, V195, P637, DOI 10.1084/jem.20011908
   Ly D, 2013, J EXP MED, V210, P729, DOI 10.1084/jem.20120624
   Manolova V, 2006, EUR J IMMUNOL, V36, P1083, DOI 10.1002/eji.200535544
   Matsuda JL, 2000, J EXP MED, V192, P741, DOI 10.1084/jem.192.5.741
   Miller MM, 2005, P NATL ACAD SCI USA, V102, P8674, DOI 10.1073/pnas.0500105102
   Moody DB, 2004, SCIENCE, V303, P527, DOI 10.1126/science.1089353
   Pellicci DG, 2011, NAT IMMUNOL, V12, P827, DOI 10.1038/ni.2076
   Rosat JP, 1999, J IMMUNOL, V162, P366
   Van Rhijn I, 2013, NAT IMMUNOL, V14, P706, DOI 10.1038/ni.2630
   Van Rhijn I, 2009, J EXP MED, V206, P1409, DOI 10.1084/jem.20082480
   Young DC, 2009, J BIOL CHEM, V284, P25087, DOI 10.1074/jbc.M109.000802
   YU CY, 1989, EMBO J, V8, P3727, DOI 10.1002/j.1460-2075.1989.tb08548.x
   Zajonc DM, 2005, IMMUNITY, V22, P209, DOI 10.1016/j.immuni.2004.12.009
NR 22
TC 41
Z9 41
U1 0
U2 6
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD NOV 1
PY 2013
VL 191
IS 9
BP 4499
EP 4503
DI 10.4049/jimmunol.1301660
PG 5
WC Immunology
SC Immunology
GA 238FS
UT WOS:000325929000006
PM 24089190
OA Green Accepted, Bronze
DA 2020-12-15
ER

PT J
AU Tavares, AH
   Jeronimo, MS
   Magalhaes, KG
   Silva-Pereira, I
   Bocca, AL
AF Tavares, A. H.
   Jeronimo, M. S.
   Magalhaes, K. G.
   Silva-Pereira, I.
   Bocca, A. L.
TI Paracoccidioides brasiliensis isolates differing in virulence induce a
   differential transcriptional response of murine dendritic cells
SO MYCOSES
LA English
DT Meeting Abstract
C1 [Tavares, A. H.; Jeronimo, M. S.; Magalhaes, K. G.; Silva-Pereira, I.; Bocca, A. L.] Univ Brasilia, Brasilia, DF, Brazil.
RI Magalhaes, Kelly Grace/L-6081-2019; Silva-Pereira, Ildinete/C-7509-2011;
   Magalhaes, Kelly G/A-6966-2010
OI Magalhaes, Kelly Grace/0000-0002-7435-5272; Silva-Pereira,
   Ildinete/0000-0003-1403-9363; Magalhaes, Kelly G/0000-0002-7435-5272
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0933-7407
J9 MYCOSES
JI Mycoses
PD JUN
PY 2012
VL 55
SU 4
SI SI
BP 314
EP 315
PG 2
WC Dermatology; Mycology
SC Dermatology; Mycology
GA 956DK
UT WOS:000305069801327
DA 2020-12-15
ER

PT J
AU Saavedra, P
   Capparelli, M
   Matos, L
   Zamboni, D
   Casadevall, A
   Bocca, A
   Magalhaes, K
AF Saavedra, Pedro
   Capparelli, Manuella
   Matos, Larissa
   Zamboni, Dario
   Casadevall, Arturo
   Bocca, Anamelia
   Magalhaes, Kelly
TI Cryptococcus neoformans activates the inflammasome and its capsule plays
   an important role in this process
SO JOURNAL OF IMMUNOLOGY
LA English
DT Meeting Abstract
CT 99th Annual Meeting of the American-Association-of-Immunologists
CY MAY 04-08, 2012
CL Boston, MA
SP Amer Assoc Immunol
C1 [Saavedra, Pedro; Capparelli, Manuella; Matos, Larissa; Bocca, Anamelia; Magalhaes, Kelly] Univ Brasilia, Dept Cell Biol, Brasilia, DF, Brazil.
   [Zamboni, Dario] Univ Sao Paulo, Med Sch Ribeirao Preto, Dept Cell Biol & Microbial Pathogenesis, Sao Paulo, Brazil.
   [Casadevall, Arturo] Yeshiva Univ, Dept Microbiol & Immunol, Albert Einstein Coll Med, Bronx, NY USA.
RI Magalhaes, Kelly Grace/L-6081-2019; Magalhaes, Kelly G/A-6966-2010
OI Magalhaes, Kelly Grace/0000-0002-7435-5272; Magalhaes, Kelly
   G/0000-0002-7435-5272
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAY 1
PY 2012
VL 188
PG 1
WC Immunology
SC Immunology
GA 950OX
UT WOS:000304659700511
DA 2020-12-15
ER

PT J
AU Luna-Gomes, T
   Magalhaes, KG
   Mesquita-Santos, FP
   Bakker-Abreu, I
   Samico, RF
   Molinaro, R
   Calheiros, AS
   Diaz, BL
   Bozza, PT
   Weller, PF
   Bandeira-Melo, C
AF Luna-Gomes, Tatiana
   Magalhaes, Kelly G.
   Mesquita-Santos, Fabio P.
   Bakker-Abreu, Ilka
   Samico, Rafaela F.
   Molinaro, Raphael
   Calheiros, Andrea S.
   Diaz, Bruno L.
   Bozza, Patricia T.
   Weller, Peter F.
   Bandeira-Melo, Christianne
TI Eosinophils as a Novel Cell Source of Prostaglandin D-2: Autocrine Role
   in Allergic Inflammation
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID LEUKOTRIENE C-4 SYNTHESIS; LIPID BODIES; CHEMOATTRACTANT RECEPTOR;
   CUTTING EDGE; MAST-CELLS; D SYNTHASE; ACTIVATION; CRTH2; METABOLITE;
   EXPRESSION
AB PGD(2) is a key mediator of allergic inflammatory diseases that is mainly synthesized by mast cells, which constitutively express high levels of the terminal enzyme involved in PGD(2) synthesis, the hematopoietic PGD synthase (H-PGDS). In this study, we investigated whether eosinophils are also able to synthesize, and therefore, supply biologically active PGD(2). PGD(2) synthesis was evaluated within human blood eosinophils, in vitro differentiated mouse eosinophils, and eosinophils infiltrating inflammatory site of mouse allergic reaction. Biological function of eosinophil-derived PGD(2) was studied by employing inhibitors of synthesis and activity. Constitutive expression of H-PGDS was found within nonstimulated human circulating eosinophils. Acute stimulation of human eosinophils with A23187 (0.1-5 mu M) evoked PGD(2) synthesis, which was located at the nuclear envelope and was inhibited by pretreatment with HQL-79 (10 mu M), a specific H-PGDS inhibitor. Prestimulation of human eosinophils with arachidonic acid (10 mu M) or human eotaxin (6 nM) also enhanced HQL-79-sensitive PGD(2) synthesis, which, by acting on membrane-expressed specific receptors (D prostanoid receptors 1 and 2), displayed an autocrine/paracrine ability to trigger leukotriene C-4 synthesis and lipid body biogenesis, hallmark events of eosinophil activation. In vitro differentiated mouse eosinophils also synthesized paracrine/autocrine active PGD(2) in response to arachidonic acid stimulation. In vivo, at late time point of the allergic reaction, infiltrating eosinophils found at the inflammatory site appeared as an auxiliary PGD(2)-synthesizing cell population. Our findings reveal that eosinophils are indeed able to synthesize and secrete PGD(2), hence representing during allergic inflammation an extra cell source of PGD(2), which functions as an autocrine signal for eosinophil activation. The Journal of Immunology, 2011, 187: 6518-6526.
C1 [Luna-Gomes, Tatiana; Mesquita-Santos, Fabio P.; Bakker-Abreu, Ilka; Samico, Rafaela F.; Diaz, Bruno L.; Bandeira-Melo, Christianne] Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, Lab Inflamac, BR-21941902 Rio De Janeiro, Brazil.
   [Magalhaes, Kelly G.; Mesquita-Santos, Fabio P.; Molinaro, Raphael; Calheiros, Andrea S.; Bozza, Patricia T.] Inst Oswaldo Cruz, Fdn Oswaldo Cruz, Lab Imunofarmacol, BR-21045900 Rio De Janeiro, Brazil.
   [Weller, Peter F.] Beth Israel Deaconess Med Ctr, Harvard Med Sch, Dept Med, Div Allergy & Inflammat, Boston, MA 02215 USA.
RP Bandeira-Melo, C (corresponding author), Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, Lab Inflamac, Ave Carlos Chagas Filho S-N,Cidade Univ, BR-21941902 Rio De Janeiro, Brazil.
EM pweller@bidmc.harvard.edu; cbmelo@biof.ufrj.br
RI Molinaro, Raphael RMC/H-4357-2012; Fisiologia, Ciencias
   Biologicas/C-2407-2012; de Melo, Christianne Bandeira/B-7724-2009;
   Magalhaes, Kelly G/A-6966-2010; Bandeira-Melo, Christianne/X-5619-2019;
   Magalhaes, Kelly Grace/L-6081-2019; Diaz, Bruno L./A-5673-2009
OI de Melo, Christianne Bandeira/0000-0003-3305-3865; Magalhaes, Kelly
   G/0000-0002-7435-5272; Bandeira-Melo, Christianne/0000-0003-3305-3865;
   Magalhaes, Kelly Grace/0000-0002-7435-5272; Diaz, Bruno
   L./0000-0001-8393-3823; Bozza, Patricia/0000-0001-8349-9529
FU Conselho Nacional de Pesquisas and Fundacao Carlos Chagas Filho de
   Amparo a Pesquisa do Estado do Rio de Janeiro from Brazil and National
   Institutes of Health [AI020241, AI051645, AI022571]; NATIONAL INSTITUTE
   OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [R01AI020241,
   R01AI022571, R01AI020241, R37AI020241, R01AI022571, R37AI020241,
   R01AI020241, R01AI022571, R01AI020241, R01AI020241, R01AI020241,
   R01AI022571, R01AI022571, R01AI020241, R01AI051645, R01AI051645,
   R01AI022571, R01AI022571, R01AI022571, R01AI051645, R01AI022571,
   R01AI022571, R01AI020241, R01AI022571, R01AI020241, R01AI022571,
   R01AI022571, R01AI020241, R01AI051645, R01AI020241, R01AI020241,
   R01AI022571, R37AI020241, R01AI051645, R01AI051645, R01AI051645,
   R01AI022571, R01AI022571, R01AI020241, R01AI020241, R37AI020241,
   R01AI022571, R01AI020241, R01AI020241, R01AI020241, R01AI022571,
   R37AI020241, R01AI020241, R01AI022571, R01AI051645, R01AI020241,
   R01AI022571, R01AI022571, R01AI020241, R01AI051645, R01AI020241,
   R37AI020241, R37AI020241, R01AI020241, R01AI022571, R37AI020241,
   R37AI020241, R01AI022571, R37AI020241, R01AI022571, R01AI022571,
   R01AI020241, R01AI051645, R01AI020241] Funding Source: NIH RePORTER
FX This work was supported by Conselho Nacional de Pesquisas and Fundacao
   Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro
   from Brazil and National Institutes of Health Grants AI020241, AI051645,
   and AI022571 (to P.F.W.).
CR Arima Masafumi, 2011, Korean Journal of Internal Medicine, V26, P8, DOI 10.3904/kjim.2011.26.1.8
   Balzar S, 2011, AM J RESP CRIT CARE, V183, P299, DOI 10.1164/rccm.201002-0295OC
   Bandeira-Melo C, 2002, J ALLERGY CLIN IMMUN, V109, P393, DOI 10.1067/mai.2002.121529
   Bandeira-Melo C, 2002, J EXP MED, V196, P841, DOI 10.1084/jem.20020516
   Bandeira-Melo C, 2001, J BIOL CHEM, V276, P22779, DOI 10.1074/jbc.M101436200
   Bandeira-Melo C, 2011, METHODS MOL BIOL, V689, P163, DOI 10.1007/978-1-60761-950-5_10
   Barrett NA, 2009, IMMUNITY, V31, P425, DOI 10.1016/j.immuni.2009.08.014
   Bhattacharya M, 1999, J BIOL CHEM, V274, P15719, DOI 10.1074/jbc.274.22.15719
   Bochenek G, 2003, J ALLERGY CLIN IMMUN, V111, P743, DOI 10.1067/mai.2003.1387
   Bohm E, 2004, J BIOL CHEM, V279, P7663, DOI 10.1074/jbc.M310270200
   BOIE Y, 1995, J BIOL CHEM, V270, P18910, DOI 10.1074/jbc.270.32.18910
   Boyce JA, 2003, PROSTAG LEUKOTR ESS, V69, P195, DOI 10.1016/S0952-3278(03)00081-4
   Bozza PT, 2007, PHARMACOL THERAPEUT, V113, P30, DOI 10.1016/j.pharmthera.2006.06.006
   Bozza PT, 1996, P NATL ACAD SCI USA, V93, P11091, DOI 10.1073/pnas.93.20.11091
   CHARLESWORTH EN, 1991, J IMMUNOL, V146, P671
   Dahlen SE, 2004, THORAX, V59, P453, DOI 10.1136/thx.2004.026641
   Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0
   Dyer KD, 2008, J IMMUNOL, V181, P4004, DOI 10.4049/jimmunol.181.6.4004
   Dyer KD, 2011, J IMMUNOL METHODS, V369, P91, DOI 10.1016/j.jim.2011.04.009
   Gandhi UH, 2011, J BIOL CHEM, V286, P27471, DOI 10.1074/jbc.M111.260547
   Gazi L, 2005, PROSTAG OTH LIPID M, V75, P153, DOI 10.1016/j.prostaglandins.2004.11.003
   HAMBERG M, 1976, BIOCHIM BIOPHYS ACTA, V431, P189, DOI 10.1016/0005-2760(76)90273-3
   HARDY CC, 1984, NEW ENGL J MED, V311, P209, DOI 10.1056/NEJM198407263110401
   Heinemann A, 2003, J IMMUNOL, V170, P4752, DOI 10.4049/jimmunol.170.9.4752
   Hirai H, 2001, J EXP MED, V193, P255, DOI 10.1084/jem.193.2.255
   HIRATA M, 1994, P NATL ACAD SCI USA, V91, P11192, DOI 10.1073/pnas.91.23.11192
   Hyo S, 2007, ARCH OTOLARYNGOL, V133, P693, DOI 10.1001/archotol.133.7.693
   Joo M, 2007, J IMMUNOL, V179, P2565, DOI 10.4049/jimmunol.179.4.2565
   Kabashima K, 2003, PROSTAG LEUKOTR ESS, V69, P187, DOI 10.1016/S0952-3278(03)00080-2
   Kanaoka Y, 2003, PROSTAG LEUKOTR ESS, V69, P163, DOI 10.1016/S0952-3278(03)00077-2
   Le Mee S, 2008, STEROIDS, V73, P1148, DOI 10.1016/j.steroids.2008.05.001
   Lee TH, 2009, J ALLERGY CLIN IMMUN, V124, P417, DOI 10.1016/j.jaci.2009.04.020
   LEWIS RA, 1982, J IMMUNOL, V129, P1627
   Mesquita-Santos FP, 2011, BRIT J PHARMACOL, V162, P1674, DOI 10.1111/j.1476-5381.2010.01086.x
   Mesquita-Santos FP, 2006, J IMMUNOL, V176, P1326, DOI 10.4049/jimmunol.176.3.1326
   Monneret G, 2002, J IMMUNOL, V168, P3563, DOI 10.4049/jimmunol.168.7.3563
   Monneret G, 2001, BLOOD, V98, P1942, DOI 10.1182/blood.V98.6.1942
   Moreira LS, 2009, BBA-MOL CELL BIOL L, V1791, P156, DOI 10.1016/j.bbalip.2009.01.003
   MURRAY JJ, 1986, NEW ENGL J MED, V315, P800, DOI 10.1056/NEJM198609253151304
   NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597
   Nagata K, 1999, FEBS LETT, V459, P195, DOI 10.1016/S0014-5793(99)01251-X
   Nantel F, 2004, PROSTAG OTH LIPID M, V73, P87, DOI 10.1016/j.prostaglandins.2003.12.002
   Ogawa Y, 2006, J ALLERGY CLIN IMMUN, V118, P789, DOI 10.1016/j.jaci.2006.08.009
   Okano M, 2006, AM J RHINOL, V20, P342, DOI 10.2500/ajr.2006.20.2865
   OSullivan S, 1996, J ALLERGY CLIN IMMUN, V98, P421, DOI 10.1016/S0091-6749(96)70167-7
   PARSONS WG, 1988, J IMMUNOL, V141, P2413
   PATTERSON R, 1980, J ALLERGY CLIN IMMUN, V65, P269, DOI 10.1016/0091-6749(80)90154-2
   Philip G, 2009, J ALLERGY CLIN IMMUN, V124, P942, DOI 10.1016/j.jaci.2009.07.006
   Sandig H, 2006, FEBS LETT, V580, P373, DOI 10.1016/j.febslet.2005.11.052
   Sawyer N, 2002, BRIT J PHARMACOL, V137, P1163, DOI 10.1038/sj.bjp.0704973
   Schuligoi R, 2010, PHARMACOLOGY, V85, P372, DOI 10.1159/000313836
   Shimura C, 2010, AM J PATHOL, V176, P227, DOI 10.2353/ajpath.2010.090111
   Taba Y, 2000, CIRC RES, V86, P967, DOI 10.1161/01.RES.86.9.967
   Tanaka K, 2000, J IMMUNOL, V164, P2277, DOI 10.4049/jimmunol.164.5.2277
   Ugajin T, 2011, AM J PATHOL, V179, P775, DOI 10.1016/j.ajpath.2011.04.023
   Vieira-De-Abreu A, 2005, AM J RESP CELL MOL, V33, P254, DOI 10.1165/rcmb.2005-0145OC
   Vieira-de-Abreu A, 2011, AM J RESP CELL MOL, V44, P509, DOI 10.1165/rcmb.2010-0004OC
NR 57
TC 53
Z9 53
U1 0
U2 1
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD DEC 15
PY 2011
VL 187
IS 12
BP 6518
EP 6526
DI 10.4049/jimmunol.1101806
PG 9
WC Immunology
SC Immunology
GA 863MG
UT WOS:000298167800044
PM 22102725
OA Green Accepted, Bronze
DA 2020-12-15
ER

PT J
AU Yakimchuk, K
   Roura-Mir, C
   Magalhaes, KG
   de Jong, A
   Kasmar, AG
   Granter, SR
   Budd, R
   Steere, A
   Pena-Cruz, V
   Kirschning, C
   Cheng, TY
   Moody, DB
AF Yakimchuk, Konstantin
   Roura-Mir, Carme
   Magalhaes, Kelly G.
   de Jong, Annemieke
   Kasmar, Anne G.
   Granter, Scott R.
   Budd, Ralph
   Steere, Allen
   Pena-Cruz, Victor
   Kirschning, Carsten
   Cheng, Tan-Yun
   Moody, D. Branch
TI Borrelia burgdorferi infection regulates CD1 expression in human cells
   and tissues via IL1-beta
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Article
DE CD1; DC; IL-1; Lyme disease; T cells
ID HUMAN DENDRITIC CELLS; CUTTING EDGE; INFLAMMASOME ACTIVATION; ANTIGEN
   PRESENTATION; NLRP3 INFLAMMASOME; HOST-DEFENSE; NKT CELLS; T-CELLS;
   KAPPA-B; DISEASE
AB The appearance of group 1 CD1 proteins (CD1a, CD1b and CD1c) on maturing myeloid DC is a key event that converts myeloid DC to effective lipid APC. Here, we show that Borrelia burgdorferi, the causative agent of Lyme disease, triggers appearance of group 1 CD1 proteins at high density on the surface of human myeloid DC during infection. Within human skin, CD1b and CD1c expression was low or absent prior to infection, but increased significantly after experimental infections and in erythema migrans lesions from Lyme disease patients. The induction of CD1 was initiated by borrelial lipids acting through TLR-2 within minutes, but required 3 days for maximum effect. The delay in CD1 protein appearance involved a multi-step process whereby TLR-2 stimulated cells release soluble factors, which are sufficient to transfer the CD1-inducing effect in trans to other cells. Analysis of these soluble factors identified IL-1 beta as a previously unknown pathway leading to group 1 CD1 protein function. This study establishes that upregulation of group 1 CD1 proteins is an early event in B. burgdorferi infection and suggests a stepwise mechanism whereby bacterial cell walls, TLR activation and cytokine release cause DC precursors to express group 1 CD1 proteins.
C1 [Yakimchuk, Konstantin; Roura-Mir, Carme; Magalhaes, Kelly G.; de Jong, Annemieke; Kasmar, Anne G.; Cheng, Tan-Yun; Moody, D. Branch] Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, Boston, MA 02115 USA.
   [Granter, Scott R.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
   [Granter, Scott R.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
   [Budd, Ralph] Univ Vermont, Coll Med, Dept Med, Burlington, VT 05405 USA.
   [Steere, Allen] Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA.
   [Pena-Cruz, Victor] Dana Farber Canc Inst, Boston, MA 02115 USA.
   [Kirschning, Carsten] Univ Duisburg Essen, Inst Med Microbiol, Essen, Germany.
RP Moody, DB (corresponding author), Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, Smith Bldg,Room 514,1 Jimmy Fund Way, Boston, MA 02115 USA.
EM bmoody@rics.bwh.harvard.edu
RI Magalhaes, Kelly G/A-6966-2010; Magalhaes, Kelly Grace/L-6081-2019;
   Roura-Mir, Carme/D-4538-2013
OI Magalhaes, Kelly G/0000-0002-7435-5272; Magalhaes, Kelly
   Grace/0000-0002-7435-5272; Roura-Mir, Carme/0000-0003-0514-337X; de
   Jong, Annemieke/0000-0001-6707-6585
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [AI R01049313, AR R01048632, AR
   R0120358]; Pew Foundation; Burroughs Wellcome Fund for Translational
   ResearchBurroughs Wellcome Fund; Cancer Research Institute and Centers
   for Disease Control and Prevention [CCU110 291]; The English; Bonter;
   Mitchell Foundation; Eshe Fund; Lyme/Arthritis Research Fund at
   Massachusetts General Hospital; NATIONAL INSTITUTE OF ALLERGY AND
   INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [K08AI089858, K08AI089858,
   K08AI089858, R01AI049313, R01AI049313, R01AI049313, R01AI049313,
   R01AI049313, R01AI049313, R01AI049313, R01AI049313, R01AI049313,
   R01AI049313, R01AI049313, R01AI049313, R01AI049313, R01AI049313,
   K08AI089858, R01AI049313, R01AI049313, R01AI049313, K08AI089858,
   R01AI049313, R01AI049313] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal
   & Skin Diseases (NIAMS) [R01AR020358, R01AR020358, R01AR048632,
   R01AR020358, R01AR048632, R01AR020358, R01AR020358, R01AR020358,
   R01AR020358, R01AR020358, R01AR048632, R01AR048632, R01AR048632,
   R01AR020358, R01AR020358, R01AR048632, R01AR048632, R01AR048632,
   R01AR020358, R01AR020358, R01AR020358, R01AR020358, R01AR020358,
   R01AR048632, R01AR020358, R01AR020358, R01AR020358, R01AR020358,
   R01AR048632, R01AR048632, R01AR020358, R01AR048632, R01AR048632,
   R01AR020358, R01AR048632, R01AR020358, R01AR020358, R01AR020358,
   R01AR020358, R01AR048632, R01AR020358, R01AR048632, R01AR020358,
   R01AR020358, R01AR048632, R01AR048632] Funding Source: NIH RePORTER
FX This work was supported by grants from the NIH (AI R01049313, AR
   R01048632, AR R0120358), the Pew Foundation Scholars in the Biomedical
   Sciences Program, The Burroughs Wellcome Fund for Translational
   Research, the Cancer Research Institute and Centers for Disease Control
   and Prevention, (CCU110 291), The English, Bonter, Mitchell Foundation,
   the Eshe Fund, and the Lyme/Arthritis Research Fund at Massachusetts
   General Hospital. The authors thank Justin D. Radolf for providing B.
   burgdorferi strains and advice, Sam Behar and Steve Porcelli for
   providing antibodies to CD1, Nitin Damle and Vijay Sikand for performing
   the skin biopsies, and Jenny Shin for cutting sections of the EM biopsy
   samples.
CR Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391
   ATHANASASPLATSIS S, 1995, ARCH ORAL BIOL, V40, P157, DOI 10.1016/0003-9969(94)00152-2
   Belperron AA, 2005, J IMMUNOL, V174, P5681, DOI 10.4049/jimmunol.174.9.5681
   Boes M, 2002, NATURE, V418, P983, DOI 10.1038/nature01004
   Bolz DD, 2004, J IMMUNOL, V173, P2003, DOI 10.4049/jimmunol.173.3.2003
   CALABI F, 1989, EUR J IMMUNOL, V19, P285, DOI 10.1002/eji.1830190211
   CALABI F, 1986, NATURE, V323, P540, DOI 10.1038/323540a0
   Chow A, 2002, NATURE, V418, P988, DOI 10.1038/nature01006
   Covert MW, 2005, SCIENCE, V309, P1854, DOI 10.1126/science.1112304
   Cruz AR, 2008, INFECT IMMUN, V76, P56, DOI 10.1128/IAI.01039-07
   de la Salle H, 2005, SCIENCE, V310, P1321, DOI 10.1126/science.1115301
   De Libero G, 2007, CURR TOP MICROBIOL, V314, P51
   Dennis VA, 2009, INFECT IMMUN, V77, P1238, DOI 10.1128/IAI.01078-08
   Eggers CH, 2002, MOL MICROBIOL, V43, P281, DOI 10.1046/j.1365-2958.2002.02758.x
   Ekerfelt C, 2003, J NEUROIMMUNOL, V145, P115, DOI 10.1016/j.jneuroim.2003.08.037
   Filgueira L, 1996, J IMMUNOL, V157, P2998
   Franchi L, 2009, J IMMUNOL, V183, P792, DOI 10.4049/jimmunol.0900173
   Guerau-De-Arellano M, 2005, TRENDS MOL MED, V11, P114, DOI 10.1016/j.molmed.2005.01.003
   Hava DL, 2008, P NATL ACAD SCI USA, V105, P11281, DOI 10.1073/pnas.0804681105
   Hirschfeld M, 1999, J IMMUNOL, V163, P2382
   Irie T, 2000, FEBS LETT, V467, P160, DOI 10.1016/S0014-5793(00)01146-7
   JANEWAY CA, 1989, COLD SH Q B, V54, P1
   Jin MS, 2007, CELL, V130, P1071, DOI 10.1016/j.cell.2007.09.008
   Jones KL, 2009, CLIN IMMUNOL, V132, P93, DOI 10.1016/j.clim.2009.03.510
   Jones KL, 2006, J CLIN MICROBIOL, V44, P4407, DOI 10.1128/JCM.01077-06
   Kasmar A, 2009, CURR OPIN IMMUNOL, V21, P397, DOI 10.1016/j.coi.2009.05.022
   Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2
   Kinjo Y, 2005, NATURE, V434, P520, DOI 10.1038/nature03407
   Kinjo Y, 2006, NAT IMMUNOL, V7, P978, DOI 10.1038/ni1380
   Kinjo Y, 2009, ADV EXP MED BIOL, V633, P17, DOI 10.1007/978-0-387-79311-5_3
   Kleinnijenhuis J, 2009, EUR J IMMUNOL, V39, P1914, DOI 10.1002/eji.200839115
   Koo IC, 2008, CELL MICROBIOL, V10, P1866, DOI 10.1111/j.1462-5822.2008.01177.x
   Krutzik SR, 2005, NAT MED, V11, P653, DOI 10.1038/nm1246
   Kumar H, 2000, J IMMUNOL, V165, P4797, DOI 10.4049/jimmunol.165.9.4797
   Leslie DS, 2008, IMMUNOLOGY, V125, P289, DOI 10.1111/j.1365-2567.2008.02842.x
   Liu NY, 2004, INFECT IMMUN, V72, P3195, DOI 10.1128/IAI.72.6.3195-3203.2004
   Mariathasan S, 2006, NATURE, V440, P228, DOI 10.1038/nature04515
   Martinez FO, 2009, ANNU REV IMMUNOL, V27, P451, DOI 10.1146/annurev.immunol.021908.132532
   Mattner J, 2005, NATURE, V434, P525, DOI 10.1038/nature03408
   Meng GX, 2004, J CLIN INVEST, V113, P1473, DOI 10.1172/JCI200420762
   Moody DB, 2006, NAT IMMUNOL, V7, P811, DOI 10.1038/ni1368
   Moody DB, 2005, NAT REV IMMUNOL, V5, P387, DOI 10.1038/nri1605
   Moody DB, 2000, J EXP MED, V192, P965, DOI 10.1084/jem.192.7.965
   Muroi M, 2008, J LEUKOCYTE BIOL, V83, P702, DOI 10.1189/jlb.0907629
   Park SH, 1998, SEMIN IMMUNOL, V10, P391, DOI 10.1006/smim.1998.0139
   Pelegrin P, 2008, J IMMUNOL, V180, P7147, DOI 10.4049/jimmunol.180.11.7147
   Pelegrin P, 2006, EMBO J, V25, P5071, DOI 10.1038/sj.emboj.7601378
   PORCELLI S, 1989, NATURE, V341, P447, DOI 10.1038/341447a0
   PORCELLI S, 1992, NATURE, V360, P593, DOI 10.1038/360593a0
   Roura-Mir C, 2005, J IMMUNOL, V175, P1758, DOI 10.4049/jimmunol.175.3.1758
   Roura-Mir C, 2005, J IMMUNOL, V174, P3773, DOI 10.4049/jimmunol.174.6.3773
   Salazar JC, 2003, J IMMUNOL, V171, P2660, DOI 10.4049/jimmunol.171.5.2660
   Salazar JC, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000444
   SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109
   Smed-Sorensen A, 2008, BLOOD, V111, P5037, DOI 10.1182/blood-2007-07-099549
   Steere AC, 2004, NAT REV IMMUNOL, V4, P143, DOI 10.1038/nri1267
   Stenger S, 1998, J IMMUNOL, V161, P3582
   Szatmari I, 2004, IMMUNITY, V21, P95, DOI 10.1016/j.immuni.2004.06.003
   Trombetta ES, 2005, ANNU REV IMMUNOL, V23, P975, DOI 10.1146/annurev.immunol.22.012703.104538
   Tschopp J, 2010, NAT REV IMMUNOL, V10, P210, DOI 10.1038/nri2725
   Tupin E, 2008, P NATL ACAD SCI USA, V105, P19863, DOI 10.1073/pnas.0810519105
   Werner SL, 2005, SCIENCE, V309, P1857, DOI 10.1126/science.1113319
   Wormser GP, 2008, J INFECT DIS, V198, P1358, DOI 10.1086/592279
NR 63
TC 32
Z9 33
U1 0
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2980
EI 1521-4141
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD MAR
PY 2011
VL 41
IS 3
BP 694
EP 705
DI 10.1002/eji.201040808
PG 12
WC Immunology
SC Immunology
GA 731HU
UT WOS:000288097700015
PM 21246541
OA Green Accepted
DA 2020-12-15
ER

PT J
AU Magalhaes, KG
   Almeida, PE
   Atella, GC
   Maya-Monteiro, CM
   Castro-Faria-Neto, HC
   Pelajo-Machado, M
   Lenzi, HL
   Bozza, MT
   Bozza, PT
AF Magalhaes, Kelly G.
   Almeida, Patricia E.
   Atella, Georgia C.
   Maya-Monteiro, Clarissa M.
   Castro-Faria-Neto, Hugo C.
   Pelajo-Machado, Marcelo
   Lenzi, Henrique L.
   Bozza, Marcelo T.
   Bozza, Patricia T.
TI Schistosomal-Derived Lysophosphatidylcholine Are Involved in Eosinophil
   Activation and Recruitment through Toll-Like Receptor-2-Dependent
   Mechanisms
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID GRANULOMA-FORMATION; LYSOPHOSPHOLIPID RECEPTORS; TISSUE EOSINOPHILIA;
   MANSONI INFECTION; LIVER FIBROSIS; RAPID METHOD; TH2; CYTOKINE; CELLS;
   IL-4
AB Parasite-derived lipids may play important roles in host-pathogen interactions and escape mechanisms. Herein, we evaluated the role of schistosomal-derived lipids in Toll-like receptor (TLR)-2 and eosinophil activation in Schistosoma mansoni infection. Mice lacking TLR2 exhibited reduced liver eosinophilic granuloma, compared with that of wild-type animals, following S. mansoni infection. Decreased eosinophil accumulation and eosinophil lipid body (lipid droplet) formation, at least partially due to reduced production of eotaxin, interleukin (IL)-5, and IL-13 in S. mansoni-infected TLR2(-/-) mice, compared with the corresponding production in wild-type mice, was noted. Although no differences were observed in survival rates during the acute schistosomal infection (up to 50 days), increased survival of TLR2(-/-) mice, compared with survival of wild-type mice, was observed during the chronic phase of infection. Schistosomal lipid extract- and schistosomal-derived lysophosphatidylcholine (lyso-PC)-stimulated macrophages in vitro induced TLR2-dependent NF-kB activation and cytokine production. Furthermore, in vivo schistosomal lyso-PC administration induced eosinophil recruitment and cytokine production, in a mechanism largely dependent on TLR2. Taken together, our results suggest that schistosomal-derived lyso-PC may participate in cytokine production and eosinophil activation through a TLR2-dependent pathway in S. mansoni infection. Moreover, our results suggest that TLR2-dependent inflammatory reaction, cytokine production, and eosinophil recruitment and activation may contribute to the pathogenesis and lethality in the chronic phase of infection.
C1 [Magalhaes, Kelly G.; Almeida, Patricia E.; Maya-Monteiro, Clarissa M.; Castro-Faria-Neto, Hugo C.; Bozza, Patricia T.] Fiocruz MS, Lab Imunofarmacol, IOC, BR-21045900 Rio De Janeiro, Brazil.
   [Magalhaes, Kelly G.; Pelajo-Machado, Marcelo; Lenzi, Henrique L.] Fiocruz MS, Lab Patol, IOC, BR-21045900 Rio De Janeiro, Brazil.
   [Atella, Georgia C.] Univ Fed Rio de Janeiro, Inst Microbiol, Inst Bioquim Med, BR-21941 Rio De Janeiro, Brazil.
   [Bozza, Marcelo T.] Univ Fed Rio de Janeiro, Inst Microbiol, Dept Imunol, BR-21941 Rio De Janeiro, Brazil.
RP Bozza, PT (corresponding author), Fiocruz MS, Lab Imunofarmacol, IOC, Av Brasil 4365, BR-21045900 Rio De Janeiro, Brazil.
EM pbozza@ioc.fiocruz.br
RI Magalhaes, Kelly Grace/L-6081-2019; Atella, Georgia/AAK-7897-2020;
   Magalhaes, Kelly G/A-6966-2010
OI Magalhaes, Kelly Grace/0000-0002-7435-5272; Magalhaes, Kelly
   G/0000-0002-7435-5272; Pelajo Machado, Marcelo/0000-0002-7295-7018;
   Almeida, Patricia Elaine de/0000-0002-9081-8601; Bozza,
   Marcelo/0000-0003-3683-7550; Bozza, Patricia/0000-0001-8349-9529
FU PAPES-FIOCRUZ, Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq, Brazil)National Council for Scientific and
   Technological Development (CNPq); Fundacao de Amparo a Pesquisa do Rio
   de Janeiro (FAPERJ, Brazil)Carlos Chagas Filho Foundation for Research
   Support of the State of Rio de Janeiro (FAPERJ)
FX PAPES-FIOCRUZ, Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq, Brazil); Fundacao de Amparo a Pesquisa do Rio de
   Janeiro (FAPERJ, Brazil).
CR Aksoy E, 2005, J BIOL CHEM, V280, P277, DOI 10.1074/jbc.M411223200
   Akuthota P, 2008, CLIN EXP ALLERGY, V38, P1254, DOI 10.1111/j.1365-2222.2008.03037.x
   Behm CA, 2000, PARASITOL TODAY, V16, P202, DOI 10.1016/S0169-4758(99)01620-8
   BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911
   Bozza PT, 2007, PHARMACOL THERAPEUT, V113, P30, DOI 10.1016/j.pharmthera.2006.06.006
   BOZZA PT, 1993, EUR J PHARM-ENVIRON, V248, P41, DOI 10.1016/0926-6917(93)90023-J
   Brouwers JFHM, 1998, MOL BIOCHEM PARASIT, V96, P49, DOI 10.1016/S0166-6851(98)00103-0
   Cabrera-Vera TM, 2003, ENDOCR REV, V24, P765, DOI 10.1210/er.2000-0026
   Chiaramonte MG, 1999, J IMMUNOL, V162, P920
   D'Avila H, 2007, INFECT IMMUN, V75, P1507, DOI 10.1128/IAI.01326-06
   DAVID JR, 1980, AM J TROP MED HYG, V29, P842, DOI 10.4269/ajtmh.1980.29.842
   Davies SJ, 2005, INT J PARASITOL, V35, P851, DOI 10.1016/j.ijpara.2005.02.017
   de Jesus AR, 2004, INFECT IMMUN, V72, P3391, DOI 10.1128/IAI.72.6.3391-3397.2004
   Duraes FV, 2009, IMMUNOL LETT, V125, P72, DOI 10.1016/j.imlet.2009.06.004
   FURLONG ST, 1989, EXP PARASITOL, V69, P65, DOI 10.1016/0014-4894(89)90172-0
   FURLONG ST, 1988, EXP PARASITOL, V65, P222, DOI 10.1016/0014-4894(88)90126-9
   Golodne DM, 2003, J BIOL CHEM, V278, P27766, DOI 10.1074/jbc.M212421200
   Graler MH, 2002, BBA-MOL CELL BIOL L, V1582, P168, DOI 10.1016/S1388-1981(02)00152-X
   Herbert DR, 2008, J IMMUNOL, V180, P4948, DOI 10.4049/jimmunol.180.7.4948
   Hogan SP, 2008, CLIN EXP ALLERGY, V38, P709, DOI 10.1111/j.1365-2222.2008.02958.x
   Ishii I, 2004, ANNU REV BIOCHEM, V73, P321, DOI 10.1146/annurev.biochem.73.011303.073731
   Jankovic D, 1999, J IMMUNOL, V163, P337
   Jenkins SJ, 2005, INT IMMUNOL, V17, P1409, DOI 10.1093/intimm/dxh319
   Kane CM, 2008, INFECT IMMUN, V76, P5754, DOI 10.1128/IAI.00497-08
   Kaplan MH, 1998, J IMMUNOL, V160, P1850
   Klion AD, 2004, J ALLERGY CLIN IMMUN, V113, P30, DOI 10.1016/j.jaci.2003.10.050
   Layland LE, 2007, EUR J IMMUNOL, V37, P2174, DOI 10.1002/eji.200737063
   Layland LE, 2005, EUR J IMMUNOL, V35, P3248, DOI 10.1002/eji.200526273
   LENZI H L, 1987, Memorias do Instituto Oswaldo Cruz, V82, P67, DOI 10.1590/S0074-02761987000800011
   Magalhaes ES, 2009, FASEB J, V23, P1262, DOI 10.1096/fj.08-124248
   MOLONEY NA, 1982, T ROY SOC TROP MED H, V76, P200, DOI 10.1016/0035-9203(82)90274-7
   Moolenaar WH, 1999, EXP CELL RES, V253, P230, DOI 10.1006/excr.1999.4702
   Pearce EJ, 2004, IMMUNOL REV, V201, P117, DOI 10.1111/j.0105-2896.2004.00187.x
   Penido C, 2001, AM J RESP CELL MOL, V25, P707, DOI 10.1165/ajrcmb.25.6.4401
   Ramalingam TR, 2005, CURR OPIN ALLERGY CL, V5, P392, DOI 10.1097/01.all.0000182542.30100.6f
   Reiman RM, 2006, INFECT IMMUN, V74, P1471, DOI 10.1128/IAI.74.3.1471-1479.2006
   Sabin EA, 1996, J EXP MED, V184, P1871, DOI 10.1084/jem.184.5.1871
   SHER A, 1990, P NATL ACAD SCI USA, V87, P61, DOI 10.1073/pnas.87.1.61
   Silveira-Lemos D, 2008, ACTA TROP, V108, P150, DOI 10.1016/j.actatropica.2008.04.006
   Spencer LA, 2006, P NATL ACAD SCI USA, V103, P3333, DOI 10.1073/pnas.0508946103
   Spencer LA, 2009, J LEUKOCYTE BIOL, V85, P117, DOI 10.1189/jlb.0108058
   Swartz JM, 2006, BLOOD, V108, P2420, DOI 10.1182/blood-2006-04-015933
   Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3
   Torkhovskaya TI, 2007, BIOCHEMISTRY-MOSCOW+, V72, P125, DOI 10.1134/S0006297907020010
   van der Kleij D, 2003, EUR J IMMUNOL, V33, P2953, DOI 10.1002/eji.200324340
   van der Kleij D, 2002, J BIOL CHEM, V277, P48122, DOI 10.1074/jbc.M206941200
   Van Hellemond JJ, 2006, INT J PARASITOL, V36, P691, DOI 10.1016/j.ijpara.2006.01.007
   Vanhoutte F, 2007, MICROBES INFECT, V9, P1606, DOI 10.1016/j.micinf.2007.09.013
   Vieira-De-Abreu A, 2005, AM J RESP CELL MOL, V33, P254, DOI 10.1165/rcmb.2005-0145OC
   Wynn TA, 2004, IMMUNOL REV, V201, P156, DOI 10.1111/j.0105-2896.2004.00176.x
NR 50
TC 37
Z9 38
U1 0
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD NOV 1
PY 2010
VL 202
IS 9
BP 1369
EP 1379
DI 10.1086/656477
PG 11
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 656VB
UT WOS:000282367900011
PM 20863227
OA Green Published, Bronze
DA 2020-12-15
ER

PT J
AU Taha, MO
   Goncalves, PF
   Vidigal, RO
   Sacchi, GP
   Pinheiro, FG
   Brandao, LS
   Feguri, S
   Moraes, AM
   Ghadie, MM
   Magalhaes, KG
   Simoes, MJ
   Tersariol, IL
   Monteiro, HP
   Oliveira, I
   Jurkiewicz, A
   Caricati-Neto, A
AF Taha, M. O.
   Goncalves, P. F.
   Vidigal, R. O.
   Sacchi, G. P.
   Pinheiro, F. G.
   Brandao, L. S.
   Feguri, S.
   Moraes-Filho, A. M.
   Ghadie, M. M.
   Magalhaes, K. G.
   Simoes, M. J.
   Tersariol, I. L.
   Monteiro, H. P.
   Oliveira, I., Jr.
   Jurkiewicz, A.
   Caricati-Neto, A.
TI Protective effects of heparin on hepatic ischemia and reperfusion
   lesions in rabbits (vol 41, pg 812, 2009)
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Correction
RI Tersariol, Ivarne Luiz Dos Santos/G-4042-2012; Monteiro,
   Hugo/C-8836-2012; Simoes, Manuel J/H-2642-2014; Taha,
   Murched/G-2731-2012
OI Tersariol, Ivarne Luiz Dos Santos/0000-0002-8399-4535; Simoes, Manuel
   J/0000-0003-2770-8618; 
CR Taha MO, 2009, TRANSPL P, V41, P812, DOI 10.1016/j.transproceed.2009.02.042
NR 1
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD MAY
PY 2010
VL 42
IS 4
BP 1385
EP 1386
DI 10.1016/j.transproceed.2010.04.004
PG 2
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 607JH
UT WOS:000278498000103
DA 2020-12-15
ER

PT J
AU Taha, MO
   Simoes, MJ
   Mendonca, MV
   Lugo, FR
   Carmo, R
   Lazarini, JL
   Bessa, MZ
   Marconi, TD
   Magalhaes, KG
   Soares, JH
   Tersariol, IL
   Monteiro, HP
   Oliveira, I
   Jurkiewicz, A
   Caricati-Neto, A
AF Taha, M. O.
   Simoes, M. J.
   Mendonca, M., V
   Lugo, F. R.
   Carmo-Filho, R.
   Lazarini, J. L., Jr.
   Bessa, M. Z.
   Marconi, T. D.
   Magalhaes, K. G.
   Soares, J. H.
   Tersariol, I. L.
   Monteiro, H. P.
   Oliveira, I., Jr.
   Jurkiewicz, A.
   Caricati-Neto, A.
TI Role of purines on hepatic ischemia-reperfusion lesions in rabbit (vol
   41, pg 807, 2009)
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Correction
RI Simoes, Manuel J/H-2642-2014; Monteiro, Hugo/C-8836-2012; Tersariol,
   Ivarne Luiz Dos Santos/G-4042-2012; Taha, Murched/G-2731-2012
OI Simoes, Manuel J/0000-0003-2770-8618; Tersariol, Ivarne Luiz Dos
   Santos/0000-0002-8399-4535; 
CR Taha MO, 2009, TRANSPL P, V41, P807, DOI 10.1016/j.transproceed.2009.01.057
NR 1
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD MAY
PY 2010
VL 42
IS 4
BP 1385
EP 1386
DI 10.1016/j.transproceed.2010.04.005
PG 2
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 607JH
UT WOS:000278498000104
DA 2020-12-15
ER

PT J
AU Taha, MO
   Simoes, MJ
   Haddad, MA
   Capelato, RC
   Budny, N
   Matsumoto, AH
   Soares, PC
   Santos, WM
   Armeato, GD
   Araki, CM
   Gomes, JS
   Magalhaes, KG
   Tersariol, IL
   Monteiro, HP
   Oliveira, I
   Jurkiewicz, A
   Caricati-Neto, A
AF Taha, M. O.
   Simoes, M. J.
   Haddad, M. A.
   Capelato, R. C.
   Budny, N.
   Matsumoto, A. H.
   Soares, P. C.
   Santos, W. M.
   Armeato, G. D.
   Araki, C. M.
   Gomes, J. S.
   Magalhaes, K. G.
   Tersariol, I. L.
   Monteiro, H. P.
   Oliveira, I., Jr.
   Jurkiewicz, A.
   Caricati-Neto, A.
TI L-Arginine supplementation protects against hepatic ischemia-reperfusion
   lesions in rabbits (vol 41, pg 816, 2009)
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Correction
RI Oliveira-Junior, Itamar Souza/D-7593-2013; Monteiro, Hugo/C-8836-2012;
   Simoes, Manuel J/H-2642-2014; Tersariol, Ivarne Luiz Dos
   Santos/G-4042-2012; Taha, Murched/G-2731-2012
OI Oliveira-Junior, Itamar Souza/0000-0003-0849-9734; Simoes, Manuel
   J/0000-0003-2770-8618; Tersariol, Ivarne Luiz Dos
   Santos/0000-0002-8399-4535; 
CR Taha MO, 2009, TRANSPL P, V41, P816, DOI 10.1016/j.transproceed.2009.02.050
NR 1
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD MAY
PY 2010
VL 42
IS 4
BP 1385
EP 1386
DI 10.1016/j.transproceed.2010.04.003
PG 2
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 607JH
UT WOS:000278498000102
DA 2020-12-15
ER

PT J
AU Taha, MO
   Simoes, MJ
   Noguerol, EC
   Mendonca, FP
   Pascoalick, HM
   Alves, RA
   Vivian, ME
   Morales, FP
   Campos, AC
   Magalhaes, KG
   Venerando, PS
   Tersariol, IL
   Monteiro, HP
   Oliveira, I
   Jurkiewicz, A
   Caricati-Neto, A
AF Taha, M. O.
   Simoes, M. J.
   Noguerol, E. C.
   Mendonca, F. P.
   Pascoalick, H. M.
   Alves, R. A.
   Vivian, M. E.
   Morales, F. P.
   Campos, A. C.
   Magalhaes, K. G.
   Venerando, P. S.
   Tersariol, I. L.
   Monteiro, H. P.
   Oliveira, I., Jr.
   Jurkiewicz, A.
   Caricati-Neto, A.
TI Effects of allopurinol on ischemia and reperfusion in rabbit livers (vol
   41, pg 820, 2009)
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Correction
RI Simoes, Manuel J/H-2642-2014; Monteiro, Hugo/C-8836-2012;
   Oliveira-Junior, Itamar Souza/D-7593-2013; Tersariol, Ivarne Luiz Dos
   Santos/G-4042-2012; Taha, Murched/G-2731-2012
OI Simoes, Manuel J/0000-0003-2770-8618; Oliveira-Junior, Itamar
   Souza/0000-0003-0849-9734; Tersariol, Ivarne Luiz Dos
   Santos/0000-0002-8399-4535; 
CR Taha MO, 2009, TRANSPL P, V41, P820, DOI 10.1016/j.transproceed.2009.02.051
NR 1
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD MAY
PY 2010
VL 42
IS 4
BP 1385
EP 1386
DI 10.1016/j.transproceed.2010.04.002
PG 2
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 607JH
UT WOS:000278498000101
DA 2020-12-15
ER

PT J
AU Gimenez, G
   Magalhaes, KG
   Belaunzaran, ML
   Poncini, CV
   Lammel, EM
   Cappa, SMG
   Bozza, PT
   Isola, ELD
AF Gimenez, G.
   Magalhaes, K. G.
   Belaunzaran, M. L.
   Poncini, C. V.
   Lammel, E. M.
   Gonzalez Cappa, S. M.
   Bozza, P. T.
   Isola, E. L. D.
TI Lipids from attenuated and virulent Babesia bovis strains induce
   differential TLR2-mediated macrophage activation
SO MOLECULAR IMMUNOLOGY
LA English
DT Article
DE Lipids; Babesia bovis; TLR2; Macrophages
ID NECROSIS-FACTOR-ALPHA; PROTEIN-KINASE ACTIVITY; TOLL-LIKE RECEPTORS;
   IN-VIVO; MYCOBACTERIUM-TUBERCULOSIS; INTRACELLULAR DOMAINS; EICOSANOID
   FORMATION; SIGNAL-TRANSDUCTION; BODY INDUCTION; TNF-ALPHA
AB Babesia bovis is an intraerythrocytic apicomplexan protozoa of cattle that causes an acute infection with parasite persistence. Babesiosis limitation depends on macrophages, essential effector cells of the host innate defense, which generate inflammatory cytokines and nitric oxide. Herein, we report quantitative differences in the lipid composition of merozoites from two B. bovis strains with polar behaviour: attenuated R1A and virulent S2P. Accordingly, we observed a distinct inflammatory response induced by the total lipids of R1A (L(A)) and S2P (L(V)) in murine peritoneal macrophages. L(A) and particularly its fractions phosphatidic acid and phosphatidylserine + phosphatidylinositol (PS + PI), produced a strong activation of these cells with lipid body formation, cyclooxygenase-2 expression and pro-inflammatory TNF alpha, IL-6 and KC secretion. Although L(V) did not activate these cells, the corresponding PS+PI fraction induced TNF alpha, IL-6 and KC release. Therefore, these facts might be suggesting the presence of an inhibitor in L(V). Furthermore, the employment of wild type and toll like receptor 2 knockout (TLP2KO) mice allowed us to demonstrate that macrophage activation by the stimulating lipid fractions was mediated through TLR2. Interestingly, only L(A) activated the extracellular signal-regulated kinases I and 2 (ERK1/2). Inhibitory studies employing UO126, indicated that the ERK pathway was required for TNF alpha, IL-6 and KC release. In conclusion, the absence of inflammatory response observed with the lipids of S2P virulent strain could constitute an evasion mechanism of the innate immune response enabling parasite establishment in the host. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Gimenez, G.; Belaunzaran, M. L.; Poncini, C. V.; Lammel, E. M.; Gonzalez Cappa, S. M.; Isola, E. L. D.] Univ Buenos Aires, Fac Med, Dept Microbiol Parasitol & Inmunol, RA-1121 Buenos Aires, DF, Argentina.
   [Magalhaes, K. G.; Bozza, P. T.] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Imunofarmacol, Rio De Janeiro, Brazil.
RP Gimenez, G (corresponding author), Univ Buenos Aires, Fac Med, Dept Microbiol Parasitol & Inmunol, Paraguay 2155 Piso 13, RA-1121 Buenos Aires, DF, Argentina.
EM paradife@fmed.uba.ar
RI Magalhaes, Kelly G/A-6966-2010; Magalhaes, Kelly Grace/L-6081-2019
OI Magalhaes, Kelly G/0000-0002-7435-5272; Magalhaes, Kelly
   Grace/0000-0002-7435-5272; Bozza, Patricia/0000-0001-8349-9529; poncini,
   carolina/0000-0003-3419-8062
FU Agencia Nacional cle Promocion Cientifica y Tecnologica
   (FONCYT)ANPCyTFONCyT; Consejo Nacional de Investigaciones Cientificas y
   Tocnicas (CONICET)Consejo Nacional de Investigaciones Cientificas y
   Tecnicas (CONICET); Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq)National Council for Scientific and Technological
   Development (CNPq); Funda o de Amparo A Pesquisa do Estado do Rio cle
   Janeiro (FAPERJ), BrazilCarlos Chagas Filho Foundation for Research
   Support of the State of Rio de Janeiro (FAPERJ)
FX We are indebted to Dr. I. Echaide (Instituto Nacional de Tecnologia
   Agropecuaria, Rafaela, Santa Fe, Argentina) for providing B. bovis
   cultures. We thank Dr. S. Akira (Department of Host Defense, Research
   Institute for Microbial Disease, Osakajapan) for providing the TLR2KO
   mice. This work was supported by grants from Agencia Nacional cle
   Promocion Cientifica y Tecnologica (FONCYT) and Consejo Nacional de
   Investigaciones Cientificas y Tocnicas (CONICET), Argentina and from
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) and
   Funda o de Amparo A Pesquisa do Estado do Rio cle Janeiro (FAPERJ),
   Brazil.
CR Akira S, 2003, J BIOL CHEM, V278, P38105, DOI 10.1074/jbc.R300028200
   Almeida PE, 2009, J IMMUNOL, V183, P1337, DOI 10.4049/jimmunol.0900365
   Anziani O. S., 1993, Revista de Medicina Veterinaria (Buenos Aires), V74, P47
   BARON CB, 1984, P NATL ACAD SCI-BIOL, V81, P6899, DOI 10.1073/pnas.81.21.6899
   BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911
   Bozza PT, 2009, BBA-MOL CELL BIOL L, V1791, P540, DOI 10.1016/j.bbalip.2009.01.005
   Bozza PT, 1997, J EXP MED, V186, P909, DOI 10.1084/jem.186.6.909
   Bozza PT, 1998, J LEUKOCYTE BIOL, V64, P563
   Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732
   Brown WC, 1999, PARASITOL TODAY, V15, P275, DOI 10.1016/S0169-4758(99)01471-4
   D'Avila H, 2008, INT IMMUNOPHARMACOL, V8, P1308, DOI 10.1016/j.intimp.2008.01.035
   D'Avila H, 2006, J IMMUNOL, V176, P3087, DOI 10.4049/jimmunol.176.5.3087
   Debierre-Grockiego F, 2006, INFECT IMMUN, V74, P5487, DOI 10.1128/IAI.01934-05
   DVORAK AM, 1993, INT ARCH ALLERGY IMM, V101, P136, DOI 10.1159/000236511
   Fell AH, 1998, PARASITOL TODAY, V14, P364, DOI 10.1016/S0169-4758(98)01298-8
   Florin-Christensen J, 2000, MOL BIOCHEM PARASIT, V106, P147, DOI 10.1016/S0166-6851(99)00209-1
   GOODGER BV, 1990, INT J PARASITOL, V20, P685, DOI 10.1016/0020-7519(90)90129-B
   Lasker MV, 2006, J IMMUNOL, V177, P11, DOI 10.4049/jimmunol.177.1.11
   LEE J, 1995, J IMMUNOL, V155, P2158
   LEVY MG, 1980, SCIENCE, V207, P1218, DOI 10.1126/science.7355284
   MANGOLD AJ, 1993, VET PARASITOL, V51, P143, DOI 10.1016/0304-4017(93)90205-2
   Martin S, 2006, NAT REV MOL CELL BIO, V7, P373, DOI 10.1038/nrm1912
   Means TK, 1999, J IMMUNOL, V163, P3920
   Melo RCN, 2003, TISSUE CELL, V35, P59, DOI 10.1016/S0040-8166(02)00105-2
   Murphy DJ, 2001, PROG LIPID RES, V40, P325, DOI 10.1016/S0163-7827(01)00013-3
   Nebl T, 2005, PARASITOLOGY, V130, pS45, DOI 10.1017/S0031182005008152
   Osterud B, 2003, PHYSIOL REV, V83, P1069, DOI 10.1152/physrev.00005.2003
   Pacheco P, 2002, J IMMUNOL, V169, P6498, DOI 10.4049/jimmunol.169.11.6498
   PAWLOWSKI NA, 1983, J EXP MED, V158, P393, DOI 10.1084/jem.158.2.393
   Quesniaux VJ, 2004, J IMMUNOL, V172, P4425, DOI 10.4049/jimmunol.172.7.4425
   Ramsay RG, 2003, INT J IMMUNOPATH PH, V16, P59
   Reiling N, 2001, J IMMUNOL, V167, P3339, DOI 10.4049/jimmunol.167.6.3339
   Riedel DD, 2000, MICROBES INFECT, V2, P463, DOI 10.1016/S1286-4579(00)00319-1
   Roach SK, 2002, INFECT IMMUN, V70, P3040, DOI 10.1128/IAI.70.6.3040-3052.2002
   ROACH TIA, 1993, J IMMUNOL, V150, P1886
   Ruckdeschel K, 1997, J BIOL CHEM, V272, P15920, DOI 10.1074/jbc.272.25.15920
   SCHOFIELD L, 1993, J EXP MED, V177, P145, DOI 10.1084/jem.177.1.145
   Shoda LKM, 2000, INFECT IMMUN, V68, P5139, DOI 10.1128/IAI.68.9.5139-5145.2000
   Surewicz K, 2004, CELL IMMUNOL, V228, P34, DOI 10.1016/j.cellimm.2004.03.007
   Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3
   Tauchi-Sato K, 2002, J BIOL CHEM, V277, P44507, DOI 10.1074/jbc.M207712200
   Tsatsanis C, 2006, INT J BIOCHEM CELL B, V38, P1654, DOI 10.1016/j.biocel.2006.03.021
   Underhill DM, 1999, NATURE, V401, P811, DOI 10.1038/44605
   van Meer G, 2001, J CELL BIOL, V152, pF29, DOI 10.1083/jcb.152.5.F29
   WRIGHT IG, 1988, PARASITOL TODAY, V4, P214, DOI 10.1016/0169-4758(88)90161-5
   Yadav M, 2004, J IMMUNOL, V172, P5588, DOI 10.4049/jimmunol.172.9.5588
   Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X
NR 47
TC 9
Z9 9
U1 0
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0161-5890
J9 MOL IMMUNOL
JI Mol. Immunol.
PD JAN
PY 2010
VL 47
IS 4
BP 747
EP 755
DI 10.1016/j.molimm.2009.10.014
PG 9
WC Biochemistry & Molecular Biology; Immunology
SC Biochemistry & Molecular Biology; Immunology
GA 555JS
UT WOS:000274507400016
PM 19910051
DA 2020-12-15
ER

PT J
AU Bozza, PT
   D'Avila, H
   Almeida, PE
   Magalhaes, KG
   Molinaro, R
   Almeida, CJ
   Maya-Monteiro, CM
AF Bozza, Patricia T.
   D'Avila, Heloisa
   Almeida, Patricia E.
   Magalhaes, Kelly G.
   Molinaro, Raphael
   Almeida, Cecilia J.
   Maya-Monteiro, Clarissa M.
TI Lipid droplets in host-pathogen interactions
SO CLINICAL LIPIDOLOGY
LA English
DT Review
DE eicosanoids; inflammation; intracellular pathogen; lipid bodies; lipid
   droplet; LPS; nuclear receptor; sepsis; tuberculosis
ID PROLIFERATOR-ACTIVATED RECEPTOR; DIFFERENTIATION-RELATED PROTEIN;
   ENDOPEROXIDE SYNTHASE CYCLOOXYGENASE; ULTRASTRUCTURAL IMMUNOGOLD
   LOCALIZATION; MACROPHAGE-GENE-EXPRESSION; BODY FORMATION; IN-VIVO;
   FATTY-ACIDS; PPAR-GAMMA; FACTOR ACETYLHYDROLASE
AB Increased cytoplasmic lipid droplets (also known as lipid bodies or adiposomes) in nonadipocytic cells are commonly observed pathological features of a number of infectious diseases. Although the understanding of the functional significance of lipid droplets to host-pathogen interactions and microbial pathogenesis is still very limited, great advances in this growing field have been made in the past few years. Here, we review the recent findings that are starting to uncover the molecular mechanisms that regulate lipid accumulation into lipid droplets and the functions that this organelle may play during infection, with an emphasis on the potential implications of lipid droplets on human infectious diseases.
C1 [Bozza, Patricia T.; Almeida, Patricia E.; Magalhaes, Kelly G.; Molinaro, Raphael; Almeida, Cecilia J.; Maya-Monteiro, Clarissa M.] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Imunofarmacol, BR-21045900 Rio De Janeiro, Brazil.
   [D'Avila, Heloisa] Univ Fed Juiz, Juiz, Brazil.
RP Bozza, PT (corresponding author), Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Imunofarmacol, Av Brasil,4365 Manguinhos, BR-21045900 Rio De Janeiro, Brazil.
EM pbozza@ioc.fiocruz.br
RI Magalhaes, Kelly Grace/L-6081-2019; maya-monteiro, clarissa/A-9091-2010;
   Molinaro, Raphael RMC/H-4357-2012; Magalhaes, Kelly G/A-6966-2010
OI Magalhaes, Kelly Grace/0000-0002-7435-5272; Magalhaes, Kelly
   G/0000-0002-7435-5272; Almeida, Patricia Elaine de/0000-0002-9081-8601;
   Bozza, Patricia/0000-0001-8349-9529
FU PRONEX-MCT; Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq, Brazil)National Council for Scientific and
   Technological Development (CNPq); PAPES-FIOCRUZ; Fundacao de Amparo a
   Pesquisa do Rio de Janeiro (FAPERJ, Brazil)Carlos Chagas Filho
   Foundation for Research Support of the State of Rio de Janeiro (FAPERJ)
FX The work of the authors is supported by PRONEX-MCT, Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq, Brazil), PAPES-FIOCRUZ,
   Fundacao de Amparo a Pesquisa do Rio de Janeiro (FAPERJ, Brazil). The
   authors have no other relevant affiliations or dfinancial involvement
   with any organization or entity with a financial interest in orfinancial
   conflict with the subject matter or materials discussed in the
   manuscript apart from those disclosed.
CR Accioly MT, 2008, CANCER RES, V68, P1732, DOI 10.1158/0008-5472.CAN-07-1999
   Aliberti J, 2005, PROSTAG LEUKOTR ESS, V73, P283, DOI 10.1016/j.plefa.2005.05.018
   Almeida PE, 2009, J IMMUNOL, V183, P1337, DOI 10.4049/jimmunol.0900365
   Anderson RGW, 2002, SCIENCE, V296, P1821, DOI 10.1126/science.1068886
   Arend A, 2004, PROSTAG OTH LIPID M, V74, P1, DOI 10.1016/j.prostaglandins.2004.05.002
   Assuncao-Miranda I, 2010, FASEB J, V24, P218, DOI 10.1096/fj.09-139469
   Bandeira-Melo C, 2003, PROSTAG LEUKOTR ESS, V69, P135, DOI 10.1016/S0952-3278(03)00074-7
   Bandeira-Melo C, 2001, J BIOL CHEM, V276, P22779, DOI 10.1074/jbc.M101436200
   BANDEIRAMELO C, 2010, METHODS MOL IN PRESS
   BEIL WJ, 1995, J LEUKOCYTE BIOL, V58, P284
   Beller M, 2006, MOL CELL PROTEOMICS, V5, P1082, DOI 10.1074/mcp.M600011-MCP200
   Bickel PE, 2009, BBA-MOL CELL BIOL L, V1791, P419, DOI 10.1016/j.bbalip.2009.04.002
   Binns D, 2006, J CELL BIOL, V173, P719, DOI 10.1083/jcb.200511125
   Bostrom P, 2007, NAT CELL BIOL, V9, P1286, DOI 10.1038/ncb1648
   Bozza PT, 2007, PHARMACOL THERAPEUT, V113, P30, DOI 10.1016/j.pharmthera.2006.06.006
   Bozza PT, 2009, BBA-MOL CELL BIOL L, V1791, P540, DOI 10.1016/j.bbalip.2009.01.005
   Bozza PT, 1997, J EXP MED, V186, P909, DOI 10.1084/jem.186.6.909
   Bozza PT, 1996, P NATL ACAD SCI USA, V93, P11091, DOI 10.1073/pnas.93.20.11091
   Bozza PT, 1996, J EXP MED, V183, P1515, DOI 10.1084/jem.183.4.1515
   Bozza PT, 1998, J LEUKOCYTE BIOL, V64, P563
   Brasaemle DL, 2007, J LIPID RES, V48, P2547, DOI 10.1194/jlr.R700014-JLR200
   Brasaemle DL, 2004, J BIOL CHEM, V279, P46835, DOI 10.1074/jbc.M409340200
   Brasaemle DL, 1997, J LIPID RES, V38, P2249
   Brown DA, 2001, CURR BIOL, V11, pR446, DOI 10.1016/S0960-9822(01)00257-3
   Caceres N, 2009, TUBERCULOSIS, V89, P175, DOI 10.1016/j.tube.2008.11.001
   Cao F, 2007, INFECT IMMUN, V75, P753, DOI 10.1128/IAI.01386-06
   Cardona PJ, 2000, SCAND J IMMUNOL, V52, P156, DOI 10.1046/j.1365-3083.2000.00763.x
   Castrillo A, 2003, MOL CELL, V12, P805, DOI 10.1016/S1097-2765(03)00384-8
   Cermelli S, 2006, CURR BIOL, V16, P1783, DOI 10.1016/j.cub.2006.07.062
   Charron AJ, 2002, J CELL SCI, V115, P3049
   Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866
   Chawla A, 2001, NAT MED, V7, P48
   Chen JS, 2002, J CELL BIOCHEM, V86, P784, DOI 10.1002/jcb.10266
   Chung SY, 2005, J LIPID RES, V46, P885, DOI 10.1194/jlr.M400476-JLR200
   Cocchiaro JL, 2008, P NATL ACAD SCI USA, V105, P9379, DOI 10.1073/pnas.0712241105
   Combs TP, 2005, J BIOL CHEM, V280, P24085, DOI 10.1074/jbc.M412802200
   Coppens I, 2005, INT J PARASITOL, V35, P597, DOI 10.1016/j.ijpara.2005.01.009
   Coppens I, 2006, CELL MICROBIOL, V8, P1, DOI 10.1111/j.1462-5822.2005.00647.x
   Soares JBR, 2007, FEBS LETT, V581, P1742, DOI 10.1016/j.febslet.2007.03.054
   Cruz D, 2008, J CLIN INVEST, V118, P2917, DOI 10.1172/JCI34189
   D'Avila H, 2008, CELL MICROBIOL, V10, P2589, DOI 10.1111/j.1462-5822.2008.01233.x
   D'Avila H, 2008, INT IMMUNOPHARMACOL, V8, P1308, DOI 10.1016/j.intimp.2008.01.035
   D'Avila H, 2007, INFECT IMMUN, V75, P1507, DOI 10.1128/IAI.01326-06
   D'Avila H, 2006, J IMMUNOL, V176, P3087, DOI 10.4049/jimmunol.176.5.3087
   Dalen KT, 2007, BBA-MOL CELL BIOL L, V1771, P210, DOI 10.1016/j.bbalip.2006.11.011
   de Assis EF, 2003, J IMMUNOL, V171, P2090, DOI 10.4049/jimmunol.171.4.2090
   Deretic V, 2009, CELL HOST MICROBE, V5, P527, DOI 10.1016/j.chom.2009.05.016
   Diaz BL, 2003, PROSTAG LEUKOTR ESS, V69, P87, DOI 10.1016/S0952-3278(03)00069-3
   Dvorak AM, 2003, HISTOL HISTOPATHOL, V18, P943, DOI 10.14670/HH-18.943
   Dvorak AM, 2001, HISTOCHEM J, V33, P397, DOI 10.1023/A:1013771827069
   DVORAK AM, 1994, INT ARCH ALLERGY IMM, V105, P245
   DVORAK AM, 1992, J HISTOCHEM CYTOCHEM, V40, P759, DOI 10.1177/40.6.1316915
   DVORAK AM, 1993, INT ARCH ALLERGY IMM, V101, P136, DOI 10.1159/000236511
   Dvorak Ann M, 2005, Chem Immunol Allergy, V85, P252
   Fan YY, 2004, J IMMUNOL, V173, P6151, DOI 10.4049/jimmunol.173.10.6151
   Fan YY, 2003, J NUTR, V133, P1913
   Flynn JL, 2001, ANNU REV IMMUNOL, V19, P93, DOI 10.1146/annurev.immunol.19.1.93
   Freire-de-Lima CG, 2000, NATURE, V403, P199, DOI 10.1038/35003208
   Fujimoto T, 2001, J CELL BIOL, V152, P1079, DOI 10.1083/jcb.152.5.1079
   Fujimoto T, 2006, AUTOPHAGY, V2, P299, DOI 10.4161/auto.2904
   Fujimoto Y, 2004, BBA-MOL CELL RES, V1644, P47, DOI 10.1016/j.bbamcr.2003.10.018
   FURLONG ST, 1995, J LIPID RES, V36, P1
   Gao J, 1999, J BIOL CHEM, V274, P16825, DOI 10.1074/jbc.274.24.16825
   GEARING KL, 1993, P NATL ACAD SCI USA, V90, P1440, DOI 10.1073/pnas.90.4.1440
   Gobert GN, 1997, PARASITOLOGY, V115, P33, DOI 10.1017/S0031182097008925
   Gomes RN, 2006, SHOCK, V26, P41, DOI 10.1097/01.shk.0000209562.00070.1a
   GREENBERG AS, 1991, J BIOL CHEM, V266, P11341
   Gronke S, 2003, CURR BIOL, V13, P603, DOI 10.1016/S0960-9822(03)00175-1
   Gross DN, 2006, MOL ENDOCRINOL, V20, P459, DOI 10.1210/me.2005-0323
   Guo Y, 2009, J CELL SCI, V122, P749, DOI 10.1242/jcs.037630
   Heid HW, 1998, CELL TISSUE RES, V294, P309, DOI 10.1007/s004410051181
   Imamura M, 2002, AM J PHYSIOL-ENDOC M, V283, pE775, DOI 10.1152/ajpendo.00040.2002
   Ishii KJ, 2008, CELL HOST MICROBE, V3, P352, DOI 10.1016/j.chom.2008.05.003
   Jackson KE, 2004, MOL MICROBIOL, V54, P109, DOI 10.1111/j.1365-2958.2004.04284.x
   KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160
   Kondo H, 2008, TOHOKU J EXP MED, V214, P167, DOI 10.1620/tjem.214.167
   Kumar Y, 2006, CURR BIOL, V16, P1646, DOI 10.1016/j.cub.2006.06.060
   Larigauderie G, 2004, ARTERIOSCL THROM VAS, V24, P504, DOI 10.1161/01.ATV.0000115638.27381.97
   Leite MS, 2005, SHOCK, V23, P173, DOI 10.1097/01.shk.0000148072.12094.77
   Lim KG, 1996, J IMMUNOL, V156, P2566
   Liu PS, 2004, J BIOL CHEM, V279, P3787, DOI 10.1074/jbc.M311945200
   Londos C, 2005, BIOCHIMIE, V87, P45, DOI 10.1016/j.biochi.2004.12.010
   Luo MK, 2005, NAT CHEM BIOL, V1, P149, DOI 10.1038/nchembio717
   Ma DWL, 2004, FASEB J, V18, P1040, DOI 10.1096/fj.03-1430fje
   Mandal AK, 2004, P NATL ACAD SCI USA, V101, P6587, DOI 10.1073/pnas.0308523101
   Martin S, 2006, NAT REV MOL CELL BIO, V7, P373, DOI 10.1038/nrm1912
   Martin S, 2005, J BIOL CHEM, V280, P42325, DOI 10.1074/jbc.M506651200
   MATTOS KA, 2010, J LEUKOC BI IN PRESS
   Maya-Monteiro CM, 2008, CELL CYCLE, V7, P1713, DOI 10.4161/cc.7.12.6157
   Maya-Monteiro CM, 2008, J BIOL CHEM, V283, P2203, DOI 10.1074/jbc.M706706200
   MCGOOKEY DJ, 1983, J CELL BIOL, V97, P1156, DOI 10.1083/jcb.97.4.1156
   McLauchlan J, 2009, BBA-MOL CELL BIOL L, V1791, P552, DOI 10.1016/j.bbalip.2008.12.012
   Meadows JW, 2005, J CLIN ENDOCR METAB, V90, P2344, DOI 10.1210/jc.2004-1199
   Means TK, 1999, J IMMUNOL, V163, P3920
   Means TK, 2001, J IMMUNOL, V166, P4074, DOI 10.4049/jimmunol.166.6.4074
   Melo RCN, 2006, INFLAMM RES, V55, P342, DOI 10.1007/s00011-006-5205-0
   Melo RCN, 2003, TISSUE CELL, V35, P59, DOI 10.1016/S0040-8166(02)00105-2
   MEYER F, 1970, BIOCHIM BIOPHYS ACTA, V210, P257, DOI 10.1016/0005-2760(70)90170-0
   Miura S, 2002, J BIOL CHEM, V277, P32253, DOI 10.1074/jbc.M204410200
   MOREIRA LS, 2009, BIOCHIM BIOPHYS ACTA, V179, P156
   Moreno JM, 2002, IMMUNOLOGY, V106, P257, DOI 10.1046/j.1365-2567.2002.01403.x
   Murphy DJ, 2001, PROG LIPID RES, V40, P325, DOI 10.1016/S0163-7827(01)00013-3
   Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3
   Nanhuck RM, 2009, CLIN NUTR, V28, P556, DOI 10.1016/j.clnu.2009.05.008
   Neyrolles O, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000043
   Nishikawa Y, 2005, CELL MICROBIOL, V7, P849, DOI 10.1111/j.1462-5822.2005.00518.x
   Ohsaki Y, 2006, MOL BIOL CELL, V17, P2674, DOI 10.1091/mbc.E05-07-0659
   Ozeki S, 2005, J CELL SCI, V118, P2601, DOI 10.1242/jcs.02401
   Pacheco P, 2002, J IMMUNOL, V169, P6498, DOI 10.4049/jimmunol.169.11.6498
   Pacheco P, 2007, J IMMUNOL, V179, P8500, DOI 10.4049/jimmunol.179.12.8500
   Palacpac NMQ, 2004, J CELL SCI, V117, P1469, DOI 10.1242/jcs.00988
   Penido C, 2003, J IMMUNOL, V171, P6788, DOI 10.4049/jimmunol.171.12.6788
   Peters-Golden M, 2001, FEBS LETT, V487, P323, DOI 10.1016/S0014-5793(00)02374-7
   Peyron P, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000204
   Phillips RM, 2003, J BIOL CHEM, V278, P41326, DOI 10.1074/jbc.M302472200
   Pinheiro RO, 2009, MICROBES INFECT, V11, P181, DOI 10.1016/j.micinf.2008.11.006
   Ploegh HL, 2007, NATURE, V448, P435, DOI 10.1038/nature06004
   Plotkowski MC, 2008, MICROB PATHOGENESIS, V45, P30, DOI 10.1016/j.micpath.2008.01.008
   Pol A, 2001, J CELL BIOL, V152, P1057, DOI 10.1083/jcb.152.5.1057
   Pol A, 2004, MOL BIOL CELL, V15, P99, DOI 10.1091/mbc.E03-06-0368
   Quittnat F, 2004, MOL BIOCHEM PARASIT, V138, P107, DOI 10.1016/j.molbiopara.2004.08.004
   Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178
   RIDLEY DS, 1987, PATHOLOGY, V19, P186, DOI 10.3109/00313028709077132
   Robenek H, 2005, J LIPID RES, V46, P1331, DOI 10.1194/jlr.M400323-JLR200
   Robenek MJ, 2004, FASEB J, V18, P866, DOI 10.1096/fj.03-0782fje
   Rodriguez-Acosta A, 1998, J SUBMICR CYTOL PATH, V30, P299
   Saliba AM, 2005, CELL MICROBIOL, V7, P1811, DOI 10.1111/j.1462-5822.2005.00635.x
   Salluh JI, 2007, PROSTAG LEUKOTR ESS, V77, P1, DOI 10.1016/j.plefa.2007.04.001
   Sato S, 2006, J BIOCHEM, V139, P921, DOI 10.1093/jb/mvj104
   Schadinger SE, 2005, AM J PHYSIOL-ENDOC M, V288, pE1195, DOI 10.1152/ajpendo.00513.2004
   Silva AR, 2009, BBA-MOL CELL BIOL L, V1791, P1066, DOI 10.1016/j.bbalip.2009.06.004
   Silva AR, 2002, J IMMUNOL, V168, P4112, DOI 10.4049/jimmunol.168.8.4112
   Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145
   Sorgi CA, 2009, J IMMUNOL, V182, P4025, DOI 10.4049/jimmunol.0801795
   Stanley RG, 2009, ATHEROSCLEROSIS, V207, P131, DOI 10.1016/j.atherosclerosis.2009.04.037
   Stulnig TM, 2001, J BIOL CHEM, V276, P37335, DOI 10.1074/jbc.M106193200
   Szeles L, 2007, BBA-MOL CELL BIOL L, V1771, P1014, DOI 10.1016/j.bbalip.2007.02.005
   Takeuchi O, 2002, J IMMUNOL, V169, P10, DOI 10.4049/jimmunol.169.1.10
   Tanigawa K, 2008, FEMS MICROBIOL LETT, V289, P72, DOI 10.1111/j.1574-6968.2008.01369.x
   Targett-Adams P, 2005, BBA-GENE STRUCT EXPR, V1728, P95, DOI 10.1016/j.bbaexp.2005.01.017
   Thore CR, 1998, NEUROSCI LETT, V242, P29, DOI 10.1016/S0304-3940(98)00040-8
   Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5
   TRIGGIANI M, 1995, J EXP MED, V182, P1181, DOI 10.1084/jem.182.5.1181
   Umlauf E, 2004, J BIOL CHEM, V279, P23699, DOI 10.1074/jbc.M310546200
   Vieira-De-Abreu A, 2005, AM J RESP CELL MOL, V33, P254, DOI 10.1165/rcmb.2005-0145OC
   Vielemeyer O, 2004, MOL BIOCHEM PARASIT, V135, P195, DOI 10.1016/j.molbiopara.2003.08.017
   Wan HC, 2007, FASEB J, V21, P167, DOI 10.1096/fj.06-6711com
   Wang SM, 2003, HISTOCHEM CELL BIOL, V120, P285, DOI 10.1007/s00418-003-0575-7
   Weibel GL, 2009, J LIPID RES, V50, P2371, DOI 10.1194/jlr.M900081-JLR200
   Weller PF, 1999, INT ARCH ALLERGY IMM, V118, P450, DOI 10.1159/000024161
   Wolins NE, 2006, DIABETES, V55, P3418, DOI 10.2337/db06-0399
   Wolins NE, 2001, J BIOL CHEM, V276, P5101, DOI 10.1074/jbc.M006775200
   Wooten RE, 2008, BBA-MOL CELL RES, V1783, P1544, DOI 10.1016/j.bbamcr.2008.03.008
   Wymann MP, 2008, NAT REV MOL CELL BIO, V9, P162, DOI 10.1038/nrm2335
   Xu GH, 2005, J BIOL CHEM, V280, P42841, DOI 10.1074/jbc.M506569200
   Yaqoob P, 2003, TRENDS IMMUNOL, V24, P639, DOI 10.1016/j.it.2003.10.002
   Yu WG, 1998, AM J PATHOL, V152, P759
   Yu WG, 2000, BLOOD, V95, P1078, DOI 10.1182/blood.V95.3.1078.003k16_1078_1085
NR 158
TC 11
Z9 11
U1 0
U2 9
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1758-4299
EI 1758-4302
J9 CLIN LIPIDOL
JI Clin. Lipidol.
PD DEC
PY 2009
VL 4
IS 6
BP 791
EP 807
DI 10.2217/CLP.09.63
PG 17
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 532XA
UT WOS:000272782500016
DA 2020-12-15
ER

PT J
AU Silva, AR
   Pacheco, P
   Vieira-De-Abreu, A
   Maya-Monteiro, CM
   D'Alegria, B
   Magalhaes, KG
   de Assis, EF
   Bandeira-Melo, C
   Castro-Faria-Neto, HC
   Bozza, PT
AF Silva, Adriana R.
   Pacheco, Patricia
   Vieira-de-Abreu, Adriana
   Maya-Monteiro, Clarissa M.
   D'Alegria, Barbara
   Magalhaes, Kelly G.
   de Assis, Edson F.
   Bandeira-Melo, Christianne
   Castro-Faria-Neto, Hugo C.
   Bozza, Patricia T.
TI Lipid bodies in oxidized LDL-induced foam cells are
   leukotriene-synthesizing organelles: a MCP-1/CCL2 regulated phenomenon
SO BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
LA English
DT Article
DE Atherosclerosis; Foam cell; Lipid droplet; Lipoxygenase; Leukotriene;
   Inflammation; MCP-1/CCL2; ERK; Macrophage
ID MONOCYTE CHEMOATTRACTANT PROTEIN-1; 5-LIPOXYGENASE ACTIVATING PROTEIN;
   DIFFERENTIATION-RELATED PROTEIN; LOW-DENSITY-LIPOPROTEIN; DOUBLE
   KNOCKOUT MICE; EICOSANOID FORMATION; IN-VIVO; ATHEROSCLEROTIC LESIONS;
   PHOSPHOLIPASE A(2); PLAQUE INSTABILITY
AB Lipid-laden foam macrophages are emerging as key players in early atherogenesis. Even though cytoplasmic lipid bodies (lipid droplets) are now recognized as organelles with cell functions beyond lipid storage, the mechanisms controlling lipid body biogenesis within macrophages and their additional functions in atherosclerosis are not completely elucidated. Here we studied oxLDL-elicited macrophage machinery involved in lipid body biogenesis as well as lipid body roles in leukotriene (IT) synthesis. Both in vivo and in vitro, oxLDL (but not native LDL) induced rapid assembly of cytoplasmic lipid bodies-bearing ADRP within mice macrophages. Such oxLDL-elicited foamy-like phenotype was a pertussis toxin-sensitive process that depended on a paracrine activity of endogenous MCP-1/CCL2 and activation of ERK. Pretreatment with neutralizing anti-MCP-1/CCL2 inhibited macrophage ADRP protein expression induced by oxLDL By directly immuno-localizing leukotrienes at their sites of synthesis, we showed that oxLDL-induced newly formed lipid bodies function as active sites of LTB4 and LTC4 synthesis, since oxLDL-induced lipid bodies within foam macrophages compartmentalized the enzyme 5-lipoxygenase and five lipoxygenase-activating protein (FLAP) as well as newly formed LTB4 and LTC4. Consistent with MCP-1/CCL-2 role in ox-LDL-induced lipid body biogenesis, in CCR2 deficient mice both ox-LDL-induced lipid body assembly and LT release were reduced as compared to wild type mice. In conclusion, oxLDL-driven foam cells are enriched with leukotriene-synthesizing lipid bodies - specialized organelles whose biogenic process is mediated by MCP-1/CCL2-triggered CCR2 activation and ERK-dependent downstream signaling - that may amplify inflammatory mediator production in atherosclerosis. (C) 2009 Elsevier B.V. All rights reserved.
C1 [Pacheco, Patricia; Vieira-de-Abreu, Adriana; Maya-Monteiro, Clarissa M.; D'Alegria, Barbara; Magalhaes, Kelly G.; de Assis, Edson F.; Castro-Faria-Neto, Hugo C.; Bozza, Patricia T.] Fundacao Oswaldo Cruz, Lab Imunofarmacol, Inst Oswaldo Cruz, BR-21045900 Rio De Janeiro, Brazil.
   [Silva, Adriana R.; D'Alegria, Barbara] Fundacao Oswaldo Cruz, Lab Inflamacao, Inst Oswaldo Cruz, BR-21045900 Rio De Janeiro, Brazil.
   [Bandeira-Melo, Christianne] Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, Lab Inflamacao, BR-21941 Rio De Janeiro, Brazil.
RP Bozza, PT (corresponding author), Fundacao Oswaldo Cruz, Lab Imunofarmacol, Inst Oswaldo Cruz, Av Brasil 4365, BR-21045900 Rio De Janeiro, Brazil.
EM pbozza@ioc.fiocruz.br
RI Silva, Adriana Ribeiro/U-7811-2019; Magalhaes, Kelly G/A-6966-2010;
   maya-monteiro, clarissa/A-9091-2010; Silva, Adriana R/C-5931-2014; de
   Melo, Christianne Bandeira/B-7724-2009; Bandeira-Melo,
   Christianne/X-5619-2019; Magalhaes, Kelly Grace/L-6081-2019
OI Silva, Adriana Ribeiro/0000-0002-5137-4251; Magalhaes, Kelly
   G/0000-0002-7435-5272; Silva, Adriana R/0000-0002-5137-4251; de Melo,
   Christianne Bandeira/0000-0003-3305-3865; Bandeira-Melo,
   Christianne/0000-0003-3305-3865; Magalhaes, Kelly
   Grace/0000-0002-7435-5272; Bozza, Patricia/0000-0001-8349-9529
FU PAPES-FIOCRUZ; PRONEX-MCT; Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq, Brazil)National Council for Scientific
   and Technological Development (CNPq); Fundacao de Amparo a Pesquisa do
   Rio de Janeiro (FAPERJ, Brazil)Carlos Chagas Filho Foundation for
   Research Support of the State of Rio de Janeiro (FAPERJ)
FX This work was supported by PAPES-FIOCRUZ, PRONEX-MCT, Conselho Nacional
   de Desenvolvimento Cientifico e Tecnologico (CNPq, Brazil), and Fundacao
   de Amparo a Pesquisa do Rio de Janeiro (FAPERJ, Brazil). The authors
   thank the Program for Technological Development in Tools for
   Health-PDTISFIOCRUZ for use of its CLSM facility and Pedro Paulo Manso
   and Bernardo Pascarelli for the assistance with CLSM analysis.
CR Aleksandrov DA, 2006, FEBS J, V273, P548, DOI 10.1111/J.1742-4658.2005.05087.X
   Andersson L, 2006, J CELL SCI, V119, P2246, DOI 10.1242/jcs.02941
   Back M, 2005, P NATL ACAD SCI USA, V102, P17501, DOI 10.1073/pnas.0505845102
   Back M, 2006, ANN MED, V38, P493, DOI 10.1080/07853890600982737
   Balestrieri B, 2006, J BIOL CHEM, V281, P6691, DOI 10.1074/jbc.M508314200
   Bandeira-Melo C, 2002, J ALLERGY CLIN IMMUN, V109, P393, DOI 10.1067/mai.2002.121529
   Bandeira-Melo C, 2001, J BIOL CHEM, V276, P22779, DOI 10.1074/jbc.M101436200
   Bozza PT, 2007, PHARMACOL THERAPEUT, V113, P30, DOI 10.1016/j.pharmthera.2006.06.006
   Bozza PT, 2009, BBA-MOL CELL BIOL L, V1791, P540, DOI 10.1016/j.bbalip.2009.01.005
   Bozza PT, 1997, J EXP MED, V186, P909, DOI 10.1084/jem.186.6.909
   Bozza PT, 1998, J LEUKOCYTE BIOL, V64, P563
   Brasaemle DL, 2007, J LIPID RES, V48, P2547, DOI 10.1194/jlr.R700014-JLR200
   Brasaemle DL, 2004, J BIOL CHEM, V279, P46835, DOI 10.1074/jbc.M409340200
   Brasaemle DL, 1997, J LIPID RES, V38, P2249
   Cipollone F, 2005, ARTERIOSCL THROM VAS, V25, P1665, DOI 10.1161/01.ATV.0000172632.96987.2d
   Clement S, 2008, HEPATOLOGY, V48, P799, DOI 10.1002/hep.22404
   D'Avila H, 2006, J IMMUNOL, V176, P3087, DOI 10.4049/jimmunol.176.5.3087
   Dawson TC, 1999, ATHEROSCLEROSIS, V143, P205
   de Assis EF, 2003, J IMMUNOL, V171, P2090, DOI 10.4049/jimmunol.171.4.2090
   DVORAK AM, 1992, J HISTOCHEM CYTOCHEM, V40, P759, DOI 10.1177/40.6.1316915
   Dwyer JH, 2004, NEW ENGL J MED, V350, P29, DOI 10.1056/NEJMoa025079
   Fujimoto Y, 2004, BBA-MOL CELL RES, V1644, P47, DOI 10.1016/j.bbamcr.2003.10.018
   Getz GS, 2005, J LIPID RES, V46, P619, DOI 10.1194/jlr.E500002-JLR200
   Heid HW, 1998, CELL TISSUE RES, V294, P309, DOI 10.1007/s004410051181
   Helgadottir A, 2004, NAT GENET, V36, P233, DOI 10.1038/ng1311
   Jala VR, 2004, TRENDS IMMUNOL, V25, P315, DOI 10.1016/j.it.2004.04.003
   Jawien J, 2008, J PHYSIOL PHARMACOL, V59, P633
   Jawien J, 2006, EUR J CLIN INVEST, V36, P141, DOI 10.1111/j.1365-2362.2006.01606.x
   Johnson MM, 1999, AM J RESP CELL MOL, V21, P253, DOI 10.1165/ajrcmb.21.2.3489
   Kuziel WA, 1997, P NATL ACAD SCI USA, V94, P12053, DOI 10.1073/pnas.94.22.12053
   Larigauderie G, 2004, ARTERIOSCL THROM VAS, V24, P504, DOI 10.1161/01.ATV.0000115638.27381.97
   Larigauderie G, 2006, ATHEROSCLEROSIS, V189, P142, DOI 10.1016/j.atherosclerosis.2005.12.016
   Leite MS, 2005, SHOCK, V23, P173, DOI 10.1097/01.shk.0000148072.12094.77
   Liu PS, 2004, J BIOL CHEM, V279, P3787, DOI 10.1074/jbc.M311945200
   Magnusson B, 2006, ARTERIOSCL THROM VAS, V26, P1566, DOI 10.1161/01.ATV.0000223345.11820.da
   Mandal AK, 2004, P NATL ACAD SCI USA, V101, P6587, DOI 10.1073/pnas.0308523101
   Matsukawa A, 1999, J IMMUNOL, V163, P6148
   Maxfield FR, 2002, J CLIN INVEST, V110, P891, DOI 10.1172/JCI200216500
   MCGOOKEY DJ, 1983, J CELL BIOL, V97, P1156, DOI 10.1083/jcb.97.4.1156
   Mesquita-Santos FP, 2006, J IMMUNOL, V176, P1326, DOI 10.4049/jimmunol.176.3.1326
   Nuotio K, 2007, STROKE, V38, P1791, DOI 10.1161/STROKEAHA.106.478867
   Olofsson SO, 2009, BBA-MOL CELL BIOL L, V1791, P448, DOI 10.1016/j.bbalip.2008.08.001
   Pacheco P, 2002, J IMMUNOL, V169, P6498, DOI 10.4049/jimmunol.169.11.6498
   Pacheco P, 2007, J IMMUNOL, V179, P8500, DOI 10.4049/jimmunol.179.12.8500
   Paul A, 2008, CIRC RES, V102, P1492, DOI 10.1161/CIRCRESAHA.107.168070
   Peters-Golden M, 2003, PROSTAG LEUKOTR ESS, V69, P99, DOI 10.1016/S0952-3278(03)00070-X
   Qiu H, 2006, P NATL ACAD SCI USA, V103, P8161, DOI 10.1073/pnas.0602414103
   Radmark O, 2005, BIOCHEM BIOPH RES CO, V338, P102, DOI 10.1016/j.bbrc.2005.08.013
   Robenek H, 2005, J BIOL CHEM, V280, P5789, DOI 10.1074/jbc.M407194200
   ROSS R, 1995, ANNU REV PHYSIOL, V57, P791, DOI 10.1146/annurev.ph.57.030195.004043
   Sanchez-Galan E, 2009, CARDIOVASC RES, V81, P216, DOI 10.1093/cvr/cvn277
   Schmitz G, 2009, BBA-MOL CELL BIOL L, V1791, P524, DOI 10.1016/j.bbalip.2008.12.007
   Silva AR, 2002, J IMMUNOL, V168, P4112, DOI 10.4049/jimmunol.168.8.4112
   Soberman RJ, 2003, J CLIN INVEST, V111, P1107, DOI 10.1172/JCI200318338
   Spanbroek R, 2003, P NATL ACAD SCI USA, V100, P1238, DOI 10.1073/pnas.242716099
   Tabata T, 2003, BIOCHEM BIOPH RES CO, V305, P380, DOI 10.1016/S0006-291X(03)00771-X
   Umlauf E, 2004, J BIOL CHEM, V279, P23699, DOI 10.1074/jbc.M310546200
   Vieira-De-Abreu A, 2005, AM J RESP CELL MOL, V33, P254, DOI 10.1165/rcmb.2005-0145OC
   Wang XK, 1999, FEBS LETT, V462, P145, DOI 10.1016/S0014-5793(99)01521-5
   Weller PF, 1999, INT ARCH ALLERGY IMM, V118, P450, DOI 10.1159/000024161
   WELLER PF, 1991, AM J PATHOL, V138, P141
   WOODS JW, 1993, J EXP MED, V178, P1935, DOI 10.1084/jem.178.6.1935
   Yu WG, 1998, AM J PATHOL, V152, P759
   Zhao B, 2005, J LIPID RES, V46, P2114, DOI 10.1194/jlr.M500207-JLR200
   Zhao L, 2004, NAT MED, V10, P966, DOI 10.1038/nm1099
NR 65
TC 41
Z9 42
U1 0
U2 7
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1388-1981
EI 0006-3002
J9 BBA-MOL CELL BIOL L
JI Biochim. Biophys. Acta Mol. Cell Biol. Lipids
PD NOV
PY 2009
VL 1791
IS 11
BP 1066
EP 1075
DI 10.1016/j.bbalip.2009.06.004
PG 10
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA 509WC
UT WOS:000271048800004
PM 19573621
DA 2020-12-15
ER

PT J
AU Almeida, PE
   Silva, AR
   Maya-Monteiro, CM
   Torocsik, D
   D'Avila, H
   Dezso, B
   Magalhaes, KG
   Castro-Faria-Neto, HC
   Nagy, L
   Bozza, PT
AF Almeida, Patricia E.
   Silva, Adriana R.
   Maya-Monteiro, Clarissa M.
   Torocsik, Daniel
   D'Avila, Heloisa
   Dezsoe, Balazs
   Magalhaes, Kelly G.
   Castro-Faria-Neto, Hugo C.
   Nagy, Laszlo
   Bozza, Patricia T.
TI Mycobacterium bovis Bacillus Calmette-Guerin Infection Induces
   TLR2-Dependent Peroxisome Proliferator-Activated Receptor gamma
   Expression and Activation: Functions in Inflammation, Lipid Metabolism,
   and Pathogenesis
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID TOLL-LIKE RECEPTORS; RETINOID-X-RECEPTOR; MACROPHAGE-GENE-EXPRESSION;
   INNATE IMMUNE-RESPONSE; PPAR-GAMMA; BODY FORMATION; IN-VIVO;
   INTRACELLULAR DOMAINS; NUCLEAR RECEPTORS; OXIDIZED LDL
AB Macrophages have important roles in both lipid metabolism and inflammation and are central to immunity to intracellular pathogens. Foam-like, lipid-laden macrophages are present during the course of mycobacterial infection and have recently been implicated in mycobacterial pathogenesis. In this study, we analyzed the molecular mechanisms underlying the formation of macrophage lipid bodies (lipid droplets) during Mycobacterium bovis bacillus Calmette-Guerin (BCG) infection, focusing on the role of the lipid-activated nuclear receptor peroxisome proliferator-activated receptor gamma (PPAR gamma). We found that BCG infection induced increased expression of PPAR gamma that paralleled the augmented lipid body formation and PGE(2) synthesis in mouse peritoneal macrophages. BCG-induced PPAR gamma expression and lipid body formation were diminished in macrophages from TLR2-deficient mice, suggesting a key role for TLR2. The function of PPAR gamma in modulating BCG infection was demonstrated by the capacity of the PPAR gamma agonist BRL49653 to potentiate lipid body formation and PGE(2) production; furthermore, pretreatment with the PPAR gamma antagonist GW9662 inhibited BCG-induced lipid body formation and PGE(2) production. BCG-induced MIP-1 alpha, IL12p70, TNF-alpha, and IL6 production was not inhibited by GW9662 treatment. Nonpathogenic Mycobacterium smegmatis failed to induce PPAR gamma expression or lipid body formation. Moreover, inhibition of PPAR gamma by GW9662 enhanced the mycobacterial killing capacity of macrophages. Our findings show that PPAR gamma is involved in lipid body biogenesis, unravels a cross-talk between the innate immune receptor TLR2 and the lipid-activated nuclear receptor PPAR gamma that coordinates lipid metabolism and inflammation in BCG-infected macrophages, thereby potentially affecting mycobacterial pathogenesis. The Journal of Immunology, 2009, 183: 1337-1345.
C1 [Almeida, Patricia E.; Maya-Monteiro, Clarissa M.; D'Avila, Heloisa; Magalhaes, Kelly G.; Castro-Faria-Neto, Hugo C.; Bozza, Patricia T.] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Imunofarmacol, BR-21045900 Rio De Janeiro, Brazil.
   [Silva, Adriana R.] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Inflamacao, BR-21045900 Rio De Janeiro, Brazil.
   [Torocsik, Daniel; Nagy, Laszlo] Univ Debrecen, Dept Biochem & Mol Biol, Debrecen, Hungary.
   [Dezsoe, Balazs] Univ Debrecen, Dept Pathol, Med & Hlth Sci Ctr, Res Ctr Mol Med, Debrecen, Hungary.
RP Bozza, PT (corresponding author), Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Imunofarmacol, Ave Brasil 4365, BR-21045900 Rio De Janeiro, Brazil.
EM pbozza@ioc.fiocruz.br
RI maya-monteiro, clarissa/A-9091-2010; Nagy, Laszlo/A-3814-2008; Silva,
   Adriana Ribeiro/U-7811-2019; Magalhaes, Kelly G/A-6966-2010; Magalhaes,
   Kelly Grace/L-6081-2019; Silva, Adriana R/C-5931-2014
OI Nagy, Laszlo/0000-0001-6653-2155; Silva, Adriana
   Ribeiro/0000-0002-5137-4251; Magalhaes, Kelly G/0000-0002-7435-5272;
   Magalhaes, Kelly Grace/0000-0002-7435-5272; Silva, Adriana
   R/0000-0002-5137-4251; Bozza, Patricia/0000-0001-8349-9529; Almeida,
   Patricia Elaine de/0000-0002-9081-8601; Dezso,
   Balazs/0000-0002-7871-0219
FU Howard Hughes Medical InstituteHoward Hughes Medical Institute; Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico (Brazil)National
   Council for Scientific and Technological Development (CNPq); Fundacao de
   Amparo a Pesquisa do Estado do Rio de Janeiro (Brazil)Carlos Chagas
   Filho Foundation for Research Support of the State of Rio de Janeiro
   (FAPERJ); Programa Nucleos de Excelencia (Brazil); Programa de Apoio a
   Pesquisa Estrategica em Saude; Wellcome Trust Senior Research
   FellowshipWellcome Trust
FX This work was supported by a mini-grant from the Howard Hughes Medical
   Institute to P.T.B. and L.N. and by the Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (Brazil), Fundacao de Amparo a
   Pesquisa do Estado do Rio de Janeiro (Brazil), Programa Nucleos de
   Excelencia (Brazil), and Programa de Apoio a Pesquisa Estrategica em
   Saude (Fundaqao Oswaldo Cruz, Brazil). L.N. is an International Scholar
   of the Howard Hughes Medical Institute and holds a Wellcome Trust Senior
   Research Fellowship in Biomedical Sciences in Central Europe.
CR Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015
   Benevolo-de-Andrade TC, 2005, MEM I OSWALDO CRUZ, V100, P459, DOI 10.1590/S0074-02762005000500002
   Berney M, 2007, APPL ENVIRON MICROB, V73, P3283, DOI 10.1128/AEM.02750-06
   Bozza PT, 2007, PHARMACOL THERAPEUT, V113, P30, DOI 10.1016/j.pharmthera.2006.06.006
   Bozza PT, 2009, BBA-MOL CELL BIOL L, V1791, P540, DOI 10.1016/j.bbalip.2009.01.005
   Caceres N, 2009, TUBERCULOSIS, V89, P175, DOI 10.1016/j.tube.2008.11.001
   Cao F, 2007, INFECT IMMUN, V75, P753, DOI 10.1128/IAI.01386-06
   Cardona Pere-Joan, 2007, Inflammation & Allergy Drug Targets, V6, P27
   Cardona PJ, 2000, SCAND J IMMUNOL, V52, P156, DOI 10.1046/j.1365-3083.2000.00763.x
   Chawla A, 2003, P NATL ACAD SCI USA, V100, P1268, DOI 10.1073/pnas.0337331100
   Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866
   Chawla A, 2001, NAT MED, V7, P48
   Chen JS, 2005, J CELL BIOCHEM, V94, P1028, DOI 10.1002/jcb.20361
   D'Avila H, 2008, CELL MICROBIOL, V10, P2589, DOI 10.1111/j.1462-5822.2008.01233.x
   D'Avila H, 2008, INT IMMUNOPHARMACOL, V8, P1308, DOI 10.1016/j.intimp.2008.01.035
   D'Avila H, 2007, INFECT IMMUN, V75, P1507, DOI 10.1128/IAI.01326-06
   D'Avila H, 2006, J IMMUNOL, V176, P3087, DOI 10.4049/jimmunol.176.5.3087
   de Assis EF, 2003, J IMMUNOL, V171, P2090, DOI 10.4049/jimmunol.171.4.2090
   Desreumaux P, 2001, J EXP MED, V193, P827, DOI 10.1084/jem.193.7.827
   Dubuquoy L, 2003, GASTROENTEROLOGY, V124, P1265, DOI 10.1016/S0016-5085(03)00271-3
   Ferwerda G, 2008, CELL MICROBIOL, V10, P2058, DOI 10.1111/j.1462-5822.2008.01188.x
   Gallardo-Soler A, 2008, MOL ENDOCRINOL, V22, P1394, DOI 10.1210/me.2007-0525
   GEARING KL, 1993, P NATL ACAD SCI USA, V90, P1440, DOI 10.1073/pnas.90.4.1440
   HernandezPando R, 1997, INFECT IMMUN, V65, P3317, DOI 10.1128/IAI.65.8.3317-3327.1997
   Hoebe K, 2005, NATURE, V433, P523, DOI 10.1038/nature03253
   Jo EK, 2007, CELL MICROBIOL, V9, P1087, DOI 10.1111/j.1462-5822.2007.00914.x
   KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160
   Kumar Y, 2006, CURR BIOL, V16, P1646, DOI 10.1016/j.cub.2006.06.060
   Martin S, 2006, NAT REV MOL CELL BIO, V7, P373, DOI 10.1038/nrm1912
   Means TK, 1999, J IMMUNOL, V163, P3920
   Means TK, 2001, J IMMUNOL, V166, P4074, DOI 10.4049/jimmunol.166.6.4074
   Melo RCN, 2003, TISSUE CELL, V35, P59, DOI 10.1016/S0040-8166(02)00105-2
   Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3
   Neyrolles O, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000043
   Odegaard JI, 2007, NATURE, V447, P1116, DOI 10.1038/nature05894
   Ogawa S, 2005, CELL, V122, P707, DOI 10.1016/j.cell.2005.06.029
   Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497
   Pacheco P, 2002, J IMMUNOL, V169, P6498, DOI 10.4049/jimmunol.169.11.6498
   Pacheco P, 2007, J IMMUNOL, V179, P8500, DOI 10.4049/jimmunol.179.12.8500
   Pascual G, 2005, NATURE, V437, P759, DOI 10.1038/nature03988
   Peyron P, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000204
   Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178
   RIDLEY DS, 1987, PATHOLOGY, V19, P186, DOI 10.3109/00313028709077132
   Siddiqui AM, 2006, CRIT CARE MED, V34, P1874, DOI 10.1097/01.CCM.0000221921.71300.BF
   Sorgi CA, 2009, J IMMUNOL, V182, P4025, DOI 10.4049/jimmunol.0801795
   Szanto A, 2005, MOL PHARMACOL, V67, P1935, DOI 10.1124/mol.104.006445
   Szatmari I, 2008, EMBO J, V27, P2353, DOI 10.1038/emboj.2008.160
   Szatmari I, 2007, BLOOD, V110, P3271, DOI 10.1182/blood-2007-06-096222
   Takeuchi O, 2002, J IMMUNOL, V169, P10, DOI 10.4049/jimmunol.169.1.10
   Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3
   Targett-Adams P, 2005, BBA-GENE STRUCT EXPR, V1728, P95, DOI 10.1016/j.bbaexp.2005.01.017
   Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5
   Triantafilou M, 2006, J BIOL CHEM, V281, P31002, DOI 10.1074/jbc.M602794200
   Vosper H, 2001, J BIOL CHEM, V276, P44258, DOI 10.1074/jbc.M108482200
   Yu WG, 1998, AM J PATHOL, V152, P759
   Zhou M, 2008, AM J PHYSIOL-REG I, V294, pR84, DOI 10.1152/ajpregu.00340.2007
NR 56
TC 103
Z9 106
U1 0
U2 5
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD JUL 15
PY 2009
VL 183
IS 2
BP 1337
EP 1345
DI 10.4049/jimmunol.0900365
PG 9
WC Immunology
SC Immunology
GA 468JD
UT WOS:000267812600061
PM 19561094
OA Bronze
DA 2020-12-15
ER

PT J
AU Bozza, PT
   Magalhaes, KG
   Weller, PF
AF Bozza, Patricia T.
   Magalhaes, Kelly G.
   Weller, Peter F.
TI Leukocyte lipid bodies - Biogenesis and functions in inflammation
SO BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
LA English
DT Review
DE Lipid droplet; Inflammation; Foam cell; Eicosanoid; Leukocyte;
   Eosinophils; Neutrophils
ID DIFFERENTIATION-RELATED PROTEIN; PLATELET-ACTIVATING-FACTOR;
   LOW-DENSITY-LIPOPROTEIN; FOAM CELL-FORMATION; ENDOPEROXIDE SYNTHASE
   CYCLOOXYGENASE; DROPLET-ASSOCIATED PROTEINS; ULTRASTRUCTURAL IMMUNOGOLD
   LOCALIZATION; DOMINANT-NEGATIVE MUTANT; INNATE IMMUNE-RESPONSE; HUMAN
   FETAL MEMBRANES
AB Lipid body accumulation within leukocytes is a common feature in both clinical and experimental infectious, neoplasic and other inflammatory conditions. Here, we will review the contemporary evidence related to the biogenesis and structure of leukocyte lipid bodies (also known as lipid droplets) as inflammatory organelles. Studies of leukocyte lipid bodies are providing functional, ultrastructural and protein compositional evidences that lipid bodies are not solely storage depots of neutral lipid. Over the past years substantial progresses have been made to demonstrate that lipid body biogenesis is a highly regulated process, that culminate in the compartmentalization of a specific set of proteins and lipids, that place leukocyte lipid bodies as inducible cytoplasmic organelles with roles in cell signaling and activation, regulation of lipid metabolism, membrane trafficking and control of the synthesis and secretion of inflammatory mediators. Pertinent to the roles of lipid bodies in inflammation and cell signaling, enzymes involved in eicosanoid synthesis are localized at lipid bodies and lipid bodies are sites for eicosanoid generation. Collectively, lipid bodies in leukocytes are emerging as critical regulators of different inflammatory diseases, key markers of leukocyte activation and attractive targets for novel anti-inflammatory therapies. (C) 2009 Elsevier B.V. All rights reserved.
C1 [Bozza, Patricia T.; Magalhaes, Kelly G.] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Imunofarmacol, BR-21045900 Rio De Janeiro, Brazil.
   [Weller, Peter F.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med, Boston, MA 02215 USA.
RP Bozza, PT (corresponding author), Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Imunofarmacol, Av Brasil 4365, BR-21045900 Rio De Janeiro, Brazil.
EM pbozza@ioc.fiocruz.br
RI Magalhaes, Kelly Grace/L-6081-2019; Magalhaes, Kelly G/A-6966-2010
OI Magalhaes, Kelly Grace/0000-0002-7435-5272; Magalhaes, Kelly
   G/0000-0002-7435-5272; Bozza, Patricia/0000-0001-8349-9529
FU PRONEX-MCT; Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq, Brazil)National Council for Scientific and
   Technological Development (CNPq); PAPES-FIOCRUZ; Fundacao de Amparo a
   Pesquisa do Rio de Janeiro (FAPERJ, Brazil)Carlos Chagas Filho
   Foundation for Research Support of the State of Rio de Janeiro (FAPERJ);
   NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [AI022571, AI020241, AI051645];
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [R01AI020241, R01AI022571, R01AI051645, R01AI022571, R01AI020241,
   R01AI051645, R01AI020241, R01AI020241, R01AI022571, R01AI022571,
   R01AI020241, R01AI020241, R01AI020241, R01AI051645, R01AI020241,
   R01AI020241, R01AI022571, R01AI051645, R01AI022571, R01AI020241,
   R37AI020241, R01AI022571, R01AI051645, R01AI022571, R01AI020241,
   R01AI022571, R01AI022571, R01AI020241, R01AI022571, R01AI020241,
   R01AI051645, R37AI020241, R37AI020241, R01AI022571, R37AI020241,
   R37AI020241, R01AI022571, R01AI051645, R01AI020241, R37AI020241,
   R01AI020241, R01AI022571, R01AI022571, R01AI022571, R01AI020241,
   R01AI022571, R01AI022571, R37AI020241, R01AI020241, R01AI051645,
   R01AI020241, R01AI020241, R37AI020241, R37AI020241, R01AI020241,
   R01AI022571, R01AI022571, R01AI020241, R01AI022571, R01AI022571,
   R01AI051645, R37AI020241, R01AI020241, R01AI020241, R01AI022571,
   R01AI020241, R01AI022571, R01AI022571, R01AI051645] Funding Source: NIH
   RePORTER
FX The work of the authors is supported by PRONEX-MCT, Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq, Brazil), PAPES-FIOCRUZ,
   Fundacao de Amparo a Pesquisa do Rio de Janeiro (FAPERJ, Brazil) (to
   PTB) and NIH grants (AI022571, AI020241, AI051645) (to PFW). We thank
   Dr. Clarissa Maya-Monteiro and Dr. Cecilia Almeida for their critical
   suggestions and discussion. We would like to thank present and past
   members of our Laboratories for important contributions.
CR Accioly MT, 2008, CANCER RES, V68, P1732, DOI 10.1158/0008-5472.CAN-07-1999
   Arend A, 2004, PROSTAG OTH LIPID M, V74, P1, DOI 10.1016/j.prostaglandins.2004.05.002
   Arm JP, 2004, ALLERGY ASTHMA PROC, V25, P37
   Bandeira-Melo C, 2002, J ALLERGY CLIN IMMUN, V109, P393, DOI 10.1067/mai.2002.121529
   Bandeira-Melo C, 2002, J IMMUNOL, V168, P4756, DOI 10.4049/jimmunol.168.9.4756
   Bandeira-Melo C, 2002, J EXP MED, V196, P841, DOI 10.1084/jem.20020516
   Bandeira-Melo C, 2001, AM J RESP CELL MOL, V24, P653, DOI 10.1165/ajrcmb.24.6.f209
   Bandeira-Melo C, 2001, J BIOL CHEM, V276, P22779, DOI 10.1074/jbc.M101436200
   BANDEIRAMELO C, 2005, MEM I O CRUZ S1, V100
   Bartemes KR, 1999, J IMMUNOL, V162, P2982
   Bartz R, 2007, J LIPID RES, V48, P837, DOI 10.1194/jlr.M600413-JLR200
   BEIL WJ, 1995, J LEUKOCYTE BIOL, V58, P284
   Beller M, 2006, MOL CELL PROTEOMICS, V5, P1082, DOI 10.1074/mcp.M600011-MCP200
   Berthier S, 2003, J BIOL CHEM, V278, P25499, DOI 10.1074/jbc.M209755200
   BETZ M, 1991, J IMMUNOL, V146, P108
   Binns D, 2006, J CELL BIOL, V173, P719, DOI 10.1083/jcb.200511125
   Bostrom P, 2005, ARTERIOSCL THROM VAS, V25, P1945, DOI 10.1161/01.ATV.0000179676.41064.d4
   Bostrom P, 2007, NAT CELL BIOL, V9, P1286, DOI 10.1038/ncb1648
   Boullier A, 2005, J LIPID RES, V46, P969, DOI 10.1194/jlr.M400496-JLR200
   Bozza PT, 2007, PHARMACOL THERAPEUT, V113, P30, DOI 10.1016/j.pharmthera.2006.06.006
   Bozza PT, 2005, MEM I OSWALDO CRUZ, V100, P113, DOI 10.1590/S0074-02762005000900020
   Bozza PT, 2002, PROSTAG LEUKOTR ESS, V67, P237, DOI 10.1054/plef.2002.0425
   Bozza PT, 1997, J EXP MED, V186, P909, DOI 10.1084/jem.186.6.909
   Bozza PT, 1996, P NATL ACAD SCI USA, V93, P11091, DOI 10.1073/pnas.93.20.11091
   Bozza PT, 1996, J EXP MED, V183, P1515, DOI 10.1084/jem.183.4.1515
   Bozza PT, 2001, PROSTAG LEUKOTR ESS, V64, P227, DOI 10.1054/plef.2001.0264
   Bozza PT, 1998, J LEUKOCYTE BIOL, V64, P563
   Brasaemle DL, 2007, J LIPID RES, V48, P2547, DOI 10.1194/jlr.R700014-JLR200
   Brasaemle DL, 2004, J BIOL CHEM, V279, P46835, DOI 10.1074/jbc.M409340200
   Brasaemle DL, 1997, J LIPID RES, V38, P2249
   Brown DA, 2001, CURR BIOL, V11, pR446, DOI 10.1016/S0960-9822(01)00257-3
   BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255
   Buechler C, 2001, BBA-MOL CELL BIOL L, V1532, P97, DOI 10.1016/S1388-1981(01)00121-4
   Busse W, 2005, CHEST, V127, P1312, DOI 10.1378/chest.127.4.1312
   Cao F, 2007, INFECT IMMUN, V75, P753, DOI 10.1128/IAI.01386-06
   Cardona PJ, 2000, SCAND J IMMUNOL, V52, P156, DOI 10.1046/j.1365-3083.2000.00763.x
   Cermelli S, 2006, CURR BIOL, V16, P1783, DOI 10.1016/j.cub.2006.07.062
   Chen JS, 2002, J CELL BIOCHEM, V86, P784, DOI 10.1002/jcb.10266
   Chen JS, 2001, J CELL BIOCHEM, V83, P187, DOI 10.1002/jcb.1225
   Chung SY, 2005, J LIPID RES, V46, P885, DOI 10.1194/jlr.M400476-JLR200
   D'Avila H, 2008, CELL MICROBIOL, V10, P2589, DOI 10.1111/j.1462-5822.2008.01233.x
   D'Avila H, 2008, INT IMMUNOPHARMACOL, V8, P1308, DOI 10.1016/j.intimp.2008.01.035
   D'Avila H, 2007, INFECT IMMUN, V75, P1507, DOI 10.1128/IAI.01326-06
   D'Avila H, 2006, J IMMUNOL, V176, P3087, DOI 10.4049/jimmunol.176.5.3087
   de Assis EF, 2003, J IMMUNOL, V171, P2090, DOI 10.4049/jimmunol.171.4.2090
   de Villiers WJS, 1999, J LEUKOCYTE BIOL, V66, P740
   Dvorak AM, 2003, HISTOL HISTOPATHOL, V18, P943, DOI 10.14670/HH-18.943
   DVORAK AM, 1984, J CELL BIOL, V99, P1678, DOI 10.1083/jcb.99.5.1678
   DVORAK AM, 1983, J IMMUNOL, V131, P2965
   Dvorak AM, 2001, HISTOCHEM J, V33, P397, DOI 10.1023/A:1013771827069
   DVORAK AM, 1994, INT ARCH ALLERGY IMM, V105, P245
   DVORAK AM, 1992, J HISTOCHEM CYTOCHEM, V40, P759, DOI 10.1177/40.6.1316915
   DVORAK AM, 1993, INT ARCH ALLERGY IMM, V101, P136, DOI 10.1159/000236511
   DVORAK AM, 1991, BIOCH CONTENTS GRANU
   Dvorak Ann M, 2005, Chem Immunol Allergy, V85, P252
   FRANKE WW, 1987, CELL, V49, P131, DOI 10.1016/0092-8674(87)90763-X
   Fujimoto T, 2001, J CELL BIOL, V152, P1079, DOI 10.1083/jcb.152.5.1079
   Fujimoto T, 2006, AUTOPHAGY, V2, P299, DOI 10.4161/auto.2904
   Fujimoto Y, 2004, BBA-MOL CELL RES, V1644, P47, DOI 10.1016/j.bbamcr.2003.10.018
   GALLI SJ, 1985, PROSTAGLANDINS LEUKO, P221
   Ghosh M, 2006, PROG LIPID RES, V45, P487, DOI 10.1016/j.plipres.2006.05.003
   GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333
   GREENBERG AS, 1991, J BIOL CHEM, V266, P11341
   Gronke S, 2003, CURR BIOL, V13, P603, DOI 10.1016/S0960-9822(03)00175-1
   Gross DN, 2006, MOL ENDOCRINOL, V20, P459, DOI 10.1210/me.2005-0323
   Heid HW, 1998, CELL TISSUE RES, V294, P309, DOI 10.1007/s004410051181
   Henderson WR, 2002, AM J RESP CRIT CARE, V165, P108, DOI 10.1164/ajrccm.165.1.2105051
   Hodgkinson CP, 2008, ARTERIOSCL THROM VAS, V28, P2275, DOI 10.1161/ATVBAHA.108.175992
   Inazawa Y, 2003, CELL STRUCT FUNCT, V28, P487, DOI 10.1247/csf.28.487
   Johnson MM, 1999, AM J RESP CELL MOL, V21, P253, DOI 10.1165/ajrcmb.21.2.3489
   Kanaoka Y, 2004, J IMMUNOL, V173, P1503, DOI 10.4049/jimmunol.173.3.1503
   Kapinsky M, 2001, ARTERIOSCL THROM VAS, V21, P1004, DOI 10.1161/01.ATV.21.6.1004
   Kerkhoff C, 1999, J BIOL CHEM, V274, P32672, DOI 10.1074/jbc.274.46.32672
   Kondo H, 2008, TOHOKU J EXP MED, V214, P167, DOI 10.1620/tjem.214.167
   Larigauderie G, 2004, ARTERIOSCL THROM VAS, V24, P504, DOI 10.1161/01.ATV.0000115638.27381.97
   Leite MS, 2005, SHOCK, V23, P173, DOI 10.1097/01.shk.0000148072.12094.77
   Leonarduzzi G, 2005, MOL NUTR FOOD RES, V49, P1044, DOI 10.1002/mnfr.200500090
   Li AC, 2002, NAT MED, V8, P1235, DOI 10.1038/nm1102-1235
   Lim KG, 1996, J IMMUNOL, V156, P2566
   Liu PS, 2004, J BIOL CHEM, V279, P3787, DOI 10.1074/jbc.M311945200
   Londos C, 2005, BIOCHIMIE, V87, P45, DOI 10.1016/j.biochi.2004.12.010
   Martin S, 2006, NAT REV MOL CELL BIO, V7, P373, DOI 10.1038/nrm1912
   Martin S, 2005, J BIOL CHEM, V280, P42325, DOI 10.1074/jbc.M506651200
   Maya-Monteiro CM, 2008, CELL CYCLE, V7, P1713, DOI 10.4161/cc.7.12.6157
   Maya-Monteiro CM, 2008, J BIOL CHEM, V283, P2203, DOI 10.1074/jbc.M706706200
   MCGOOKEY DJ, 1983, J CELL BIOL, V97, P1156, DOI 10.1083/jcb.97.4.1156
   Meadows JW, 2005, J CLIN ENDOCR METAB, V90, P2344, DOI 10.1210/jc.2004-1199
   Meadows JW, 2003, J CLIN ENDOCR METAB, V88, P433, DOI 10.1210/jc.2002-021061
   Melo RCN, 2005, TRAFFIC, V6, P1047, DOI 10.1111/j.1600-0854.2005.00344.x
   Melo RCN, 2005, TRAFFIC, V6, P866, DOI 10.1111/j.1600-0854.2005.00322.x
   Melo RCN, 2003, TISSUE CELL, V35, P59, DOI 10.1016/S0040-8166(02)00105-2
   Mermelstein CS, 2001, CELL TISSUE RES, V306, P75, DOI 10.1007/s004410100428
   Mesquita-Santos FP, 2006, J IMMUNOL, V176, P1326, DOI 10.4049/jimmunol.176.3.1326
   Miura S, 2002, J BIOL CHEM, V277, P32253, DOI 10.1074/jbc.M204410200
   MUKHERJEE A, 1989, INT J LEPROSY, V57, P506
   Murphy DJ, 2001, PROG LIPID RES, V40, P325, DOI 10.1016/S0163-7827(01)00013-3
   Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3
   Namatame I, 2004, P NATL ACAD SCI USA, V101, P737, DOI 10.1073/pnas.0307757100
   Ohsaki Y, 2006, MOL BIOL CELL, V17, P2674, DOI 10.1091/mbc.E05-07-0659
   Ozeki S, 2005, J CELL SCI, V118, P2601, DOI 10.1242/jcs.02401
   Pacheco P, 2002, J IMMUNOL, V169, P6498, DOI 10.4049/jimmunol.169.11.6498
   Pacheco P, 2007, J IMMUNOL, V179, P8500, DOI 10.4049/jimmunol.179.12.8500
   Paciga M, 2005, AM J PHYSIOL-ENDOC M, V289, pE197, DOI 10.1152/ajpendo.00581.2004
   Paul A, 2008, CIRC RES, V102, P1492, DOI 10.1161/CIRCRESAHA.107.168070
   Pinheiro RO, 2009, MICROBES INFECT, V11, P181, DOI 10.1016/j.micinf.2008.11.006
   Plotkowski MC, 2008, MICROB PATHOGENESIS, V45, P30, DOI 10.1016/j.micpath.2008.01.008
   Pol A, 2001, J CELL BIOL, V152, P1057, DOI 10.1083/jcb.152.5.1057
   Pol A, 2004, MOL BIOL CELL, V15, P99, DOI 10.1091/mbc.E03-06-0368
   Rahaman SO, 2006, CELL METAB, V4, P211, DOI 10.1016/j.cmet.2006.06.007
   REGINATO AJ, 1985, ANN RHEUM DIS, V44, P537, DOI 10.1136/ard.44.8.537
   RENZ H, 1988, J IMMUNOL, V141, P2388
   Robenek H, 2005, J LIPID RES, V46, P1331, DOI 10.1194/jlr.M400323-JLR200
   Robenek H, 2006, J CELL SCI, V119, P4215, DOI 10.1242/jcs.03191
   Robenek MJ, 2004, FASEB J, V18, P866, DOI 10.1096/fj.03-0782fje
   ROSS R, 1995, ANNU REV PHYSIOL, V57, P791, DOI 10.1146/annurev.ph.57.030195.004043
   Roulin K, 1999, EXP CELL RES, V247, P410, DOI 10.1006/excr.1998.4382
   Salluh JI, 2007, PROSTAG LEUKOTR ESS, V77, P1, DOI 10.1016/j.plefa.2007.04.001
   Sarbassov DD, 2005, CURR OPIN CELL BIOL, V17, P596, DOI 10.1016/j.ceb.2005.09.009
   Sato S, 2006, J BIOCHEM, V139, P921, DOI 10.1093/jb/mvj104
   Scarfo LM, 2001, AM J PHYSIOL-HEART C, V280, pH294
   SCHLESINGER PA, 1982, ARTHRITIS RHEUM, V25, P1365, DOI 10.1002/art.1780251114
   Schmitz G, 2008, REV PHYSIOL BIOCH P, V160, P93, DOI 10.1007/112_2008_802
   Seachord CL, 2005, BIOL REPROD, V72, P1305, DOI 10.1095/biolreprod.104.037523
   Silva AR, 2002, J IMMUNOL, V168, P4112, DOI 10.4049/jimmunol.168.8.4112
   Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0
   Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145
   Stow JL, 2006, NAT REV IMMUNOL, V6, P919, DOI 10.1038/nri1980
   Targett-Adams P, 2005, BBA-GENE STRUCT EXPR, V1728, P95, DOI 10.1016/j.bbaexp.2005.01.017
   Tauchi-Sato K, 2002, J BIOL CHEM, V277, P44507, DOI 10.1074/jbc.M207712200
   Thore CR, 1998, NEUROSCI LETT, V242, P29, DOI 10.1016/S0304-3940(98)00040-8
   Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5
   TRIGGIANI M, 1995, J EXP MED, V182, P1181, DOI 10.1084/jem.182.5.1181
   Umlauf E, 2004, J BIOL CHEM, V279, P23699, DOI 10.1074/jbc.M310546200
   van Manen HJ, 2005, P NATL ACAD SCI USA, V102, P10159, DOI 10.1073/pnas.0502746102
   Vieira-de-Abreu A, 2005, INT IMMUNOPHARMACOL, V5, P1966, DOI 10.1016/j.intimp.2005.06.003
   Vieira-De-Abreu A, 2005, AM J RESP CELL MOL, V33, P254, DOI 10.1165/rcmb.2005-0145OC
   Wan HC, 2007, FASEB J, V21, P167, DOI 10.1096/fj.06-6711com
   Wang SM, 2003, HISTOCHEM CELL BIOL, V120, P285, DOI 10.1007/s00418-003-0575-7
   Wei P, 2005, J BIOCHEM, V138, P399, DOI 10.1093/jb/mvi136
   WEINSTEIN J, 1980, ARCH INTERN MED, V140, P560, DOI 10.1001/archinte.140.4.560
   Weller PF, 1999, INT ARCH ALLERGY IMM, V118, P450, DOI 10.1159/000024161
   WELLER PF, 1991, J CELL BIOL, V113, P137, DOI 10.1083/jcb.113.1.137
   WELLER PF, 1985, BLOOD, V65, P1269
   WELLER PF, 1991, AM J PATHOL, V138, P141
   WELLER PF, 1989, AM J PATHOL, V135, P947
   White MA, 2005, ANNU REV PHARMACOL, V45, P587, DOI 10.1146/annurev.pharmtox.45.120403.095807
   Wolins NE, 2001, J BIOL CHEM, V276, P5101, DOI 10.1074/jbc.M006775200
   Wooten RE, 2008, BBA-MOL CELL RES, V1783, P1544, DOI 10.1016/j.bbamcr.2008.03.008
   Wymann MP, 2008, NAT REV MOL CELL BIO, V9, P162, DOI 10.1038/nrm2335
   Xu WB, 2006, BIOCHEM BIOPH RES CO, V351, P376, DOI 10.1016/j.bbrc.2006.10.051
   Yaqoob P, 2003, TRENDS IMMUNOL, V24, P639, DOI 10.1016/j.it.2003.10.002
   Yu WG, 1998, AM J PATHOL, V152, P759
   Yu WG, 2000, BLOOD, V95, P1078, DOI 10.1182/blood.V95.3.1078.003k16_1078_1085
   Zhao ZZ, 2005, ARTERIOSCL THROM VAS, V25, P168, DOI 10.1161/01.ATV.0000149145.00865.d9
NR 154
TC 149
Z9 150
U1 0
U2 13
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1388-1981
J9 BBA-MOL CELL BIOL L
JI Biochim. Biophys. Acta Mol. Cell Biol. Lipids
PD JUN
PY 2009
VL 1791
IS 6
BP 540
EP 551
DI 10.1016/j.bbalip.2009.01.005
PG 12
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA 463XH
UT WOS:000267466900018
PM 19416659
OA Green Accepted
DA 2020-12-15
ER

PT J
AU Taha, MO
   Simoes, MJ
   Mendonca, MV
   Lugo, FRC
   Carmo, R
   Lazarini, JL
   Bessa, MZ
   Marconi, TD
   Magalhaes, KG
   Soares, JH
   Tersariol, ILS
   Monteiro, HP
   Oliveira, I
   Jurkiewicz, A
   Caricati-Neto, A
AF Taha, M. O.
   Simoes, M. J.
   Mendonca, M. V.
   Lugo, F. R. C.
   Carmo-Filho, R.
   Lazarini-Junior, J. L.
   Bessa, M. Z.
   Marconi, T. D.
   Magalhaes, K. G.
   Soares, J. H.
   Tersariol, I. L. S.
   Monteiro, H. P.
   Oliveira-, I., Jr.
   Jurkiewicz, A.
   Caricati-Neto, A.
TI Role of Purines on Hepatic Ischemia-Reperfusion Lesions in Rabbit
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 7th Portuguese-Brazilian Transplantation Conference
CY OCT 01-04, 2008
CL Algarve, PORTUGAL
ID LIVER-INJURY; RAT-LIVER; METABOLISM; ADENOSINE; TRANSPLANTATION;
   DELIVERY; PROTECTS; REFLOW; MICE
AB In this work, we evaluate the effects of adenosine 5' triphosphate (ATP) on hepatic lesions caused by ischemia/reperfusion (I/R) in liver rabbit. Rabbits were pretreated with ATP (15 mg/kg IV) or saline solution 0.9% (SS), before the hepatic I/R procedure. We evaluated the effects of ATP on hepatic injury before and after I/R. The warm hepatic I/R procedure caused profound acute liver injury, as indicated by elevated serum aspartate aminotransferase, alanine aminotransferase, and lactic dehydrogenase levels, as well as a high apoptotic cell count. All these changes were attenuate by ATP treatment before the hepatic I/R procedure. These results suggested that ATP exerted protective effects on hepatic I/R lesions in the rabbit. This ATP effect may be related to improved energy metabolism during reperfusion in ischemic livers protecting against functional damage of cellular and subcellular membranes during lipid peroxidation.
C1 [Taha, M. O.; Soares, J. H.] Univ Fed Sao Paulo, Dept Surg, Escola Paulista Med, BR-04023900 Sao Paulo, Brazil.
   [Simoes, M. J.; Oliveira-, I., Jr.] Univ Fed Sao Paulo, Dept Morphol, Escola Paulista Med, BR-04023900 Sao Paulo, Brazil.
   [Monteiro, H. P.] Univ Fed Sao Paulo, Dept Biochem, Escola Paulista Med, BR-04023900 Sao Paulo, Brazil.
   [Lazarini-Junior, J. L.; Bessa, M. Z.; Marconi, T. D.; Magalhaes, K. G.; Jurkiewicz, A.; Caricati-Neto, A.] Univ Fed Sao Paulo, Dept Pharmacol, Escola Paulista Med, BR-04023900 Sao Paulo, Brazil.
   [Tersariol, I. L. S.] Univ Mogi das Cruzes, Sao Paulo, Brazil.
   [Mendonca, M. V.; Lugo, F. R. C.; Carmo-Filho, R.] Fed Univ Grande Dourados, Sch Med, Grande Dourados, MS, Brazil.
RP Taha, MO (corresponding author), Univ Fed Sao Paulo, Dept Surg, Escola Paulista Med, Rua Botucatu 740, BR-04023900 Sao Paulo, Brazil.
EM taha@uol.com.br
RI Simoes, Manuel J/H-2642-2014; Monteiro, Hugo/C-8836-2012;
   Oliveira-Junior, Itamar Souza/D-7593-2013; Taha, Murched/G-2731-2012
OI Simoes, Manuel J/0000-0003-2770-8618; Oliveira-Junior, Itamar
   Souza/0000-0003-0849-9734; 
CR BAUE AE, 1974, ANGIOLOGY, V25, P31, DOI 10.1177/000331977402500106
   BRUDER G, 1982, BIOCHIM BIOPHYS ACTA, V701, P357, DOI 10.1016/0167-4838(82)90239-4
   DRUGAS GT, 1991, CIRC SHOCK, V34, P278
   ERNSTER L, MEMBRANE MITOCHONDRI, P172
   FREDERIKS WM, 1987, EXP MOL PATHOL, V47, P291, DOI 10.1016/0014-4800(87)90014-1
   He SQ, 2006, LIVER TRANSPLANT, V12, P1869, DOI 10.1002/lt.21001
   HIRASAWA H, 1978, SURGERY, V83, P655
   Ishizaki N, 1997, TRANSPLANTATION, V63, P202, DOI 10.1097/00007890-199701270-00005
   KAMIIKE W, 1982, J BIOCHEM-TOKYO, V91, P1349, DOI 10.1093/oxfordjournals.jbchem.a133822
   LOHSE W, 1984, TRANSPLANTATION, V38, P559, DOI 10.1097/00007890-198411000-00028
   MARUBAYASHI S, 1980, TRANSPLANTATION, V30, P294, DOI 10.1097/00007890-198010000-00011
   MITTNACHT S, 1979, J BIOL CHEM, V254, P9871
   ROUNDS S, 1994, J LAB CLIN MED, V123, P309
   TAKI Y, 1990, TRANSPLANTATION, V49, P535, DOI 10.1097/00007890-199003000-00012
   Todo S, 1997, TRANSPLANTATION, V63, P217, DOI 10.1097/00007890-199701270-00007
   TRUMP BF, 1976, CIRCULATION       S1, V53, P1
   WANG WY, 1988, EUR SURG RES, V20, P181, DOI 10.1159/000128759
   WARNICK CT, 1981, CAN J BIOCHEM CELL B, V59, P116, DOI 10.1139/o81-017
   Wu J, 2004, HEPATOLOGY, V40, P195, DOI 10.1002/hep.20288
NR 19
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD APR
PY 2009
VL 41
IS 3
BP 807
EP 811
DI 10.1016/j.transproceed.2009.01.057
PG 5
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 437RJ
UT WOS:000265504300007
PM 19376358
DA 2020-12-15
ER

PT J
AU Taha, MO
   Goncalves, PFZRA
   Vidigal, ROG
   Sacchi, GPS
   Pinheiro, FG
   Brandao, LSG
   Feguri, S
   Moraes, AM
   Ghadie, MM
   Magalhaes, KG
   Simoes, MJ
   Tersariol, ILS
   Monteiro, HP
   Oliveira, I
   Jurkiewicz, A
   Caricati-Neto, A
AF Taha, M. O.
   Goncalves, P. F. Z. R. A.
   Vidigal, R. O. G.
   Sacchi, G. P. S.
   Pinheiro, F. G.
   Brandao, L. S. G.
   Feguri, S.
   Moraes-Filho, A. M.
   Ghadie, M. M.
   Magalhaes, K. G.
   Simoes, M. J.
   Tersariol, I. L. S.
   Monteiro, H. P.
   Oliveira, I., Jr.
   Jurkiewicz, A.
   Caricati-Neto, A.
TI Protective Effects of Heparin on Hepatic Ischemia and Reperfusion
   Lesions in Rabbits
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 7th Portuguese-Brazilian Transplantation Conference
CY OCT 01-04, 2008
CL Algarve, PORTUGAL
ID MOLECULAR-WEIGHT HEPARIN; CEREBRAL-ISCHEMIA; CONTROLLED-TRIAL; BRAIN
   ISCHEMIA; STROKE; INJURY
AB Because the role of heparin (HEP) in hepatic ischemia/reperfusion (I/R) injury is still not fully understood, we investigated the effects of treatment with HEP on hepatic I/R injury in rabbits. For I/R procedures, the portal vein and hepatic artery were occluded by a metallic clamp to promote ischemia. The clamp was removed after 30 minutes to allow reperfusion. Rabbits undergoing the I/R procedure were treated with HEP (100 U/kg) or saline solution 0.9% (SS). When compared with levels before I/R, the serum aspartate aminotransferase, alanine aminotransferase, and lactate dehydrogenase, levels were increased by the hepatic I/R procedure, among rabbits treated with SS or HER However, the increase in these enzymes was lower among rabbits treated with HEP. Histologic analysis of hepatic tissue of rabbits undergoing I/R and treated with SS showed marked lesions in the central lobule with significant inflammatory infiltration. In contrast, a significant reduction in lesions caused by I/R was observed in the livers of rabbits treated with HER After starting reperfusion, we visualized apoptotic cells with nuclear staining among rabbits submitted to I/R and treated with SS, but not those treated with HER These results suggested that HEP was able to attenuate hepatic lesions caused by I/R in the livers of rabbits.
C1 [Taha, M. O.] Univ Fed Sao Paulo, Escola Paulista Med, Dept Surg, BR-04023900 Sao Paulo, Brazil.
   [Simoes, M. J.; Oliveira, I., Jr.] Univ Fed Sao Paulo, Escola Paulista Med, Dept Morphol, BR-04023900 Sao Paulo, Brazil.
   [Monteiro, H. P.] Univ Fed Sao Paulo, Escola Paulista Med, Dept Biochem, BR-04023900 Sao Paulo, Brazil.
   [Ghadie, M. M.; Magalhaes, K. G.; Jurkiewicz, A.; Caricati-Neto, A.] Univ Fed Sao Paulo, Escola Paulista Med, Dept Pharmacol, BR-04023900 Sao Paulo, Brazil.
   [Goncalves, P. F. Z. R. A.; Vidigal, R. O. G.; Sacchi, G. P. S.; Pinheiro, F. G.; Brandao, L. S. G.; Feguri, S.; Moraes-Filho, A. M.] Fed Univ Grande Dourados, Dept Med, Grande Dourados, MS, Brazil.
   [Tersariol, I. L. S.] Univ Mogi Cruzws, Sao Paulo, Brazil.
RP Taha, MO (corresponding author), Univ Fed Sao Paulo, Escola Paulista Med, Dept Surg, Rua Botucatu 740, BR-04023900 Sao Paulo, Brazil.
EM taha@uol.com.br
RI Taha, Murched/G-2731-2012; Oliveira-Junior, Itamar Souza/D-7593-2013;
   Monteiro, Hugo/C-8836-2012; Simoes, Manuel J/H-2642-2014
OI Oliveira-Junior, Itamar Souza/0000-0003-0849-9734; Simoes, Manuel
   J/0000-0003-2770-8618
CR Adams HP, 1998, JAMA-J AM MED ASSOC, V279, P1265, DOI 10.1001/jama.279.16.1265
   Bath PMW, 2001, LANCET, V358, P702, DOI 10.1016/S0140-6736(01)05837-8
   BERGE E, 1999, CEREBROVASC DIS, V1, P127
   Culmsee C, 2006, DRUG DISCOV TODAY TH, V3, P621
   Diener HC, 2001, STROKE, V32, P22, DOI 10.1161/01.STR.32.1.22
   Durukan A, 2007, PHARMACOL BIOCHEM BE, V87, P179, DOI 10.1016/j.pbb.2007.04.015
   *FISS BIS INV GROU, 1998, CEREBROVASC DIS, V8, P19
   Fuh KC, 2002, SURGERY, V131, P601, DOI 10.1067/msy.2002.123802
   GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440
   He SQ, 2006, LIVER TRANSPLANT, V12, P1869, DOI 10.1002/lt.21001
   KAY R, 1995, NEW ENGL J MED, V333, P1588, DOI 10.1056/NEJM199512143332402
   LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84
   Love S, 1999, BRAIN PATHOL, V9, P119
   Margaill I, 2005, FREE RADICAL BIO MED, V39, P429, DOI 10.1016/j.freeradbiomed.2005.05.003
   Samama MM, 1997, THROMB HAEMOSTASIS, V78, P173
   White BC, 2000, J NEUROL SCI, V179, P1, DOI 10.1016/S0022-510X(00)00386-5
   Zhang YY, 2006, J ETHNOPHARMACOL, V108, P355, DOI 10.1016/j.jep.2006.05.022
NR 17
TC 13
Z9 18
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD APR
PY 2009
VL 41
IS 3
BP 812
EP 815
DI 10.1016/j.transproceed.2009.02.042
PG 4
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 437RJ
UT WOS:000265504300008
PM 19376359
DA 2020-12-15
ER

PT J
AU Taha, MO
   Simoes, MJ
   Haddad, MA
   Capelato, RC
   Budny, N
   Matsumoto, AH
   Soares, PCM
   Santos, WM
   Armeato, GD
   Araki, CM
   Gomes, JSM
   Magalhaes, KG
   Tersariol, ILS
   Monteiro, HP
   Oliveira, I
   Jurkiewicz, A
   Caricati-Neto, A
AF Taha, M. O.
   Simoes, M. J.
   Haddad, M. A.
   Capelato, R. C.
   Budny, N.
   Matsumoto, A. H.
   Soares, P. C. M.
   Santos, W. M.
   Armeato, G. D.
   Araki, C. M.
   Gomes, J. S. M.
   Magalhaes, K. G.
   Tersariol, I. L. S.
   Monteiro, H. P.
   Oliveira, I., Jr.
   Jurkiewicz, A.
   Caricati-Neto, A.
TI L-Arginine Supplementation Protects Against Hepatic Ischemia-Reperfusion
   Lesions in Rabbits
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 7th Portuguese-Brazilian Transplantation Conference
CY OCT 01-04, 2008
CL Algarve, PORTUGAL
ID NITRIC-OXIDE SYNTHESIS; LIVER-INJURY; BLOOD-FLOW; RAT-LIVER;
   ENDOTHELIUM; INHIBITION; TRANSPLANTATION; VASODILATION; ATTENUATION;
   EXPRESSION
AB We evaluated the effects of a substrate in the biosynthesis of nitric oxide (NO)-L-arginine (LARG)-on hepatic lesions caused by ischemia/reperfusion (I/R) injury in rabbit livers. Rabbits were pretreated with LARG (150 mg/kg IV) or saline solution 0.9% (SS) before the hepatic I/R procedure. The effects of LARG on hepatic injury were evaluated before and after I/R. The warm hepatic I/R procedure produced profound acute liver injury, as indicated by elevated values of serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), and lactic dehydrogenase (LDH), as well as a high apoptotic cell count. All changes were attenuated by treatment with LARG before the hepatic I/R procedure. These results suggested that LARG produced protective effects on hepatic I/R lesions. This protective effect of LARG was probably associated with blocking generation of superoxide anions during the hepatic I/R procedure.
C1 [Taha, M. O.; Haddad, M. A.; Gomes, J. S. M.; Magalhaes, K. G.] Univ Fed Sao Paulo, Escola Paulista Med, Dept Surg, BR-04023900 Sao Paulo, Brazil.
   [Simoes, M. J.; Oliveira, I., Jr.] Univ Fed Sao Paulo, Escola Paulista Med, Dept Morphol, BR-04023900 Sao Paulo, Brazil.
   [Monteiro, H. P.] Univ Fed Sao Paulo, Escola Paulista Med, Dept Biochem, BR-04023900 Sao Paulo, Brazil.
   [Haddad, M. A.; Gomes, J. S. M.; Magalhaes, K. G.; Jurkiewicz, A.; Caricati-Neto, A.] Univ Fed Sao Paulo, Escola Paulista Med, Dept Pharmacol, BR-04023900 Sao Paulo, Brazil.
   [Capelato, R. C.; Budny, N.; Matsumoto, A. H.; Soares, P. C. M.; Santos, W. M.; Armeato, G. D.; Araki, C. M.] Fed Univ Grande Dourados, Dept Med, Grande Dourados, MS, Brazil.
   [Tersariol, I. L. S.] Univ Mogi Cruzws, Sao Paulo, Brazil.
RP Taha, MO (corresponding author), Univ Fed Sao Paulo, Escola Paulista Med, Dept Surg, Rua Botucatu 740, BR-04023900 Sao Paulo, Brazil.
EM taha@uol.com.br
RI Monteiro, Hugo/C-8836-2012; Simoes, Manuel J/H-2642-2014; Taha,
   Murched/G-2731-2012; Oliveira-Junior, Itamar Souza/D-7593-2013
OI Simoes, Manuel J/0000-0003-2770-8618; Oliveira-Junior, Itamar
   Souza/0000-0003-0849-9734
CR BACK KJ, 1993, J BIOL CHEM, V268, P21120
   BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620
   DAVENPECK KL, 1994, GASTROENTEROLOGY, V107, P1050, DOI 10.1016/0016-5085(94)90229-1
   DINERMAN JL, 1993, CIRC RES, V73, P217, DOI 10.1161/01.RES.73.2.217
   FINEMAN JR, 1991, AM J PHYSIOL, V261, pH1563
   GIRERD XJ, 1990, CIRC RES, V67, P1301, DOI 10.1161/01.RES.67.6.1301
   HARBRECHT BG, 1995, J LEUKOCYTE BIOL, V57, P297
   HINO M, 1989, J ANTIBIOT, V42, P1578, DOI 10.7164/antibiotics.42.1578
   HOTTER G, 1995, TRANSPLANTATION, V59, P417, DOI 10.1097/00007890-199502150-00018
   Ishizaki N, 1997, TRANSPLANTATION, V63, P202, DOI 10.1097/00007890-199701270-00005
   JAESCHKE H, 1992, LIFE SCI, V50, P1797, DOI 10.1016/0024-3205(92)90064-V
   KAWADA N, 1993, EUR J BIOCHEM, V213, P815, DOI 10.1111/j.1432-1033.1993.tb17824.x
   Koeppel TA, 1997, J HEPATOL, V27, P163, DOI 10.1016/S0168-8278(97)80297-8
   KOUREMBANAS S, 1993, J CLIN INVEST, V92, P99, DOI 10.1172/JCI116604
   KUBES P, 1991, P NATL ACAD SCI USA, V88, P4651, DOI 10.1073/pnas.88.11.4651
   Langle F, 1997, TRANSPLANTATION, V63, P1225
   LEFER DJ, 1993, CIRCULATION, V88, P2337, DOI 10.1161/01.CIR.88.5.2337
   MA TT, 1995, GASTROENTEROLOGY, V108, P463, DOI 10.1016/0016-5085(95)90075-6
   NUSSLER AK, 1993, J LEUKOCYTE BIOL, V54, P171
   PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0
   RADAMUSKI MW, 1987, LANCET, V2, P1057
   RAPOPORT RM, 1983, CIRC RES, V52, P352, DOI 10.1161/01.RES.52.3.352
   REES D, 1989, P NATL ACAD SCI USA, V86, P3875
   Shiraishi M, 1997, J SURG RES, V69, P429, DOI 10.1006/jsre.1997.5094
   Todo S, 1997, TRANSPLANTATION, V63, P217, DOI 10.1097/00007890-199701270-00007
   TSAO PS, 1990, AM J PHYSIOL, V259, pH1660
   Urakami A, 1997, J AM COLL SURGEONS, V185, P358, DOI 10.1016/S1072-7515(97)00025-2
   WANG Y, 1995, SHOCK, V4, P282, DOI 10.1097/00024382-199510000-00009
NR 28
TC 6
Z9 6
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD APR
PY 2009
VL 41
IS 3
BP 816
EP 819
DI 10.1016/j.transproceed.2009.02.050
PG 4
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 437RJ
UT WOS:000265504300009
PM 19376360
DA 2020-12-15
ER

PT J
AU Taha, MO
   Simoes, MJ
   Noguerol, EC
   Mendonca, FP
   Pascoalick, HMA
   Alves, RAM
   Vivian, MEM
   Morales, FP
   Campos, ACA
   Magalhaes, KG
   Venerando, PS
   Tersariol, ILS
   Monteiro, HP
   Oliveira, I
   Jurkiewicz, A
   Caricati-Neto, A
AF Taha, M. O.
   Simoes, M. J.
   Noguerol, E. C.
   Mendonca, F. P.
   Pascoalick, H. M. A.
   Alves, R. A. M.
   Vivian, M. E. M.
   Morales, F. P.
   Campos, A. C. A.
   Magalhaes, K. G.
   Venerando, P. S.
   Tersariol, I. L. S.
   Monteiro, H. P.
   Oliveira, I., Jr.
   Jurkiewicz, A.
   Caricati-Neto, A.
TI Effects of Allopurinol on Ischemia and Reperfusion in Rabbit Livers
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 7th Portuguese-Brazilian Transplantation Conference
CY OCT 01-04, 2008
CL Algarve, PORTUGAL
ID HEPATIC ISCHEMIA/REPERFUSION INJURY; NADPH OXIDASE; OXIDATIVE STRESS;
   SUPEROXIDE; APOPTOSIS; DELIVERY; PROTECTS; WARM; RATS; MICE
AB In this work, we evaluated the effects of allopurinol (ALO), an inhibitor of xanthine oxidase (XO), on hepatic lesions caused by ischemia/reperfusion (I/R) in the rabbit liver. Rabbits were pretreated with ALO (10 mg/kg IV) or saline solution 0.9% before the hepatic I/R procedure. The effects of ALO on hepatic injury were evaluated before and after I/R. A standard, warm hepatic I/R procedure caused profound acute liver injury, as indicated by elevated serum aspartate aminotransferase, alanine aminotransferase, and lactic dehydrogenase levels, as well as a high apoptotic cell count. All of these changes were reversed by the administration of ALO before the hepatic I/R procedure. In conclusion, ALO exerted protective effects on hepatic I/R lesions. This protective effect of ALO was probably associated with blocking the generation of superoxide anions during the hepatic I/R procedure by inhibiting XO activity.
C1 [Taha, M. O.; Venerando, P. S.] Univ Fed Sao Paulo, Escola Paulista Med, Dept Surg, BR-04023900 Sao Paulo, Brazil.
   [Simoes, M. J.; Oliveira, I., Jr.] Univ Fed Sao Paulo, Escola Paulista Med, Dept Morphol, BR-04023900 Sao Paulo, Brazil.
   [Monteiro, H. P.] Univ Fed Sao Paulo, Escola Paulista Med, Dept Biochem, BR-04023900 Sao Paulo, Brazil.
   [Magalhaes, K. G.; Jurkiewicz, A.; Caricati-Neto, A.] Univ Fed Sao Paulo, Escola Paulista Med, Dept Pharmacol, BR-04023900 Sao Paulo, Brazil.
   [Noguerol, E. C.; Mendonca, F. P.; Pascoalick, H. M. A.; Alves, R. A. M.; Vivian, M. E. M.; Morales, F. P.; Campos, A. C. A.] Fed Univ Grande Dourados, Dept Med, Grande Dourados, MS, Brazil.
   [Tersariol, I. L. S.] Univ Mogi Cruzws, Sao Paulo, Brazil.
RP Taha, MO (corresponding author), Univ Fed Sao Paulo, Escola Paulista Med, Dept Surg, Rua Botucatu 740, BR-04023900 Sao Paulo, Brazil.
EM taha@uol.com.br
RI Taha, Murched/G-2731-2012; Oliveira-Junior, Itamar Souza/D-7593-2013;
   Monteiro, Hugo/C-8836-2012; Simoes, Manuel J/H-2642-2014
OI Oliveira-Junior, Itamar Souza/0000-0003-0849-9734; Simoes, Manuel
   J/0000-0003-2770-8618
CR Arteel GE, 2003, GASTROENTEROLOGY, V124, P778, DOI 10.1053/gast.2003.50087
   Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476
   Cheng GJ, 2001, GENE, V269, P131, DOI 10.1016/S0378-1119(01)00449-8
   Czaja MJ, 2002, ANTIOXID REDOX SIGN, V4, P759, DOI 10.1089/152308602760598909
   Dorman RB, 2006, AM J PHYSIOL-GASTR L, V290, pG1025, DOI 10.1152/ajpgi.00246.2005
   Harada H, 2004, ARCH BIOCHEM BIOPHYS, V423, P103, DOI 10.1016/j.abb.2003.08.035
   He SQ, 2006, LIVER TRANSPLANT, V12, P1869, DOI 10.1002/lt.21001
   Jaeschke H, 2003, GASTROENTEROLOGY, V125, P1246, DOI 10.1016/S0016-5085(03)01209-5
   Kono H, 2001, AM J PHYSIOL-GASTR L, V280, pG1005
   Lentsch AB, 2000, HEPATOLOGY, V32, P169, DOI 10.1053/jhep.2000.9323
   MOCHIDA S, 1994, LIVER, V14, P234
   Rhoden E, 2000, EUR SURG RES, V32, P215, DOI 10.1159/000008767
   STOLK J, 1994, AM J RESP CELL MOL, V11, P95, DOI 10.1165/ajrcmb.11.1.8018341
   Wu J, 2004, HEPATOLOGY, V40, P195, DOI 10.1002/hep.20288
   Yamamori T, 2004, BIOCHEM BIOPH RES CO, V316, P720, DOI 10.1016/j.bbrc.2004.02.108
NR 15
TC 19
Z9 19
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPL P
JI Transplant. Proc.
PD APR
PY 2009
VL 41
IS 3
BP 820
EP 823
DI 10.1016/j.transproceed.2009.02.051
PG 4
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 437RJ
UT WOS:000265504300010
PM 19376361
DA 2020-12-15
ER

PT J
AU Magalhaes, KG
   Jannotti-Passos, LK
   Caldeira, RL
   Berne, MEA
   Muller, G
   Carvalho, OS
   Lenzi, HL
AF Magalhaes, Kelly Grace
   Jannotti-Passos, Liana K.
   Caldeira, Roberta L.
   Berne, Maria Elisabeth Aires
   Muller, Gertrude
   Carvalho, Omar S.
   Lenzi, Henrique Leonel
TI Isolation and detection of Fasciola hepatica DNA in Lymnaea viatrix from
   formalin-fixed and paraffin-embedded tissues through multiplex-PCR
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Fasciola hepatica; detection; multiplex-PCR; DNA isolation;
   formalin-fixed; paraffin-embedded
ID POLYMERASE-CHAIN-REACTION; LARVAL STAGES; EXTRACTION; AMPLIFICATION;
   TRUNCATULA; SPOROCYSTS; EXPRESSION; RETRIEVAL; COLUMELLA; ASSAY
AB Detection of Fasciola hepatica infection in Lymnaea viatrix through analysis of histological cuts is based upon morphological characters of the parasite during the intra-mollusk phase of parasitism. At this stage, trematode forms are very similar and, thus, very difficult to differentiate. Specific detection may also be impaired by the presence of other helminthes in the mollusk. Histological samples are usually fixed in formalin, embedded in paraffin, sectioned and HE stained. In the current study, a method for the extraction of DNA from formalin-fixed, paraffin-embedded tissues was standardized by means of deparaffinizing with xylol and digesting with proteinase K. Extracted DNA was amplified in a multiplex-PCR, by using simultaneous primers in a single reaction under high stringency conditions. Results showed specific amplification of DNA from the trematode and the snails. The technique was sensitive enough to detect E hepatica infections in L. viatrix, in histological sections in which the presence of larval stages could not be observed through brightfield microscopy. The profiles generated were: stair bands referring to F hepatica DNAmt amplification; a band of 1200 bp referring to L. viatrix ITS and another of 1300 bp referring to F hepatica ITS and other trematodes. Multiplex-PCR has shown to be a fast, safe, highly sensitive and specific method, which is able to amplify DNA from fixed tissues, despite a low DNA quantity and its degradation caused by fixation processes. Such methodology may be useful in studies on fascioliasis epidemiology, enabling the use of material from histological collections. (C) 2008 Elsevier B.V. All rights reserved.
C1 [Magalhaes, Kelly Grace; Jannotti-Passos, Liana K.; Caldeira, Roberta L.; Carvalho, Omar S.] Ctr Pesquisas Rene Rachou Fundacao Oswaldo Cruz, Lab Helmintoses Intestinais, BR-30190002 Belo Horizonte, MG, Brazil.
   [Magalhaes, Kelly Grace; Lenzi, Henrique Leonel] Inst Oswaldo Cruz Fundacao Oswaldo Cruz, Lab Patol, BR-21045960 Rio De Janeiro, Brazil.
   [Berne, Maria Elisabeth Aires; Muller, Gertrude] Univ Fed Pelotas, Inst Biol, Dept Microbiol & Parasitol, Pelotas, RS, Brazil.
RP Carvalho, OS (corresponding author), Ctr Pesquisas Rene Rachou Fundacao Oswaldo Cruz, Lab Helmintoses Intestinais, Av Augusto Lima 1715, BR-30190002 Belo Horizonte, MG, Brazil.
EM kellygrace@ioc.fiocruz.br
RI Caldeira, Roberta/AAZ-3858-2020; Magalhaes, Kelly Grace/L-6081-2019;
   Magalhaes, Kelly G/A-6966-2010
OI Caldeira, Roberta/0000-0003-4706-0732; Magalhaes, Kelly
   Grace/0000-0002-7435-5272; Magalhaes, Kelly G/0000-0002-7435-5272
CR Cao W, 2003, CANCER DETECT PREV, V27, P397, DOI 10.1016/S0361-090X(03)00103-X
   CARSON FL, 1973, AM J CLIN PATHOL, V59, P365
   Chattopadhyay S, 2004, J CLIN MICROBIOL, V42, P2821, DOI 10.1128/JCM.42.6.2821-2824.2004
   CHEN BF, 1993, J HISTOCHEM CYTOCHEM, V41, P765, DOI 10.1177/41.5.8385683
   COOMBS NJ, 1999, NUCLEIC ACIDS RES, V15, P12
   Coura R, 2005, J CLIN PATHOL, V58, P894, DOI 10.1136/jcp.2004.021352
   de Carvalho Gilcia A., 2001, Boletin Chileno de Parasitologia, V56, P3
   de Souza CP, 2002, MEM I OSWALDO CRUZ, V97, P407, DOI 10.1590/S0074-02762002000300023
   HODASI JKM, 1972, PARASITOLOGY, V65, P359, DOI 10.1017/S0031182000045145
   Howe JR, 1997, HISTOL HISTOPATHOL, V12, P595
   Korbler T, 2003, EXP MOL PATHOL, V74, P336, DOI 10.1016/S0014-4800(03)00024-8
   Kurabachew M, 2004, DIAGN MICR INFEC DIS, V49, P99, DOI 10.1016/j.diagmicrobio.2004.03.010
   LESSA CSS, 2001, THESIS U FEDERAL RUR
   Lewis F, 2001, J PATHOL, V195, P66, DOI 10.1002/1096-9896(200109)195:1<66::AID-PATH921>3.0.CO;2-F
   LOKER ES, 1982, J PARASITOL, V68, P84, DOI 10.2307/3281328
   Magalhaes KG, 2004, MEM I OSWALDO CRUZ, V99, P421, DOI 10.1590/S0074-02762004000400013
   Mas-Coma S, 2005, INT J PARASITOL, V35, P1255, DOI 10.1016/j.ijpara.2005.07.010
   Mendonca CLGF, 1999, MEM I OSWALDO CRUZ, V94, P549, DOI 10.1590/S0074-02761999000400022
   Molloy JB, 2006, VET PARASITOL, V137, P62, DOI 10.1016/j.vetpar.2005.12.024
   MOORE MN, 1973, Z PARASITENKD, V43, P1, DOI 10.1007/BF00329532
   Paska C, 2004, DIAGN MOL PATHOL, V13, P234, DOI 10.1097/01.pdm.0000134778.37729.9f
   PATNAIK MM, 1966, JPN J MED SCI BIOL, V19, P253, DOI 10.7883/yoken1952.19.253
   Poljak M, 2000, PFLUG ARCH EUR J PHY, V439, pR42, DOI 10.1007/s004240000085
   PREVERAUDSINDOU M, 1994, PARASITOL RES, V80, P342, DOI 10.1007/BF02351877
   RONDELAUD D, 1983, ANN PARASIT HUM COMP, V58, P109, DOI 10.1051/parasite/1983582109
   Sato Y, 2001, DIAGN MOL PATHOL, V10, P265, DOI 10.1097/00019606-200112000-00009
   Shi SR, 2004, HISTOCHEM CELL BIOL, V122, P211, DOI 10.1007/s00418-004-0693-x
   Shi SR, 2002, J HISTOCHEM CYTOCHEM, V50, P1005, DOI 10.1177/002215540205000802
   SHIBATA D, 1994, HUM PATHOL, V25, P561, DOI 10.1016/0046-8177(94)90219-4
   Smooker PM, 1997, EXP PARASITOL, V85, P86, DOI 10.1006/expr.1996.4098
   SOUTHGATE VR, 1970, PARASITOLOGY, V61, P293, DOI 10.1017/S0031182000041123
   Sun YQ, 2007, CLIN CHIM ACTA, V377, P108, DOI 10.1016/j.cca.2006.09.003
   WILSON RA, 1980, Z PARASITENKD, V61, P109, DOI 10.1007/BF00925458
   Wu L, 2002, APPL IMMUNOHISTO M M, V10, P269, DOI 10.1097/00022744-200209000-00015
NR 34
TC 24
Z9 26
U1 0
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD APR 15
PY 2008
VL 152
IS 3-4
BP 333
EP 338
DI 10.1016/j.vetpar.2007.12.019
PG 6
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA 288DJ
UT WOS:000254966100021
PM 18243563
DA 2020-12-15
ER

PT J
AU Jannotti-Passos, LK
   Magalhaes, KG
   Carvalho, OS
   Vidigal, THDA
AF Jannotti-Passos, LK
   Magalhaes, KG
   Carvalho, OS
   Vidigal, THDA
TI Multiplex PCR for both identification of Brazilian Biomphalaria species
   (Gastropoda : Planorbidae) and diagnosis of infection by Schistosoma
   mansoni (Trematoda : Schistosomatidae)
SO JOURNAL OF PARASITOLOGY
LA English
DT Article
ID GLABRATA
AB A simple and single-step technique based on multiplex PCR (multiplex polymerase chain reaction) has been developed for simultaneous identification of Brazilian Biomphalaria species, the intermediate hosts of Schistosoma mansoni, and their diagnosis of infection by the trematode. We used species-specific primer-directed both to the internal transcribed spacer 2 (ITS2) of ribosomal DNA from 3 of the S. mansoni host species and to the mitochondrial DNA (mtDNA) from the trematode. Those primers were used simultaneously in a single multiplex-PCR reaction. and template DNA was obtained front S. mansoni-infected and noninfected snails. The results were visualized in silver stained polyacrylamide gels, revealing the presence of specific hands. The methodology has shown to be efficient, fast, and reproducible for Biomphalaria species identification and diagnosis of snails infected by S. mansoni during prepatent periods.
C1 Fiocruz MS, Ctr Pesquisas Rene Rachou, BR-30190002 Belo Horizonte, MG, Brazil.
   Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Zool, Lab Malacol & Sistemat Mol, Belo Horizonte, MG, Brazil.
RP Jannotti-Passos, LK (corresponding author), Fiocruz MS, Ctr Pesquisas Rene Rachou, Av Augusto Lima 1715, BR-30190002 Belo Horizonte, MG, Brazil.
EM passoslk@cpqrr.fiocruz.br
RI Magalhaes, Kelly Grace/L-6081-2019; Magalhaes, Kelly G/A-6966-2010
OI Magalhaes, Kelly Grace/0000-0002-7435-5272; Magalhaes, Kelly
   G/0000-0002-7435-5272
CR Carvalho ODS, 1998, MEM I OSWALDO CRUZ, V93, P39
   Carvalho OS, 2001, PARASITOLOGY, V123, pS197, DOI 10.1017/S0031182001008058
   CHU KY, 1970, B WORLD HEALTH ORGAN, V42, P569
   Hanelt B, 1997, J PARASITOL, V83, P387, DOI 10.2307/3284399
   Jannotti-Passos Liana Konovaloff, 2000, Revista do Instituto de Medicina Tropical de Sao Paulo, V42, P291, DOI 10.1590/S0036-46652000000500010
   JannottiPassos LK, 1997, J PARASITOL, V83, P395, DOI 10.2307/3284400
   Mosquera MD, 2002, J CLIN MICROBIOL, V40, P111, DOI 10.1128/JCM.40.1.111-116.2002
   PARAENSE W L, 1987, Memorias do Instituto Oswaldo Cruz, V82, P577
   PARAENSE W. L., 1963, REV INST MED TROP SAO PAULO, V5, P15
   Paraense W.L., 1975, ARQUIVO MUSEU NACL R, V55, P105
   PARAENSE WL, 1959, AM J TROP MED HYG, V8, P456, DOI 10.4269/ajtmh.1959.8.456
   PARAENSE WL, 1986, MODERNOS CONHECIMENT, P117
   Pelandakis M, 2002, APPL ENVIRON MICROB, V68, P2061, DOI 10.1128/AEM.68.4.2061-2065.2002
   Vidigal THDA, 2000, PARASITOLOGY, V121, P611, DOI 10.1017/S0031182000006831
   Vidigal THDA, 2002, MEM I OSWALDO CRUZ, V97, P95, DOI 10.1590/S0074-02762002000900019
   Vidigal THDA, 2002, MEM I OSWALDO CRUZ, V97, P47, DOI 10.1590/S0074-02762002000900011
   Vidigal THDA, 2000, MEM I OSWALDO CRUZ, V95, P57, DOI 10.1590/S0074-02762000000100009
   *WHO, 1993, CONTR SCHIST 2 REP W
NR 18
TC 16
Z9 17
U1 0
U2 3
PU ALLEN PRESS INC
PI LAWRENCE
PA 810 E 10TH ST, LAWRENCE, KS 66044 USA
SN 0022-3395
EI 1937-2345
J9 J PARASITOL
JI J. Parasitol.
PD APR
PY 2006
VL 92
IS 2
BP 401
EP 403
DI 10.1645/GE-593R1.1
PG 3
WC Parasitology
SC Parasitology
GA 039TG
UT WOS:000237329400031
PM 16729704
DA 2020-12-15
ER

PT J
AU Magalhaes, KG
   Passos, LKJ
   Carvalho, OD
AF Magalhaes, KG
   Passos, LKJ
   Carvalho, OD
TI Detection of Lymnaea columella Infection by Fasciola hepatica through
   Multiplex-PCR
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article
DE Fasciola hepatica; Lymnaea columella; multiplex polymerase chain
   reaction; DNA mitochondrial; diagnosis
ID POLYMERASE-CHAIN-REACTION; DNA-PROBE; SNAILS; IDENTIFICATION; TREMATODA;
   ASSAY
AB From complete mitochondrial DNA sequence of Fasciola hepatica available in Genbank, specific primers were designed for a conserved and repetitive region of this trematode. A pair of primers was used for diagnosis of infected Lymnaea columella by F. hepatica during the pre-patent period simultaneously with another pair of primers which amplified the internal transcribed spacer (ITS) region of rDNA from L. columella in a single Multiplex-PCR. The amplification generated a ladder band profile specific for F. hepatica. This profile was observed in positive molluscs at different times of infection, including adult worms from the trematode. The Multiplex-PCR technique showed to be a fast and safe tool for fascioliasis diagnosis, enabling the detection of F. hepatica miracidia in L. columella during the pre-patent period and identification of transmission areas.
C1 Fiocruz MS, Ctr Pesquisas Rene Rachou, BR-30190002 Belo Horizonte, MG, Brazil.
RP Carvalho, OD (corresponding author), Fiocruz MS, Ctr Pesquisas Rene Rachou, Av Augusto Lima 1715, BR-30190002 Belo Horizonte, MG, Brazil.
EM omar@cpqrr.fiocruz.br
RI Magalhaes, Kelly Grace/L-6081-2019; Magalhaes, Kelly G/A-6966-2010
OI Magalhaes, Kelly Grace/0000-0002-7435-5272; Magalhaes, Kelly
   G/0000-0002-7435-5272
CR de Souza CP, 2000, MEM I OSWALDO CRUZ, V95, P739, DOI 10.1590/S0074-02762000000500023
   de Souza CP, 2002, MEM I OSWALDO CRUZ, V97, P407, DOI 10.1590/S0074-02762002000300023
   Fettene M, 2003, J MED ENTOMOL, V40, P112, DOI 10.1603/0022-2585-40.1.112
   HEUSSLER V, 1993, MOL CELL PROBE, V7, P261, DOI 10.1006/mcpr.1993.1039
   KANE RA, 1994, MOL BIOCHEM PARASIT, V63, P153, DOI 10.1016/0166-6851(94)90018-3
   KAPLAN RM, 1995, INT J PARASITOL, V25, P601, DOI 10.1016/0020-7519(94)00159-L
   Kaplan RM, 1997, INT J PARASITOL, V27, P1585, DOI 10.1016/S0020-7519(97)00139-2
   Le TH, 2001, PARASITOLOGY, V123, P609, DOI 10.1017/S0031182001008733
   Lessa CSS, 2000, REV BRAS CIENCIA VET, V1, P63
   LOKER ES, 1982, J PARASITOL, V68, P84, DOI 10.2307/3281328
   Mas-Coma S, 2001, PARASITOLOGY, V123, pS115, DOI 10.1017/S0031182001008034
   Mosquera MD, 2002, J CLIN MICROBIOL, V40, P111, DOI 10.1128/JCM.40.1.111-116.2002
   PARAENSE W L, 1986, Memorias do Instituto Oswaldo Cruz, V81, P121
   Paraense W.L., 1982, Memorias do Instituto Oswaldo Cruz, V77, P437
   PARAENSE W L, 1983, Memorias do Instituto Oswaldo Cruz, V78, P477
   Paraense W.L., 1982, Memorias do Instituto Oswaldo Cruz, V77, P181
   Patsoula E, 2003, ANN TROP MED PARASIT, V97, P15, DOI 10.1179/000349803125002535
   Pelandakis M, 2002, APPL ENVIRON MICROB, V68, P2061, DOI 10.1128/AEM.68.4.2061-2065.2002
   Prepelitchi L, 2003, MEM I OSWALDO CRUZ, V98, P889, DOI 10.1590/S0074-02762003000700005
   Rivera ING, 2003, ENVIRON MICROBIOL, V5, P599, DOI 10.1046/j.1462-2920.2003.00443.x
   ROGNLIE MC, 1994, J PARASITOL, V80, P748, DOI 10.2307/3283253
   Saleha A A, 1991, Southeast Asian J Trop Med Public Health, V22 Suppl, P361
   SHUBKIN CD, 1992, J PARASITOL, V78, P817, DOI 10.2307/3283311
   SILVA RE, 1995, 14 C BRAS PAR GOIAS, P205
   Stothard JR, 2002, MEM I OSWALDO CRUZ, V97, P31, DOI 10.1590/S0074-02762002000900008
NR 25
TC 32
Z9 35
U1 0
U2 2
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PD JUN
PY 2004
VL 99
IS 4
BP 421
EP 424
DI 10.1590/S0074-02762004000400013
PG 4
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA 836PW
UT WOS:000222569000013
PM 15322633
OA DOAJ Gold
DA 2020-12-15
ER

PT J
AU de Souza, CP
   Magalhaes, KG
   Passos, LKJ
   dos Santos, GCP
   Ribeiro, F
   Katz, N
AF de Souza, CP
   Magalhaes, KG
   Passos, LKJ
   dos Santos, GCP
   Ribeiro, F
   Katz, N
TI Aspects of the maintenance of the life cycle of Fasciola hepatica in
   Lymnaea columella in Minas Gerais, Brazil
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article
DE fascioliasis; Lymnaea columella; infection; Fasciola hepatica; Minas
   Gerais; Brazil
ID POTENTIAL BASIS; INFECTION; MIRACIDIA; SM14
AB Fascioliasis is a parasitic disease of domestic ruminants that occurs worldwide. The lymnaeid intermediate hosts of Fasciola hepatica include Lymnaea columella, which is widely distributed in Brazil. A colony of L. columella from Belo Horizonte, MG, was reared in our laboratory to be used in studies of the F. hepatica life cycle, the intermediate host-parasite relationship and development of an anti-helminthic vaccine. In the first experiment 1, 180 snails were exposed to miracidia of F. hepatica eggs removed from the biliary tracts of cattle from the State of Rio Grande do Sul. In the second and third experiments the snails were exposed to miracidia that had emerged from F. hepatica eggs from Uruguay, maintained in rabbits. The rates of infection in the first, second and third experiments were 0, 42.1 and 0% respectively. Over, 15,806 metacercariae were obtained and stored at 4(2)C. Four rabbits infected with 32-44 metacercariae and two with 200. Three rabbits begin to eliminate weighing 1.5 kg each were in eggs of the parasite in the feces from 84 days after infection onwards. The biological cycle of F. hepatica in L, columella and the rabbit was completed within 124 days.
C1 Fiocruz MS, Ctr Pesquisas Rene Rachou, Lab Malacol, BR-30190002 Belo Horizonte, MG, Brazil.
   Fiocruz MS, Ctr Pesquisas Rene Rachou, Lab Equistossomose, BR-30190002 Belo Horizonte, MG, Brazil.
RP de Souza, CP (corresponding author), Fiocruz MS, Ctr Pesquisas Rene Rachou, Lab Malacol, Av Augusto Lima 1715, BR-30190002 Belo Horizonte, MG, Brazil.
EM souzacp@cpqrr.fiocruz.br
RI Magalhaes, Kelly Grace/L-6081-2019; Magalhaes, Kelly G/A-6966-2010
OI Magalhaes, Kelly Grace/0000-0002-7435-5272; Magalhaes, Kelly
   G/0000-0002-7435-5272
CR Abrous M, 1998, REV MED VET-TOULOUSE, V149, P943
   BORAY JC, 1966, ANN TROP MED PARASIT, V60, P114, DOI 10.1080/00034983.1966.11686394
   CHAIA GERALDO, 1956, REV BRASIL MALARIOL E DOENCAS TROP, V8, P355
   DACAL ARC, 1988, REV I MED TROP, V30, P361, DOI 10.1590/S0036-46651988000500006
   de Souza CP, 2000, MEM I OSWALDO CRUZ, V95, P739, DOI 10.1590/S0074-02762000000500023
   GOMES DL, 1985, THESIS U FEDERAL RUR
   KATZ N, 1997, BIOTECNOL CI DESENVO, V2, P18
   Kendall S. B., 1949, Journal of Helminthology, V23, P179, DOI 10.1017/S0022149X00032491
   LUTZ Adolpho, 1919, Memorias do Instituto Oswaldo Cruz, V11, P121, DOI 10.1590/S0074-02761919000100006
   Luz E, 1996, ARQ BIOL TECNOL, V39, P401
   PARAENSE W L, 1986, Memorias do Instituto Oswaldo Cruz, V81, P121
   Paraense W.L., 1982, Memorias do Instituto Oswaldo Cruz, V77, P437
   PARAENSE W L, 1983, Memorias do Instituto Oswaldo Cruz, V78, P477
   Paraense W.L., 1982, Memorias do Instituto Oswaldo Cruz, V77, P181
   PESSOA SB, 1982, PARASITOLOGIA, P425
   REY L, 1991, PARASITOLOGIA, P411
   Saleha A A, 1991, Southeast Asian J Trop Med Public Health, V22 Suppl, P361
   SILVA RE, 1995, 14 C BRAS PAR GOIAS, P205
   Souza Cecilia Pereira de, 1998, Revista da Sociedade Brasileira de Medicina Tropical, V31, P449
   TENDLER M, 1995, MEM I OSWALDO CRUZ, V90, P255, DOI 10.1590/S0074-02761995000200022
   Tendler M, 1996, P NATL ACAD SCI USA, V93, P269, DOI 10.1073/pnas.93.1.269
NR 21
TC 17
Z9 17
U1 0
U2 6
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PD APR
PY 2002
VL 97
IS 3
BP 407
EP 410
DI 10.1590/S0074-02762002000300023
PG 4
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA 548TH
UT WOS:000175405500023
PM 12048573
OA DOAJ Gold
DA 2020-12-15
ER

PT J
AU Vidigal, THDA
   Magalhaes, KG
   Kissinger, JC
   Caldeira, RL
   Simpson, AJG
   Carvalho, OS
AF Vidigal, THDA
   Magalhaes, KG
   Kissinger, JC
   Caldeira, RL
   Simpson, AJG
   Carvalho, OS
TI A Multiplex-PCR approach to identification of the Brazilian intermediate
   hosts of Schistosoma mansoni
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article; Proceedings Paper
CT 8th International Symposium on Schistosomiasis
CY DEC 02-05, 2001
CL RECIFE, BRAZIL
DE Biomphalaria; Multiplex-PCR; internal transcribed spacer 2
ID POLYMERASE-CHAIN-REACTION; RESTRICTION ENZYME DIGESTION;
   BIOMPHALARIA-TENAGOPHILA; REACTION AMPLIFICATION; INTERGENIC SPACER;
   SNAIL HOSTS; OCCIDENTALIS; MOLLUSCA; REGIONS
AB Due to difficulties concerning morphological identification of planorbid snails of the genus Biomphalaria, and given a high variation of characters and in the organs with muscular tissue, we designed specific polymerase chain reaction (PCR) primers for Brazilian snail hosts of Schistosoma mansoni from available sequences of internal transcribed spacer 2 (ITS2) of the ribosomal RNA gene. From the previous sequencing of the ITS2 region, one primer was designed to anchor in the 5.8S conserved region and three other species-specific primers in the 28S region, flanking the ITS2 region. These four primers were simultaneously used in the same reaction (Multiplex-PCR), under high stringency conditions. Amplification of the ITS2 region of Biomphalaria snails produced distinct profiles (between 280 and 350 bp) for B. glabrata, B. tenagophila and B. straminea. The present study demonstrates that Multiplex-PCR of ITS2-DNAr showed to be a promising auxiliary tool for the morphological identification of Biomphalaria snails, the intermediate hosts of S. mansoni.
C1 Fiocruz MS, Ctr Pesquisas Rene Rachou, BR-30190002 Belo Horizonte, MG, Brazil.
   UFMG, Inst Ciencias Biol, Dept Zool, Belo Horizonte, MG, Brazil.
   Univ Penn, Dept Biol, Philadelphia, PA 19104 USA.
   Inst Ludwig Pesquisa Sobre Canc, Canc Genet Lab, Sao Paulo, Brazil.
RP Carvalho, OS (corresponding author), Fiocruz MS, Ctr Pesquisas Rene Rachou, Av Augusto de Lima 1715, BR-30190002 Belo Horizonte, MG, Brazil.
RI Kissinger, Jessica/M-9920-2019; Caldeira, Roberta/AAZ-3858-2020;
   Magalhaes, Kelly Grace/L-6081-2019; Magalhaes, Kelly G/A-6966-2010;
   Kissinger, Jessica C/E-9610-2010
OI Kissinger, Jessica/0000-0002-6413-1101; Caldeira,
   Roberta/0000-0003-4706-0732; Magalhaes, Kelly Grace/0000-0002-7435-5272;
   Magalhaes, Kelly G/0000-0002-7435-5272; Kissinger, Jessica
   C/0000-0002-6413-1101
CR Caldeira RL, 1998, MEM I OSWALDO CRUZ, V93, P219, DOI 10.1590/S0074-02761998000700039
   Fujita SI, 2001, J CLIN MICROBIOL, V39, P3617, DOI 10.1128/JCM.39.10.3617-3622.2001
   Manguin S, 2002, MED VET ENTOMOL, V16, P46, DOI 10.1046/j.0269-283x.2002.00344.x
   Mosquera MD, 2002, J CLIN MICROBIOL, V40, P111, DOI 10.1128/JCM.40.1.111-116.2002
   PARAENSE W L, 1988, Memorias do Instituto Oswaldo Cruz, V83, P1, DOI 10.1590/S0074-02761988000100001
   Paraense W.L., 1981, Memorias do Instituto Oswaldo Cruz, V76, P199
   PARAENSE W. L., 1966, REV BRASIL BIOL, V26, P115
   Paraense W.L., 1975, ARQUIVO MUSEU NACL R, V55, P105
   Paraense W.L., 1984, MEM I O CRUZ, V79, P465
   Pelandakis M, 2002, APPL ENVIRON MICROB, V68, P2061, DOI 10.1128/AEM.68.4.2061-2065.2002
   Pires ER, 1997, MEM I OSWALDO CRUZ, V92, P101, DOI 10.1590/S0074-02761997000100021
   Spatz L, 1999, J MOLLUS STUD, V65, P143, DOI 10.1093/mollus/65.2.143
   Vidigal THDA, 2000, PARASITOLOGY, V121, P611, DOI 10.1017/S0031182000006831
   Vidigal THDA, 1998, EXP PARASITOL, V89, P180, DOI 10.1006/expr.1998.4286
   Vidigal THDA, 1996, MEM I OSWALDO CRUZ, V91, P739, DOI 10.1590/S0074-02761996000600016
   Vidigal THDA, 2000, MEM I OSWALDO CRUZ, V95, P57, DOI 10.1590/S0074-02762000000100009
NR 16
TC 5
Z9 6
U1 0
U2 1
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PY 2002
VL 97
SU 1
BP 95
EP 97
DI 10.1590/S0074-02762002000900019
PG 3
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA 607VH
UT WOS:000178811100019
PM 12426601
OA DOAJ Gold
DA 2020-12-15
ER

PT J
AU de Souza, CP
   Magalhaes, KG
AF de Souza, CP
   Magalhaes, KG
TI Rearing of Lymnaea columella (Say, 1817), intermediate host of Fasciola
   hepatica (Linnaeus, 1758)
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article
DE fasciolosis; Lymnaea columella; intermediate host; Minas Gerais; Brazil;
   rearing techniques
AB The intermediate host of Fasciola hepatica, Lymnaea columella, collected in Belo Horizonte, Minas Gerais, Brazil, was reared in our laboratory. The aim of the cur rent study was ro standardize a rearing and maintenance technique. Two kinds of diet were tested: fresh lettuce (A) and rodent ration + 10% CaCO3 plus fresh lettuce (B). The age for the beginning of oviposition ranged from 27 to 57 days. Ten days after oviposition at 24.7 degrees C, 100% eclosion occurred. The complete life cycle varied from 37 to 67 days. The aver age numbers of eggs per egg mass were 26.3 and 31.1 with diets (A) and(B), respectively The lettuce and ration fed snails presented a increased growth although the difference was nor statistically significant (p > 0.05). The mortality rate varied from 40 to 64% after 90 days. The maximum longevity was 183 days, 21.5 mm length and 11 mm wide. The methodology to mass breed and maintain these snails was found to be suitable in the laboratory.
C1 Fiocruz MS, Ctr Pesquisas Rene Rachou, Lab Malacol, BR-30190002 Belo Horizonte, MG, Brazil.
RP Magalhaes, KG (corresponding author), Fiocruz MS, Ctr Pesquisas Rene Rachou, Lab Malacol, Av Augusto Lima 1715, BR-30190002 Belo Horizonte, MG, Brazil.
EM souzacp@netra.fiocruz.br
RI Magalhaes, Kelly Grace/L-6081-2019; Magalhaes, Kelly G/A-6966-2010
OI Magalhaes, Kelly Grace/0000-0002-7435-5272; Magalhaes, Kelly
   G/0000-0002-7435-5272
CR DACAL ARC, 1988, REV I MED TROP, V30, P361, DOI 10.1590/S0036-46651988000500006
   GAZZINELLI G, 1970, AM J TROP MED HYG, V19, P1034, DOI 10.4269/ajtmh.1970.19.1034
   MADSEN H, 1981, J PARASITOL, V67, P735, DOI 10.2307/3280458
   Noland Lowell E., 1943, NAUTILUS, V57, P8
   OLIVIER L, 1960, 145 WHO
   PARAENSE W L, 1986, Memorias do Instituto Oswaldo Cruz, V81, P121
   Paraense W.L., 1982, Memorias do Instituto Oswaldo Cruz, V77, P437
   PARAENSE W L, 1983, Memorias do Instituto Oswaldo Cruz, V78, P477
   Paraense W.L., 1982, Memorias do Instituto Oswaldo Cruz, V77, P181
   Sanchez Ricardo, 1995, Revista Cubana de Medicina Tropical, V47, P71
   SILVA RE, 1995, 14 C BRAS PAR GOIAS, P205
   Souza C. P., 1985, Memorias do Instituto Oswaldo Cruz, V80, P55, DOI 10.1590/S0074-02761985000100009
   SOUZA C P D, 1987, Memorias do Instituto Oswaldo Cruz, V82, P73
   Souza Cecilia Pereira de, 1998, Revista da Sociedade Brasileira de Medicina Tropical, V31, P449
NR 14
TC 8
Z9 9
U1 0
U2 2
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PD SEP-OCT
PY 2000
VL 95
IS 5
BP 739
EP 741
DI 10.1590/S0074-02762000000500023
PG 3
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA 352TU
UT WOS:000089234600023
PM 10998227
OA DOAJ Gold
DA 2020-12-15
ER

EF